<SEC-DOCUMENT>0001104659-15-035555.txt : 20150507
<SEC-HEADER>0001104659-15-035555.hdr.sgml : 20150507
<ACCEPTANCE-DATETIME>20150507160559
ACCESSION NUMBER:		0001104659-15-035555
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20150331
FILED AS OF DATE:		20150507
DATE AS OF CHANGE:		20150507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FATE THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001434316
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36076
		FILM NUMBER:		15841732

	BUSINESS ADDRESS:	
		STREET 1:		3535 GENERAL ATOMICS COURT
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858.875.1803

	MAIL ADDRESS:	
		STREET 1:		3535 GENERAL ATOMICS COURT
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>a15-6944_110q.htm
<DESCRIPTION>10-Q
<TEXT>


<html>
<head>


  </head>
<body lang="EN-US">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Mark One)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .6in;text-indent:-.35in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">x</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b>QUARTERLY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt .6in;text-indent:-.35in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For the quarterly period ended March&nbsp;31, 2015</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">OR</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:12.0pt;margin:0in 0in .0001pt .6in;text-indent:-.35in;"><b><font size="3" face="Wingdings" style="font-size:12.0pt;font-weight:bold;">o</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b>TRANSITION REPORT UNDER SECTION&nbsp;13 OR 15(d)&nbsp;OF THE EXCHANGE ACT OF 1934</b></p>
<p style="margin:0in 0in .0001pt .6in;text-indent:-.35in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">From the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Commission File Number 001-36076</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FATE THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in its charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">65-1311552</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of incorporation or organization)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification No.)</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3535 General Atomics Court, Suite&nbsp;200, San Diego, CA</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">92121</font></b></p>    </td>   </tr>
<tr>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.94%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.92%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(858) 875-1800</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.&nbsp;&nbsp;Yes&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;No&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;No&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Large&nbsp;accelerated&nbsp;filer   </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accelerated&nbsp;filer   </font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Non-accelerated   filer </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Do   not check if a smaller reporting company)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Smaller&nbsp;reporting&nbsp;company   </font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;No&nbsp;</font><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of May&nbsp;5, 2015, 20,683,345 shares of the registrant&#146;s common stock, par value $0.001 per share, were issued and outstanding.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\107913\15-6944-1\task7399884\6944-1-ba.htm',USER='107913',CD='May  8 00:58 2015' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FATE THERAPEUTICS,&nbsp;INC.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORM&nbsp;10-Q</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">TABLE OF CONTENTS</font></b><a name="TableOfContents"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="93%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:93.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="6%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:6.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Page</font></b></p>    </td>   </tr>
<tr>
<td width="93%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:93.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Parti_FinancialInformation_010017" title="Click to goto ">PART&nbsp;I.   FINANCIAL INFORMATION</a></font></p>    </td>
<td width="6%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements_010018">Item 1.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_FinancialStatements_010018">Financial Statements</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedConsolidatedBalanceSheet_014016" title="Click to goto ">Condensed Consolidated Balance Sheets as of   March&nbsp;31, 2015 (unaudited) and December&nbsp;31, 2014</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedConsolidatedStatementsOf_014020" title="Click to goto ">Condensed Consolidated Statements of Operations and   Comprehensive Loss for the three months&nbsp;ended March&nbsp;31, 2015 and   2014 (unaudited)</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#CondensedConsolidatedStatementsOf_014024" title="Click to goto ">Condensed Consolidated Statements of Cash Flows for   the three months ended March&nbsp;31, 2015 and&nbsp;2014&nbsp;(unaudited)</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#NotesToCondensedConsolidatedFinan_014059" title="Click to goto ">Notes to Condensed Consolidated Financial Statements   (unaudited)</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_011924">Item 2.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_ManagementsDiscussionAndAna_011924">Management&#146;s   Discussion and Analysis of Financial Condition and Results of Operations</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_011958">Item 3.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_QuantitativeAndQualitativeD_011958">Quantitative   and Qualitative Disclosures About Market Risk</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures_011959">Item 4.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_ControlsAndProcedures_011959">Controls and   Procedures</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="93%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:93.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#PartIi_OtherInformation_012004" title="Click to goto ">PART&nbsp;II.   OTHER INFORMATION</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings_012005">Item 1.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1_LegalProceedings_012005">Legal Proceedings</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors_012006">Item   1A.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item1a_RiskFactors_012006">Risk Factors</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_013005">Item 2.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item2_UnregisteredSalesOfEquitySe_013005">Unregistered   Sales of Equity Securities and Use of Proceeds</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_DefaultsUponSeniorSecuritie_013006">Item 3.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item3_DefaultsUponSeniorSecuritie_013006">Defaults Upon   Senior Securities</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_MineSafetyDisclosure_013007">Item 4.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item4_MineSafetyDisclosure_013007">Mine Safety   Disclosures</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5_OtherInformation_013009">Item 5.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item5_OtherInformation_013009">Other Information</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_013010">Item   6.</a></font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Item6_Exhibits_013010">Exhibits</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38</font></p>    </td>   </tr>
<tr>
<td width="11%" valign="top" style="padding:0in 0in 0in 0in;width:11.92%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="81%" valign="top" style="padding:0in 0in 0in 0in;width:81.66%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="93%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:93.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#Signatures_013159" title="Click to goto ">SIGNATURES</a></font></p>    </td>
<td width="6%" valign="bottom" style="padding:0in 0in 0in 0in;width:6.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_005251_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\C901937\15-6944-1\task7387491\6944-1-bg.htm',USER='C901937',CD='May  4 04:42 2015' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART&nbsp;I. FINANCIAL INFORMATION</font></b><a name="Parti_FinancialInformation_010017"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.&#160;&#160; Financial Statements</font></b><a name="Item1_FinancialStatements_010018"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Consolidated Balance Sheets</font></b><a name="CondensedConsolidatedBalanceSheet_014016"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(in thousands, except share and per share data)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March<br>   31,</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December<br>   31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(unaudited)</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Assets</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current assets:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42,349</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49,101</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other current assets </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">443</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">771</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42,792</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49,872</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Property and equipment, net </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,544</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,200</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Restricted cash </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">122</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">122</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other assets </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44,490</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51,204</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liabilities and stockholders&#146;   equity</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current liabilities:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,271</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">645</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,827</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,260</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of deferred rent </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">85</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Repurchase liability for unvested equity awards </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">45</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt, current portion </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,256</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,546</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total current liabilities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,413</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,581</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred rent </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">100</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">312</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">149</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt, net of current portion </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16,414</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,083</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Commitments and contingencies (Note 4) </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stockholders&#146; equity:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preferred stock, $0.001 par value; authorized   shares&#151;5,000,000 at March&nbsp;31, 2015&nbsp;and&nbsp;December&nbsp;31, 2014;   no shares issued or outstanding </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Common stock, $0.001 par value; authorized shares   &#151; 150,000,000 at March&nbsp;31, 2015&nbsp;and&nbsp;December&nbsp;31, 2014;   issued and outstanding shares &#151; 20,637,217 at&nbsp;March&nbsp;31,   2015&nbsp;and 20,569,399 at December&nbsp;31, 2014 </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additional paid-in capital </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">141,503</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">140,711</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accumulated deficit </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(120,273</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(112,392</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total stockholders&#146; equity </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21,251</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28,340</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total liabilities and stockholders&#146; equity </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44,490</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">51,204</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_005529_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\105538\15-6944-1\task7387405\6944-1-fa.htm',USER='105538',CD='May  4 02:58 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></b><a name="CondensedConsolidatedStatementsOf_014020"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(in thousands, except share and per share data)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(unaudited)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating expenses:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,568</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,522</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,756</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,415</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total operating expenses </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7,324</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6,937</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Loss from operations </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7,324</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,937</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income (expense):</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest income </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Interest expense </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(558</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(43</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total other expense, net </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(557</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(43</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss and comprehensive loss </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7,881</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,980</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss per common share, basic and diluted </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.38</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(0.34</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 1.125pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Weighted-average common shares used to   compute&nbsp;basic and diluted net loss per share </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,554,478</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,346,856</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_005843_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\105538\15-6944-1\task7387405\6944-1-fa.htm',USER='105538',CD='May  4 02:58 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate Therapeutics,&nbsp;Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</font></b><a name="CondensedConsolidatedStatementsOf_014024"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(in thousands)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended&nbsp;March<br>   31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="26%" colspan="5" valign="bottom" style="padding:0in 0in 0in 0in;width:26.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(unaudited)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="70%" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Operating activities</font></b></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net loss </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(7,881</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" style="padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,980</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Adjustments to reconcile net loss to net cash   used in operating activities:</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Depreciation and amortization </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">128</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">123</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-based compensation </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">608</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">871</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amortization of discounts and debt issuance costs   </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">44</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Noncash interest expense </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">164</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deferred rent </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(10</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(9</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-based milestone charges and change in fair   value of exchangeable shares </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">375</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Changes in operating assets and liabilities:</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Prepaid expenses and other current assets </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">303</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">304</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 30.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accounts payable and accrued expenses </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">269</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">43</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in operating activities </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,375</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(5,255</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investing activities</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase of property and equipment </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(452</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(398</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash used in investing activities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(452</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(398</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financing activities</font></b><font size="2" style="font-size:10.0pt;">  </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Issuance of common stock, net of repurchases and   issuance costs </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Payments on long-term debt </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(500</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net cash provided by (used in) financing   activities </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">75</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(502</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Net change in cash and cash equivalents </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,752</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(6,155</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" style="padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents at beginning of the   period </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">49,101</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="12%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.0%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">54,036</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="70%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:70.0%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents at end of the period </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">42,349</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="10%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:10.7%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">47,881</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">See accompanying notes.</font></i></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5<a name="PB_5_005951_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\105538\15-6944-1\task7387405\6944-1-fa.htm',USER='105538',CD='May  4 02:58 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate Therapeutics, Inc.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></b><a name="NotesToCondensedConsolidatedFinan_014059"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(Unaudited)</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Organization and Summary of Significant Accounting Policies</font></b></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Organization</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Fate Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) was incorporated in the state of Delaware on April&nbsp;27, 2007 and has its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases. The Company has built a novel platform to program the function and fate of cells <i>ex vivo</i> using pharmacologic modulators, such as small molecules. The Company&#146;s lead product candidate, ProHema&#174;, is an <i>ex vivo</i> programmed hematopoietic cellular therapeutic, which is currently in clinical development for the treatment of hematologic malignancies and rare genetic disorders in patients undergoing hematopoietic stem cell transplantation. The Company is also developing <i>ex vivo</i> programmed hematopoietic and myogenic cellular product candidates using its patent-protected induced pluripotent stem cell technology.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March 31, 2015, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated revenues from its planned principal operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Initial Public Offering</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On October&nbsp;4, 2013, the Company completed its initial public offering (the &#147;IPO&#148;) whereby it sold 7,666,667 shares of common stock at a public offering price of $6.00 per share. Gross proceeds from the offering were $46.0&nbsp;million. After giving effect to underwriting discounts, commissions and other cash costs related to the offering, net proceeds were $40.5&nbsp;million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Use of Estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company&#146;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (&#147;GAAP&#148;). The preparation of the Company&#146;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#146;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#146;s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company&#146;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Principles of Consolidation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Canada, Fate Therapeutics&nbsp;Ltd., incorporated in the United Kingdom, and Destin Therapeutics&nbsp;Inc., incorporated in Canada, which was dissolved in June 2014. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Cash and Cash Equivalents</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Unaudited Interim Financial Information</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and following the requirements of the United States Securities and Exchange Commission (&#147;SEC&#148;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted.&#160; In management&#146;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#146;s financial position and its results of operations and comprehensive loss and its cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company&#146;s financial statements and accompanying notes for the fiscal year ended December 31, 2014, contained in the Company&#146;s Annual Report on Form 10-K for the year ended December 31, 2014 filed by the Company with the SEC on March 12, 2015. The results for the three months ended March 31, 2015 are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6<a name="PB_6_010129_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\psubra\15-6944-1\task7397156\6944-1-fn.htm',USER='105330',CD='May  7 04:56 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Revenue Recognition</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company recognizes revenues when all four of the following criteria are met: (i)&nbsp;persuasive evidence that an agreement exists; (ii)&nbsp;delivery of the products and/or services has occurred; (iii)&nbsp;the selling price is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&#146;s control.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Beginning in 2011, revenue has been allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&#147;VSOE&#148;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&#147;TPE&#148;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&nbsp;the consideration being earned should be commensurate with either the Company&#146;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the Company&#146;s performance to achieve the milestone; (ii)&nbsp;the consideration being earned should relate solely to past performance; (iii)&nbsp;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&nbsp;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&#146;s revenue recognition criteria are recorded as deferred revenue on the Company&#146;s consolidated balance sheets.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Stock-Based Compensation</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7<a name="PB_7_010146_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\psubra\15-6944-1\task7397156\6944-1-fn.htm',USER='105330',CD='May  7 04:56 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition is determined to be probable of achievement or when it has been achieved</font><font size="2" style="font-size:10.0pt;">.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Net Loss per Common Share</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 58,453 shares and 88,043 shares for the three months ended March 31, 2015 and 2014, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents for the periods presented include warrants for the purchase of common stock, and common stock options outstanding under the Company&#146;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#146;s net loss position.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the three months ended March 31, 2015, the Company realized a net loss of $7.9 million. Shares of potentially dilutive securities totaled 3.1 million for the three months ended March 31, 2015, including options to purchase 3.0 million shares of common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For the three months ended March 31, 2014, the Company realized a net loss of $7.0 million. Shares of potentially dilutive securities totaled 2.5 million for the three months ended March 31, 2014, including options to purchase 2.4 million shares of common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Recent Accounting Pronouncements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In August 2014, the Financial Accounting Standards Board (the &#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) 2014-15, which defined management&#146;s responsibility to evaluate whether there is substantial doubt about an entity&#146;s ability to continue as a going concern and to provide related disclosure. ASU 2014-15 defined the term substantial doubt and requires an assessment for a period of one year after the date of the issuance of the financial statements. It requires certain disclosures when substantial doubt is alleviated as a result of consideration of management&#146;s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The guidance becomes effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company does not believe that the adoption of this guidance will have a material impact on its Consolidated Financial Statements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In May 2014, the FASB issued ASU 2014-09, which created a single, principle-based revenue recognition model that will supersede and replace nearly all existing U.S. GAAP revenue recognition guidance. Entities will recognize revenue in a manner that depicts the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. The model provides that entities follow five steps: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue. For public business entities, the guidance becomes effective for annual reporting periods beginning after December 15, 2016, and interim periods therein. The Company is currently evaluating the impact the adoption of this guidance will have on its Consolidated Financial Statements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Asset Acquisition of Verio Therapeutics Inc.</font></b></p>
<p style="margin:0in 0in .0001pt 22.5pt;text-indent:-22.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On April&nbsp;7, 2010, the Company acquired Verio Therapeutics&nbsp;Inc. (&#147;Verio&#148;), a development stage company headquartered in Ottawa, Ontario to gain access to its exclusively licensed intellectual property. In connection with the asset acquisition of Verio, the stockholders of Verio received 900,000 non-voting shares of Fate Canada (the &#147;Exchangeable Shares&#148;) that were initially exchangeable into 138,462 shares of the Company&#146;s common stock and, subject to the validation of certain scientific data and the achievement of certain preclinical, clinical, commercial and financial milestones, were exchangeable for up to 884,605 shares of the Company&#146;s common stock.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">8<a name="PB_8_010224_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='8',FILE='C:\JMS\psubra\15-6944-1\task7397156\6944-1-fn.htm',USER='105330',CD='May  7 04:56 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a result of the Company&#146;s IPO on October&nbsp;4, 2013, 480,763 shares of the Company&#146;s common stock were issued during the fourth quarter of 2013 pursuant to the redemption of the Exchangeable Shares. The total number of shares of the Company&#146;s common stock issued upon the exchange of the Exchangeable Shares as a result of the IPO had increased from 138,462 shares of the Company&#146;s common stock to a total of 480,763 shares of the Company&#146;s common stock based upon the achievement of certain contractual milestones.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the three months ended March 31, 2014, based on the achievement of certain preclinical milestones, an additional 38,463 shares of the Company&#146;s common stock were earned and issued, resulting in a $0.4&nbsp;million charge to research and development expense. The Company may issue an additional 365,379 shares of the Company&#146;s common stock based on the achievement of additional contractual milestones as follows: (i)&nbsp;38,461 shares for the achievement of certain preclinical milestones, (ii)&nbsp;211,538 shares for the achievement of certain clinical milestones and (iii)&nbsp;115,380 shares for the achievement of certain commercialization milestones, such that the maximum aggregate number of shares of the Company&#146;s common stock issuable in connection with the Verio acquisition is 884,605.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">At the date of achievement of a milestone, the fair value of the additional shares is charged to research and development expense and recorded in additional paid-in capital.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Fair Value Measurements</font></b></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates currently available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Level 1: Observable inputs such as quoted prices in active markets;</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</font></p>
<p style="margin:0in 0in .0001pt 46.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#146;s cash equivalents. As of March 31, 2015 and December&nbsp;31, 2014, the carrying amount of cash equivalents was $35.3 million, which approximates fair value and was determined based upon Level 1 inputs. Cash equivalents primarily consisted of money market funds. As of March 31, 2015 and December&nbsp;31, 2014, the Company did not hold any Level 2 or Level 3 financial assets that are recorded at fair value on a recurring basis.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None of the Company&#146;s non-financial assets or liabilities is recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March 31, 2015 and December&nbsp;31, 2014, the Company had no material liabilities measured at fair value on a recurring basis.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Accrued Expenses, Long-Term Debt, Commitments and Contingencies</font></b></p>
<p style="margin:0in 0in .0001pt 24.5pt;text-indent:-24.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Accrued Expenses</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current accrued expenses consist of the following (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="78%" style="border-collapse:collapse;margin-left:.9in;width:78.66%;">
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.84%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.18%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March&nbsp;31,<br>   2015</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.18%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December&nbsp;31,<br>   2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.28%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued payroll and other employee benefits</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.96%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">562</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.96%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,234</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.28%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued clinical trial costs</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">498</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">415</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.28%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued other</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">767</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">611</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.28%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.84%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Accrued expenses</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.96%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,827</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.18%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.96%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,260</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.28%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">9<a name="PB_9_010525_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='9',FILE='C:\JMS\psubra\15-6944-1\task7397156\6944-1-fn.htm',USER='105330',CD='May  7 04:56 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the three months ended March 31, 2015, the Company issued 19,956 shares of its common stock to certain senior executives of the Company as consideration for a portion of their 2014 annual bonuses. All related amounts were accrued for as liabilities as of December 31, 2014. Future senior executive bonus amounts, timing, and method of payment are at the sole discretion of the Board of Directors of the Company. As such, all relevant bonus estimates are accrued for as liabilities as of March 31, 2015.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term accrued expenses consist primarily of accruals for the final payment fees associated with our long-term debt.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Long-Term Debt</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt and unamortized discount balances are as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="77%" style="border-collapse:collapse;margin-left:.95in;width:77.32%;">
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.2%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">March</font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;"><br>    </font></b><b><font size="1" style="font-size:8.0pt;font-weight:bold;">31,&nbsp;2015</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">December<br>   31,2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.2%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,000</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20,000</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Less debt discount, net of current portion</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(167</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(371</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.2%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt, net of discount</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,833</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19,629</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.2%;">
<p style="margin:0in 0in .0001pt 20.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Less current portion of long-term debt</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(3,419</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1,546</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.2%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Long-term debt, net of current portion</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16,414</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18,083</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.2%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of long-term debt</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,419</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,546</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.2%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of debt discount</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(163</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0.375pt 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="15%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.2%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Current portion of long-term debt, net</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,256</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="14%" valign="bottom" style="border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.24%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,546</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.24%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; On July&nbsp;30, 2014, the Company entered into an Amended and Restated Loan and Security Agreement (the &#147;Restated LSA&#148;) with Silicon Valley Bank (the &#147;Bank&#148;), collateralized by substantially all of the Company&#146;s assets, excluding certain intellectual property. The Restated LSA amends and restates the Loan and Security Agreement, dated as of January&nbsp;5, 2009, as amended, by and between the Company and the Bank (the &#147;Loan Agreement&#148;). Pursuant to the Restated LSA, the Bank agreed to make loans to the Company in an aggregate principal amount of up to $20.0&nbsp;million, comprised of (i)&nbsp;a $10.0&nbsp;million term loan, funded at the closing date (the &#147;Term A Loan&#148;) and (ii)&nbsp;subject to the achievement of a specified clinical milestone relating to the Company&#146;s Phase&nbsp;2 clinical trial of ProHema, additional term loans totaling up to $10.0&nbsp;million in the aggregate, which were available until December&nbsp;31, 2014 (each, a &#147;Term B Loan&#148;). On December&nbsp;24, 2014, the Company elected to draw on the full $10.0&nbsp;million under a Term B Loan.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Term A Loan and the Term B Loan mature on January&nbsp;1, 2018 and June&nbsp;1, 2018, respectively and bear interest at a fixed annual rate of 6.94% and 7.07%, respectively. Interest became payable in cash on a monthly basis beginning the first day of each month following the month in which the funding date of each loan occurred. The Company is required to make a monthly payment of interest only during the first twelve months following the funding date of each loan, and thereafter is required to repay the principal and interest under each loan in thirty equal monthly installments based on a thirty-month amortization schedule. The Company is required to make a final payment fee of 7.5%, equaling $0.8&nbsp;million, of the funded amount for each of the Term A Loan and Term B Loan on the respective maturity dates. The final payment fees are accrued as interest expense over the terms of the loans and recorded in long-term accrued expenses.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A portion of the proceeds from the Term A Loan were used to repay loans outstanding under the Loan Agreement and to pay for transaction fees related to the Restated LSA, including a commitment fee of $0.4&nbsp;million paid by the Company to the Bank. Net proceeds from the Term A Loan, after repayment of loans outstanding under the Loan Agreement and transaction fees, were $8.8&nbsp;million. The Company determined that the repayment of the Loan Agreement was a debt extinguishment, and accounted for the Term A Loan at fair value as of the issuance date accordingly.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from the Term B Loan were $10.0&nbsp;million. In connection with the funding of the Term&nbsp;B&nbsp;Loan, the Company issued the Bank and one of its affiliates fully-exercisable warrants to purchase an aggregate of 98,039 shares of the Company&#146;s common stock (the &#147;Warrants&#148;) at an exercise price of $4.08 per share. The Warrants expire in December 2021. The aggregate fair value of the Warrants was determined to be $0.4&nbsp;million using the Black-Scholes option pricing model and was recorded as a debt discount on the Term B Loan and is amortized to interest expense over the term of the Term B Loan using the effective interest method.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company determined the effective interest rates of the Term A Loan and Term B Loan to be 10.3% and 12.0%, respectively. For the three months ended March 31, 2015, the Company recorded $0.6&nbsp;million in aggregate interest expense related to the Term A and Term B Loans.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10<a name="PB_10_010707_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='10',FILE='C:\JMS\psubra\15-6944-1\task7397156\6944-1-fn.htm',USER='105330',CD='May  7 04:56 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warrants to purchase 36,074 shares of the Company&#146;s common stock at a weighted average exercise price of $7.21 per share issued in connection with the Loan Agreement remain outstanding as of March 31, 2015, with 5,305 and 30,769 of such warrants having expiration dates in January 2019 and August 2021, respectively.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Facility Lease</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company leases certain office and laboratory space from a stockholder of the Company under a non-cancelable operating lease. In March 2015, we extended the term of the lease on this facility an additional 15 months through September 2017. The lease is subject to additional charges for common area maintenance and other costs. In connection with the lease, the Company entered into a cash-collateralized irrevocable standby letter of credit in the amount of $0.1 million. As of March 31, 2015, future minimum payments under the operating lease are $2.5 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In January 2015, the Company entered into a sublease for additional laboratory space. The sublease is accounted for as an operating lease and expires in September 2017. Under the sublease, total future minimum payments as of March 31, 2015 are $0.8 million.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.3pt;text-indent:-22.3pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">5.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Stockholders&#146; Equity</font></b></p>
<p style="margin:0in 0in .0001pt 22.3pt;text-indent:-22.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Stock option activity under all equity and stock option plans is summarized as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="86%" style="border-collapse:collapse;margin-left:.5in;width:86.66%;">
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Number&nbsp;of<br>   Options</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Weighted-<br>   Average&nbsp;Price</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at December&nbsp;31, 2014 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,425,969</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.83</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Granted </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">793,152</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.87</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Canceled </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(213,630</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.49</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="top" style="padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exercised </font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(47,862</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0.375pt 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="13%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.56</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="65%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:65.4%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Balance at March 31, 2015 </font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:13.84%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,957,629</font></p>    </td>
<td width="2%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:2.88%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="12%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:12.54%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.03</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="59%" style="border-collapse:collapse;margin-left:1.65in;width:59.32%;">
<tr>
<td width="49%" valign="bottom" style="padding:0in 0in 0in 0in;width:49.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="44%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:44.7%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.6%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="bottom" style="padding:0in 0in 0in 0in;width:49.48%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.6%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="bottom" style="padding:0in 0in 0in 0in;width:49.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:20.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="20%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:20.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.6%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development </font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">304</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:18.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">565</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="bottom" style="padding:0in 0in 0in 0in;width:49.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative </font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.26%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">304</font></p>    </td>
<td width="4%" valign="bottom" style="padding:0in 0in 0in 0in;width:4.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="20%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:20.22%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">306</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:49.48%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.32%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">608</font></p>    </td>
<td width="4%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:4.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="18%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:18.94%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">871</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.6%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March 31, 2015, the outstanding options included 122,780 performance-based options for which the achievement of the performance-based vesting provisions was determined not to be probable. The aggregate grant date fair value of these unvested options at March 31, 2015 was $0.5 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of March 31, 2015, the unrecognized compensation cost related to outstanding options (excluding those with performance-based conditions) was $4.9 million and is expected to be recognized as expense over approximately 3.0 years.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="77%" style="border-collapse:collapse;margin-left:.85in;width:77.32%;">
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="34%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:34.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk-free interest rate</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.6</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.0</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected volatility</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">82.5</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">94.5</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected term (in years)</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.0</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.1</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected dividend yield</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">11<a name="PB_11_011055_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='11',FILE='C:\JMS\psubra\15-6944-1\task7397156\6944-1-fn.htm',USER='105330',CD='May  7 04:56 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the non-employee stock option grants were as follows:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.05pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="77%" style="border-collapse:collapse;margin-left:.85in;width:77.32%;">
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="34%" colspan="3" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:34.26%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="3%" valign="bottom" style="border:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:3.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="bottom" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="15%" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Risk-free interest rate </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.2</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.2</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected volatility </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">87.1</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">94.5</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Remaining contractual term (in years) </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.0</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6.7</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="61%" valign="top" style="padding:0in 0in 0in 0in;width:61.22%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Expected dividend yield </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>
<td width="15%" valign="bottom" style="padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">0.0</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">%</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt 22.3pt;text-indent:-22.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 22.3pt;text-indent:-22.3pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">6.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Subsequent Events</font></b></p>
<p style="margin:0in 0in .0001pt 22.3pt;text-indent:-22.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May 4, 2015, the Company entered into a research collaboration and license agreement (the &#147;Agreement&#148;) with Juno Therapeutics, Inc. (&#147;Juno&#148;) to identify small molecules to program the therapeutic properties of Juno&#146;s genetically-engineered T cell product candidates. Pursuant to the terms of the Agreement, Juno has agreed to pay the Company an upfront payment of $5.0 million and to purchase 1,000,000 shares of the Company&#146;s common stock at $8.00 per share.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the collaboration&#146;s research plan, the Company will be responsible for screening and identifying small molecule modulators of immunological cells, while Juno will be responsible for the development and commercialization of engineered T cell immunotherapies incorporating the Company&#146;s modulators. Juno has agreed to fund all of the Company&#146;s collaboration activities for an exclusive four-year research term beginning on the effective date of the Agreement, with minimum annual payments to the Company for research funding. Juno has the option to extend the exclusive research term for an additional two years, subject to the payment of an extension fee, and the continued funding of all collaboration activities during the extended term, with minimum annual payments to the Company for research funding.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under the Agreement, the Company has granted Juno an exclusive worldwide license to certain of its intellectual property, including its intellectual property arising under the collaboration, to make, use, sell and otherwise exploit genetically-engineered T cell immunotherapies using or incorporating small molecule modulators directed against certain designated tumor-associated antigen targets, subject to the selection of a target by Juno. The Company has retained exclusive rights to such intellectual property, including its intellectual property arising under the collaboration, for all other purposes, including its use outside of those targets selected by Juno.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For each product developed by Juno that incorporates modulators identified through the research collaboration, the Company is eligible to receive approximately $50.0 million in target selection fees and clinical, regulatory and commercial milestones, as well as low single-digit royalties on sales.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">12<a name="PB_12_011204_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='12',FILE='C:\JMS\psubra\15-6944-1\task7397156\6944-1-fn.htm',USER='105330',CD='May  7 04:56 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2.&#160; Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</font></b><a name="Item2_ManagementsDiscussionAndAna_011924"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">The following discussion and analysis should be read in conjunction with our financial statements and accompanying notes included in this Quarterly Report on Form&nbsp;10-Q and the financial statements and accompanying notes thereto for the fiscal year ended December&nbsp;31, 2014 and the related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations, which are contained in our Annual Report on Form&nbsp;10-K filed with the Securities and Exchange Commission on March 12, 2015.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This Quarterly Report on Form&nbsp;10-Q contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). Such forward-looking statements, which represent our intent, belief, or current expectations, involve risks and uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;believe,&#148; &#147;should&#148; and similar expressions. Factors that could cause or contribute to differences in results include, but are not limited to, those set forth under &#147;Risk Factors&#148; under Item&nbsp;1A of Part II below. Except as required by law, we undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases. We have built a novel platform to program the function and fate of cells <i>ex vivo</i> using pharmacologic modulators, such as small molecules. Our lead product candidate, ProHema</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">&#174;</font><font size="2" style="font-size:10.0pt;">, is an <i>ex vivo</i> programmed hematopoietic cellular therapeutic, which is currently in clinical development for the treatment of hematologic malignancies and rare genetic disorders in patients undergoing hematopoietic stem cell transplantation. We are also developing <i>ex vivo</i> programmed hematopoietic and myogenic cellular product candidates using our patent-protected induced pluripotent stem cell technology. We believe that our programmed cellular product candidates have disease-transformative or curative potential across a broad range of orphan indications.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Since our inception in 2007, we have devoted substantially all of our resources to the research and development of our product candidates and cellular programming technology, the creation, licensing and protection of related intellectual property and the provision of general and administrative support for these activities. To date, we have funded our operations primarily through the public sale of common stock, the private placement of preferred stock and convertible notes and through commercial bank debt that included the issuance of warrants.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have never been profitable and have incurred net losses in each year since inception. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur operating losses for at least the next several years. Our net losses may fluctuate significantly from quarter to quarter and year to year. We expect our expenses will increase substantially in connection with our ongoing activities as we:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">conduct clinical trials of our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">continue our research and development efforts;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">manufacture preclinical study and clinical trial materials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">maintain, expand and protect our intellectual property portfolio;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">engage with regulatory authorities for the development of, and seek regulatory approvals for, our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">hire additional clinical, regulatory, quality control and technical personnel to advance our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">hire additional scientific personnel to advance our research and development efforts; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">hire general and administrative personnel to operate as a public company and support our operations.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not expect to generate any revenues from sales of our therapeutics unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, we will seek to fund our operations through public or private equity or debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative effect on our financial condition and ability to develop our product candidates.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">13<a name="PB_13_011404_3020"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='13',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Financial Operations Overview</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We conduct substantially all of our activities through Fate Therapeutics,&nbsp;Inc., a Delaware corporation, at our facilities in San Diego, California. Fate Therapeutics,&nbsp;Inc. owns 100% of the voting shares of Fate Therapeutics (Canada)&nbsp;Inc., or Fate Canada, that were outstanding at March&nbsp;31, 2015 and directs all of its operational activities, which are insignificant. The following information is presented on a consolidated basis to include the accounts of Fate Therapeutics,&nbsp;Inc. and Fate Canada. All intercompany transactions and balances are eliminated in consolidation.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Revenue</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">To date, we have not generated any revenues from therapeutic product sales. Our revenues have been derived from collaboration activities and grant revenues.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Collaboration revenues have been generated exclusively from our collaboration arrangement with Becton, Dickinson and Company, or BD. In September 2010, we entered into a worldwide exclusive license and collaboration agreement with BD for the joint development and worldwide commercialization of certain induced pluripotent stem cell, or iPSC, tools and technologies for use in drug discovery and development. The license and collaboration agreement was assigned by BD to Corning Incorporated in October 2012. In connection with the agreement, we received an upfront, non-refundable license payment, and received research funding for the conduct of joint development activities during the three-year period ended September&nbsp;30, 2013.&#160; We are eligible to receive certain commercialization milestones and royalties on the sale of iPSC reagent products. We do not anticipate generating any significant revenues under the arrangement with BD in the future.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Grant revenue has been generated primarily through research and development grant programs offered by the U.S. government and its agencies. In April 2011, we were awarded a $2.1&nbsp;million grant from the U.S. Army Telemedicine&nbsp;&amp; Advanced Technology Research Center, or TATRC, to identify and develop regenerative medicines for acute sound-induced hearing loss. All funding under the TATRC grant was expended in full as of May 2013.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expenses consist of development costs associated with the research and development of our product candidates and cellular programming technology. These costs are expensed as incurred and include:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">salaries and employee-related costs, including stock-based compensation;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs associated with conducting our preclinical, clinical and regulatory activities, including fees paid to third-party professional consultants and service providers;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs incurred under clinical trial agreements with investigative sites;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs for laboratory supplies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">costs to acquire, develop and manufacture preclinical study and clinical trial materials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">charges associated with the achievement of milestones pursuant to our asset acquisition of Verio Therapeutics&nbsp;Inc., or Verio, that was completed in April 2010; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We plan to increase our current level of research and development expenses for the foreseeable future as we continue the development of our product candidates and cellular programming technology. Our current planned research and development activities over the next twelve months consist primarily of the following:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">14<a name="PB_14_011411_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='14',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">conducting our Phase&nbsp;2 clinical trial of ProHema to examine its safety and its curative potential in adult patients with orphan hematologic malignancies undergoing allogeneic hematopoietic stem cell transplants, or HSCT (the PUMA study);</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">initiating and conducting our Phase&nbsp;1b clinical trial of ProHema to examine its safety and curative potential in pediatric patients with inherited metabolic disorders, or IMDs, including lysosomal storage disorders, or LSDs, undergoing allogeneic HSCT (the PROVIDE study);</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">conducting our Phase&nbsp;1b clinical trial of ProHema to examine its safety and curative potential in pediatric patients with orphan hematologic malignancies undergoing allogeneic HSCT (the PROMPT study); and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">researching the therapeutic potential of our programmed cellular product candidates, including those derived from human induced pluripotent stem cells.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Due to the inherently unpredictable nature of preclinical and clinical development, and given our novel therapeutic approach and the current stage of development of our product candidates, we cannot determine and are unable to estimate with certainty the timelines we will require and the costs we will incur for the development of our product candidates, including ProHema. Clinical and preclinical development timelines and costs, and the potential of development success, can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes our research and development expenses by major programs for the periods indicated (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="71%" style="border-collapse:collapse;margin-left:1.15in;width:71.34%;">
<tr>
<td width="57%" valign="bottom" style="padding:0in 0in 0in 0in;width:57.94%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="37%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:37.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="57%" valign="bottom" style="padding:0in 0in 0in 0in;width:57.94%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.5%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="57%" valign="bottom" style="padding:0in 0in 0in 0in;width:57.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:16.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="57%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:57.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">HSC modulation platform </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,146</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,150</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="57%" valign="bottom" style="padding:0in 0in 0in 0in;width:57.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other preclinical programs and technologies </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">671</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1,587</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="57%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:57.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total direct research and development expenses </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:16.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,817</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;padding:0in 0in 0in 0in;width:16.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3,737</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="57%" valign="bottom" style="padding:0in 0in 0in 0in;width:57.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Unallocated expenses </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">751</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="16%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:16.82%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">785</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="57%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:57.94%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total research and development expenses </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,568</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border:none;border-bottom:double windowtext 2.25pt;padding:0in 0in 0in 0in;width:1.3%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="15%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;border-bottom:double windowtext 2.25pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:15.52%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,522</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;Unallocated expenses consist primarily of facility costs, general equipment and supply costs, depreciation, and other miscellaneous costs, all of which we do not allocate to specific programs as these expenses are deployed across all of our research and development operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for our employees in executive, operational, finance and human resource functions; professional fees for accounting, legal and tax services; costs for obtaining, prosecuting and maintaining our intellectual property; and other costs and fees, including director and officer insurance premiums, to support our operations as a public company. We anticipate that our general and administrative expenses will increase in the future as we increase our research and development activities, maintain compliance with exchange listing and SEC requirements and continue to operate as a public company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Other income (expense) consists primarily of interest income earned on cash and cash equivalents, interest expense on convertible notes and on amounts outstanding under our credit facilities, and debt extinguishments. We anticipate that our interest expense will increase in the future in connection with our term loans outstanding with Silicon Valley Bank.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our management&#146;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">15<a name="PB_15_011546_7056"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='15',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The estimates and judgments involved in the accounting policies as described in Item 7 of our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014 continue to be our critical accounting policies. There were no material changes to our critical accounting policies and estimates during the three months ended March 31, 2015.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See Note 1 to the Condensed Consolidated Financial Statements for information related to recent accounting pronouncements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Results of Operations</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Comparison of the Three Months Ended March&nbsp;31, 2015 and 2014</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The following table summarizes the results of our operations for the three months ended March&nbsp;31, 2015 and 2014 (in thousands):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="83%" style="border-collapse:collapse;margin-left:.5in;width:83.32%;">
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="31%" colspan="5" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:31.82%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Three&nbsp;Months&nbsp;Ended<br>   March&nbsp;31,</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Increase&nbsp;/</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.58%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2015</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.42%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">2014</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:14.4%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">(Decrease)</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.22%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="border:none;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.22%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="46%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Research and development expense </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,568</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.06%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4,522</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.36%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">$</font></p>    </td>
<td width="13%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:13.04%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">46</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="bottom" style="padding:0in 0in 0in 0in;width:46.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">General and administrative expense </font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,756</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2,415</font></p>    </td>
<td width="3%" valign="bottom" style="padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" style="padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">341</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="46%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:46.58%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total other expense, net </font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(557</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.42%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(43</font></p>    </td>
<td width="3%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:3.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">)</font></p>    </td>
<td width="14%" colspan="2" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:14.4%;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">514</font></p>    </td>
<td width="1%" valign="bottom" bgcolor="#CCEEFF" style="background:#CCEEFF;padding:0in 0in 0in 0in;width:1.22%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr height="0">
<td width="290" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="19" style="border:none;"></td>
<td width="8" style="border:none;"></td>
<td width="81" style="border:none;"></td>
<td width="7" style="border:none;"></td>   </tr> </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Research and development expenses.<b>&nbsp;</b></font></i><font size="2" style="font-size:10.0pt;"> Research and development expenses were $4.6 million for the three&nbsp;months ended March 31, 2015, compared to $4.5 million for the three months ended March&nbsp;31, 2014. The difference in research and development expenses primarily includes the following changes:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.3 million increase in third-party professional consultant and service provider expenses relating to the conduct of our PUMA study and the preparation for the commencement of our PROMPT and PROVIDE studies of ProHema; which was offset by a</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.4 million non-cash charge during the three months ended March 31, 2014 related to the achievement of a pre-clinical milestone under our agreement with the former Verio stockholders.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">General and administrative expenses.&nbsp;</font></i><font size="2" style="font-size:10.0pt;">&nbsp;General and administrative expenses were $2.8 million for the three&nbsp;months ended March 31, 2015, compared to $2.4 million for the three months ended March&nbsp;31, 2014.&#160; The increase in general and administrative expenses primarily reflects the following:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.1 million increase in compensation and benefits expense, including employee stock-based compensation expense;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.1 million increase in facility and infrastructure costs; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">$0.1 million increase in corporate registration fees.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Other expense, net.</font></i><font size="2" style="font-size:10.0pt;">&nbsp;&nbsp;Other expense, net was $0.6 million for the three months ended March 31, 2015, compared to $43,000 for the three months ended March&nbsp;31, 2014.&#160; The change in other expense was primarily due to interest expense related to our term loans entered into during 2014 with Silicon Valley Bank.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Liquidity and Capital Resources</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have incurred losses and negative cash flows from operations since inception. As of March 31, 2015, we had an accumulated deficit of $120.3 million and anticipate that we will continue to incur net losses for the foreseeable future.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">16<a name="PB_16_011652_5335"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='16',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Operating Activities</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cash used in operating activities increased $1.1 million from $5.3 million for the three months ended March 31, 2014 to $6.4 million for the three months ended March 31, 2015. The primary driver of operating cash requirements was our net loss for each period. During the three months ended March 31, 2015, we used cash from operating activities of $6.4 million, while our net loss was $7.9 million. The difference was primarily a result of $0.9 million of non-cash charges and deferrals, consisting of $0.6 million of stock-based compensation, $0.2 million of non-cash interest expense related to the final payment fees associated with our long-term debt, and $0.1 million of depreciation expense, and a $0.6 million net change in our operating assets and liabilities.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Investing Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">During the three months ended March 31, 2015 and 2014, investing activities used cash of $0.5 million and $0.4 million, respectively, for the purchase of property and equipment.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Financing Activities</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Financing activities provided cash of $0.1 million for the three months ended March 31, 2015 related to the issuance of common stock. Financing activities used cash of $0.5 million for the three months ended March 31, 2014, primarily related to payments on long-term debt.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;From our inception through March&nbsp;31, 2015 we have funded our consolidated operations primarily through the public sale of common stock, the private placement of preferred stock and convertible notes, commercial bank debt and revenues from collaboration activities and grants. As of March&nbsp;31, 2015, we had cash and cash equivalents of $42.3&nbsp;million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our IPO on October 4, 2013 resulted in net proceeds of $40.5 million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Silicon Valley Bank Debt Facility</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On July&nbsp;30, 2014, we entered into an Amended and Restated Loan and Security Agreement (the &#147;Restated LSA&#148;) with Silicon Valley Bank (the &#147;Bank&#148;), collateralized by substantially all of our assets, excluding certain intellectual property. The Restated LSA amends and restates the Loan and Security Agreement, dated as of January&nbsp;5, 2009, as amended, by and between the Company and the Bank (the &#147;Loan Agreement&#148;). Pursuant to the Restated LSA, the Bank agreed to make loans to us in an aggregate principal amount of up to $20.0&nbsp;million, comprised of (i)&nbsp;a $10.0&nbsp;million term loan, funded at the closing date (the &#147;Term A Loan&#148;) and (ii)&nbsp;subject to the achievement of a specified clinical milestone relating to our Phase&nbsp;2 clinical trial of ProHema, additional term loans totaling up to $10.0&nbsp;million in the aggregate, which were available until December&nbsp;31, 2014 (each, a &#147;Term B Loan&#148;). On December&nbsp;24, 2014, the Company elected to draw $10.0&nbsp;million under the Term B Loan.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Term A Loan and the Term B Loan mature on January&nbsp;1, 2018 and June&nbsp;1, 2018, respectively and bear interest at a fixed annual rate of 6.94% and 7.07%, respectively. Interest became payable in cash on a monthly basis beginning the first day of each month following the month in which the funding date of each loan occurred. The Company is required to make a monthly payment of interest only during the first twelve months following the funding date of each loan, and thereafter is required to repay the principal and interest under each loan in thirty equal monthly installments based on a thirty-month amortization schedule. The Company is required to make a final payment fee of 7.5%, equaling $0.8&nbsp;million, of the funded amount for each of the Term A Loan and Term B Loan on their respective maturity dates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A portion of the proceeds from the Term A Loan were used to repay loans outstanding under the Loan Agreement and to pay for transaction fees related to the Restated LSA, including a commitment fee of $0.4&nbsp;million paid by the Company to the Bank. Net proceeds from the Term A Loan, after repayment of loans outstanding under the Loan Agreement and transaction fees, were $8.8&nbsp;million.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Proceeds from the Term B Loan were $10.0&nbsp;million. In connection with the funding of the Term B Loan, the Company issued the Bank and one of its affiliates fully-exercisable warrants to purchase an aggregate of 98,039 shares of the Company&#146;s common stock (the &#147;Warrants&#148;) at an exercise price of $4.08 per share. The Warrants expire in December 2021. The aggregate fair value of the Warrants was determined to be $0.4&nbsp;million using the Black-Scholes option pricing model. The net proceeds from the Term A and Term B Loans have been used for, and we expect to continue to use net proceeds for, working capital purposes, including the research and development of our product candidates and cellular programming technology.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">17<a name="PB_17_011704_5796"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='17',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Shelf Registration Statement</font></i></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In October 2014, the SEC declared effective a shelf registration filed by us in October 2014. The shelf registration statement allows us to issue certain securities, including shares of our common stock, from time to time for an aggregate offering price of up to $100 million. The specific terms of any offering, if any, under the shelf registration statement would be established at the time of such offering. As of May 7, 2015, we had not sold any shares under this shelf registration statement.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .5in;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Agreement with Juno Therapeutics,&nbsp;Inc.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;4, 2015, the Company entered into a research collaboration and license agreement (the &#147;Agreement&#148;) with Juno Therapeutics,&nbsp;Inc. (&#147;Juno&#148;) to identify small molecule modulators for programming the therapeutic properties of genetically-engineered chimeric antigen receptor (CAR) and T cell receptor (TCR) based cellular immunotherapies. Pursuant to the terms of the Agreement, Juno has agreed to pay the Company an upfront payment of $5.0 million, and to purchase one million shares of the Company&#146;s common stock, at $8.00 per share, for an aggregate purchase price of $8.0 million on May&nbsp;7, 2015.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Operating Capital Requirements</font></i></b></p>
<p style="margin:0in 0in .0001pt 11.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We anticipate that we will continue to incur losses for the foreseeable future, and we expect the losses to increase as we continue the research and development of, and seek regulatory approvals for, our product candidates. Our product candidates have not yet achieved regulatory approval, and we may not be successful in achieving commercialization of our product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We believe our existing cash and cash equivalents as of March 31, 2015 will be sufficient to fund our projected operating requirements for at least the next twelve months. However, we are subject to all the risks and uncertainties incident in the research and development of therapeutic products. For example, the FDA or other regulatory authorities may require us to generate additional data or conduct additional preclinical studies or clinical trials, or may impose other requirements beyond those that we currently anticipate. Additionally, it is possible for a product candidate to show promising results in preclinical studies or in clinical trials, but fail to establish sufficient safety and efficacy data necessary to obtain regulatory approvals. As a result of these and other risks and uncertainties and the probability of success, the duration and the cost of our research and development activities required to advance a product candidate cannot be accurately estimated and are subject to considerable variation. We may encounter difficulties, complications, delays and other unknown factors and unforeseen expenses in the course of our research and development activities, any of which may significantly increase our capital requirements and could adversely affect our liquidity.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We will require additional capital for the research and development of our product candidates, and we may be forced to seek additional funds sooner than expected to pursue our research and development activities. We expect to finance our capital requirements in the foreseeable future through the sale of public or private equity or debt securities. However, additional capital may not be available to us on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the research or development of one or more of our product candidates. If we do raise additional funds through the issuance of additional equity or debt securities, it could result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. Additionally, if we incur indebtedness, we may become subject to financial or other covenants that could adversely restrict, impair or affect our ability to conduct our business, such as requiring us to relinquish rights to certain of our product candidates or technologies or limiting our ability to acquire, sell or license intellectual property rights or incur additional debt. Any of these events could significantly harm our business, operations, financial condition and prospects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our forecast of the period of time through which our existing cash and cash equivalents will be adequate to support our operations is a forward-looking statement and involves significant risks and uncertainties. We have based this forecast on assumptions that may prove to be wrong, and actual results could vary materially from our expectations, which may adversely affect our capital resources and liquidity. We could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the initiation, progress, size, timing, duration, costs and results of preclinical studies and clinical trials for our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the time, cost and outcome of seeking and obtaining regulatory approvals by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than, or evaluate clinical endpoints other than those that we currently expect;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the number and characteristics of product candidates that we pursue;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the extent to which we are required to pay milestone or other payments under our in-license agreements and the timing of such payments;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our need to expand our research and development activities, including our need and ability to hire additional employees;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our need to implement additional infrastructure and internal systems and hire additional employees to operate as a public company;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">18<a name="PB_18_011810_2897"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='18',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the establishment of collaborations and strategic alliances;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the effect of competing technological and market developments; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the cost of establishing sales, distribution, marketing and manufacturing capabilities, and the pricing and reimbursement, for any products for which we may receive regulatory approval.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we cannot continue or expand our research and development operations, or otherwise capitalize on our business opportunities, because we lack sufficient capital, our business, operations, financial condition and prospects could be materially adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Contractual Obligations and Commitments</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In July 2014, we </font><font size="2" style="font-size:10.0pt;">entered into the Restated LSA with the Bank.&#160; Pursuant to the Restated LSA, the Bank agreed to make loans to us in an aggregate principal amount of up to $20.0 million, which we have fully drawn upon. See Note 4 of the Condensed Consolidated Financial Statements for further details.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have no material contractual obligations not fully recorded on our Condensed Consolidated Balance Sheets or fully disclosed in the notes to the financial statements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 3.&#160; Quantitative and Qualitative Disclosures about Market Risk</font></b><a name="Item3_QuantitativeAndQualitativeD_011958"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Interest Rate Risk</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our cash and cash equivalents as of March 31, 2015 consisted of cash and money market mutual funds. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. However, because of the short-term nature of the instruments in our portfolio, a 10% change in market interest rates would not have a material impact on our financial condition and/or results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our outstanding debt bears interest at a fixed rate and therefore has no exposure to changes in interest rates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 4.&#160; Controls and Procedures</font></b><a name="Item4_ControlsAndProcedures_011959"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Disclosure Controls and Procedures</font></i></b></p>
<p style="margin:0in 0in .0001pt 12.2pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2015.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></i></b></p>
<p style="margin:0in 0in .0001pt;text-indent:13.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">There were no changes in our internal control over financial reporting that occurred during our latest fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">19<a name="PB_19_011836_7748"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='19',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PART II. OTHER INFORMATION</font></b><a name="PartIi_OtherInformation_012004"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1.&#160; Legal Proceedings</font></b><a name="Item1_LegalProceedings_012005"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are not a party to any material legal proceedings at this time. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse effect on us because of defense and settlement costs, diversion of management resources and other factors.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 1A.&#160; Risk Factors</font></b><a name="Item1a_RiskFactors_012006"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">You should carefully consider the following risk factors, as well as the other information in this Quarterly Report on Form 10-Q, and in our other public filings. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business.</font></i></p>
<p style="margin:0in 0in .0001pt;text-indent:27.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to the Discovery, Development and Regulation of Our Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to complete the preclinical or clinical development of, or to obtain regulatory approval for, our product candidates, our business would be significantly harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All of our product candidates are currently in research or clinical development, including our lead product candidate, ProHema, which is currently in Phase&nbsp;2 clinical development. We have not completed clinical development of or obtained regulatory approval for any of our product candidates. Only a small percentage of research and development programs ultimately result in commercially successful products, and we cannot assure you that any of our product candidates will demonstrate the safety and efficacy profile necessary to support further preclinical study, clinical development or regulatory approval.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may delay or cancel our ongoing research and development activities for any of our product candidates for a variety of reasons, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">determining that a product candidate is ineffective or causes harmful side effects during preclinical studies or clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">difficulty establishing predictive preclinical models for demonstration of safety and efficacy of a product candidate in one or more potential therapeutic areas for clinical development;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">difficulties in manufacturing a product candidate, including the inability to manufacture a product candidate in a sufficient quantity, suitable form, or in a cost-effective manner, or under processes acceptable to the FDA for marketing approval;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the proprietary rights of third parties, which may preclude us from developing or commercializing a product candidate;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">determining that a product candidate may be uneconomical to develop or commercialize, or may fail to achieve market acceptance or adequate reimbursement;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our inability to secure strategic partners which may be necessary for advancement of a product candidate into clinical development or commercialization; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our prioritization of other product candidates for advancement.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additionally, we will only obtain regulatory approval to market a product candidate if we can demonstrate, to the satisfaction of the FDA or comparable foreign regulatory authorities, in well-designed and conducted clinical trials that the product candidate is manufactured in accordance with applicable regulatory requirements, is safe and effective, and otherwise meets the appropriate standards required for approval for a particular indication. Our ability to obtain regulatory approval of our product candidates depends on, among other things, completion of additional preclinical studies and clinical trials, whether our clinical trials demonstrate statistically significant efficacy with safety profiles that do not potentially outweigh the therapeutic benefit, and whether regulatory agencies agree that the data from our clinical trials and our manufacturing processes are sufficient to support approval. The final </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">20<a name="PB_20_011842_141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='20',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">results of our current and future clinical trials may not meet the FDA&#146;s or other regulatory agencies&#146; requirements to approve a product candidate for marketing, and the regulatory agencies may otherwise determine that our manufacturing processes or facilities are insufficient to support approval. We may need to conduct preclinical studies and clinical trials that we currently do not anticipate. If we fail to complete preclinical or clinical development of, or obtain regulatory approval for, our product candidates, we will not be able to generate any revenues from product sales, which will harm our business, prospects, financial condition and results of operations.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Development of our product candidates will require substantial additional funding, without which we will be unable to complete clinical development of, or obtain regulatory approval for, our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Developing therapeutic products, including conducting preclinical studies and clinical trials of cellular therapeutics, is expensive. Based upon our currently expected level of operating expenditures, we believe that we will be able to fund our operations for at least the next twelve months. However, our resources will likely be insufficient to conduct research and development programs to the full extent currently planned. We will require substantial additional capital to conduct the research and development and clinical and regulatory activities necessary to bring our product candidates to market. Our future capital requirements will depend on many factors, including, but not limited to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the progress, results, timing and costs of our preclinical studies and clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">continued progress in our research and development programs, including the preclinical studies and clinical trials of our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to initiate, and the progress, results, size, timing and costs of, additional future clinical trials of our product candidates that will be necessary to support any application for regulatory approval;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the cost of commercialization activities and arrangements, including the commercial manufacturing of our product candidates; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our ability to establish and maintain strategic arrangements and alliances with third-party collaborators to advance the research, development and commercialization of therapeutic products.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We cannot guarantee that additional capital will be available in sufficient amounts or on terms acceptable to us, if at all. We intend to seek additional funding through the public or private sales of our securities, including equity securities. Any additional equity financings will be dilutive to our stockholders and any additional debt financings may involve operating covenants that restrict our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we cannot raise additional capital or obtain adequate funds, we may be required to curtail significantly our research and clinical programs or may not be able to continue our research or clinical development of our product candidates. Our failure to raise additional capital, or obtain adequate funds, will have a material adverse effect on our business, operating results, prospects, and market price of shares of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Interim results from ongoing clinical trials and results from preclinical studies and earlier clinical trials are not predictive of our ongoing or future clinical trials.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">All of our product candidates are still in an early stage of development, and we cannot be assured that the development of any of our product candidates will ultimately be successful. For example, although an independent data monitoring committee, or iDMC, supported the continuation of our Phase&nbsp;2 PUMA study of ProHema based upon two scheduled interim data reviews, the PUMA study has not been completed and the interim data reviews, which were based upon data from a limited number of subjects who are still under evaluation and subject to ongoing safety surveillance, may not be predictive of safety or efficacy of ProHema in the final analysis of the PUMA study. In addition, although the results of our completed Phase&nbsp;1b ProHema-01 study in adults with hematologic malignancies undergoing double umbilical cord blood transplant demonstrated human proof-of-concept, we may not achieve or duplicate these results in the PUMA study or in planned additional clinical trials of ProHema, including the PROMPT or PROVIDE studies in pediatric patients.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">21<a name="PB_21_011857_7608"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='21',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The results of our ongoing and future clinical trials may differ from interim results or from results achieved in earlier clinical trials or in preclinical studies for a variety of reasons, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">we may not demonstrate the potency and efficacy benefits observed in preclinical studies or earlier clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our efforts to standardize and automate the manufacture of ProHema may adversely affect its safety, purity, potency or efficacy;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the expansion in the number of participating clinical centers, which are independent institutions and are more geographically dispersed, may introduce additional variability and complexity in conducting clinical trials and in evaluating clinical results;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">deviations in the manufacture of ProHema by cell processing facilities at clinical centers participating in clinical trials that we conduct;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">use of our product candidates in pediatric patients may result in side effects or other adverse events not observed in adult patients;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">differences in study design, including differences in conditioning regimens, eligibility criteria, and patient populations;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">safety or adverse events in patients enrolled in current or future clinical trials; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">later-stage trials that enroll a larger number of patients may not produce the same or similar results as earlier trials with fewer patients.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Results from preclinical testing and early clinical trials are not necessarily predictive of the results of later clinical trials, and interim results from any clinical trial do not necessarily predict final results of that trial. Even if our ongoing clinical trials are successful, we will likely need to conduct additional clinical trials, including registrational trials and trials in additional patient populations or under different treatment conditions, before we are able to seek approvals for our product candidates from the FDA and regulatory authorities outside the United States to market and sell these product candidates. Our failure to meet the requirements to support marketing approval for our product candidates in our ongoing and future clinical trials would substantially harm our business and prospects.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may face delays in completing our clinical trials, and we may not be able to complete them at all.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have not completed the clinical trials necessary to support an application for approval to market any of our product candidates. We may experience delays in our ongoing clinical trials, and we do not know whether we will be able to initiate, enroll patients in, or complete, our planned clinical trials on time, if at all. Our current and future clinical trials of our product candidates may be delayed, unsuccessful or terminated as a result of many factors, including factors related to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">difficulties in identifying eligible patients for participation in our clinical trials due to our focus on the development of product candidates for the treatment of rare diseases;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">difficulties enrolling a sufficient number of suitable patients to conduct our clinical trials, including difficulties relating to patients enrolling in studies with agents sponsored by our competitors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">difficulties in achieving study endpoints, demonstrating efficacy and safety, and completing data analysis in clinical trials for any of our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the occurrence of unexpected safety issues or adverse events in any current or subsequent clinical trial of any product candidate;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">securing and maintaining the support of clinical investigators and investigational sites, and obtaining institutional review board, or IRB, approval at each site for the conduct of our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">governmental or regulatory delays, failure to obtain regulatory approval, or uncertainty or changes in regulatory requirements, policy or guidelines;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">22<a name="PB_22_011905_8146"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='22',FILE='C:\JMS\psubra\15-6944-1\task7397187\6944-1-ga.htm',USER='105330',CD='May  7 05:16 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">reaching agreement on acceptable terms with third-party service providers and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different service providers and clinical trial sites;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">failure of clinical trial sites to manufacture certain of our product candidates consistently in accordance with our protocol-specified processes at their cell processing facilities for use in our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">our failure, or the failure of third-party service providers or clinical trial sites, to ensure the proper and timely conduct and analysis of our clinical trials;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">inability to reach agreement on clinical trial design and parameters with regulatory authorities, investigators and IRBs;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">obtaining sufficient quantities of critical reagents and other materials and equipment necessary for the manufacture and processing of any product candidate;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">data monitoring committees recommending suspension, termination or a clinical hold for various reasons, including concerns about patient safety;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the serious, life-threatening diseases of the patients in our clinical trials, who may die or suffer adverse medical events for reasons that may not be related to our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">failure of patients to complete clinical trials due to safety issues, side effects, or other reasons; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">approval of competitive agents that may materially alter the standard of care or otherwise render our product candidates or clinical trial designs obsolete.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we experience delays in the completion of any clinical trial of our product candidates or any of these clinical trials are terminated before completion, the commercial prospects of our product candidates will be harmed. In addition, any delays in commencing or completing our clinical trials will increase our costs, slow down our product candidate development and approval process, and jeopardize our ability to commence product sales and generate revenues. Furthermore, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any of these occurrences would significantly harm our business, prospects, financial condition and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our clinical development of ProHema could be substantially delayed if the FDA requires us to conduct unanticipated studies or trials or imposes other requirements or restrictions.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The FDA may require us to generate additional preclinical, product or clinical data, including data supporting the use of our nutrient rich media, or NRM, formulation, or our reduced volume formulation for pediatric use, as a condition to continuing and completing the PUMA and PROMPT studies, or to initiating and completing the PROVIDE study or any other subsequent clinical trials, of ProHema. Additionally, the FDA may in the future have comments, or impose requirements, on our protocols for conducting the PUMA, PROMPT, or PROVIDE studies, or any other subsequent clinical trials, of ProHema. Any requirements to generate additional data or redesign or modify our protocols, or other additional comments, requirements or impositions by the FDA, may cause delays in the conduct of the PUMA study, the PROMPT study or the PROVIDE study, or other subsequent clinical development activities for ProHema, and could require us to incur additional development costs and resources, seek funding for these increased costs or resources or delay our timeline for, or cease, our clinical development activities for ProHema, or could create uncertainty and additional complexity in our ability to obtain regulatory approval for ProHema.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Further, if the results of our clinical trials are inconclusive, or if there are safety concerns or adverse events associated with our product candidates, we may:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be delayed in obtaining, or unable to obtain, regulatory approval for our product candidates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">be required to amend the protocols for our clinical trials, perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">obtain approval for indications or patient populations that are not as broad as intended or desired;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23<a name="PB_23_012328_7091"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='23',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings or contraindications; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">have regulatory authorities withdraw their approval of the product or impose restrictions on its use.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our plans for clinical development and commercialization of our product candidates could be substantially delayed or restricted if the FDA or other regulatory authorities impose additional requirements on our manufacturing processes or if we are required to change our manufacturing processes to comply with regulatory requirements.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The requirement that ProHema be manufactured in close proximity to transplant centers within a short period of time before transplantation may present unprecedented complexities associated with ensuring consistent manufacture in compliance with regulatory requirements as necessary for marketing approval. The FDA has indicated that we will need to standardize the process for manufacturing ProHema, and that ProHema used in registrational clinical trials must be manufactured in compliance with FDA regulatory requirements. In addition, the FDA may impose additional requirements on our processes for the manufacture of ProHema or our other product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">While ProHema is currently manufactured at clinical cell processing facilities operated by or affiliated with our clinical sites, we may be required to identify alternative processes for the manufacture of ProHema in compliance with applicable regulatory requirements, and in the future we may manufacture ProHema at facilities operated by us, by transplant centers, or by third parties. Any requirements to modify our manufacturing processes, and any delays in, or inability to, establish manufacturing processes acceptable to the FDA could require us to incur additional development costs or result in delays to our clinical development plans, or could create uncertainty and additional complexity in our ability to obtain regulatory approval for ProHema. Any such events could delay or prevent our ability to obtain regulatory approval or commercialize ProHema, which would adversely affect our business, financial condition and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We study our product candidates in patient populations with significant comorbidities that may result in deaths or serious adverse or unacceptable side effects and require us to abandon or limit our clinical development activities.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Patients undergoing treatment with certain of our product candidates, including ProHema, may also receive chemotherapy, radiation, and/or other high dose or myeloablative treatments in the course of treatment of their disease, and may therefore experience side effects or adverse events, including death, that are unrelated to our product candidates. While these side effects or adverse events may be unrelated to our product candidates, they may still affect the success of our clinical studies. The inclusion of critically ill patients in our clinical studies may result in deaths or other adverse medical events due to underlying disease or to other therapies or medications that such patients may be using. Any of these events could prevent us from advancing ProHema or other product candidates through clinical development, and from obtaining regulatory approval, and would impair our ability to commercialize our product candidates. Any inability to advance ProHema or any other product candidate through clinical development would have a material adverse effect on our business, and the value of our common stock would decline.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our planned clinical development activities for ProHema in pediatric patients, including our PROMPT and PROVIDE studies, present additional operational, technical and timeline risks.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Many clinical centers that could potentially participate in our pediatric clinical trials of ProHema are distinct and separate from the centers participating in the PUMA study, and finding a sufficient number of qualified centers that would be interested in participating in our pediatric trials may take additional time. There are fewer eligible patients with hematologic malignancies and rare genetic disorders for our PROMPT and PROVIDE studies because the total number of pediatric patients who undergo allogeneic HSCT for the treatment of such diseases and disorders is lower than it is in adults. This may increase the time to commencement of our planned and future pediatric studies, or may delay or limit our ability to enroll patients in these studies, and any of these events may impair our ability to complete our planned and future pediatric studies, including our PROMPT and PROVIDE studies.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Further, to evaluate ProHema in pediatric patients, we have developed a reduced volume formulation of ProHema for children, due to their smaller size and requirement for smaller infusion volume. Although we have received permission from the FDA to use a formulation of ProHema having a reduced volume for the treatment of pediatric patients in our planned PROMPT and PROVIDE studies, the FDA may require us to generate additional preclinical, product, or clinical data to support the use of any reduced volume formulation of ProHema in these studies prior to or following their commencement, or in any subsequent trials of ProHema, or may impose other restrictions on the use of any reduced volume formulation of ProHema. Any such requirement or imposition may present technical challenges and may cause further delays in the commencement or conduct of our planned pediatric clinical trials. Any delays in, or any inability to conduct, our planned clinical development activities for pediatric patients would have an adverse effect on our business operations.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">24<a name="PB_24_012336_455"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='24',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Because our product candidates are based on novel technologies, it is difficult to predict the applicable regulatory pathway to approval and the time, the cost and our ability to successfully complete clinical development, and to obtain the necessary regulatory and reimbursement approvals required for commercialization, of our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ProHema and other product candidates that we may develop based on our cell programming technology represent novel therapeutics, and we face uncertainties associated with the clinical development, regulatory pathways to approval, and reimbursement required for successful commercialization of these product candidates. The clinical development and regulatory approval of novel product candidates such as ours can be more expensive and take longer than for other more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due a lack of prior experiences on the side of both developers and regulatory agencies. Additionally, due to the uncertainties associated with the clinical development and the regulatory pathways of our product candidates, we may be required to modify or change our clinical development plans or our regulatory pathways for approval. Any such modification or changes could delay or prevent our ability to develop, obtain regulatory approval or commercialize our product candidates, which would adversely affect our business, financial condition and results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cellular therapeutics, and stem cell therapies in particular, represent a relatively new therapeutic area, and the FDA has cautioned consumers about potential safety risks associated with these therapies. To date, there are relatively few approved cellular therapeutics. In addition, there are currently no approved products in any major territory throughout the world with a label designation that supports the use of a product to improve multi-lineage engraftment or survival in patients undergoing HSCT, which makes it difficult to determine the time and cost required to obtain regulatory approvals in the United States or other jurisdictions for ProHema or any other product candidates that we may develop.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Regulatory requirements governing cell therapy products have changed frequently and the FDA or other regulatory bodies may change the requirements for or identify different regulatory pathways for approval for any of our product candidates.&#160; For example, the FDA established the Office of Cellular, Tissue and Gene Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review, and it is possible that new or different bodies may be established or be granted the responsibility for regulating pharmacologically modulated cellular therapeutics such as ours.&#160; In particular, there is uncertainty as to whether the FDA will regulate pharmacologically modulated cellular therapeutics, such as ProHema and other product candidates that we may develop, as biological products (and therefore subject to approval under a biologics license application, or BLA) or as drug products (and therefore subject to approval under a new drug application, or NDA) and to date our discussions with the FDA have not been determinate.&#160; As a result, we may be required to change our regulatory strategy or to modify our applications for regulatory approval, which could delay and impair our ability to complete the clinical development of, and obtain regulatory approval for our product candidates.&#160; Changes in regulatory authorities and advisory groups, or any new requirements or guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory pathways, positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with the FDA and other regulatory authorities, and our products will likely be reviewed by the FDA&#146;s advisory committee. We also must comply with applicable requirements, and if we fail to do so, we may be required to delay or discontinue development of our product candidates. Delays or unexpected costs in obtaining, or the failure to obtain, the regulatory approval necessary to bring a potential product to market could impair our ability to generate sufficient product revenues to maintain our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, qualification testing, post-approval clinical data, labeling and promotional activities for such product, will be subject to continual and additional requirements of the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information, reports, registration and listing requirements, requirements relating to current good manufacturing practices, or cGMP, quality control, quality assurance and corresponding maintenance of records and documents, and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of pharmaceutical and biological products to ensure such products are marketed only for the approved indications and in accordance with the provisions of the approved labeling. Later discovery of previously unknown problems with our products, manufacturing processes, or failure to comply with regulatory requirements, may lead to various adverse conditions, including significant delays in bringing our product candidates to market and or being precluded from manufacturing or selling our product candidates, any of which could significantly harm our business.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">25<a name="PB_25_012344_4141"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='25',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We expect to rely on orphan drug status to develop and commercialize certain of our product candidates, but our orphan drug designations may not confer marketing exclusivity or other expected commercial benefits.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect to rely on orphan drug exclusivity for ProHema and potential future product candidates that we may develop. Orphan drug status confers seven years of marketing exclusivity in the United States under the Federal Food, Drug, and Cosmetic Act, and up to ten years of marketing exclusivity in Europe for a particular product in a specified indication. The FDA has granted orphan designation for ProHema for the enhancement of stem cell engraftment to treat neutropenia, thrombocytopenia, lymphopenia and anemia, and the European Commission has granted orphan designation for ProHema for the treatment of acute myeloid leukemia. While we have been granted these orphan designations, we will not be able to rely on these designations to exclude other companies from manufacturing or selling biological products using the same principal molecular structural features for the same indication beyond these timeframes. Furthermore, any marketing exclusivity in Europe can be reduced from ten years to six years if the initial designation criteria have significantly changed since the market authorization of the orphan product.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For any product candidate for which we have been granted orphan drug designation in a particular indication, it is possible that another company also holding orphan drug designation for the same product candidate will receive marketing approval for the same indication before we do. If that were to happen, our applications for that indication may not be approved until the competing company&#146;s period of exclusivity expires. Even if we are the first to obtain marketing authorization for an orphan drug indication in the United States, there are circumstances under which a competing product may be approved for the same indication during the seven-year period of marketing exclusivity, such as if the later product is shown to be clinically superior to our orphan product, or if the later product is deemed a different product than ours. Further, the seven-year marketing exclusivity would not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation, or for the use of other types of products in the same indications as our orphan product.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be subject to certain regulations, including federal and state healthcare fraud and abuse laws and health information privacy and security laws. Any failure to comply with these regulations could have a material adverse effect on our business and financial condition.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be subject to various federal and state healthcare laws, including, without limitation, fraud and abuse laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws. Additionally, if our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Reliance on Third Parties</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We depend on facilities operated by transplant centers for the manufacture of ProHema under specific conditions. Any failure by these facilities to manufacture ProHema consistently and under the proper conditions may result in delays to our clinical development plans and impair our ability to obtain approval for, or commercialize, ProHema.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ProHema is currently manufactured at clinical cell processing facilities operated by or affiliated with our clinical sites and is required to be manufactured in close proximity to the treatment site on the same day as product administration. The FDA has stated that we will be required to standardize the manufacture of ProHema, including our oversight for facility and raw material and vendor qualification through to final product analytical testing and release. The manufacture of ProHema for use in registrational clinical trials and commercialization will be subject to the requirements of applicable regulatory authorities, including the FDA, and the use of our current manufacturing processes to manufacture ProHema for commercialization may require each of the clinical cell processing facilities at which ProHema is manufactured to comply with cGMP and other regulatory requirements, and be subject&#160; to inspections by the FDA or other applicable regulatory authorities that would be conducted after the submission of a BLA or other marketing application. Although we are responsible for ensuring compliance with applicable regulatory requirements and for overseeing all aspects of product manufacture and release prior to applying for marketing approval, we do not control the activities of these third-party cell processing facilities and are completely dependent on their ability to comply with the FDA&#146;s requirements and to properly execute the protocol for the manufacture of ProHema. In particular, if the FDA requires each of the clinical cell processing facilities to comply with cGMP, there can be no guarantee that they will be able to do so. Because of these manufacturing requirements, if the applicable clinical cell processing facilities are unable to manufacture ProHema in a manner that conforms to our specifications and the FDA&#146;s strict regulatory requirements, we may be required to identify alternative processes or facilities for the</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">26<a name="PB_26_012359_8627"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='26',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">manufacture of ProHema, which may require us to spend significant additional time and resources, and would impair our ability to complete the clinical development of, and to commercialize, ProHema. To comply with applicable regulatory requirements and our protocols for the manufacture of ProHema, the clinical cell processing facility may be required to possess or obtain certain equipment, including but not limited to biosafety cabinets, warming devices, cell washing devices, freezers or other materials, or to modify aspects of its operations, including its physical facility or layout, environmental systems, monitoring systems, quality systems or training procedures. If a clinical cell processing facility is unwilling or unable to comply with these regulatory requirements or with our protocols for the manufacture of ProHema, it will be restricted or prohibited from manufacturing ProHema and making it available for administration to patients. Any failure by these clinical cell processing facilities to properly manufacture ProHema may adversely affect the safety and efficacy profile of ProHema or cause the FDA or other regulatory authorities to impose restrictions or prohibitions on the manufacture and use of ProHema in both the clinical and the commercial setting, which would have an adverse effect on our business.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We depend on third-party suppliers for various components, materials and equipment required for the manufacture of ProHema and do not have supply arrangements for certain of these components.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently rely, and expect to continue to rely, on third-party suppliers for components necessary for the manufacture of ProHema. We have not entered into, and may not be able to enter into, agreements for the supply of certain components. Even if we are able to enter into such agreements, we may be limited to a sole third-party for the supply of certain required components, including FT1050 and components for our NRM formulation. Additionally, to date, we and our clinical cell processing facilities have purchased equipment, materials and disposables, such as automated cell washing devices, automated cell warming units, commercially available media and cell transfer and wash sets, used for the manufacture of ProHema from third parties. We rely on the general commercial availability of these materials, and we do not have any current contractual relationships for the supply of these materials. Accordingly, we may incur delays or increased costs due to any interruption in supply, and we cannot guarantee that we will have an adequate supply of components, equipment, materials and disposables to complete our planned clinical development and commercialization of ProHema.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are required to change suppliers, or modify the components, equipment, materials or disposables used for the manufacture of ProHema, we may be required to change our manufacturing processes or clinical trial protocols or to provide additional data to regulatory authorities in order to use any alternative components, equipment, materials or disposables, any of which could delay, or increase the costs required to complete, our clinical development and commercialization of ProHema. Additionally, any such change or modification may adversely affect the safety, efficacy or potency of ProHema, and could adversely affect our clinical development of ProHema and harm our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face a variety of challenges and uncertainties associated with our dependence on the availability of human umbilical cord blood units, or CBUs, at cord blood banks for the manufacture of ProHema.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CBUs are one of the raw materials for the manufacture of ProHema. The CBUs currently used in the manufacture of ProHema are procured directly by the clinical cell processing facilities from cord blood banks. The availability of CBUs for the manufacture of ProHema depends on a number of regulatory, political, economic and technical factors outside of our control, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">government policies relating to the regulation of CBUs for clinical use;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the availability of government funding for cord blood banks;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">individual cord blood bank policies and practices relating to CBU acquisition and banking;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the pricing of CBUs;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the methods used in searching for and matching CBUs to patients, which involve emerging technology related to current and future CBU parameters that guide the selection of an appropriate CBU for transplantation; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">methods for the procurement and shipment of CBUs and their handling and storage at clinical sites.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">27<a name="PB_27_012419_7906"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='27',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Additionally, we do not have control over the supply, availability, price or types of CBUs that these clinical cell processing facilities use in the manufacture of ProHema. We rely heavily on these third parties to procure CBUs from cord blood banks that are compliant with government regulations and within the current standard of care. In addition, we may identify specific characteristics of CBUs, such as their volume and red blood cell content, which may limit their ability to be used to manufacture ProHema even though these CBUs may otherwise be suitable for use in allogeneic transplant. As a result, the requirement for CBUs to meet our specifications may limit the potential inventory of CBUs eligible for use in the manufacture of ProHema.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In the United States, cord blood banks are required to file&nbsp;a biologics license application, or BLA, and to meet certain continued regulatory requirements, in order to bank and provide CBUs for transplantation. CBUs from a cord blood bank that maintains a BLA are considered to be licensed and have a product label describing their intended use. While the FDA currently allows unlicensed CBUs to be used for transplantation, and we have used both unlicensed and licensed CBUs in the manufacture of ProHema for our clinical trials, the FDA may later prohibit the use of unlicensed CBUs for transplantation or require ProHema to be manufactured using only licensed CBUs. Additionally, although CBUs from foreign cord blood banks, which are generally unlicensed, are currently available in the United States for use in transplantation and we have used CBUs from foreign cord blood banks in our clinical trials, changes in U.S. and foreign regulations may prohibit or limit the future use of foreign CBUs in the United States. Any inability to procure adequate supplies of CBUs will adversely affect our ability to develop and commercialize ProHema.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We currently rely on third parties to support the conduct of our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have relied upon and expect to continue to rely upon third parties for the execution of our clinical trials, and we control only certain aspects of their activities. We are responsible for complying, and we are responsible for ensuring that our third-party service providers comply, with good clinical practices, or GCP, which are regulations and guidelines enforced by the FDA, as well as comparable foreign regulations and guidelines, for all of our product candidates in clinical development. Regulatory authorities enforce these regulations through periodic inspections of trial sponsors, principal investigators and trial sites. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our registrational clinical trials must be conducted with product produced under applicable regulatory requirements.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If third-party service providers do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials and the development of our product candidates may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We rely on third parties for the manufacture of our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We do not independently conduct all aspects of our product manufacturing, and currently rely and expect to continue to rely on third-party manufacturers for the manufacture of any product candidates that we may develop. These third-party manufacturers will be required to comply with applicable FDA regulatory requirements and other applicable laws and regulations. We will have no control over the ability of these third parties to comply with these requirements, or to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any other applicable regulatory authorities do not approve the facilities of these third parties for the manufacture of our product candidates or any products that we may successfully develop, or if it withdraws any such approval, or if our suppliers or contract manufacturers decide they no longer want to supply or manufacture for us, we may need to find alternative manufacturing facilities, in which case we might not be able to identify manufacturers for clinical or commercial supply on acceptable terms, or at all. In addition, we anticipate that the manufacture of our product candidates will be difficult, and it is possible that any third-party manufacturers that we engage may experience delays or technical challenges in such manufacture. Any of these factors would significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, and would adversely affect our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we are unable to protect our intellectual property, other companies could develop products based on our discoveries, which may reduce demand for our products and harm our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our commercial success will depend in part on our ability to obtain and maintain intellectual property protection for our product candidates, the processes used to manufacture them and the methods for using them, in order to prevent third parties from </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">28<a name="PB_28_012440_3736"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='28',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">making, using, selling, offering to sell or importing our product candidates. We own and have exclusive licenses to patent portfolios for our product candidates, although we cannot be certain that our existing patents and patent applications provide adequate protection or that any additional patents will issue to us with claims that provide adequate protection of our other product candidates. Further, we cannot predict the breadth of claims that may be enforced in our patents if we attempt to enforce them or if they are challenged in court or in other proceedings. If we are unable to secure and maintain protection for our product candidates, or if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Others have filed, and in the future are likely to file, patent applications covering products and technologies that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed or in-licensed by us, or that we or our licensors will not be involved in interference, opposition, reexamination, review, reissue, post grant review or invalidity proceedings before U.S. or non-U.S. patent offices.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We also rely upon unpatented trade secrets and improvements, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, through confidentiality agreements with our commercial collaborators, employees and consultants. We also have invention or patent assignment agreements with our employees and some, but not all, of our commercial collaborators and consultants. However, if our employees, commercial collaborators or consultants breach these agreements, we may not have adequate remedies for any such breach, and our trade secrets may otherwise become known or independently discovered by our competitors, which would adversely affect our business position.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We depend on our licensors to prosecute and maintain patents and patent applications that are material to our business. Any failure by our licensors to effectively protect these intellectual property rights could adversely affect our business and operations.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certain rights to our key technologies and product candidates, including intellectual property relating to ProHema and our induced pluripotent stem cell (iPSC) technology, are licensed from third parties. As a licensee of third party intellectual property, we rely on our licensors to file and prosecute patent applications and maintain patents, and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for certain of our licensed patents, patent applications and other intellectual property rights, and we cannot be certain that such activities will result in valid and enforceable patents and other intellectual property rights. Additionally, our licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and we cannot be certain that our licensors will allocate sufficient resources or prioritize enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to comply with our obligations under our license agreements, we could lose rights to our product candidates or key technologies.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We have obtained rights to develop, market and sell some of our product candidates, including ProHema, through intellectual property license agreements with third parties. These license agreements impose various diligence, milestone payment, royalty and other obligations on us. If we fail to comply with our obligations under our license agreements, we could lose some or all of our rights to develop, market and sell products covered by these licenses, and our ability to form collaborations or partnerships may be impaired. In addition, disputes may arise under our license agreements with third parties, which could prevent or impair our ability to maintain our current licensing arrangements on acceptable terms and to develop and commercialize the affected product candidates.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we choose to go to court to stop another party from using the inventions claimed in any patents we obtain, that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced against that third party. These lawsuits are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents. There is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that such other party&#146;s activities do not infringe our rights to such patents. If we were not successful in defending our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">29<a name="PB_29_012456_9621"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='29',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Our competitors may have filed, and may in the future file, patent applications covering products and technologies similar to ours. Any such patent application may have priority over our patent applications, which could further require us to obtain rights from third parties to issued patents covering such products and technologies. We cannot guarantee that the manufacture, use or marketing of ProHema or any other product candidates that we develop will not infringe third-party patents.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">A third party may claim that we are using inventions covered by the third party&#146;s patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling our product candidates. Patent litigation is costly and time consuming. We may not have sufficient resources to address these actions, and such actions could affect our results of operations and divert the attention of managerial and scientific personnel.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If a patent infringement suit were brought against us, we may be forced to stop or delay developing, manufacturing, or selling potential products that are claimed to infringe a third party&#146;s intellectual property, unless that third party grants us rights to use its intellectual property. In such cases, we may be required to obtain licenses to patents or proprietary rights of others in order to continue development, manufacture or sale of our products. If we are unable to obtain a license or develop or obtain non-infringing technology, or if we fail to defend an infringement action successfully, or if we are found to have infringed a valid patent, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates, any of which could harm our business significantly.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade secrets.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we could lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to the Commercialization of Our Product Candidates</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have limited marketing experience and do not have a sales force or distribution capabilities, and if our products are approved, we may be unable to commercialize them successfully.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We currently have limited experience in marketing and selling therapeutic products. If any of our product candidates are approved for marketing, we intend to establish marketing and sales capabilities internally or we may selectively seek to enter into partnerships with other entities to utilize their marketing and distribution capabilities. If we are unable to develop adequate marketing and sales capabilities on our own or effectively partner with third parties, our product revenues will suffer.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The commercial success of our product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payers and others in the medical community.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The commercial success of our products, if approved for marketing, will depend in part on the medical community, patients and third-party payers accepting our product candidates as effective and safe. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our products, if approved for marketing, will depend on a number of factors, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the safety and efficacy of the products, and advantages over alternative treatments;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the labeling of any approved product;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#146;s approved labeling;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the emergence, and timing of market introduction, of competitive products;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">30<a name="PB_30_012504_8715"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='30',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the effectiveness of our marketing strategy; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">sufficient third-party insurance coverage or governmental reimbursement.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Any failure to achieve market acceptance for our product candidates will harm our business, results and financial condition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We expect to face uncertainty regarding the pricing of ProHema and any other product candidates that we may develop. If pricing policies for our product candidates are unfavorable, our commercial success will be impaired.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Due to the targeted indication of HSCT procedures in general and our HSC product candidates in particular, we face significant uncertainty as to the pricing of any such products for which we may receive marketing approval. While we anticipate that pricing for any cellular therapeutic product candidates that we develop will be relatively high due to their anticipated use in a one-time, potentially life-saving procedure with curative intent, the biopharmaceutical industry has recently experienced significant pricing pressures, including in the area of orphan drug products. Additionally, because our target patient populations are relatively small, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If pricing is set at unsatisfactory levels, our ability to successfully market and sell our product candidates will be adversely affected.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new products could limit our product revenues.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford expensive treatments, such as HSCT. There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products by government and third-party payers. In particular, there is no body of established practices and precedents for reimbursement of stem cell products, and it is difficult to predict what the regulatory authority or private payer will decide with respect to reimbursement levels for novel products such as ours. Our products may not qualify for coverage or direct reimbursement and may be subject to limited reimbursement. If reimbursement or insurance coverage is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be sufficient to allow us to establish or maintain pricing to generate income.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, reimbursement agencies in foreign jurisdictions may be more conservative than those in the United States. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts by governmental and third-party payers, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Failure to obtain or maintain adequate reimbursement for any products for which we receive marketing approval will adversely affect our ability to achieve commercial success.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If the market opportunities for our product candidates are smaller than we believe they are, our revenues may be adversely affected and our business may suffer. Because the target patient populations of our product candidates are small, we must be able to successfully identify patients and capture a significant market share to achieve and maintain profitability.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We focus our research and product development on treatments for orphan diseases and rare genetic disorders. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates. These estimates may prove to be incorrect, and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected or may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Additionally, because our target patient populations are small, we will be required to capture a significant market share to achieve and maintain profitability.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31<a name="PB_31_012512_563"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='31',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Business and Industry</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">The success of our product candidates, including ProHema, is substantially dependent on developments within the field of HSCT, some of which are beyond our control.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our product candidates, including ProHema, are designed and are being developed as therapeutic entities for use in HSCT. Any adverse developments in the field of stem cell therapeutics generally, and in the practice of HSCT in particular, will negatively affect our ability to develop and commercialize our product candidates. If the market for HSCT procedures declines or fails to grow at anticipated levels for any reason, or if the need for patients to undergo HSCT procedures is obviated due to the development and commercialization of therapeutics targeting the underlying cause of diseases addressed by HSCT, our business prospects will be significantly harmed.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We face competition from biotechnology and pharmaceutical companies, universities, and other research institutions, and many of our competitors have greater financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations. In particular, there are several companies and institutions developing products that may obviate the need for HSCT, or may be competitive to products in our research pipeline, or may render our product candidates obsolete or noncompetitive. Should one or more of these products be successful, the market for our products may be reduced or eliminated, and we may not achieve commercial success.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We may not be able to retain or attract qualified management, finance, scientific and clinical personnel and consultants due to the intense competition for qualified personnel and consultants among biotechnology, pharmaceutical and other businesses. If we are not able to retain and attract necessary personnel and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we fail to maintain an effective system of disclosure controls and procedures and internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a public company, we are required to comply with the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, and the related rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing and maintaining corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures. Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We cannot assure that we will not have material weaknesses or significant deficiencies in our internal control over financial reporting. If we are unable to successfully remediate any material weakness or significant deficiency in our internal control over financial reporting, or identify any material weaknesses or significant deficiencies that may exist, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, and our stock price may decline materially as a result.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We are party to a loan and security agreement that contains operating and financial covenants that may restrict our business and financing activities.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In July 2014, we entered into an amended and restated loan and security agreement with Silicon Valley Bank, pursuant to which we have been extended term loans in the aggregate principal amount of $20.0&nbsp;million. Borrowings under this loan and security agreement are secured by substantially all of our assets, excluding certain intellectual property rights. The loan and security agreement restricts our ability, among other things, to:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">sell, transfer or otherwise dispose of any of our business or property, subject to limited exceptions;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">make material changes to our business or management;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32<a name="PB_32_012520_9497"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='32',FILE='C:\JMS\108645\15-6944-1\task7397157\6944-1-gc.htm',USER='108645',CD='May  7 05:00 2015' -->


<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">enter into transactions resulting in significant changes to the voting control of our stock;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">make certain changes to our organizational structure;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">consolidate or merge with other entities or acquire other entities;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">incur additional indebtedness or create encumbrances on our assets;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">pay dividends, other than dividends paid solely in shares of our common stock, or make distributions on and, in certain cases, repurchase our stock;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">enter into transactions with our affiliates;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">repay subordinated indebtedness; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">make certain investments.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, we are required under our loan agreement to comply with various operating covenants that may restrict our ability to finance our operations, engage in business activities or expand or fully pursue our business strategies. A breach of any of these covenants could result in a default under the loan and security agreement, which could cause all of the outstanding indebtedness under the facility to become immediately due and payable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If we are unable to generate sufficient cash to repay our debt obligations when they become due and payable, we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively affect our business operations and financial condition.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have entered into a strategic research collaboration and license agreement with Juno Therapeutics,&nbsp;Inc. to pursue the identification and application of small molecule modulators to program certain genetically-engineered T cells.&#160; Our collaboration may be terminated, or may not be successful, due to a number of factors, which could have a material adverse effect on our business and operating results.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are party to a strategic research collaboration and license agreement with Juno Therapeutics,&nbsp;Inc., or Juno, for the identification and application of small molecule modulators for programming the </font><font size="2" style="font-size:10.0pt;">therapeutic properties of </font><font size="2" style="font-size:10.0pt;">genetically-engineered chimeric antigen receptor (CAR) and T cell receptor (TCR) based cellular </font><font size="2" style="font-size:10.0pt;">immunotherapies</font><font size="2" style="font-size:10.0pt;"> directed against certain targets designated by Juno. Under the agreement, Juno has agreed to fund our collaboration research activities for an initial research term ending in May&nbsp;2019, subject to a two-year extension under certain circumstances, and we are eligible to receive target selection fees and clinical, regulatory, and commercial milestones, as well as royalties on sales, should any products using our modulators be developed and commercialized.&#160; Our collaboration with Juno may be terminated, or may not be successful, due to a number of factors.&#160; For example, we may be unable to identify small molecule modulators that are effective in modulating genetically-engineered T cell products, or Juno may elect not to develop any genetically-engineered T cell products incorporating any modulators that are identified through the collaboration.&#160; If the collaboration is unsuccessful for these or other reasons, or is otherwise terminated for any reason, we may not receive all or any of the research program funding, target selection fees, milestone payments or royalties under the agreement. Any of the foregoing could result in a material adverse effect on our business, results of operations and prospects and would likely cause our stock price to decline.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In addition, during the term of our research activities under the agreement, we have agreed to collaborate exclusively with Juno on the research and development of small molecule modulators with respect to T cells that have been genetically-engineered to express chimeric antigen receptors or T cell receptors against certain targets designated by Juno.&#160; Furthermore, during the term of the agreement, we will be unable to conduct, or enable third parties to conduct, research, development and commercialization activities using small molecule modulators to program T cell product candidates that have been genetically-engineered to express chimeric antigen receptors or T cell receptors directed against certain targets selected by Juno.&#160; These restrictions may prevent us from exploiting our small molecule modulators or impair our ability to pursue research, development and commercialization opportunities that we would otherwise deem to be beneficial to our business.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">33<a name="PB_33_012758_3641"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='33',FILE='C:\JMS\C901862\15-6944-1\task7398318\6944-1-ge.htm',USER='C901862',CD='May  7 14:09 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">If we engage in an acquisition, reorganization or business combination, we will incur a variety of risks that could adversely affect our business operations or our stockholders.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">From time to time we have considered, and we will continue to consider in the future, strategic business initiatives intended to further the expansion and development of our business. These initiatives may include acquiring businesses, technologies or products or entering into a business combination with another company. If we pursue such a strategy, we could, among other things:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">issue equity securities that would dilute our current stockholders&#146; percentage ownership;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">incur substantial debt that may place strains on our operations;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">spend substantial operational, financial and management resources to integrate new businesses, technologies and products;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">assume substantial actual or contingent liabilities;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">reprioritize our development programs and even cease development and commercialization of our product candidates; or</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">merge with, or otherwise enter into a business combination with, another company in which our stockholders would receive cash or shares of the other company on terms that certain of our stockholders may not deem desirable.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Although we intend to evaluate and consider acquisitions, reorganizations and business combinations in the future, we have no agreements or understandings with respect to any acquisition, reorganization or business combination at this time.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by participants in clinical trials, consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates. We carry product liability insurance and we believe our product liability insurance coverage is sufficient in light of our current clinical programs. In addition, if and when we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain insurance coverage for any approved products on commercially reasonable terms or in sufficient amounts to protect us against losses due to liability.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. In addition, under some of our agreements with clinical trial sites, we are required to indemnify the sites and their personnel against product liability and other claims. A successful product liability claim or series of claims brought against us or any third parties whom we are required to indemnify could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for a variety of reasons. Such events, whether or not resulting from our product candidates, could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively affect or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our development and commercialization efforts, delay our regulatory approval process, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We use hazardous chemicals, biological materials and infectious agents in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our research and development and manufacturing processes involve the controlled use of hazardous materials, including chemicals, biological materials and infectious disease agents. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed our insurance coverage and our total assets.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">34<a name="PB_34_012840_5250"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='34',FILE='C:\JMS\C901862\15-6944-1\task7398318\6944-1-ge.htm',USER='C901862',CD='May  7 14:09 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA or foreign regulators, provide accurate information to the FDA or foreign regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee and independent contractor misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. If any actions alleging such conduct are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant effect on our business, including the imposition of significant fines or other sanctions.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Risks Related to Our Financial Condition and the Ownership of Our Common Stock</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have a limited operating history, have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are a clinical-stage biopharmaceutical discovery and development company, formed in 2007, with a limited operating history. We have not yet obtained regulatory approval for any product candidates or generated any revenues from therapeutic product sales. Since inception, we have incurred significant net losses in each year and as of March&nbsp;31, 2015 we had an accumulated deficit of approximately $120.3 million. We expect to continue to incur losses for the foreseeable future as we continue to fund our ongoing and planned clinical trials of ProHema and our other ongoing and planned research and development activities. We also expect to incur significant operating and capital expenditures as we continue our development of, and seek regulatory approval for, our product candidates, in-license or acquire new product development opportunities, implement additional infrastructure and internal systems and hire additional scientific, clinical, and marketing personnel. We anticipate that our net losses for the next several years could be significant as we conduct our planned operations.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Because of the numerous risks and uncertainties associated with pharmaceutical and biological product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. In addition, our expenses could increase if we are required by the FDA, or comparable foreign regulatory authorities, to perform studies or trials in addition to those currently expected, or if there are any delays in completing our clinical trials, preclinical studies or the research and development of any of our product candidates. The amount of our future net losses will depend, in part, on the rate of increase in our expenses, our ability to generate revenues and our ability to raise additional capital. These net losses have had, and will continue to have, an adverse effect on our stockholders&#146; equity and working capital.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our stock price is subject to fluctuation based on a variety of factors.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The market price of shares of our common stock could be subject to wide fluctuations as a result of many risks listed in this section, and others beyond our control, including:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the results of our clinical trials and preclinical studies, and the results of clinical trials and preclinical studies by others;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">developments related to the FDA or to regulations applicable to stem cell therapeutics generally or our product candidates in particular, including but not limited to regulatory pathways and clinical trial requirements for approvals;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">developments related to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">additions or departures of key management or scientific personnel;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">actual or anticipated changes in our research and development activities and our business prospects, including in relation to our competitors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">developments of technological innovations or new therapeutic products by us or others in the field of stem cell therapeutics or immunotherapeutics;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">announcements or expectations of additional equity or debt financing efforts;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">35<a name="PB_35_012846_7672"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='35',FILE='C:\JMS\C901862\15-6944-1\task7398318\6944-1-ge.htm',USER='C901862',CD='May  7 14:09 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">sales of our common stock by us, including pursuant to the terms of our stock purchase agreement with Juno Therapeutics,&nbsp;Inc., or by our insiders or our other stockholders;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">comments by securities analysts;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">fluctuations in our operating results; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">general economic and market conditions.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock. In addition, the stock market in general, and The NASDAQ Global Market and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our principal stockholders exercise significant control over our company.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As of May&nbsp;5, 2015, our executive officers, directors and entities affiliated with our five percent stockholders beneficially own, in the aggregate, shares representing approximately 75% of our outstanding voting stock. Although we are not aware of any voting arrangements in place among these stockholders, if these stockholders were to choose to act together, as a result of their stock ownership, they would be able to influence our management and affairs and control all matters submitted to our stockholders for approval, including the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership may have the effect of delaying or preventing a change in control of our company or affecting the liquidity and volatility of our common stock, and might affect the market price of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We expect that significant additional capital will be needed in the future to continue our planned operations, and we may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding and other collaborations, strategic alliances and licensing arrangements. These financing activities may have an adverse effect on our stockholders&#146; rights, the market price of our common stock and on our operations, and may require us to relinquish rights to some of our technologies, intellectual property or product candidates, issue additional equity or debt securities, or otherwise agree to terms unfavorable to us. We have an effective shelf registration statement on file with the SEC that provides for the sale of up to $100&nbsp;million in the aggregate of shares of our common stock, preferred stock, debt securities, warrants and/or units by us. Any such sale or issuance of securities may result in dilution to our stockholders and may cause the market price of our stock to decline, and new investors could gain rights superior to our existing stockholders. In addition, in July&nbsp;2014, we entered into an amended and restated loan and security agreement with Silicon Valley Bank, which imposes restrictive covenants on our operations. Any future debt financings may impose additional restrictive covenants or otherwise adversely affect the holdings or the rights of our stockholders, and any additional equity financings will be dilutive to our stockholders. Furthermore, additional equity or debt financing might not be available to us on reasonable terms, if at all.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">We have broad discretion over the use of our cash and cash equivalents and may not use them effectively.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our management has broad discretion to use our cash and cash equivalents, and any additional funds that we may raise, to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use to fund operations, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Provisions of Delaware law or our charter documents could delay or prevent an acquisition of our company, and could make it more difficult for you to change management.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions may also prevent or delay </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">36<a name="PB_36_012911_536"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='36',FILE='C:\JMS\C901862\15-6944-1\task7398318\6944-1-ge.htm',USER='C901862',CD='May  7 14:09 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">attempts by stockholders to replace or remove our current management or members of our board of directors. These provisions include:</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">a classified board of directors with limitations on the removal of directors;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">advance notice requirements for stockholder proposals and nominations;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the inability of stockholders to act by written consent or to call special meetings;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the ability of our board of directors to make, alter or repeal our amended and restated bylaws; and</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">the authority of our board of directors to issue preferred stock with such terms as our board of directors may determine.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">As a result, these provisions could limit the price that investors are willing to pay in the future for shares of our common stock. These provisions might also discourage a potential acquisition proposal or tender offer, even if the acquisition proposal or tender offer is at a premium over the then-current market price for our common stock.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards may be subject to limitation and may result in increased future tax liability to us.</font></i></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Generally, a change of more than 50% in the ownership of a corporation&#146;s stock, by value, over a three-year period constitutes an ownership change for U.S. federal income tax purposes. An ownership change may limit a company&#146;s ability to use its net operating loss carryforwards attributable to the period prior to such change. We have not performed a detailed analysis to determine whether an ownership change under Section&nbsp;382 of the Internal Revenue Code has occurred after each of our previous private placements of preferred stock or after the issuance of shares of common stock in connection with our IPO. In the event we have undergone an ownership change under Section&nbsp;382, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may become subject to limitations, which could potentially result in increased future tax liability to us.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">37<a name="PB_37_012928_5926"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='37',FILE='C:\JMS\C901862\15-6944-1\task7398318\6944-1-ge.htm',USER='C901862',CD='May  7 14:09 2015' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Unregistered Sales of Equity Securities and Use of Proceeds</font></b><a name="Item2_UnregisteredSalesOfEquitySe_013005"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt .75in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 3.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Defaults Upon Senior Securities</font></b><a name="Item3_DefaultsUponSeniorSecuritie_013006"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 4.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Mine Safety Disclosure</font></b><a name="Item4_MineSafetyDisclosure_013007"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Not applicable.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Other Information</font></b><a name="Item5_OtherInformation_013009"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">None.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 6.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Exhibits</font></b><a name="Item6_Exhibits_013010"></a></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">See Exhibit&nbsp;Index.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">38<a name="PB_38_012936_4688"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='38',FILE='C:\JMS\C901862\15-6944-1\task7398318\6944-1-ge.htm',USER='C901862',CD='May  7 14:09 2015' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b><a name="Signatures_013159"></a></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.66%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Fate   Therapeutics,&nbsp;Inc.</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: May&nbsp;7, 2015</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Christian Weyer</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian   Weyer</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal   Executive Officer)</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ J.   Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">J.   Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer and Chief Operating Officer</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.34%;">
<p style="margin:0in 0in .0001pt 10.0pt;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="5%" valign="top" style="padding:0in 0in 0in 0in;width:5.26%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.4%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal   Financial and Accounting Officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">39<a name="PB_39_013151_2983"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='39',FILE='C:\JMS\105538\15-6944-1\task7387405\6944-1-jc.htm',USER='105538',CD='May  4 01:32 2015' -->


<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="#TableOfContents" title="Click to go to Table of Contents">Table of Contents</a></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Index to Exhibits</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="12%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>   Number</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="85%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:85.52%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description&nbsp;of&nbsp;Document</font></b></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>
<td width="85%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended   and Restated Certificate of Incorporation (filed as Exhibit&nbsp;3.2 to the   registrant&#146;s Registration Statement on Form&nbsp;S-1/A (File   No.&nbsp;333-190608) filed with the SEC on August&nbsp;29, 2013 and   incorporated herein by reference).</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended   and Restated Bylaws (filed as Exhibit&nbsp;3.4 to the registrant&#146;s   Registration Statement on Form&nbsp;S-1/A (File No.&nbsp;333-190608) filed   with the SEC on August&nbsp;29, 2013 and incorporated herein by reference).</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Specimen   Common Stock Certificate (filed as Exhibit&nbsp;4.1 to the registrant&#146;s   Registration Statement on Form&nbsp;S-1/A (File No.&nbsp;333-190608) filed   with the SEC on August&nbsp;29, 2013 and incorporated herein by reference).</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.1*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Amended   and Restated Senior Executive Incentive Bonus Plan, adopted by the   Registrant&#146;s Board of Directors on January&nbsp;5, 2015 (filed as   Exhibit&nbsp;10.1 to the Registrant&#146;s Current Report on Form&nbsp;8-K filed   with the SEC on January&nbsp;7, 2015 and incorporated herein by reference).</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">10.2*</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Form&nbsp;of   Unrestricted Stock Award Agreement under the Registrant&#146;s 2013 Stock Option   and Incentive Plan (filed as Exhibit&nbsp;10.2 to the Registrant&#146;s Current Report   on Form&nbsp;8-K filed with the SEC on January&nbsp;7, 2015 and incorporated   herein by reference).</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Executive Officer pursuant to Rules&nbsp;13a-14 and 15-d-14   promulgated pursuant to the Securities Exchange Act of 1934, as amended, as   adopted pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">31.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Financial Officer pursuant to Rules&nbsp;13a-14 and 15-d-14   promulgated pursuant to the Securities Exchange Act of 1934, as amended, as   adopted pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.1</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Executive Officer pursuant to 18 U.S.C. Section&nbsp;1350, as   adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">32.2</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certification   of Principal Financial Officer pursuant to 18 U.S.C. Section&nbsp;1350, as   adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.INS</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Instance Document</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.SCH</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Schema Document</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.CAL</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Calculation Linkbase Document</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.DEF</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Definition Linkbase Document</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.LAB</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Label Linkbase Document</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.34%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">101.PRE</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.14%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="85%" valign="top" style="padding:0in 0in 0in 0in;width:85.52%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">XBRL   Taxonomy Extension Presentation Linkbase Document</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin-left:.4pt;">
<div style="margin-left:.45pt;">
<div style="margin:0in 0in .0001pt .9pt;text-indent:-.05pt;"><hr size="1" width="25%" noshade color="black" align="left"></div>
</div>
</div>
<p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">* Indicates a management contract or any compensatory plan, contract or arrangement.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">40<a name="PB_40_013259_6228"></a></font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='40',FILE='C:\JMS\105538\15-6944-1\task7387405\6944-1-je.htm',USER='105538',CD='May  4 01:33 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a15-6944_1ex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PURSUANT TO RULE 13a-14(a)&nbsp;AND 15d-14(a)&nbsp;OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, Christian Weyer, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1. I have reviewed this quarterly report on Form&nbsp;10-Q of Fate Therapeutics,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b. Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c. Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May 7, 2015</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Christian Weyer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian   Weyer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal   Executive Officer)</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105538\15-6944-1\task7387405\6944-1-ma.htm',USER='105538',CD='May  4 02:51 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a15-6944_1ex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;31.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">PURSUANT TO RULE 13a-14(a)&nbsp;AND 15d-14(a)&nbsp;OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION&nbsp;302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">I, J. Scott Wolchko, certify that:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1. I have reviewed this quarterly report on Form&nbsp;10-Q of Fate Therapeutics,&nbsp;Inc.;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4. The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) for the registrant and have:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b. Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">c. Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions):</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:   May&nbsp;7, 2015</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ J.   Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">J.   Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer and Chief Operating Officer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Principal   Financial Officer)</font></p>    </td>   </tr>  </table>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105538\15-6944-1\task7387405\6944-1-mc.htm',USER='105538',CD='May  4 02:52 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a15-6944_1ex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.1</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&nbsp;1350,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AS ADOPTED PURSUANT TO</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the quarterly report of Fate Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) on Form&nbsp;10-Q for the period ended March&nbsp;31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;),&nbsp;I, Christian Weyer, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: May&nbsp;7, 2015</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/   Christian Weyer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Christian   Weyer</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">President   and Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section&nbsp;1350 and is not being filed as part of the Report or as a separate disclosure document.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105538\15-6944-1\task7387405\6944-1-me.htm',USER='105538',CD='May  4 02:00 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a15-6944_1ex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>


<html>
<head>

  </head>
<body lang="EN-US">
<div>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit&nbsp;32.2</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION&nbsp;1350,</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AS ADOPTED PURSUANT TO</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">SECTION&nbsp;906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In connection with the quarterly report of Fate Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) on Form&nbsp;10-Q for the period ended March&nbsp;31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;),&nbsp;I, J. Scott Wolchko, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
<p style="margin:0in 0in .0001pt;text-indent:23.1pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(1)&nbsp;The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(2)&nbsp;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p>
<p style="margin:0in 0in .0001pt;text-indent:47.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: May&nbsp;7, 2015</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ J.   Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">J.   Scott Wolchko</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief   Financial Officer and Chief Operating Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section&nbsp;1350 and is not being filed as part of the Report or as a separate disclosure document.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105538\15-6944-1\task7387405\6944-1-mg.htm',USER='105538',CD='May  4 02:01 2015' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>fate-20150331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2015 9:51:27 AM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:fate="http://www.fatetherapeutics.com/20150331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="fate-20150331.xsd" />
  <!--Context Section-->
  <context id="As_Of_10_4_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <instant>2013-10-04</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember_us-gaap_VestingAxis_fate_VestingBasedOnPerformanceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">fate:VestingBasedOnPerformanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:NonEmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:NonEmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_7_30_2014_To_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermALoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermALoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-30</startDate>
      <endDate>2014-07-30</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_LeaseArrangementTypeAxis_fate_SubleaseLeaseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">fate:SubleaseLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_LeaseArrangementTypeAxis_fate_OperatingLeaseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">fate:OperatingLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermALoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermALoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermBLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-07-30</instant>
    </period>
  </context>
  <context id="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-07-30</instant>
    </period>
  </context>
  <context id="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanTranche1Member_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermBLoanTranche1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-07-30</instant>
    </period>
  </context>
  <context id="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermBLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-07-30</instant>
    </period>
  </context>
  <context id="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-07-30</instant>
    </period>
  </context>
  <context id="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermALoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermALoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-07-30</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermBLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <instant>2014-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember_us-gaap_VestingAxis_fate_VestingBasedOnPerformanceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fate:EmployeeAndNonEmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">fate:VestingBasedOnPerformanceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_5_4_2015_To_5_4_2015_us-gaap_CounterpartyNameAxis_fate_JunoTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fate_CollaborationAndLicenseAgreementTermsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fate:JunoTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fate:CollaborationAndLicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-05-04</startDate>
      <endDate>2015-05-04</endDate>
    </period>
  </context>
  <context id="Duration_3_1_2015_To_3_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <startDate>2015-03-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_4_6_2010_To_4_7_2010_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2010-04-06</startDate>
      <endDate>2010-04-07</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2014_To_3_31_2014_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermBLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_LongtermDebtTypeAxis_fate_TermALoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermALoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_7_30_2014_To_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-07-30</startDate>
      <endDate>2014-07-30</endDate>
    </period>
  </context>
  <context id="Duration_10_3_2013_To_10_4_2013">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <startDate>2013-10-03</startDate>
      <endDate>2013-10-04</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_fate_WarrantsExpirationPeriodAxis_fate_WarrantsExpirationPeriodJanuary2019Member_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="fate:WarrantsExpirationPeriodAxis">fate:WarrantsExpirationPeriodJanuary2019Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_fate_WarrantsExpirationPeriodAxis_fate_WarrantsExpirationPeriodAugust2021Member_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="fate:WarrantsExpirationPeriodAxis">fate:WarrantsExpirationPeriodAugust2021Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fate:AmendedAndRestatedLoanAndSecurityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">fate:TermBLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fate:VerioTherapeuticsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_5_4_2015_us-gaap_CounterpartyNameAxis_fate_JunoTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fate_CollaborationAndLicenseAgreementTermsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">fate:JunoTherapeuticsIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">fate:CollaborationAndLicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-05-04</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2014">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="As_Of_5_5_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <instant>2015-05-05</instant>
    </period>
  </context>
  <context id="Duration_1_1_2015_To_3_31_2015">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001434316</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-03-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit14">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2015_To_3_31_2015">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2015_To_3_31_2015">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2015_To_3_31_2015">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2015_To_3_31_2015">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2015_To_3_31_2015">2015-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2015_To_3_31_2015">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2015_To_3_31_2015">0001434316</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_5_5_2015" unitRef="Unit1" decimals="INF">20683345</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2015_To_3_31_2015">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2015_To_3_31_2015">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2015_To_3_31_2015">FATE THERAPEUTICS INC</dei:EntityRegistrantName>
  <fate:AccruedClinicalTrialCostsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">415000</fate:AccruedClinicalTrialCostsCurrent>
  <fate:AccruedClinicalTrialCostsCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">498000</fate:AccruedClinicalTrialCostsCurrent>
  <fate:AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;4.&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Accrued Expenses, Long-Term Debt, Commitments and Contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Accrued Expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Current accrued expenses consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 78.00%;margin-left:64.8pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accrued payroll and other employee benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;562&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,234&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accrued clinical trial costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;498&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;415&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;767&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;611&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accrued expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,827&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,260&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;During the three months ended March 31, 2015, the Company issued 19,956 shares of its common stock to certain senior executives of the Company as consideration for a portion of their 2014 annual bonuses. All related amounts were accrued for as liabilities as of December 31, 2014. Future senior executive bonus amounts, timing, and method of payment are at the sole discretion of the Board of Directors of the Company. As such, all relevant bonus estimates are accrued for as liabilities as of March 31, 2015.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Long-term accrued expenses consist primarily of accruals for the final payment fees associated with our long-term debt.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Long-Term Debt&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Long-term debt and unamortized discount balances are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:68.4pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Less debt discount, net of current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(167
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(371
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Long-term debt, net of discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,833
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,629
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Less current portion of long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,419
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,546
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Long-term debt, net of current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,414
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,083
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,419
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,546
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Current portion of debt discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(163
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Current portion of long-term debt, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,256
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,546
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On July&amp;nbsp;30, 2014, the Company entered into an Amended and Restated Loan and Security Agreement (the &amp;#x201C;Restated LSA&amp;#x201D;) with Silicon Valley Bank (the &amp;#x201C;Bank&amp;#x201D;), collateralized by substantially all of the Company&amp;#x2019;s assets, excluding certain intellectual property. The Restated LSA amends and restates the Loan and Security Agreement, dated as of January&amp;nbsp;5, 2009, as amended, by and between the Company and the Bank (the &amp;#x201C;Loan Agreement&amp;#x201D;). Pursuant to the Restated LSA, the Bank agreed to make loans to the Company in an aggregate principal amount of up to $20.0&amp;nbsp;million, comprised of (i)&amp;nbsp;a $10.0&amp;nbsp;million term loan, funded at the closing date (the &amp;#x201C;Term A Loan&amp;#x201D;) and (ii)&amp;nbsp;subject to the achievement of a specified clinical milestone relating to the Company&amp;#x2019;s Phase&amp;nbsp;2 clinical trial of ProHema, additional term loans totaling up to $10.0&amp;nbsp;million in the aggregate, which were available until December&amp;nbsp;31, 2014 (each, a &amp;#x201C;Term B Loan&amp;#x201D;). On December&amp;nbsp;24, 2014, the Company elected to draw on the full $10.0&amp;nbsp;million under a Term B Loan.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Term A Loan and the Term B Loan mature on January&amp;nbsp;1, 2018 and June&amp;nbsp;1, 2018, respectively and bear interest at a fixed annual rate of 6.94% and 7.07%, respectively. Interest became payable in cash on a monthly basis beginning the first day of each month following the month in which the funding date of each loan occurred. The Company is required to make a monthly payment of interest only during the first twelve months following the funding date of each loan, and thereafter is required to repay the principal and interest under each loan in thirty equal monthly installments based on a thirty-month amortization schedule. The Company is required to make a final payment fee of 7.5%, equaling $0.8&amp;nbsp;million, of the funded amount for each of the Term A Loan and Term B Loan on the respective maturity dates. The final payment fees are accrued as interest expense over the terms of the loans and recorded in long-term accrued expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;A portion of the proceeds from the Term A Loan were used to repay loans outstanding under the Loan Agreement and to pay for transaction fees related to the Restated LSA, including a commitment fee of $0.4&amp;nbsp;million paid by the Company to the Bank. Net proceeds from the Term A Loan, after repayment of loans outstanding under the Loan Agreement and transaction fees, were $8.8&amp;nbsp;million. The Company determined that the repayment of the Loan Agreement was a debt extinguishment, and accounted for the Term A Loan at fair value as of the issuance date accordingly.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Proceeds from the Term B Loan were $10.0&amp;nbsp;million. In connection with the funding of the Term&amp;nbsp;B&amp;nbsp;Loan, the Company issued the Bank and one of its affiliates fully-exercisable warrants to purchase an aggregate of 98,039 shares of the Company&amp;#x2019;s common stock (the &amp;#x201C;Warrants&amp;#x201D;) at an exercise price of $4.08 per share. The Warrants expire in December 2021. The aggregate fair value of the Warrants was determined to be $0.4&amp;nbsp;million using the Black-Scholes option pricing model and was recorded as a debt discount on the Term B Loan and is amortized to interest expense over the term of the Term B Loan using the effective interest method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company determined the effective interest rates of the Term A Loan and Term B Loan to be 10.3% and 12.0%, respectively. For the three months ended March 31, 2015, the Company recorded $0.6&amp;nbsp;million in aggregate interest expense related to the Term A and Term B Loans.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Warrants to purchase 36,074 shares of the Company&amp;#x2019;s common stock at a weighted average exercise price of $7.21 per share issued in connection with the Loan Agreement remain outstanding as of March 31, 2015, with 5,305 and 30,769 of such warrants having expiration dates in January 2019 and August 2021, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Facility Lease&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company leases certain office and laboratory space from a stockholder of the Company under a non-cancelable operating lease. In March 2015, we extended the term of the lease on this facility an additional 15 months through September 2017. The lease is subject to additional charges for common area maintenance and other costs. In connection with the lease, the Company entered into a cash-collateralized irrevocable standby letter of credit in the amount of $0.1 million. As of March 31, 2015, future minimum payments under the operating lease are $2.5 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In January 2015, the Company entered into a sublease for additional laboratory space. The sublease is accounted for as an operating lease and expires in September 2017. Under the sublease, total future minimum payments as of March 31, 2015 are $0.8 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</fate:AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock>
  <fate:AmountReceivableForProductDevelopment contextRef="As_Of_5_4_2015_us-gaap_CounterpartyNameAxis_fate_JunoTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fate_CollaborationAndLicenseAgreementTermsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">50000000</fate:AmountReceivableForProductDevelopment>
  <fate:AssetAcquisitionTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.5pt;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;2.&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 16pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Asset Acquisition of Verio Therapeutics Inc.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.5pt;text-indent: -22.5pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On April&amp;nbsp;7, 2010, the Company acquired Verio Therapeutics&amp;nbsp;Inc. (&amp;#x201C;Verio&amp;#x201D;), a development stage company headquartered in Ottawa, Ontario to gain access to its exclusively licensed intellectual property. In connection with the asset acquisition of Verio, the stockholders of Verio received 900,000 non-voting shares of Fate Canada (the &amp;#x201C;Exchangeable Shares&amp;#x201D;) that were initially exchangeable into 138,462 shares of the Company&amp;#x2019;s common stock and, subject to the validation of certain scientific data and the achievement of certain preclinical, clinical, commercial and financial milestones, were exchangeable for up to 884,605 shares of the Company&amp;#x2019;s common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;As a result of the Company&amp;#x2019;s IPO on October&amp;nbsp;4, 2013, 480,763 shares of the Company&amp;#x2019;s common stock were issued during the fourth quarter of 2013 pursuant to the redemption of the Exchangeable Shares. The total number of shares of the Company&amp;#x2019;s common stock issued upon the exchange of the Exchangeable Shares as a result of the IPO had increased from 138,462 shares of the Company&amp;#x2019;s common stock to a total of 480,763 shares of the Company&amp;#x2019;s common stock based upon the achievement of certain contractual milestones.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;During the three months ended March 31, 2014, based on the achievement of certain preclinical milestones, an additional 38,463 shares of the Company&amp;#x2019;s common stock were earned and issued, resulting in a $0.4&amp;nbsp;million charge to research and development expense. The Company may issue an additional 365,379 shares of the Company&amp;#x2019;s common stock based on the achievement of additional contractual milestones as follows: (i)&amp;nbsp;38,461 shares for the achievement of certain preclinical milestones, (ii)&amp;nbsp;211,538 shares for the achievement of certain clinical milestones and (iii)&amp;nbsp;115,380 shares for the achievement of certain commercialization milestones, such that the maximum aggregate number of shares of the Company&amp;#x2019;s common stock issuable in connection with the Verio acquisition is 884,605.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;At the date of achievement of a milestone, the fair value of the additional shares is charged to research and development expense and recorded in additional paid-in capital.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</fate:AssetAcquisitionTextBlock>
  <fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember" unitRef="Unit1" decimals="INF">365379</fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones>
  <fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember" unitRef="Unit1" decimals="INF">211538</fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones>
  <fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember" unitRef="Unit1" decimals="INF">115380</fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones>
  <fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember" unitRef="Unit1" decimals="INF">38461</fate:BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones>
  <fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="INF">36074</fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion>
  <fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember" unitRef="Unit1" decimals="INF">98039</fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion>
  <fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion contextRef="Duration_1_1_2015_To_3_31_2015_fate_WarrantsExpirationPeriodAxis_fate_WarrantsExpirationPeriodAugust2021Member_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="INF">30769</fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion>
  <fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion contextRef="Duration_1_1_2015_To_3_31_2015_fate_WarrantsExpirationPeriodAxis_fate_WarrantsExpirationPeriodJanuary2019Member_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="INF">5305</fate:ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion>
  <fate:CommonStockIssuableUponRedemptionOfExchangeableShares contextRef="Duration_10_3_2013_To_10_4_2013" unitRef="Unit1" decimals="INF">480763</fate:CommonStockIssuableUponRedemptionOfExchangeableShares>
  <fate:DebtInstrumentDiscountCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">163000</fate:DebtInstrumentDiscountCurrent>
  <fate:DebtInstrumentDiscountNonCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">371000</fate:DebtInstrumentDiscountNonCurrent>
  <fate:DebtInstrumentDiscountNonCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">167000</fate:DebtInstrumentDiscountNonCurrent>
  <fate:DebtInstrumentTermForPaymentOfInterest contextRef="Duration_7_30_2014_To_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">P12M</fate:DebtInstrumentTermForPaymentOfInterest>
  <fate:DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest contextRef="Duration_7_30_2014_To_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">P30M</fate:DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest>
  <fate:DebtInstrumentUnusedBorrowingCapacityFeePercentage contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_LongtermDebtTypeAxis_fate_TermALoanMember" unitRef="Unit13" decimals="INF">0.103</fate:DebtInstrumentUnusedBorrowingCapacityFeePercentage>
  <fate:DebtInstrumentUnusedBorrowingCapacityFeePercentage contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember" unitRef="Unit13" decimals="INF">0.12</fate:DebtInstrumentUnusedBorrowingCapacityFeePercentage>
  <fate:DeemedEarnedCommonStockYetToBeIssued contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember" unitRef="Unit1" decimals="INF">38463</fate:DeemedEarnedCommonStockYetToBeIssued>
  <fate:ExchangeableStockIssuedDuringPeriodSharesAcquisitions contextRef="Duration_4_6_2010_To_4_7_2010_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember" unitRef="Unit1" decimals="INF">900000</fate:ExchangeableStockIssuedDuringPeriodSharesAcquisitions>
  <fate:ExchangeableStockIssuedDuringPeriodSharesAcquisitions contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit1" decimals="INF">884605</fate:ExchangeableStockIssuedDuringPeriodSharesAcquisitions>
  <fate:InitialFairValueAndAdjustmentOfExchangeableShares contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">375000</fate:InitialFairValueAndAdjustmentOfExchangeableShares>
  <fate:InitialPublicOfferingPolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Initial Public Offering&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On October&amp;nbsp;4, 2013, the Company completed its initial public offering (the &amp;#x201C;IPO&amp;#x201D;) whereby it sold 7,666,667 shares of common stock at a public offering price of $6.00 per share. Gross proceeds from the offering were $46.0&amp;nbsp;million. After giving effect to underwriting discounts, commissions and other cash costs related to the offering, net proceeds were $40.5&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</fate:InitialPublicOfferingPolicyTextBlock>
  <fate:LongTermDebtGrossCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">1546000</fate:LongTermDebtGrossCurrent>
  <fate:LongTermDebtGrossCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">3419000</fate:LongTermDebtGrossCurrent>
  <fate:NetProceedsFromIssuanceInitialPublicOffering contextRef="Duration_10_3_2013_To_10_4_2013" unitRef="Unit12" decimals="-5">40500000</fate:NetProceedsFromIssuanceInitialPublicOffering>
  <fate:OperatingLeaseExtendedTerm contextRef="Duration_3_1_2015_To_3_31_2015">P15M</fate:OperatingLeaseExtendedTerm>
  <fate:RepurchaseLiabilityForUnvestedEquityAwardsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">45000</fate:RepurchaseLiabilityForUnvestedEquityAwardsCurrent>
  <fate:RepurchaseLiabilityForUnvestedEquityAwardsCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">33000</fate:RepurchaseLiabilityForUnvestedEquityAwardsCurrent>
  <fate:ResearchTerm contextRef="Duration_5_4_2015_To_5_4_2015_us-gaap_CounterpartyNameAxis_fate_JunoTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fate_CollaborationAndLicenseAgreementTermsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">P4Y</fate:ResearchTerm>
  <fate:ResearchTermExtension contextRef="Duration_5_4_2015_To_5_4_2015_us-gaap_CounterpartyNameAxis_fate_JunoTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fate_CollaborationAndLicenseAgreementTermsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">P2Y</fate:ResearchTermExtension>
  <fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember_us-gaap_VestingAxis_fate_VestingBasedOnPerformanceMember" unitRef="Unit12" decimals="-5">500000</fate:ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue>
  <fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit1" decimals="INF">88043</fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding>
  <fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit1" decimals="INF">58453</fate:SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding>
  <fate:UpfrontPaymentReceivable contextRef="As_Of_5_4_2015_us-gaap_CounterpartyNameAxis_fate_JunoTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fate_CollaborationAndLicenseAgreementTermsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="-5">5000000</fate:UpfrontPaymentReceivable>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">149000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">312000</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">645000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">1271000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">2260000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">1827000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">1234000</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">562000</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">140711000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">141503000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">871000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">306000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">565000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">608000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="Unit12" decimals="-3">304000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="Unit12" decimals="-3">304000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">8000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">44000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:Assets contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">51204000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">44490000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">49872000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">42792000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="As_Of_3_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember" unitRef="Unit12" decimals="-3">0</us-gaap:AssetsFairValueDisclosureNonrecurring>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Duration_4_6_2010_To_4_7_2010_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember" unitRef="Unit1" decimals="INF">138462</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit1" decimals="INF">884605</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2013" unitRef="Unit12" decimals="-3">54036000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2014" unitRef="Unit12" decimals="-3">47881000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">49101000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">42349000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-5">35300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="As_Of_3_31_2015_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-5">35300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-6155000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-6752000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2015_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit14" decimals="2">7.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2015_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit14" decimals="2">4.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_12_31_2014" unitRef="Unit12" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="As_Of_3_31_2015" unitRef="Unit12" />
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_3_31_2015" unitRef="Unit14" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_3_31_2015" unitRef="Unit1" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">20569399</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_3_31_2015" unitRef="Unit1" decimals="INF">20637217</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_5_4_2015_us-gaap_CounterpartyNameAxis_fate_JunoTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fate_CollaborationAndLicenseAgreementTermsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit1" decimals="INF">1000000</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">20569399</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_3_31_2015" unitRef="Unit1" decimals="INF">20637217</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">21000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">21000</us-gaap:CommonStockValue>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Principles of Consolidation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Canada, Fate Therapeutics&amp;nbsp;Ltd., incorporated in the United Kingdom, and Destin Therapeutics&amp;nbsp;Inc., incorporated in Canada, which was dissolved in June 2014. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">20000000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentCarryingAmount contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">20000000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermALoanMember" unitRef="Unit12" decimals="-5">10000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="-5">20000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember_us-gaap_RangeAxis_us-gaap_MaximumMember" unitRef="Unit12" decimals="-5">10000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanTranche1Member_us-gaap_RangeAxis_us-gaap_MinimumMember" unitRef="Unit12" decimals="-5">10000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFeeAmount contextRef="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember" unitRef="Unit12" decimals="-5">400000</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermALoanMember" unitRef="Unit13" decimals="INF">0.0694</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember" unitRef="Unit13" decimals="INF">0.0707</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_3_31_2015_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermALoanMember" unitRef="Unit13" decimals="INF">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DeferredRentCreditCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">85000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">26000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">51000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">100000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">123000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">128000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;5.&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 16pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Stockholders&amp;#x2019; Equity&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Stock option activity under all equity and stock option plans is summarized as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Average&amp;nbsp;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:65.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Balance at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,425,969
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.83
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:65.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;793,152
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:65.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Canceled &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(213,630
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.49
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:65.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(47,862
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.56
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Balance at March 31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,957,629
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.03
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 59.00%;margin-left:118.8pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:44.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;304&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;565&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;General and administrative &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;304&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;306&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;608&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;871&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;As of March 31, 2015, the outstanding options included 122,780 performance-based options for which the achievement of the performance-based vesting provisions was determined not to be probable. The aggregate grant date fair value of these unvested options at March 31, 2015 was $0.5 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;As of March 31, 2015, the unrecognized compensation cost related to outstanding options (excluding those with performance-based conditions) was $4.9 million and is expected to be recognized as expense over approximately 3.0 years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:61.2pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.6&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;82.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;94.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.1&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the non-employee stock option grants were as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23.05pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:61.2pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Risk-free interest rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.2&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.2&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected volatility &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;87.1&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;94.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Remaining contractual term (in years) &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected dividend yield &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit14" decimals="2">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit14" decimals="2">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Net Loss per Common Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 58,453 shares and 88,043 shares for the three months ended March 31, 2015 and 2014, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents for the periods presented include warrants for the purchase of common stock, and common stock options outstanding under the Company&amp;#x2019;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&amp;#x2019;s net loss position.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;For the three months ended March 31, 2015, the Company realized a net loss of $7.9 million. Shares of potentially dilutive securities totaled 3.1 million for the three months ended March 31, 2015, including options to purchase 3.0 million shares of common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;For the three months ended March 31, 2014, the Company realized a net loss of $7.0 million. Shares of potentially dilutive securities totaled 2.5 million for the three months ended March 31, 2014, including options to purchase 2.4 million shares of common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit12" decimals="-5">4900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-5">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;3.&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Fair Value Measurements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates currently available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Level 1: Observable inputs such as quoted prices in active markets;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Financial assets measured at fair value on a recurring basis consist of the Company&amp;#x2019;s cash equivalents. As of March 31, 2015 and December&amp;nbsp;31, 2014, the carrying amount of cash equivalents was $35.3 million, which approximates fair value and was determined based upon Level 1 inputs. Cash equivalents primarily consisted of money market funds. As of March 31, 2015 and December&amp;nbsp;31, 2014, the Company did not hold any Level 2 or Level 3 financial assets that are recorded at fair value on a recurring basis.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;None of the Company&amp;#x2019;s non-financial assets or liabilities is recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;As of March 31, 2015 and December&amp;nbsp;31, 2014, the Company had no material liabilities measured at fair value on a recurring basis.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-5">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-5">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="As_Of_12_31_2014_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-5">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="As_Of_3_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="Unit12" decimals="-5">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">2415000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">2756000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">43000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">269000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-304000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-303000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit1" decimals="-5">2400000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit1" decimals="-5">3000000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <us-gaap:InterestExpense contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">43000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">558000</us-gaap:InterestExpense>
  <us-gaap:InterestExpenseDebt contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember" unitRef="Unit12" decimals="-5">600000</us-gaap:InterestExpenseDebt>
  <us-gaap:InvestmentIncomeInterest contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">1000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:LettersOfCreditOutstandingAmount contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-5">100000</us-gaap:LettersOfCreditOutstandingAmount>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">51204000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">44490000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">4581000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">6413000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LineOfCreditFacilityCommitmentFeeAmount contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember" unitRef="Unit12" decimals="-5">800000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
  <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember" unitRef="Unit13" decimals="INF">0.075</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
  <us-gaap:LongTermDebt contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">19629000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebt contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">19833000</us-gaap:LongTermDebt>
  <us-gaap:LongTermDebtCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">1546000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">3256000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">18083000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">16414000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-502000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">75000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-398000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-452000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-5255000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-6375000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-6980000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-7881000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In August 2014, the Financial Accounting Standards Board (the &amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2014-15, which defined management&amp;#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern and to provide related disclosure. ASU 2014-15 defined the term substantial doubt and requires an assessment for a period of one year after the date of the issuance of the financial statements. It requires certain disclosures when substantial doubt is alleviated as a result of consideration of management&amp;#x2019;s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The guidance becomes effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company does not believe that the adoption of this guidance will have a material impact on its Consolidated Financial Statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, which created a single, principle-based revenue recognition model that will supersede and replace nearly all existing U.S. GAAP revenue recognition guidance. Entities will recognize revenue in a manner that depicts the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. The model provides that entities follow five steps: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue. For public business entities, the guidance becomes effective for annual reporting periods beginning after December 15, 2016, and interim periods therein. The Company is currently evaluating the impact the adoption of this guidance will have on its Consolidated Financial Statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonfinancialLiabilitiesFairValueDisclosure contextRef="As_Of_3_31_2015_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember" unitRef="Unit12" decimals="-5">0</us-gaap:NonfinancialLiabilitiesFairValueDisclosure>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">6937000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">7324000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-6937000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-7324000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_3_31_2015_us-gaap_LeaseArrangementTypeAxis_fate_OperatingLeaseMember" unitRef="Unit12" decimals="-5">2500000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="As_Of_3_31_2015_us-gaap_LeaseArrangementTypeAxis_fate_SubleaseLeaseMember" unitRef="Unit12" decimals="-5">800000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;1.&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Organization and Summary of Significant Accounting Policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Organization&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Fate Therapeutics,&amp;nbsp;Inc. (the &amp;#x201C;Company&amp;#x201D;) was incorporated in the state of Delaware on April&amp;nbsp;27, 2007 and has its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases. The Company has built a novel platform to program the function and fate of cells &lt;/font&gt;&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;ex vivo&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; using pharmacologic modulators, such as small molecules. The Company&amp;#x2019;s lead product candidate, ProHema&amp;#xAE;, is an &lt;/font&gt;&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;ex vivo&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; programmed hematopoietic cellular therapeutic, which is currently in clinical development for the treatment of hematologic malignancies and rare genetic disorders in patients undergoing hematopoietic stem cell transplantation. The Company is also developing &lt;/font&gt;&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;ex vivo&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; programmed hematopoietic and myogenic cellular product candidates using its patent-protected induced pluripotent stem cell technology.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;As of March 31, 2015, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated revenues from its planned principal operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Initial Public Offering&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On October&amp;nbsp;4, 2013, the Company completed its initial public offering (the &amp;#x201C;IPO&amp;#x201D;) whereby it sold 7,666,667 shares of common stock at a public offering price of $6.00 per share. Gross proceeds from the offering were $46.0&amp;nbsp;million. After giving effect to underwriting discounts, commissions and other cash costs related to the offering, net proceeds were $40.5&amp;nbsp;million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company&amp;#x2019;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (&amp;#x201C;GAAP&amp;#x201D;). The preparation of the Company&amp;#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&amp;#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&amp;#x2019;s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company&amp;#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Principles of Consolidation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Canada, Fate Therapeutics&amp;nbsp;Ltd., incorporated in the United Kingdom, and Destin Therapeutics&amp;nbsp;Inc., incorporated in Canada, which was dissolved in June 2014. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Cash and Cash Equivalents&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Unaudited Interim Financial Information&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and following the requirements of the United States Securities and Exchange Commission (&amp;#x201C;SEC&amp;#x201D;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted.&amp;nbsp;&amp;nbsp;In management&amp;#x2019;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&amp;#x2019;s financial position and its results of operations and comprehensive loss and its cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company&amp;#x2019;s &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;financial statements and accompanying notes for the fiscal year ended December 31, 2014, contained in the Company&amp;#x2019;s Annual Report on Form 10-K for the year ended December 31, 2014 filed by the Company with the SEC on March 12, 2015. &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;The results for the three months ended March 31, 2015 are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company recognizes revenues when all four of the following criteria are met: (i)&amp;nbsp;persuasive evidence that an agreement exists; (ii)&amp;nbsp;delivery of the products and/or services has occurred; (iii)&amp;nbsp;the selling price is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&amp;#x2019;s control.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Beginning in 2011, revenue has been allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&amp;#x201C;VSOE&amp;#x201D;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&amp;#x201C;TPE&amp;#x201D;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&amp;nbsp;the consideration being earned should be commensurate with either the Company&amp;#x2019;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the Company&amp;#x2019;s performance to achieve the milestone; (ii)&amp;nbsp;the consideration being earned should relate solely to past performance; (iii)&amp;nbsp;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&amp;nbsp;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&amp;#x2019;s revenue recognition criteria are recorded as deferred revenue on the Company&amp;#x2019;s consolidated balance sheets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition is determined to be probable of achievement or when it has been achieved.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Net Loss per Common Share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 58,453 shares and 88,043 shares for the three months ended March 31, 2015 and 2014, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents for the periods presented include warrants for the purchase of common stock, and common stock options outstanding under the Company&amp;#x2019;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&amp;#x2019;s net loss position.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;For the three months ended March 31, 2015, the Company realized a net loss of $7.9 million. Shares of potentially dilutive securities totaled 3.1 million for the three months ended March 31, 2015, including options to purchase 3.0 million shares of common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;For the three months ended March 31, 2014, the Company realized a net loss of $7.0 million. Shares of potentially dilutive securities totaled 2.5 million for the three months ended March 31, 2014, including options to purchase 2.4 million shares of common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Recent Accounting Pronouncements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In August 2014, the Financial Accounting Standards Board (the &amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2014-15, which defined management&amp;#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&amp;#x2019;s ability to continue as a going concern and to provide related disclosure. ASU 2014-15 defined the term substantial doubt and requires an assessment for a period of one year after the date of the issuance of the financial statements. It requires certain disclosures when substantial doubt is alleviated as a result of consideration of management&amp;#x2019;s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The guidance becomes effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company does not believe that the adoption of this guidance will have a material impact on its Consolidated Financial Statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;In May 2014, the FASB issued ASU 2014-09, which created a single, principle-based revenue recognition model that will supersede and replace nearly all existing U.S. GAAP revenue recognition guidance. Entities will recognize revenue in a manner that depicts the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. The model provides that entities follow five steps: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue. For public business entities, the guidance becomes effective for annual reporting periods beginning after December 15, 2016, and interim periods therein. The Company is currently evaluating the impact the adoption of this guidance will have on its Consolidated Financial Statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">611000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">767000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">10000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">32000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-43000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">-557000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:PaidInKindInterest contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">10000</us-gaap:PaidInKindInterest>
  <us-gaap:PaidInKindInterest contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">164000</us-gaap:PaidInKindInterest>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">398000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">452000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2014" unitRef="Unit14" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_3_31_2015" unitRef="Unit14" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_3_31_2015" unitRef="Unit1" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_3_31_2015" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2014" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_3_31_2015" unitRef="Unit1" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2014" unitRef="Unit12" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_3_31_2015" unitRef="Unit12" />
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">771000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">443000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Duration_10_3_2013_To_10_4_2013" unitRef="Unit12" decimals="-5">46000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">-2000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">75000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="Duration_7_30_2014_To_7_30_2014_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermALoanMember" unitRef="Unit12" decimals="-5">8800000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_DebtInstrumentAxis_fate_AmendedAndRestatedLoanAndSecurityAgreementMember_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember" unitRef="Unit12" decimals="-5">10000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">1200000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">1544000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RepaymentsOfLongTermDebt contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">500000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">4522000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_BusinessAcquisitionAxis_fate_VerioTherapeuticsIncMember" unitRef="Unit12" decimals="-5">400000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">4568000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">122000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">122000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">-112392000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">-120273000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionMilestoneMethodFactors contextRef="Duration_1_1_2015_To_3_31_2015">(i)&#xA0;persuasive evidence that an agreement exists; (ii)&#xA0;delivery of the products and/or services has occurred; (iii)&#xA0;the selling price is fixed or determinable; and (iv)&#xA0;collectability is reasonably assured.</us-gaap:RevenueRecognitionMilestoneMethodFactors>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company recognizes revenues when all four of the following criteria are met: (i)&amp;nbsp;persuasive evidence that an agreement exists; (ii)&amp;nbsp;delivery of the products and/or services has occurred; (iii)&amp;nbsp;the selling price is fixed or determinable; and (iv)&amp;nbsp;collectability is reasonably assured.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&amp;#x2019;s control.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Beginning in 2011, revenue has been allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&amp;#x201C;VSOE&amp;#x201D;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&amp;#x201C;TPE&amp;#x201D;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&amp;nbsp;the consideration being earned should be commensurate with either the Company&amp;#x2019;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the Company&amp;#x2019;s performance to achieve the milestone; (ii)&amp;nbsp;the consideration being earned should relate solely to past performance; (iii)&amp;nbsp;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&amp;nbsp;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&amp;#x2019;s revenue recognition criteria are recorded as deferred revenue on the Company&amp;#x2019;s consolidated balance sheets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Current accrued expenses consist of the following (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 78.00%;margin-left:64.8pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December&amp;nbsp;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accrued payroll and other employee benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;562&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,234&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accrued clinical trial costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;498&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;415&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accrued other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;767&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;611&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.84%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Accrued expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,827&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.18%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,260&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Long-term debt and unamortized discount balances are as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:68.4pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,&amp;nbsp;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;31,2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;20,000
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Less debt discount, net of current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(167
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(371
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Long-term debt, net of discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,833
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;19,629
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Less current portion of long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(3,419
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(1,546
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Long-term debt, net of current portion&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;16,414
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;18,083
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,419
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,546
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Current portion of debt discount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(163
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.20%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Current portion of long-term debt, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3,256
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1,546
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.24%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 59.00%;margin-left:118.8pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:44.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Research and development &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;304&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;565&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;General and administrative &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;304&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;306&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:49.48%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;608&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;871&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-indent:23.05pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:61.2pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Risk-free interest rate &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.2&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.2&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected volatility &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;87.1&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;94.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Remaining contractual term (in years) &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.7&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected dividend yield &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:61.2pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Three&amp;nbsp;Months&amp;nbsp;Ended&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.6&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;82.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;94.5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected term (in years)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;6.1&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:61.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.22%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;0.0&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-indent:23pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Number&amp;nbsp;of&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Weighted-&lt;/font&gt;&lt;br /&gt;&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Average&amp;nbsp;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:65.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Balance at December&amp;nbsp;31, 2014 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,425,969
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;3.83
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:65.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Granted &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;793,152
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.87
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:65.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Canceled &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(213,630
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;5.49
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:65.40%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Exercised &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;(47,862
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;1.56
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:65.40%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;Balance at March 31, 2015 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2,957,629
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;4.03
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">871000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">608000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="3">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit1" decimals="INF">213630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit1" decimals="INF">793152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit1" decimals="INF">2425969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit1" decimals="INF">2957629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember_us-gaap_VestingAxis_fate_VestingBasedOnPerformanceMember" unitRef="Unit1" decimals="INF">122780</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2014_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit14" decimals="2">3.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit14" decimals="2">4.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2014_To_3_31_2014_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_NonEmployeeStockOptionMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit14" decimals="2">1.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit14" decimals="2">5.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit14" decimals="2">4.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Stock-Based Compensation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition is determined to be probable of achievement or when it has been achieved&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharePrice contextRef="As_Of_10_4_2013" unitRef="Unit14" decimals="2">6.00</us-gaap:SharePrice>
  <us-gaap:SharesIssuedPricePerShare contextRef="As_Of_5_4_2015_us-gaap_CounterpartyNameAxis_fate_JunoTherapeuticsIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_fate_CollaborationAndLicenseAgreementTermsMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit14" decimals="2">8.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2014" unitRef="Unit12" decimals="-3">28340000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2015" unitRef="Unit12" decimals="-3">21251000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit1" decimals="INF">19956</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_10_3_2013_To_10_4_2013" unitRef="Unit1" decimals="INF">7666667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_1_1_2015_To_3_31_2015_us-gaap_AwardTypeAxis_fate_EmployeeAndNonEmployeeStockOptionMember" unitRef="Unit1" decimals="INF">47862</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StraightLineRent contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit12" decimals="-3">9000</us-gaap:StraightLineRent>
  <us-gaap:StraightLineRent contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit12" decimals="-3">10000</us-gaap:StraightLineRent>
  <us-gaap:SubsequentEventsTextBlock contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;6.&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 16pt 0pt 0pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:3pt;"&gt;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Subsequent Events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On May 4, 2015, the Company entered into a research collaboration and license agreement (the &amp;#x201C;Agreement&amp;#x201D;) with Juno Therapeutics, Inc. (&amp;#x201C;Juno&amp;#x201D;) to identify small molecules to program the therapeutic properties of Juno&amp;#x2019;s genetically-engineered T cell product candidates. Pursuant to the terms of the Agreement, Juno has agreed to pay the Company an upfront payment of $5.0 million and to purchase 1,000,000 shares of the Company&amp;#x2019;s common stock at $8.00 per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Pursuant to the collaboration&amp;#x2019;s research plan, the Company will be responsible for screening and identifying small molecule modulators of immunological cells, while Juno will be responsible for the development and commercialization of engineered T cell immunotherapies incorporating the Company&amp;#x2019;s modulators. Juno has agreed to fund all of the Company&amp;#x2019;s collaboration activities for an exclusive four-year research term beginning on the effective date of the Agreement, with minimum annual payments to the Company for research funding. Juno has the option to extend the exclusive research term for an additional two years, subject to the payment of an extension fee, and the continued funding of all collaboration activities during the extended term, with minimum annual payments to the Company for research funding.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;Under the Agreement, the Company has granted Juno an exclusive worldwide license to certain of its intellectual property, including its intellectual property arising under the collaboration, to make, use, sell and otherwise exploit genetically-engineered T cell immunotherapies using or incorporating small molecule modulators directed against certain designated tumor-associated antigen targets, subject to the selection of a target by Juno. The Company has retained exclusive rights to such intellectual property, including its intellectual property arising under the collaboration, for all other purposes, including its use outside of those targets selected by Juno.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;For each product developed by Juno that incorporates modulators identified through the research collaboration, the Company is eligible to receive approximately $50.0 million in target selection fees and clinical, regulatory and commercial milestones, as well as low single-digit royalties on sales.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:UseOfEstimates contextRef="Duration_1_1_2015_To_3_31_2015">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-size:10pt;"&gt;Use of Estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;The Company&amp;#x2019;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (&amp;#x201C;GAAP&amp;#x201D;). The preparation of the Company&amp;#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&amp;#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&amp;#x2019;s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company&amp;#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_3_31_2015_us-gaap_LongtermDebtTypeAxis_fate_TermBLoanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="Unit12" decimals="-5">400000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit1" decimals="-5">2500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit1" decimals="-5">3100000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2014_To_3_31_2014" unitRef="Unit1" decimals="0">20346856</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2015_To_3_31_2015" unitRef="Unit1" decimals="0">20554478</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>fate-20150331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2015 9:51:44 AM-->
<!--Modified on: 5/7/2015 9:51:44 AM-->
<xsd:schema targetNamespace="http://www.fatetherapeutics.com/20150331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:fate="http://www.fatetherapeutics.com/20150331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00300 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" id="DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails">
        <link:definition>40401 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesCalc2" id="DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesCalc2">
        <link:definition>40402 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies - calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsInc" id="DisclosureAssetAcquisitionOfVerioTherapeuticsInc">
        <link:definition>10201 - Disclosure - Asset Acquisition of Verio Therapeutics Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingencies" id="DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingencies">
        <link:definition>10401 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10501 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10601 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesTables" id="DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesTables">
        <link:definition>30403 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30503 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" id="DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2">
        <link:definition>40102 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" id="DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails">
        <link:definition>40201 - Disclosure - Asset Acquisition of Verio Therapeutics Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40301 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>40501 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40601 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="fate-20150331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fate-20150331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fate-20150331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="fate-20150331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="InitialPublicOfferingAbstract" id="fate_InitialPublicOfferingAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" id="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" id="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VerioTherapeuticsIncMember" id="fate_VerioTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" id="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" id="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" name="ExchangeableStockIssuedDuringPeriodSharesAcquisitions" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" id="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="fate_DebtInstrumentDiscountNonCurrent" name="DebtInstrumentDiscountNonCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_LongTermDebtGrossCurrent" name="LongTermDebtGrossCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="DebtInstrumentDiscountCurrent" id="fate_DebtInstrumentDiscountCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <element id="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" name="ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="fate_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RepurchaseLiabilityForUnvestedEquityAwardsCurrent" id="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NonEmployeeStockOptionMember" id="fate_NonEmployeeStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EmployeeAndNonEmployeeStockOptionMember" id="fate_EmployeeAndNonEmployeeStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VestingBasedOnPerformanceMember" id="fate_VestingBasedOnPerformanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AssetAcquisitionAbstract" id="fate_AssetAcquisitionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AssetAcquisitionTextBlock" id="fate_AssetAcquisitionTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InitialPublicOfferingPolicyTextBlock" id="fate_InitialPublicOfferingPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" id="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="fate_NetProceedsFromIssuanceInitialPublicOffering" name="NetProceedsFromIssuanceInitialPublicOffering" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element name="CommonStockIssuableUponRedemptionOfExchangeableShares" id="fate_CommonStockIssuableUponRedemptionOfExchangeableShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones" id="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InitialFairValueAndAdjustmentOfExchangeableShares" id="fate_InitialFairValueAndAdjustmentOfExchangeableShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="WarrantsExpirationPeriodAxis" id="fate_WarrantsExpirationPeriodAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantsExpirationPeriodDomain" id="fate_WarrantsExpirationPeriodDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantsExpirationPeriodJanuary2019Member" id="fate_WarrantsExpirationPeriodJanuary2019Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantsExpirationPeriodAugust2021Member" id="fate_WarrantsExpirationPeriodAugust2021Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DeemedEarnedCommonStockYetToBeIssued" id="fate_DeemedEarnedCommonStockYetToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmendedAndRestatedLoanAndSecurityAgreementMember" id="fate_AmendedAndRestatedLoanAndSecurityAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TermALoanMember" id="fate_TermALoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TermBLoanMember" id="fate_TermBLoanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <element id="fate_DebtInstrumentTermForPaymentOfInterest" name="DebtInstrumentTermForPaymentOfInterest" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest" name="DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_TermBLoanTranche1Member" name="TermBLoanTranche1Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage" name="DebtInstrumentUnusedBorrowingCapacityFeePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_OperatingLeaseExtendedTerm" name="OperatingLeaseExtendedTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_OperatingLeaseMember" name="OperatingLeaseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" name="AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock" name="AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_JunoTherapeuticsIncMember" name="JunoTherapeuticsIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_UpfrontPaymentReceivable" name="UpfrontPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_ResearchTerm" name="ResearchTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_ResearchTermExtension" name="ResearchTermExtension" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_AmountReceivableForProductDevelopment" name="AmountReceivableForProductDevelopment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_CollaborationAndLicenseAgreementTermsMember" name="CollaborationAndLicenseAgreementTermsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="fate_SubleaseLeaseMember" name="SubleaseLeaseMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>fate-20150331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2015 9:51:44 AM-->
<!--Modified on: 5/7/2015 9:51:44 AM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesCalc2" roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635665891036798036" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_635665891036798036" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635665891036798036" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635665891036798036" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_635665891036798036" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635665891036798036" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635665891036798036" xlink:to="us-gaap_AccountsPayableCurrent_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635665891036798036" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635665891036798036" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635665891036798036" xlink:to="us-gaap_DeferredRentCreditCurrent_635665891036798036" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:label="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635665891036798036" xlink:to="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_635665891036798036" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_635665891036798036" xlink:to="us-gaap_LongTermDebtCurrent_635665891036798036" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredRentCreditNoncurrent_635665891036798036" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_635665891036798036" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LongTermDebtNoncurrent_635665891036798036" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_635665891036798036" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_635665891036798036" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635665891036798036" xlink:to="us-gaap_PreferredStockValue_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635665891036798036" xlink:to="us-gaap_CommonStockValue_635665891036798036" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635665891036798036" xlink:to="us-gaap_AdditionalPaidInCapital_635665891036798036" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_635665891036798036" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635665891036798036" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_635665891036798036" xlink:to="us-gaap_OperatingExpenses_635665891036798036" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_635665891036798036" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_635665891036798036" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635665891036798036" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_635665891036798036" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_635665891036798036" xlink:to="us-gaap_InvestmentIncomeInterest_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense_635665891036798036" xlink:to="us-gaap_InterestExpense_635665891036798036" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_NetIncomeLoss_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_DepreciationDepletionAndAmortization_635665891036798036" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_ShareBasedCompensation_635665891036798036" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_PaidInKindInterest_635665891036798036" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StraightLineRent" xlink:label="us-gaap_StraightLineRent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_StraightLineRent_635665891036798036" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_InitialFairValueAndAdjustmentOfExchangeableShares" xlink:label="fate_InitialFairValueAndAdjustmentOfExchangeableShares_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" xlink:to="fate_InitialFairValueAndAdjustmentOfExchangeableShares_635665891036798036" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635665891036798036" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635665891036798036" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635665891036798036" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635665891036798036" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635665891036798036" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635665891036798036" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635665891036798036" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635665891036798036" xlink:to="us-gaap_RepaymentsOfLongTermDebt_635665891036798036" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_635603087475148240" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentDiscountNonCurrent" xlink:label="fate_DebtInstrumentDiscountNonCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_635603087475148240" xlink:to="fate_DebtInstrumentDiscountNonCurrent_635665891036798036" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt_635603087475148240" xlink:to="us-gaap_DebtInstrumentCarryingAmount_635665891036798036" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentDiscountCurrent" xlink:label="fate_DebtInstrumentDiscountCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="fate_DebtInstrumentDiscountCurrent_635665891036798036" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_LongTermDebtGrossCurrent" xlink:label="fate_LongTermDebtGrossCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="fate_LongTermDebtGrossCurrent_635665891036798036" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesCalc2" xlink:type="extended" xlink:title="40402 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies - calc2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_LongTermDebtGrossCurrent" xlink:label="fate_LongTermDebtGrossCurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="fate_LongTermDebtGrossCurrent_635665891036798036" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_635665891036798036" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtNoncurrent_635665891036798036" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>fate-20150331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2015 9:51:44 AM-->
<!--Modified on: 5/7/2015 9:51:44 AM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30503 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891036798036" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891036798036" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_NonEmployeeStockOptionMember" xlink:label="fate_NonEmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_NonEmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Asset Acquisition of Verio Therapeutics Inc. (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_635665891036798036" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_635665891036798036" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_VerioTherapeuticsIncMember" xlink:label="fate_VerioTherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="fate_VerioTherapeuticsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635665891036798036" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_635665891036798036" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:label="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_CommonStockIssuableUponRedemptionOfExchangeableShares" xlink:label="fate_CommonStockIssuableUponRedemptionOfExchangeableShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fate_CommonStockIssuableUponRedemptionOfExchangeableShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DeemedEarnedCommonStockYetToBeIssued" xlink:label="fate_DeemedEarnedCommonStockYetToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fate_DeemedEarnedCommonStockYetToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_635665891036798036" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_635665891036798036" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635665891036798036" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635665891036798036" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635665891036798036" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635665891036798036" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureNonrecurring" xlink:label="us-gaap_AssetsFairValueDisclosureNonrecurring" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureNonrecurring" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_TermALoanMember" xlink:label="fate_TermALoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SecuredDebtMember" xlink:to="fate_TermALoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_TermBLoanMember" xlink:label="fate_TermBLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SecuredDebtMember" xlink:to="fate_TermBLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_TermBLoanTranche1Member" xlink:label="fate_TermBLoanTranche1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="fate_TermBLoanMember" xlink:to="fate_TermBLoanTranche1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="fate_AmendedAndRestatedLoanAndSecurityAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="fate_AmendedAndRestatedLoanAndSecurityAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodAxis" xlink:label="fate_WarrantsExpirationPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="fate_WarrantsExpirationPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodDomain" xlink:label="fate_WarrantsExpirationPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="fate_WarrantsExpirationPeriodAxis" xlink:to="fate_WarrantsExpirationPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodDomain" xlink:label="fate_WarrantsExpirationPeriodDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="fate_WarrantsExpirationPeriodAxis" xlink:to="fate_WarrantsExpirationPeriodDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodJanuary2019Member" xlink:label="fate_WarrantsExpirationPeriodJanuary2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="fate_WarrantsExpirationPeriodDomain" xlink:to="fate_WarrantsExpirationPeriodJanuary2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodAugust2021Member" xlink:label="fate_WarrantsExpirationPeriodAugust2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="fate_WarrantsExpirationPeriodDomain" xlink:to="fate_WarrantsExpirationPeriodAugust2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_OperatingLeaseMember" xlink:label="fate_OperatingLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="fate_OperatingLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_SubleaseLeaseMember" xlink:label="fate_SubleaseLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="fate_SubleaseLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentDiscountNonCurrent" xlink:label="fate_DebtInstrumentDiscountNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_DebtInstrumentDiscountNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_LongTermDebtGrossCurrent" xlink:label="fate_LongTermDebtGrossCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_LongTermDebtGrossCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentDiscountCurrent" xlink:label="fate_DebtInstrumentDiscountCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_DebtInstrumentDiscountCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentTermForPaymentOfInterest" xlink:label="fate_DebtInstrumentTermForPaymentOfInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_DebtInstrumentTermForPaymentOfInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest" xlink:label="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:label="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage" xlink:label="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_OperatingLeaseExtendedTerm" xlink:label="fate_OperatingLeaseExtendedTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="fate_OperatingLeaseExtendedTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_NonEmployeeStockOptionMember" xlink:label="fate_NonEmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="fate_NonEmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_VestingBasedOnPerformanceMember" xlink:label="fate_VestingBasedOnPerformanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="fate_VestingBasedOnPerformanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_CollaborationAndLicenseAgreementTermsMember" xlink:label="fate_CollaborationAndLicenseAgreementTermsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="fate_CollaborationAndLicenseAgreementTermsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635665891036954033" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635665891036954033" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_JunoTherapeuticsIncMember" xlink:label="fate_JunoTherapeuticsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="fate_JunoTherapeuticsIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_UpfrontPaymentReceivable" xlink:label="fate_UpfrontPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fate_UpfrontPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ResearchTerm" xlink:label="fate_ResearchTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fate_ResearchTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ResearchTermExtension" xlink:label="fate_ResearchTermExtension" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fate_ResearchTermExtension" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AmountReceivableForProductDevelopment" xlink:label="fate_AmountReceivableForProductDevelopment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="fate_AmountReceivableForProductDevelopment" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>fate-20150331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2015 9:51:44 AM-->
<!--Modified on: 5/7/2015 9:51:44 AM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DocumentAndEntityInformationAbstract" xlink:label="fate_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="fate_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Balance Sheets (Parenthetical)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash and Cash Equivalents, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of deferred rent</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:label="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:to="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the carrying value, as of the balance sheet date, of repurchase liability for unvested equity awards, which is expected to be paid within one year (or the operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Liability for Unvested Equity Awards Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase liability for unvested equity awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of long-term debt, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, net of current potion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 4)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, $0.001 par value; authorized shares-5,000,000 at March 31,2015 and December 31, 2014; no shares issued or outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.001 par value; authorized shares - 150,000,000 at March 31,2015 and December 31, 2014; issued and outstanding shares - 20,637,217 at March 31,2015 and 20,569,399 at December 31, 2014</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, issued shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, outstanding shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, authorized shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, outstanding shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other expense, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share, basic and diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares used to compute basic and diluted net loss per share (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Financing Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of discounts and debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid-in-Kind Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash interest expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StraightLineRent" xlink:label="us-gaap_StraightLineRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StraightLineRent" xlink:to="us-gaap_StraightLineRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StraightLineRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Straight Line Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StraightLineRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_InitialFairValueAndAdjustmentOfExchangeableShares" xlink:label="fate_InitialFairValueAndAdjustmentOfExchangeableShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_InitialFairValueAndAdjustmentOfExchangeableShares" xlink:to="fate_InitialFairValueAndAdjustmentOfExchangeableShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_InitialFairValueAndAdjustmentOfExchangeableShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the initial fair value and change in fair value amounts of exchangeable shares during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_InitialFairValueAndAdjustmentOfExchangeableShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Fair Value and Adjustment of Exchangeable Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_InitialFairValueAndAdjustmentOfExchangeableShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based milestone charges and change in fair value of exchangeable shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of repurchases and issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization and Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AssetAcquisitionAbstract" xlink:label="fate_AssetAcquisitionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AssetAcquisitionAbstract" xlink:to="fate_AssetAcquisitionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_AssetAcquisitionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition of Verio Therapeutics Inc.</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AssetAcquisitionTextBlock" xlink:label="fate_AssetAcquisitionTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AssetAcquisitionTextBlock" xlink:to="fate_AssetAcquisitionTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_AssetAcquisitionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for an asset acquisition completed during the period, including background, timing, and recognized assets and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_AssetAcquisitionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_AssetAcquisitionTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition of Verio Therapeutics Inc.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xlink:to="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses, Long-Term Debt, Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock" xlink:to="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for accrued expenses, long-term debt, commitments and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses, Long-Term Debt, Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses, Long-Term Debt, Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_InitialPublicOfferingPolicyTextBlock" xlink:label="fate_InitialPublicOfferingPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_InitialPublicOfferingPolicyTextBlock" xlink:to="fate_InitialPublicOfferingPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for initial public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_InitialPublicOfferingPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Common Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of long-term debt and unamortized discount balances (excluding convertible debt)</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_NonEmployeeStockOptionMember" xlink:label="fate_NonEmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_NonEmployeeStockOptionMember" xlink:to="fate_NonEmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_NonEmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents an arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, certain number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_NonEmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_NonEmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Employee Stock Option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock Options Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity under the Plan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of allocation of stock-based compensation for all options and restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted-average assumptions used to determine the fair value of stock option grants</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_InitialPublicOfferingAbstract" xlink:label="fate_InitialPublicOfferingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_InitialPublicOfferingAbstract" xlink:to="fate_InitialPublicOfferingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_InitialPublicOfferingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_InitialPublicOfferingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares sold in initial public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from initial public offering</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_NetProceedsFromIssuanceInitialPublicOffering" xlink:label="fate_NetProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_NetProceedsFromIssuanceInitialPublicOffering" xlink:to="fate_NetProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_NetProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_NetProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_NetProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from initial public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodFactors" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodFactors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodFactors" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodFactors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodFactors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Milestone Method, Factors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodFactors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Four criteria needed for Company to recognize revenue</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:label="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:to="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the shares excluded from the weighted-average number of shares outstanding attributable to share based payment arrangements including shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Attributable to Share Based Payment Arrangements Excluded from Weighted Average Number of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares excluded from weighted average number of shares attributable to share based payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potentially dilutive securities (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options to purchase shares of common stock included in potentially dilutive securities (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_VerioTherapeuticsIncMember" xlink:label="fate_VerioTherapeuticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_VerioTherapeuticsIncMember" xlink:to="fate_VerioTherapeuticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_VerioTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Verio Therapeutics Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_VerioTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Verio Therapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_VerioTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Verio Therapeutics Inc</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:label="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:to="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of exchangeable stock issued during the period pursuant to acquisitions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchangeable Stock Issued during Period Shares Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchangeable Shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issuable on exchange of Common Stock</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_CommonStockIssuableUponRedemptionOfExchangeableShares" xlink:label="fate_CommonStockIssuableUponRedemptionOfExchangeableShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CommonStockIssuableUponRedemptionOfExchangeableShares" xlink:to="fate_CommonStockIssuableUponRedemptionOfExchangeableShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_CommonStockIssuableUponRedemptionOfExchangeableShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of common stocks issuable on the redemption of exchangeable shares during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_CommonStockIssuableUponRedemptionOfExchangeableShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Issuable upon Redemption of Exchangeable Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fate_CommonStockIssuableUponRedemptionOfExchangeableShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued pursuant to the redemption of the exchangeable shares</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DeemedEarnedCommonStockYetToBeIssued" xlink:label="fate_DeemedEarnedCommonStockYetToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DeemedEarnedCommonStockYetToBeIssued" xlink:to="fate_DeemedEarnedCommonStockYetToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_DeemedEarnedCommonStockYetToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of common shares that were deemed earned but not issued by the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_DeemedEarnedCommonStockYetToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed Earned Common Stock Yet to be Issued</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of potential future increase in number of shares of the entity's common stock to be issued upon achievement of additional milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Equity Interests Potential Increase in Number of Shares Achievement of Additional Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of additional milestones</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of potential future increase in number of shares of the entity's common stock to be issued upon achievement of certain preclinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Equity Interests Potential Increase in Number of Shares Achievement of Certain Preclinical Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain preclinical milestones</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of potential future increase in number of shares of the entity's common stock to be issued upon achievement of certain clinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Equity Interests Potential Increase in Number of Shares Achievement of Certain Clinical Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain clinical milestones</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of potential future increase in number of shares of the entity's common stock to be issued upon achievement of certain commercialization milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Equity Interests Potential Increase in Number of Shares Achievement of Certain Commercialization Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain commercialization milestone</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosure Item Amounts [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosure Item Amounts [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Reported Amount Fair Value Disclosure [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Reported Amount Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Recurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Nonrecurring [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Nonrecurring</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Hierarchy [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Inputs Level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureNonrecurring" xlink:label="us-gaap_AssetsFairValueDisclosureNonrecurring" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureNonrecurring" xlink:to="us-gaap_AssetsFairValueDisclosureNonrecurring_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureNonrecurring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure, Nonrecurring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureNonrecurring_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonfinancial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-financial liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of assets from level 1 to level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of assets from level 2 to level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of liabilities from level 1 to level 2</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer of liabilities from level 2 to level 1</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Salaries, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll and other employee benefits</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AccruedClinicalTrialCostsCurrent" xlink:label="fate_AccruedClinicalTrialCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AccruedClinicalTrialCostsCurrent" xlink:to="fate_AccruedClinicalTrialCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical trial costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical trial costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued to senior executives</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentDiscountNonCurrent" xlink:label="fate_DebtInstrumentDiscountNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DebtInstrumentDiscountNonCurrent" xlink:to="fate_DebtInstrumentDiscountNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_DebtInstrumentDiscountNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the non-current portion of discount recognized at the issuance of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_DebtInstrumentDiscountNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Discount, Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fate_DebtInstrumentDiscountNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less debt discount, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, net of discount</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_LongTermDebtGrossCurrent" xlink:label="fate_LongTermDebtGrossCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_LongTermDebtGrossCurrent" xlink:to="fate_LongTermDebtGrossCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_LongTermDebtGrossCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of long-term debt, before unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_LongTermDebtGrossCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Debt, Gross, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fate_LongTermDebtGrossCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less current portion of long-term debt</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentDiscountCurrent" xlink:label="fate_DebtInstrumentDiscountCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DebtInstrumentDiscountCurrent" xlink:to="fate_DebtInstrumentDiscountCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_DebtInstrumentDiscountCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the current portion of discount recognized at the issuance of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_DebtInstrumentDiscountCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Discount, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="fate_DebtInstrumentDiscountCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentTermForPaymentOfInterest" xlink:label="fate_DebtInstrumentTermForPaymentOfInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DebtInstrumentTermForPaymentOfInterest" xlink:to="fate_DebtInstrumentTermForPaymentOfInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_DebtInstrumentTermForPaymentOfInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time for payment of interest on monthly basis on cash at the beginning of first day of each month, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_DebtInstrumentTermForPaymentOfInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Term for Payment of Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_DebtInstrumentTermForPaymentOfInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of monthly payment of interest</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest" xlink:label="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest" xlink:to="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time for repayment of principal and accrued interest on equal monthly installments, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Term for Repayment of Principal and Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal monthly installments to repay principal and accrued interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment fee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line of Credit Facility, Commitment Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment fee (amounts in dollars)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment fee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Proceeds after repayment of loans outstanding and transaction fees</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:label="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:to="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of common stocks into which the class of warrant or right may be converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right Warrants Issued to Purchase Shares of Common Stock on Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase shares of common stock issued on conversion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair values of warrants issued</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage" xlink:label="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage" xlink:to="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fee, expressed as a percentage of the unused borrowing capacity, for the term loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Unused Borrowing Capacity Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate interest expense</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_OperatingLeaseExtendedTerm" xlink:label="fate_OperatingLeaseExtendedTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_OperatingLeaseExtendedTerm" xlink:to="fate_OperatingLeaseExtendedTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_OperatingLeaseExtendedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents extended term of operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_OperatingLeaseExtendedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Extended Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_OperatingLeaseExtendedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extended term of lease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Letters of Credit Outstanding, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash-collateralized irrevocable standby letter of credit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum payments</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_EmployeeAndNonEmployeeStockOptionMember" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents an arrangement whereby both an employee and a non-employee is entitled to receive in the future, subject to vesting and other restrictions, certain number of shares in the entity at a specified price, as defined in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee And Non Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee And Non Employee Stock Option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_VestingBasedOnPerformanceMember" xlink:label="fate_VestingBasedOnPerformanceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_VestingBasedOnPerformanceMember" xlink:to="fate_VestingBasedOnPerformanceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_VestingBasedOnPerformanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the vesting based on performance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_VestingBasedOnPerformanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Based On Performance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_VestingBasedOnPerformanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Based On Performance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning of the period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the aggregate grant-date fair value of share-based compensation plan awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award Total Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate grant date fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost related to outstanding options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected recognition period of unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average assumptions to determine fair value of stock options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining contractual term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_UpfrontPaymentReceivable" xlink:label="fate_UpfrontPaymentReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_UpfrontPaymentReceivable" xlink:to="fate_UpfrontPaymentReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_UpfrontPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the upfront payment receivable from the party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_UpfrontPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue price</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ResearchTerm" xlink:label="fate_ResearchTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ResearchTerm" xlink:to="fate_ResearchTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_ResearchTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the research term for which funding is done by the party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_ResearchTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research term</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ResearchTermExtension" xlink:label="fate_ResearchTermExtension" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_ResearchTermExtension" xlink:to="fate_ResearchTermExtension_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_ResearchTermExtension_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period for which research term can be extended</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_ResearchTermExtension_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research term extension</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AmountReceivableForProductDevelopment" xlink:label="fate_AmountReceivableForProductDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AmountReceivableForProductDevelopment" xlink:to="fate_AmountReceivableForProductDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_AmountReceivableForProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the eligible approximate amount to be received for each product developed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_AmountReceivableForProductDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount receivable for product development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt [Member]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_TermALoanMember" xlink:label="fate_TermALoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_TermALoanMember" xlink:to="fate_TermALoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_TermALoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the term A loan matures on January 1, 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_TermALoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term A Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_TermALoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term A Loan</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_TermBLoanMember" xlink:label="fate_TermBLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_TermBLoanMember" xlink:to="fate_TermBLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_TermBLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the term loan B.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_TermBLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term B Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_TermBLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term B Loan</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_TermBLoanTranche1Member" xlink:label="fate_TermBLoanTranche1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_TermBLoanTranche1Member" xlink:to="fate_TermBLoanTranche1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_TermBLoanTranche1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the term B loan tranche one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_TermBLoanTranche1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term B Loan Tranche1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_TermBLoanTranche1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term B Loan Tranch 1 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="fate_AmendedAndRestatedLoanAndSecurityAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_AmendedAndRestatedLoanAndSecurityAgreementMember" xlink:to="fate_AmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_AmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Amended and Restated Loan and Security Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_AmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended And Restated Loan And Security Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_AmendedAndRestatedLoanAndSecurityAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended And Restated Loan And Security Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodAxis" xlink:label="fate_WarrantsExpirationPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_WarrantsExpirationPeriodAxis" xlink:to="fate_WarrantsExpirationPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_WarrantsExpirationPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants by expiration period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_WarrantsExpirationPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Expiration Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodDomain" xlink:label="fate_WarrantsExpirationPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_WarrantsExpirationPeriodDomain" xlink:to="fate_WarrantsExpirationPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_WarrantsExpirationPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period in which warrants expires.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_WarrantsExpirationPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Expiration Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_WarrantsExpirationPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Expiration Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodJanuary2019Member" xlink:label="fate_WarrantsExpirationPeriodJanuary2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_WarrantsExpirationPeriodJanuary2019Member" xlink:to="fate_WarrantsExpirationPeriodJanuary2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_WarrantsExpirationPeriodJanuary2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details of warrants that expire in January 2019.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_WarrantsExpirationPeriodJanuary2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Expiration Period January2019 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_WarrantsExpirationPeriodJanuary2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Expiration Period January2019 [Member]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodAugust2021Member" xlink:label="fate_WarrantsExpirationPeriodAugust2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_WarrantsExpirationPeriodAugust2021Member" xlink:to="fate_WarrantsExpirationPeriodAugust2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_WarrantsExpirationPeriodAugust2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents details of warrants that expire in August 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_WarrantsExpirationPeriodAugust2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Expiration Period August2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_WarrantsExpirationPeriodAugust2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Expiration Period August2021 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Arrangement, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Arrangement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Arrangement, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_OperatingLeaseMember" xlink:label="fate_OperatingLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_OperatingLeaseMember" xlink:to="fate_OperatingLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_OperatingLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_OperatingLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_OperatingLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease member</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_SubleaseLeaseMember" xlink:label="fate_SubleaseLeaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_SubleaseLeaseMember" xlink:to="fate_SubleaseLeaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_SubleaseLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease lease member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_SubleaseLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease Lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_SubleaseLeaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sublease operating lease member</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_CollaborationAndLicenseAgreementTermsMember" xlink:label="fate_CollaborationAndLicenseAgreementTermsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_CollaborationAndLicenseAgreementTermsMember" xlink:to="fate_CollaborationAndLicenseAgreementTermsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_CollaborationAndLicenseAgreementTermsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Terms of the collaboration and license agreements under research and development arrangements accounted for as a contract to perform research and development for others.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_CollaborationAndLicenseAgreementTermsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreement Terms [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_CollaborationAndLicenseAgreementTermsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and license agreement terms</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase Agreement Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_JunoTherapeuticsIncMember" xlink:label="fate_JunoTherapeuticsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="fate_JunoTherapeuticsIncMember" xlink:to="fate_JunoTherapeuticsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="fate_JunoTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the name of the counter party with whom the company entered into agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="fate_JunoTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Juno Therapeutics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="fate_JunoTherapeuticsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Juno Therapeutics, Inc</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>fate-20150331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- Created by Merrill Corporation -->
<!--XBRL document created with Merrill Bridge  5.12.31.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/7/2015 9:51:44 AM-->
<!--Modified on: 5/7/2015 9:51:44 AM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.fatetherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureAssetAcquisitionOfVerioTherapeuticsInc" roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsInc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureFairValueMeasurements" roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingencies" roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureStockholdersEquity" roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureSubsequentEvents" roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesTables" roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="fate-20150331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DocumentAndEntityInformationAbstract" xlink:label="fate_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_635665891036954033" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_635665891036954033" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_635665891036954033" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_635665891036954033" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_635665891036954033" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate_635665891036954033" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus_635665891036954033" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory_635665891036954033" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_635665891036954033" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus_635665891036954033" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_635665891036954033" order="11" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_635665891036954033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_635665891036954033" xlink:to="us-gaap_AssetsCurrentAbstract_635665891036954033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635665891036954033" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635665891036954033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635665891036954033" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_635665891036954033" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635665891036954033" xlink:to="us-gaap_AssetsCurrent_635665891036954033" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635665891036954033" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_635665891036954033" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635665891036954033" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_635665891036954033" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_635665891036954033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635665891036954033" xlink:to="us-gaap_OtherAssetsNoncurrent_635665891036954033" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_635665891036954033" xlink:to="us-gaap_Assets_635665891037110030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_AccountsPayableCurrent_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_DeferredRentCreditCurrent_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" xlink:label="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" xlink:to="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_LongTermDebtCurrent_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_LiabilitiesCurrent_635665891037110030" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_DeferredRentCreditNoncurrent_635665891037110030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_635665891037110030" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_LongTermDebtNoncurrent_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_CommitmentsAndContingencies_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_StockholdersEquityAbstract_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_PreferredStockValue_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_CommonStockValue_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_AdditionalPaidInCapital_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_StockholdersEquity_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_635665891037110030" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_635665891037110030" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_635665891037110030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_635665891037110030" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635665891037110030" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635665891037110030" xlink:to="us-gaap_GeneralAndAdministrativeExpense_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_635665891037110030" xlink:to="us-gaap_OperatingExpenses_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_635665891037110030" xlink:to="us-gaap_InvestmentIncomeInterest_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_635665891037110030" xlink:to="us-gaap_InterestExpense_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_635665891037110030" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_635665891037110030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635665891037110030" xlink:to="us-gaap_NetIncomeLoss_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635665891037110030" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635665891037110030" xlink:to="us-gaap_DepreciationDepletionAndAmortization_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635665891037110030" xlink:to="us-gaap_ShareBasedCompensation_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635665891037110030" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635665891037110030" xlink:to="us-gaap_PaidInKindInterest_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StraightLineRent" xlink:label="us-gaap_StraightLineRent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635665891037110030" xlink:to="us-gaap_StraightLineRent_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_InitialFairValueAndAdjustmentOfExchangeableShares" xlink:label="fate_InitialFairValueAndAdjustmentOfExchangeableShares_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635665891037110030" xlink:to="fate_InitialFairValueAndAdjustmentOfExchangeableShares_635665891037110030" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_635665891037110030" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635665891037110030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635665891037110030" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_635665891037110030" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_635665891037110030" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635665891037110030" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_635665891037110030" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635665891037110030" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635665891037110030" xlink:to="us-gaap_RepaymentsOfLongTermDebt_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_635665891037110030" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6356658910371100301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6356658910371100301" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - Organization and Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsInc" xlink:type="extended" xlink:title="10201 - Disclosure - Asset Acquisition of Verio Therapeutics Inc." xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AssetAcquisitionAbstract" xlink:label="fate_AssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AssetAcquisitionTextBlock" xlink:label="fate_AssetAcquisitionTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AssetAcquisitionAbstract" xlink:to="fate_AssetAcquisitionTextBlock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingencies" xlink:type="extended" xlink:title="10401 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xlink:to="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10501 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10601 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_InitialPublicOfferingPolicyTextBlock" xlink:label="fate_InitialPublicOfferingPolicyTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="fate_InitialPublicOfferingPolicyTextBlock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_635665891037110030" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_635665891037110030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_635665891037110030" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30503 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037110030" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037110030" xlink:to="us-gaap_AwardTypeAxis_635665891037110030" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635665891037110030" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891037110030" xlink:to="us-gaap_EmployeeStockOptionMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_NonEmployeeStockOptionMember" xlink:label="fate_NonEmployeeStockOptionMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891037110030" xlink:to="fate_NonEmployeeStockOptionMember_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037110030" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037110030" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037110030" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037110030" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635543269185486918" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_InitialPublicOfferingAbstract" xlink:label="fate_InitialPublicOfferingAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_635543269185486918" xlink:to="fate_InitialPublicOfferingAbstract_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_InitialPublicOfferingAbstract_635665891037110030" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_InitialPublicOfferingAbstract_635665891037110030" xlink:to="us-gaap_SharePrice_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_InitialPublicOfferingAbstract_635665891037110030" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_NetProceedsFromIssuanceInitialPublicOffering" xlink:label="fate_NetProceedsFromIssuanceInitialPublicOffering_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_InitialPublicOfferingAbstract_635665891037110030" xlink:to="fate_NetProceedsFromIssuanceInitialPublicOffering_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2" xlink:type="extended" xlink:title="40102 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodFactors" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodFactors_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodFactors_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" xlink:label="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_NetIncomeLoss_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Asset Acquisition of Verio Therapeutics Inc. (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AssetAcquisitionAbstract" xlink:label="fate_AssetAcquisitionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AssetAcquisitionAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635665891037110030" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635665891037110030" xlink:to="us-gaap_BusinessAcquisitionAxis_635665891037110030" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_635665891037110030" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_VerioTherapeuticsIncMember" xlink:label="fate_VerioTherapeuticsIncMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_635665891037110030" xlink:to="fate_VerioTherapeuticsIncMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635665891037110030" xlink:to="us-gaap_RangeAxis_635665891037110030" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635665891037110030" xlink:to="us-gaap_RangeMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635665891037110030" xlink:to="us-gaap_MaximumMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_635665891037110030" xlink:to="us-gaap_BusinessAcquisitionLineItems_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions" xlink:label="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_635665891037110030" xlink:to="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_635665891037110030" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_CommonStockIssuableUponRedemptionOfExchangeableShares" xlink:label="fate_CommonStockIssuableUponRedemptionOfExchangeableShares_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_635665891037110030" xlink:to="fate_CommonStockIssuableUponRedemptionOfExchangeableShares_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DeemedEarnedCommonStockYetToBeIssued" xlink:label="fate_DeemedEarnedCommonStockYetToBeIssued_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_635665891037110030" xlink:to="fate_DeemedEarnedCommonStockYetToBeIssued_635665891037110030" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_635665891037110030" xlink:to="us-gaap_ResearchAndDevelopmentExpense_635665891037110030" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_635665891037110030" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones_635665891037110030" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_635665891037110030" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones_635665891037110030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_635665891037110030" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones_635665891037110030" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones" xlink:label="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_635665891037110030" xlink:to="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones_635665891037110030" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Fair Value Measurements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635665891037110030" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635665891037110030" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_635665891037110030" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_635665891037110030" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain_635665891037110030" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635665891037110030" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_635665891037110030" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_635665891037110030" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_635665891037110030" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_635665891037110030" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635665891037110030" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_635665891037110030" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_635665891037110030" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_635665891037110030" xlink:to="us-gaap_FairValueInputsLevel1Member_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_635665891037110030" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsFairValueDisclosureNonrecurring" xlink:label="us-gaap_AssetsFairValueDisclosureNonrecurring_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" xlink:to="us-gaap_AssetsFairValueDisclosureNonrecurring_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonfinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" xlink:to="us-gaap_NonfinancialLiabilitiesFairValueDisclosure_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_635665891037110030" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_635665891037110030" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_635665891037110030" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_635665891037110030" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xlink:label="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_635665891037110030" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635665891037110030" xlink:to="us-gaap_DebtInstrumentAxis_635665891037110030" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_635665891037110030" xlink:to="us-gaap_DebtInstrumentNameDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AmendedAndRestatedLoanAndSecurityAgreementMember" xlink:label="fate_AmendedAndRestatedLoanAndSecurityAgreementMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_635665891037110030" xlink:to="fate_AmendedAndRestatedLoanAndSecurityAgreementMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635665891037110030" xlink:to="us-gaap_LongtermDebtTypeAxis_635665891037110030" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_635665891037110030" xlink:to="us-gaap_LongtermDebtTypeDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_635665891037110030" xlink:to="us-gaap_SecuredDebtMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_TermALoanMember" xlink:label="fate_TermALoanMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuredDebtMember_635665891037110030" xlink:to="fate_TermALoanMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_TermBLoanMember" xlink:label="fate_TermBLoanMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SecuredDebtMember_635665891037110030" xlink:to="fate_TermBLoanMember_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_TermBLoanTranche1Member" xlink:label="fate_TermBLoanTranche1Member_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_TermBLoanMember_635665891037110030" xlink:to="fate_TermBLoanTranche1Member_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635665891037110030" xlink:to="us-gaap_RangeAxis_635665891037110030" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_635665891037110030" xlink:to="us-gaap_RangeMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635665891037110030" xlink:to="us-gaap_MaximumMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_635665891037110030" xlink:to="us-gaap_MinimumMember_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635665891037110030" xlink:to="us-gaap_StatementEquityComponentsAxis_635665891037110030" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_635665891037110030" xlink:to="us-gaap_EquityComponentDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_635665891037110030" xlink:to="us-gaap_WarrantMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodAxis" xlink:label="fate_WarrantsExpirationPeriodAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635665891037110030" xlink:to="fate_WarrantsExpirationPeriodAxis_635665891037110030" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodDomain" xlink:label="fate_WarrantsExpirationPeriodDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_WarrantsExpirationPeriodAxis_635665891037110030" xlink:to="fate_WarrantsExpirationPeriodDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodJanuary2019Member" xlink:label="fate_WarrantsExpirationPeriodJanuary2019Member_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_WarrantsExpirationPeriodDomain_635665891037110030" xlink:to="fate_WarrantsExpirationPeriodJanuary2019Member_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_WarrantsExpirationPeriodAugust2021Member" xlink:label="fate_WarrantsExpirationPeriodAugust2021Member_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_WarrantsExpirationPeriodDomain_635665891037110030" xlink:to="fate_WarrantsExpirationPeriodAugust2021Member_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635665891037110030" xlink:to="us-gaap_LeaseArrangementTypeAxis_635665891037110030" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="us-gaap_LeaseArrangementTypeDomain_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis_635665891037110030" xlink:to="us-gaap_LeaseArrangementTypeDomain_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_OperatingLeaseMember" xlink:label="fate_OperatingLeaseMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_635665891037110030" xlink:to="fate_OperatingLeaseMember_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_SubleaseLeaseMember" xlink:label="fate_SubleaseLeaseMember_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain_635665891037110030" xlink:to="fate_SubleaseLeaseMember_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635665891037110030" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_635665891037110030" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_AccruedSalariesCurrent_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AccruedClinicalTrialCostsCurrent" xlink:label="fate_AccruedClinicalTrialCostsCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635665891037110030" xlink:to="fate_AccruedClinicalTrialCostsCurrent_635665891037110030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_635665891037110030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_AccruedLiabilitiesCurrent_635665891037110030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract_635665891037110030" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_635665891037110030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_635665891037110030" xlink:to="us-gaap_DebtInstrumentLineItems_635665891037110030" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_635665891037110030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_DebtInstrumentCarryingAmount_635665891037110030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentDiscountNonCurrent" xlink:label="fate_DebtInstrumentDiscountNonCurrent_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="fate_DebtInstrumentDiscountNonCurrent_635665891037266027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_LongTermDebt_635665891037266027" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_LongTermDebtGrossCurrent" xlink:label="fate_LongTermDebtGrossCurrent_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="fate_LongTermDebtGrossCurrent_635665891037266027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_LongTermDebtNoncurrent_635665891037266027" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentDiscountCurrent" xlink:label="fate_DebtInstrumentDiscountCurrent_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="fate_DebtInstrumentDiscountCurrent_635665891037266027" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_LongTermDebtCurrent_635665891037266027" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_DebtInstrumentFaceAmount_635665891037266027" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_635665891037266027" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentTermForPaymentOfInterest" xlink:label="fate_DebtInstrumentTermForPaymentOfInterest_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="fate_DebtInstrumentTermForPaymentOfInterest_635665891037266027" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest" xlink:label="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest_635665891037266027" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_635665891037266027" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_635665891037266027" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_DebtInstrumentFeeAmount_635665891037266027" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_635665891037266027" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion" xlink:label="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion_635665891037266027" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_635665891037266027" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_WarrantsAndRightsOutstanding_635665891037266027" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage" xlink:label="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage_635665891037266027" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_InterestExpenseDebt_635665891037266027" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_OperatingLeaseExtendedTerm" xlink:label="fate_OperatingLeaseExtendedTerm_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="fate_OperatingLeaseExtendedTerm_635665891037266027" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_635665891037266027" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_635665891037110030" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_635665891037266027" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:label="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="fate_ConvertiblePreferredStockAndStockholdersDeficitDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037266027" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037266027" xlink:to="us-gaap_AwardTypeAxis_635665891037266027" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_EmployeeAndNonEmployeeStockOptionMember" xlink:label="fate_EmployeeAndNonEmployeeStockOptionMember_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891037266027" xlink:to="fate_EmployeeAndNonEmployeeStockOptionMember_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891037266027" xlink:to="us-gaap_EmployeeStockOptionMember_635665891037266027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_NonEmployeeStockOptionMember" xlink:label="fate_NonEmployeeStockOptionMember_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_635665891037266027" xlink:to="fate_NonEmployeeStockOptionMember_635665891037266027" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037266027" xlink:to="us-gaap_VestingAxis_635665891037266027" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_635665891037266027" xlink:to="us-gaap_VestingDomain_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_VestingBasedOnPerformanceMember" xlink:label="fate_VestingBasedOnPerformanceMember_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_635665891037266027" xlink:to="fate_VestingBasedOnPerformanceMember_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037266027" xlink:to="us-gaap_IncomeStatementLocationAxis_635665891037266027" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_635665891037266027" xlink:to="us-gaap_IncomeStatementLocationDomain_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635665891037266027" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_635665891037266027" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_635665891037266027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037266027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_635665891037266027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_635665891037266027" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635665891037266027" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_635665891037266027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6356658910372660271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6356658910372660271" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635665891037266027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_635665891037266027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_635665891037266027" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_635665891037266027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6356658910372660271" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6356658910372660271" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037266027" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_635665891037266027" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue" xlink:label="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037266027" xlink:to="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue_635665891037266027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037266027" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_635665891037266027" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037266027" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_635665891037266027" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635665891037266027" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_635665891037266027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635665891037266027" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_635665891037266027" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635665891037266027" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_635665891037266027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_635665891037266027" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_635665891037266027" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_635665891037266027" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635665891037266027" xlink:to="us-gaap_SubsequentEventTypeAxis_635665891037266027" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_635665891037266027" xlink:to="us-gaap_SubsequentEventTypeDomain_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_635665891037266027" xlink:to="us-gaap_SubsequentEventMember_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635665891037266027" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_635665891037266027" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_635665891037266027" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_CollaborationAndLicenseAgreementTermsMember" xlink:label="fate_CollaborationAndLicenseAgreementTermsMember_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_635665891037266027" xlink:to="fate_CollaborationAndLicenseAgreementTermsMember_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635665891037266027" xlink:to="us-gaap_CounterpartyNameAxis_635665891037266027" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis_635665891037266027" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_JunoTherapeuticsIncMember" xlink:label="fate_JunoTherapeuticsIncMember_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain_635665891037266027" xlink:to="fate_JunoTherapeuticsIncMember_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_635665891037266027" xlink:to="us-gaap_SubsequentEventLineItems_635665891037266027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_UpfrontPaymentReceivable" xlink:label="fate_UpfrontPaymentReceivable_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635665891037266027" xlink:to="fate_UpfrontPaymentReceivable_635665891037266027" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635665891037266027" xlink:to="us-gaap_CommonStockSharesIssued_635665891037266027" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635665891037266027" xlink:to="us-gaap_SharesIssuedPricePerShare_635665891037266027" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ResearchTerm" xlink:label="fate_ResearchTerm_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635665891037266027" xlink:to="fate_ResearchTerm_635665891037266027" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_ResearchTermExtension" xlink:label="fate_ResearchTermExtension_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635665891037266027" xlink:to="fate_ResearchTermExtension_635665891037266027" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="fate-20150331.xsd#fate_AmountReceivableForProductDevelopment" xlink:label="fate_AmountReceivableForProductDevelopment_635665891037266027" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_635665891037266027" xlink:to="fate_AmountReceivableForProductDevelopment_635665891037266027" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#ZB>44N0$``+P/```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,E\M.PS`41/=(_$/D+6I<
MES=JRH+'$BH!'V#LVR:J8UNV*>W?<Y,^A%!I55&)NXF5V)XY\6*2Z=_.:I--
M(<3*V8*)O,LRL,KIRHX+]O;ZV+EB64S2:FF<A8+-(;+;P?%1_W7N(6:XV\:"
ME2GY&\ZC*J&6,7<>+,Z,7*AEPMLPYEZJB1P#[W6[%UPYF\"F3FHTV*!_#R/Y
M85+V,,/'"Y(`)K+L;K&P\2J8]-Y42B8DY5.K?[ATE@XY[FS7Q++R\00Q&-_H
MT,S\;K#<]XQ'$RH-V5"&]"1KQ.`SPS]=F+P[-\FWBVR@=*-1I4`[]5'C">31
M!Y`ZE@"I-GD[YK6L[(I[BW^[./)V$`<&:=ZO%=Z3HT>$XY0(QQD1CG,B'!=$
M."Z)<%P1X;@FPB&Z5$"H)*J@$JF"2J8**J$JJ*2JH!*K@DJN"BK!*J@D:X]*
MLO;^*UD3=A/@[?7O"*W,CI_CF.8&XH$_:`O17<ZE#*!?4L`6=W"`[]H[.)0T
MZJ[$.G/@0UCK;O/'CC4,SD=LFP'V!UC5R69WQZ,0A%3!NE!N*F9K1VRJ^QO^
M:(;0=&$->H,W;[OWX`L``/__`P!02P,$%``&``@````A`+55,"/U````3`(`
M``L`"`)?<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````",DL].
MPS`,QN](O$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_
M6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24
MFV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5
MP6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7S
MG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A
M363X8<'%#U1?````__\#`%!+`P04``8`"````"$`9X"!AJ,!``!?#@``&@`(
M`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````O)?+;L,@$$7WE?H/%OL&#WE7<;)H52G;
M-OT`9!/;B@T6T$?^OBA-<2.ETXTU&TL,\G!U9KC`:O/9-LF[LJXV.F,P2EFB
M=&Z*6I<9>]T]W2U8XKS4A6R,5AD[*L<VZ]N;U;-JI`\_N:KN7!*R:)>QROON
MGG.75ZJ5;F0ZI</,WMA6^C"T)>]D?I"EXB)-9]S^SL'6%SF3;9$QNRW"^KMC
M%U;^/[?9[^M</9K\K57:7UF"?QA[<)52/B25ME0^8S'D^&EF,0J*&;\N!L;$
M:F",RJ&&`R@=:C@H&P'$I1*`E6I.K&:.B0%!K`8$*H<:#J!TQ'1(.KEL\H=*
MUCHD/5M.#&%0J$N$5V@V)))HN3V2&#J[,,Q0-N&4(CT41(K)H78:U&BH*X46
M"LC1H&S$9,B^<96TJGCQ-MR57-_*%V&L;0:UF;B!>B$Q=-Y34TP,4*L!5(X8
M]"[A_+$)]]9HP-]C%`>UPP#N,,LA&S<V1D\DAG[\=XG1&70;Q:7_5C/!Q%"C
M0<D`-1I`V8A!;Q$^O.I47Z73D)^^T77YQ;-P_04``/__`P!02P,$%``&``@`
M```A`!NH_A:E`@``H`<```\```!X;"]W;W)K8F]O:RYX;6R455UOVC`4?9^T
M_Q#E?<T'E'ZH4-&5:I76;1*L?;1,<B$6CIW:3H']^MV$$BZA0O0I\<<].?><
M8^?F=I5+[PV,%5KU_>@L]#U0B4Z%FO?]OY.';Y>^9QU7*9=:0=]?@_5O!U^_
MW"RU64RU7G@(H&S?SYPKKH/`)AGDW)[I`A2NS+3)N<.AF0>V,,!3FP&X7`9Q
M&/:"G`OE;Q"NS2D8>C83"=SKI,Q!N0V(`<D=TK>9**P_N)D)"<^;CCQ>%+]X
MCKQ7TO<DMVZ4"@=IWS_'H5["WH0IB[M22%R]ZH0=/Q@T3?XQ7@HS7DHWP?:V
MZ*A7W(WC7K6SDN)9P-+NBJJAMWH1*M7+:BM*NVY&'22PK)=>1.HR7`_#L)G[
M`6*>N>TDP@<$OU80OU,_/56WMU6$H5-LI)QP:_:H-NH+C196JC]B9Y'OF6N!
M+^8QC2KB%.6[5BDH"RG#-ZNE2#F*Q>ZXY"H!@A+'!";^'`PR:-AT"$PM^`EL
MQ@Y)Y91-EZ!T3R3SCD+)H/J--.=MF-]FSI7X5P>M%GE<YCDW:Z9G;"Q(2S'M
MJ8X&[6EH+3@V3%Y+8445VJH>PRHTPV11&-K419O-`Q>&/7-9`GL";DN#@BAG
M:3WMYK)=/TP24Z*SHQ4>4PN6_=1J/@&3LWN8.@K3(Z)<M6'&3B>+3,L43QL;
M84]N36LO2&T4'A274PNO)?)FH[<V>[QU&B^B@YP>-X-Z&E]1H(.D'M>!`G7P
M].X8'63U`R78A$\EWI8D[0BXPSA(ZO&N\,0UQR:BYN*@=8R/`V$^=T#4WNB3
M::7R1'M>GYI73)OC`F_F':$]XS^9VSV)]HP_);GO9*AAU97=&(:#EL[C=H(_
M@J">QW62@[I;O,`3+A/\LU2/^FKNGO?>=VQ_KH/_````__\#`%!+`P04``8`
M"````"$`^%)4@)(#``"/"P``&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;)1676^K.!!]7VG_`^(]`<)7$B6I"E7W7FFOM%KMWOOL@).@`D:VT[3__HX]
MA&"G'^E+&YCCXS-GAK%7=R]-[3Q3+BK6KMU@ZKL.;0M65NU^[?[_W^-D[CI"
MDK8D-6OIVGVEPKW;_/G'ZL3XDSA0*AU@:,7:/4C9+3U/%`?:$#%E'6TALF.\
M(1(>^=X3':>DU(N:VIOY?N(UI&I=9%CR6SC8;E<5]($5QX:V$DDXK8D$_>)0
M=>+,UA2WT#6$/QV[2<&:#BBV55W)5TWJ.DVQ_+YO&2?;&O)^"2)2G+GUPQ5]
M4Q6<";:34Z#S4.AUS@MOX0'39E56D(&RW>%TMW;O@V4>1*ZW66F#?E;T)$:_
M'7%@I[]X5?Y=M13<ACJI"FP9>U+0[Z5Z!8N]J]6/N@+_<*>D.W*LY;_L](U6
M^X.$<L>0D4IL6;X^4%&`HT`SG<6*J6`U"("_3E.IU@!'R(O^?ZI*>5B[83*-
M4S\,`.YLJ9"/E:)TG>(H)&M^(2CHJ9!DUI.$H+Z/SVXE\5"0SN^!2+)9<79R
MH&E@2]$1U8+!$HC/B:&,(=7W,H44%<F]8M%<D(2`\CQOXOG*>P9'BQZ2(00^
MB`$2F(C\C%"%`'6#1,C;EAA"!=_V_JQ(+;(4+<S]LFO(S$3DUXC$'R"&1K!N
MK/%C;0J\=J.1%8GE1880;"7E<#YZ86P,++=OK,#0>N.-K90SA"QT#:,XL:J8
MF^'99;4A"GKZ=E$*;(D*!Y-U>V4(2;6H61HG9C@WPE$0#V%#5/(540ILB8H&
M6A2%$!25AC,KG(_#R2),A]6&J/0KHA38$G7)%44A!$5-WE!EQ-^7I<ZMT53X
MN)T5V&IGJT(90D;M/'IA^+'XRL8*;/EQL1G]0$BL.\?ZQO)SS)XW`0R7V[/7
M:$N%]=5D/09E3&)[-N9F/+JTO^%-8,WJCZNBT98N>P+VF$&7Y5YNQM_590WH
M3W3A4!T/H?0R5+%J`6)P"DW2^=PNG0E(%O,+@VF9&INC1E;'V^=G1X##UI!H
M*<AZ#%1.G783?QI:1<^O$9<188JT9K@2&<%,^\3'ZV&>7L9Q[R-B^L'IQW$4
MI5<R34P8)?/1@$6A>"_">T-#^9[FM*Z%4["CNO,$8,'P%N]CF;J/Z1O5$(#K
M4$?V]`?A^ZH53DUWL-2?II`HQPL5/DC6Z7-[RR1<A/3/`UQ\*1R"_A3`.\;D
M^4%]N<-5>O,;``#__P,`4$L#!!0`!@`(````(0`L4Q<R(P8``&,;```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;)Q976_J.!!]7VG_0Y3W)K'S`52E
M5TVZW;W2KK1:[<=S&@Q$)00EZ=>_W[''4'L2(+E]H&".Q\=G/,<.OOOV4>V<
M-]&T9;U?NLP+7$?LBWI5[C=+]Y^_GV[FKM-V^7Z5[^J]6+J?HG6_W?_\T]U[
MW;RT6R$Z!R+LVZ6[[;K#K>^WQ594>>O5![&';]9U4^4=?&PV?GMH1+Y2G:J=
MSX,@\:N\W+L8X;89$Z->K\M"/-;%:R7V'09IQ"[O@'^[+0_M,5I5C`E7Y<W+
MZ^&FJ*L#A'@N=V7WJ8*Z3E7<?M_LZR9_WL&\/UB4%\?8ZD,O?%463=W6Z\Z#
M<#X2[<]YX2]\B'1_MRIA!E)VIQ'KI?O`;K.(N_[]G1+HWU*\M\9[I]W6[[\V
MY>KW<B]`;<B3S,!S7;](Z/>5;(+.?J_WD\K`GXVS$NO\==?]5;__)LK-MH-T
MQS`C.;';U>>C:`M0%,)X/):1BGH'!.#5J4JY-$"1_$/]?R]7W7;IAHD7SX*0
M`=QY%FWW5,J0KE.\MEU=_8<@ID-A$*Z#P'\=A/')04(=!/[K(!S>7F;@XVR4
M.(]YE]_?-?6[`RL.^+:'7*Y?=@M1CJK@'$XZG9,)])%!'F24I0NE`@JTD-NW
M^S#B=_X;Y*/0F+2/838B.R)D&H'>B2.H97(<SMB1B@1+*C*#DEN*#1#[Q(TP
MR_J()#A1LYB`0N.92/#2C8R!PR@\Q45RB,'U)MEF1H,U,H0Q1Y9Y"J$&+FLA
M.P'.8A`1!HA9J*0EP3P(OJ:N*&8F8#YC)L!B"%5@,KS,3((ILY@P0XRAC=%@
MC9Q,&5F"KV4%,<;(1H,U\LP>>5Q69"<Z=YH5Q,RPE(+(%!VS8@+B)#8!%D.Y
M?1GU?3DK$DR9)20KB#&T,1JLD1=31I;@:UE!C#&RT6"-S*`PS$F/2XOJ16=/
M\Z)!%Q)#$,G9S#!I=T9J1K)$D[1K>D9RI$(O74,JL\76:I*Y,K1*L(23F8;1
MG(Z.('-TH\4>7=K==`W0)&T-%I0%@C!3/.+Q(B&0C"%$$;5I2<\S:%VN&H8.
M:=&)B8NF&H1T9HN0Q707TH@!-I.<59YI:!''9*=--0C9W'`6)B$AG&G(`)U)
M=LO0.FUQR-13#=)THMD\(8A,(P;8_)`%LP$/CNG>K$%Z!2WB6<)[*PCC#-":
MY+L,/=0NJQX=PVAQ#]#=!D8GWCO26M!/[53U#!!!X'+JE.?-"<V,G7-E3ESY
M<E$I-''CF)X0-$B3B;PY,<),`_H*<6*^5\@,F&Y,-T85$H[1J$SL172Q:,``
MF4D>S-%,[321B:<:I,DPC[+--&"`#`0VO6_<VI%/(#W7H1N#!IW2%="UHP$#
MI(@ACR0U9,PD*RE'$%9YM(#MNG<"UI`!6L291](:<&CC@0,?#.1#)0@*KU\[
M;4)L/#N!>D],Q*,EL0AB75GF`UY-G3CE"%)BH`V9+=8VRHDW7QD=O=0VP=X2
M,@Q7CVZTV*,3"QZ9''19N[K(.DTY@G#-,,YG<[I[:L3`DB'6?$43-%-;DQX;
MPW&U)D:+I8E\9#2+^_+H"DT\.*&C:Q`^0,KGD%[Y:$1?BW"2"2NTS8936TLU
MR%B=9HNM!7'=<>LC1/>U,I+035*#3!;8;4`#8K=7,C)@LPG=%4,$S9C:HIF7
M_')#CU,V)/""+X"MD33'T0?A4*+M#(4)W28U2+,+O#F/%N8?P6<4OXAL_-?L
M;>;2/\<S1[<UJQZJFCQ1A`B"5\.2"2@;!'VYF,V1N/25W`^Y,]W-0@0=U;5G
MD)W[UF8UR;5#M%]+N?AKOKB9:9!9#^=<._PAUU:]R.\'_:I$US99&"VV!I-<
M.D2[-34(^U6)H%-5\H&JM"#<8V9=P'NSAT4WFF3K"GVM3#7HN)#@:$T/'Q0Q
MLC"C2::OT(3KC&RVJ099A=FGBV=X&W3&]N`>8H)Y*#3A2']K2#7HJ"<IS'/?
M8I;Q3@-_MJ]$LQ&9V.U:IZA?Y7T%!YL_M9[N4A[450II3^&.15U(^*<OX(KC
MD&_$'WFS*?>MLQ-K"!EX,]"IP4L2_-#5!W59\%QW<+FAWF[A,DO`;]:!!^!U
M77?'#_(T*B]GU&W#_?\```#__P,`4$L#!!0`!@`(````(0#,^4VN7PH``)XW
M```9````>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;)Q;V6[;2A)]'V#^0=![
M).Z4#-L7$;LS<X$[P&`PR[,LT[80231$)4[^?KI9);$6ALOU@Y?CT\53U=5]
MFK1Y_]N/XV'VO3S7^^KT,`\7P7Q6GG;5\_[T^C#_S[^_?%K-9_5E>WK>'JI3
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MJ`NSB%(?:5<=G`#W>7;<^]9P%=G^:+Y^[)\O;P_S.%ND>1"'CCY[*NO+E[T/
M.9_MOM67ZO@_((48"H)$&"1QZO'WZ2*)TGPU)8J[7B/%?;U&B1;1*@W3;%C+
M$O)JRF2VE^WC_;GZF+G><\KK]ZWOY/#.1?;UB5V5(9M;Q7Y5,%<I'^2SC_(P
M=XO&#:_=+']_C(/H?OG=S<P..1O@N,^$$W-.H3DA9QC-B#+!L5>.;PR7YBU7
M-P\TU^X>N*;DR3XEWQ,^QPT`5+_(L!AD&,V(@X1G:#4G:A-D^<13\O'DA[EK
M05+^E%]Z`QQ8!S[G0@)&`I8`3)N[$*WUM:_Z:^X'N?XC&L.TS1VF`3CKILE<
MYP=!P),HA@@&"&V6EHX(HSBA,5E2;H'0I/J3\629C"PX</(FF62]HA=NLBV&
M"`8()!DV(DQI2)9+-B473Y:YK'C=-\"!7/(LIQ>&7(8(!@@D%SHB"T,:DN62
M3\G%DWDNL5C(&Z!`*N$JZLAED&&`09*A0Z(H<\FTG<NR\6>/CBVYO]O\()%5
MD(D9`DXKJ0``\URO4S'`R`&6`$SRFDONE^K)?"<*\[84L,J!0Z1*P$C`$H!I
M"YV=T7KVBVO8O)!:'9*@<'X+\A^\V,4(CD%.FZ;M'\7S\C8WN4]",$>VQ^9R
MCT42Y/<I[%K,PQ2#%)H=7!SCQOFO5W3H79`D-S!IX)D\*;G7-B$?YM=N7\5Q
MQZ1!H#Z.P3@T+3XJB]8T,I\T[Y?C\_)LV8QBD6Y"(%V+FH3LZK#UCN`8Y-"\
M6.0P3?RF=6MSGI?WT/%Y@>.Z\.0PDM\BPQ80`@GG(DM"YLN8US#'8!R:%QNU
M"E:L$WA>WD['YP7F2_,*5VW%,"_JT&YQL8MC6H,4XV]B7&O0K`C"<_`V.CX'
M,%V>@SBG;T+JS'&4LL;`'`8I!J/0'.B@_H;S=CH^*3!?FE0<R`-,>+5LVI5K
MWI7%C72]+S`*L13A,^']DX@>=RH.P769^%!U%9!PM;AU2E8J3L@0P^"%Z'S`
MF`;AF7BW)9D,[,_@S3P#93K$P%&Q1$PH$4L1IC":9/L->^A0@J2V/H5"C$(L
M1;A"8>#]-8RT<;N'$+P[-TB"+HC\X5^UP3#%(*7-TU*$YS#)IR/MTW$H]Q8D
MM5<O%&(48BG"%;JN&]^ID6</]@&0J$*)&`S4<BQ%N$)O1Z/74@3FY2[8>J?N
M`^IP_K92M\$0P^"%:`8PID%X!MYZQF<`1L4S$$]!-OZ1%O.W0B%&(98B7*$W
MEO$*P89<NK<:ZYN`"$AM?0J%&(58BG"%PM#&>4/486RA//DBB2J%8;!/Q%F0
MB_(;-<12A`OW'C&^M.`H?/+ED38"DKL9\H\2\P5Y``;.,$0P2&A3MA3A^KVG
M$/TC"P].Q/.01]A(VE6A$*,02Q&FU#^8I4K[#:-A#VUE2&KK5"C$*,12A"L4
MEC:NEG&7M<DF1A)5"L.@B=,X$".,&F$IPG4+&QNIN\O.Y*DR!A+5+1&C.)8B
M7*GKN`D]X-F#/0`DJE`B)I:(I0A7Z%UB\GJ*P5O<96Y;;JPV,B11I3`,-[(@
MS\1YW:@AEB)<^"07B[M<3%Q]@R0J6/J:41Q+$:YPDHO%8UP,252A]#6C.)8B
M7*%PL8$MJL.](GEG$P.)*D3W"AM["!9A$*W9!S\5&Q7!4H3KGV1F<8>92:_:
M((GJAV$M8A3'4H0K%'8U4&%PH/Z33*QL2B%&(98B3&$RR:8:-G_&%:L>0%);
ML0*1_-8#XE;(J"&6(ERP<*W^DB8=;A6)JV^01`7#L!8QBF,IPA4*?QI0"`;3
M/^F)=*%"(48AEB)<H3<(LNL/*`0[X;N]/`4F0,)38+*0#VR*(8)!0EMS2Q&N
MWQO)>/U@.TQ_)&]D$R"!-_F'E^HF;)!AD$$S@*@-PC,0]C7N#)-TV%@D[@8V
M2&I5%`HQ"K$4X4HGV5@RQL:01!4J&U,<2Q&N<)*-)5TV)DZC&R11A=+8#')^
MW3&61N&*)QE7TF5<:OU)FRIP&.AK_H(IS-H@H\W24H0K%D;F^]6WS,#.`5[%
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MS081V,7\OR3X#WX+:>DHKEFX6+][I1WN%<N3`I+PUB9?).S>=IW;3^)NHY@\
MPO`1V6(-YU/(/0AB=0V+(YJZL0IDPAW'[3W-*+E\Y0D$2>U<%0HQB,#LK;K^
MUF'I("Y=V.:XQ9MUV&<LCR!(HM*5?2J.I0A7*LRRO\TR<+O^Q8LDJE"9I.)8
MBG"%WK]&FV0&;L<W0+D0D$05PK`6,<BY+98@XZM%-S*-RC,0)CI0XR[SE-M/
M!J16;X'(3>_@XC8JAJ4(ST`XZ4`&8(5\#N11*I-^62"""ZYCLS1JC*4(5]QA
MG_ZO"P/*N^Q3;1[*/C-`^C9Z@YQVQBQ%N'9AJ",W/C!65G7UH#L#4JNB0`2T
MN_\4CL5$&37$4H0+%SX[<MOK\-M$^.0F4WZK$*,02Q&N=)*[9N"N`]L>D&AI
M)6(P4,NQ%&$*<^%^_8W;L(7K17+30%)[]4(A!I&^5K9T%-?\IVS/;5G^OH8U
M;B(.^1LD4>W*]A3'4H0KG61[^1C;0Q)5J&Q/<2Q%N$+O2*-MS[WJI&JHYQ](
M5*%$#`;JGW\R"C3#:U+P_L^Q/+^617DXU+-=]<V_`N4?I=_0V^M9GZ/F!:O;
M+]S;4>_;U_(?V_/K_E3/#N6+&QHL<N<39WB_"GZX5._-VT5/U<6]%]5\^^;>
M@RO=:R7!PI%?JNIR_<'?5/GWNIK7DQ[_#P``__\#`%!+`P04``8`"````"$`
MW3;58F$#``#Y"P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R<5EUO
MFS`4?9^T_X!X;X`0TB1*4K6INE7:I&G:Q[,#)E@%C&RG:?_][K5):AR4C_6A
M!/OXW'/OM0^>W[U5I?=*A62\7OC1(/0]6J<\8_5FX?_^]70S\3VI2)V1DM=T
MX;]3Z=\M/W^:[[AXD06ER@.&6B[\0JEF%@0R+6A%Y(`WM(:9G(N**'@5FT`V
M@I),+ZK*8!B&XZ`BK/8-PTQ<PL'SG*7TD:?;BM;*D`A:$@7Z9<$:N6>KTDOH
M*B)>MLU-RJL&*-:L9.I=D_I>E<Z>-S479%U"WF_1B*1[;OUR1%^Q5'#)<S4`
MNL`(/<YY&DP#8%K.,P898-D]0?.%?Q_-5M'8#Y9S7:`_C.ZD]=N3!=]]$2S[
MQFH*U88^80?6G+\@]#G#(5@<'*U^TAWX(;R,YF1;JI]\]Y6R3:&@W0EDA(G-
MLO='*E.H*-`,A@DRI;P$`?#?JQAN#:@(>=//'<M4L?#C\2"Y#>,(X-Z:2O7$
MD-+WTJU4O/IK0%%+94B&+0D\6Y)H>#5)W)+`\X-D.$FB9'Q>2F#2TE5Z)(HL
MYX+O/-AZ(%PV!#=R-`-F+$\,1>XO#]0%U]SC(KT4T!)Z^KH<3J;SX!7ZD+:8
MAQY,%['J040'2`#Z#B*A;K;(T^(0O/!'OO<A;AH>>'4"#P9C^HT9K:R!3F0H
MB1WYLO+@(BAC1\%'9D:!P4QU\1QU*S.GU77$0$[7B\%%KIBA4PZ#27K%[.?P
MD-D]@=U_O1A<Y(J)'3$&TR]F/^>*&?^/&%SDBADY8@RF7\Q^SA5SVQ5S>K<B
MV!61."(,QMJMUD"G)_C1L@[SZ<@(/G=.#,:*;`UT(D^OB8Q@-^>QD[/!]!>^
M?ZZC)P(/N[P4&NTJNG44M2"K&/9(-[KCJJ<;$1DCA(-VPK%:D!W=+-,CW>A7
MV65DK*_K5A,W][T_HM>[=M4R]`A!([MX/T;&]KI"CKXJ!M2_+UJ&'B%H8I80
MM/$1>,F9OACKLP7%H9/\0V3YHW;VE3W2[0NZEZ7B3'3C=6=VA66(;71KI!O=
M\<@ST8_-,0[=;QC<V_`@FX]8G$!QX*^[<_!N=P)C%)K+F[F6-&1#OQ.Q8;7T
M2II#H\+!+>0DS-7-O"C>Z.O'FBNX<NF?!5RQ*7S)PP&`<\[5_@7=^7!I7_X#
M``#__P,`4$L#!!0`!@`(````(0#R;,7JEP,``'(+```8````>&PO=V]R:W-H
M965T<R]S:&5E=#$N>&ULE%;=CIL\$+VOU'=`W"=@(,DF"JDVK+:MU$I5^_U<
M.V`2:P%3V]GLOGUG,+#@K%1RDP`^/G-\9CSV]M-+63C/3"HNJM@E<]]U6)6*
MC%?'V/WWG\?9G>LH3:N,%J)BL?O*E/MI]_'#]B+DDSHQIAU@J%3LGK2N-YZG
MTA,KJ9J+FE4PD@M94@VO\NBI6C*:-9/*P@M\?^F5E%>N8=C(*1PBSWG*'D1Z
M+EFE#8ED!=6@7YUXK3JV,IU"5U+Y=*YGJ2AKH#CP@NO7AM1URG3S]5@)20\%
MK/N%1#3MN)N7*_J2IU(HD>LYT'E&Z/6:U][:`Z;=-N.P`K3=D2R/W7NR24CD
M>KMM8]!_G%W4X-E1)W'Y+'GVC5<,W(8\:7KXQ0J6:I9!YEP',W(0X@FG?H5/
M/@11#0"#J-]=F/L`HWA]F.%S%_*Q2=L/Z60LI^="_Q27+XP?3QHB+<`&=&.3
MO3XPE4(:(-8\6"!K*@J@@%^GY%A/8"-],>IXID^Q&R[GBY4?$H`[!Z;T(T=*
MUTG/2HOR?P,B+94A"5H2^+^8\2"XF21L2>"_)2'^G$3^\N]"/+.HQJ\'JNEN
M*\7%@6H%V:JF6/MD`[SOFP)N(/8>P;$+NPG6JR`SSSM_ZSV#]VF+V!L$_/8(
M,D8D'0+3!QIZ(>#,="$(1B&8+52V-Q^&<0,KKD$$C>HH(,&Z'Q_)``^FRT!P
M[$:#U=I^&(0I*Q2:##Z,X@+)]+@(AC(<Q`W[U1@_#`+JL\]#-$8D'<+.`\R9
M+@3!8R&+<9B]02P:VTD41B%9CA%)A["%+&\1@N"Q$"O,WB`@6._(RA+2(6PA
MJUN$('@LY&X<9F\0R[80_;6=&#/>E,RH0O`0F[Q3$3R6\5;OID(,POAQ>&\O
M)QW"]F-]BQ`$CX40>X\8")9(OIO-2#`+H6?DV%UFQ%*==%A;$X&S9+H[#=I2
M9?6I?8L9%@RQ>TJ/N9*#76YRLHCIB</]3.P-W6)&<NS*Z3%7<JSFBD=@"([]
MI=N;ECF296]O8C"#!M=^634E%?C+NS",WF:-*II@,YSN$J*MI-F;O&&,7=-N
M`I^\!6Z*/NG'KQRZJ?_"'>=*BM5-]BUFE#"K%>!="7D&>]W<:,P)73)Y9`DK
M"N6DXHPW%`*F]E_[*U=[%^H'X/)2TR/[3N615\HI6`Y3_?D*I$AS_3$O6M3-
M^7\0&JXMS>,)[K8,CBE_#N!<"-V]H%_];7GW!P``__\#`%!+`P04``8`"```
M`"$`4P94IV\#```?"P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R4
MEEUOFS`4AN\G[3\@[AN^`B112-4$=:NT2=.TCVL'3+`*&&&G:?_]CFU";)*U
M22]*L5^_?7S.\<'+^]>ZLEYPQPAM$MN;N+:%FXSFI-DE]N]?CW<SVV(<-3FJ
M:(,3^PTS^W[U^=/R0+MG5F+,+7!H6&*7G+<+QV%9B6O$)K3%#<P4M*L1A]=N
MY["VPRB7B^K*\5TW<FI$&ELY++IK/&A1D`RG--O7N.'*I,,5XL#/2M*RHUN=
M76-7H^YYW]YEM&[!8DLJPM^DJ6W5V>)IU]`.;2O8]ZLW1=G16[Z<V=<DZRBC
M!9^`G:-`S_<\=^8..*V6.8$=B+!;'2X2^\%;I)YO.ZNE#-`?@@],^]MB)3U\
MZ4C^C308H@UY$AG84OHLI$^Y&(+%SMGJ1YF!'YV5XP+M*_Z3'KYBLBLYI#N$
M'8F-+?*W%+,,(@HV$S\43AFM``!^6S41I0$10:_R>2`Y+Q,[B"9A[`8>R*TM
M9OR1"$O;RO:,T_JO$GF]E3+Q>Q-X]B9>.)GZ83R[Q27H7>!Y=/%O1IGV)O`\
MF?BST`NCCS?DJ.#(6*>(H]6RHP<+"ABVSUHDCH.W`.?+P86H"NV#$,LE$#<&
M%?&R"N)@Z;Q`%K->LS[7^)%G:C9'C4B:,$ZU`0?`!CH(NTXG2B"`0GJ?4BPR
M*?W(-0G62N/+/4Q]SY^9\YL+'J8BO:`X;=/8!&1=W\3[\$*<V)")(<3^U#?_
M]5II5,V+\&W&`ZDV8*"`[_4H0@SQUE#":$2B)!J)&HAE7'TW"F+?B\TUJ2D)
MHWDPGP\2@Q:.J4XKLC_];P,XUJA89%('\73PE^6V5AH->SR0:@,&4F0BO9]+
M(?XHETJCH8P'4FW`0(EO01'B<53"45249BYS-YK;J+D39JH-&%3BZWMU/Q%B
MD^JLPI1$%93GRA\3>Z,4&IHV8*#-;T$38A,MB,?5KS0J8.,&HN8T*FW`H/*@
MGUT?,:D><XU.V+H700T/322(QX"#Z-2$!4EB2V834;3GJY/JJ6:N]XT@/IUP
M=0)[D8$X&S7IS2`Z(2KO"XBB'6N(UWTIX/IREN79J8OWJ$K4GXLS1C6K);HW
MU1C5%4=]=ENTP]]1MR,-LRI<0(+<20QAZ-0%1[UPVLH/V)9RN)C(/TNXB&+H
M]>X$Q`6E_/@"L7&&J^WJ'P```/__`P!02P,$%``&``@````A`/MBI6V4!@``
MIQL``!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;
M!W6*V+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;
MAZT#^A7V2$JR&,M+T@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^
M'],X:'MWAOU+&QZ2"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5
MBO1A&,O+/"$QS$VXB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--
MTMO*B/<8O,9*Z@&?B8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HF
MVE[5_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*N
MU^MU>[6<G@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*
M9;%$#<@^UI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:
M3Y?0VJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-
MD9HG9()]B.(NCD:"8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY
M4_3J^9/CA\^.'_YT_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9
MQ/_ZPR>__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP
M"'0SAG$E)R-QOA7#$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=
MA&*F:`GG&V'D`/<X9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5
M,PM*Q_;=D#AB[C,<*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C
M)Y`6BW9I!'Z9E^D,KG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SB
MB!4-?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H
M.BVC>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2
MQ]VG%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N
M;+>];=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44I
MABJM&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<
M7""P68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'
MQ&J/C^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#
M+5=9F]B<R\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQ
MF*0^TGHO^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E
M$;SP$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[
M4Y/99/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*
ME%2CLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,']
M.E1!GS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,
MYJT@'NA6*KM1[ORJF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5
M*`FIWQ?0.)C:`=$"5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R
M#V7)1-\IQ&KIWF5)LI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\
MN>]I!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]
M147TQ*+-JF=9`<P*6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?
MV/^H\)G]X*$WU"$_@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)
M6RW;K"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L
M(&,<8[Z4%3]F\=%]</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#
M`%!+`P04``8`"````"$`KZB%GSL,``!T;P``#0```'AL+W-T>6QE<RYX;6S4
M76UOX\81_EZ@_X'@M44"U-8;94F.Y>`DF\T!5S?(N6B!IB@HB;)9\T6EJ#L[
M1?][9Y9OLZ)(+J6E]A(A9XG2SCSSS.SL['))WGS_ZKG:9SO<.H$_U7N775VS
M_66P<ORGJ?[71_-BK&O;R/)7EAOX]E1_L[?Z][>__<W--GIS[4_/MAUI(,+?
M3O7G*-I<=SK;Y;/M6=O+8&/[\,TZ"#TK@H_A4V>["6UKM<5&GMOI=[M7'<]R
M?#V6<.TM181X5OBRVUPL`V]C1<["<9WHC<G2-6]Y_>')#T)KX0+4UYYA+5/9
M[$-!O.<LPV`;K*-+$-<)UFMG:1=13CJ3#DBZO?%WGNE%6VT9[/QHJO>S0UK\
MS8?55+_2M=CD>;`"$'_XSRZ(OOM=_.?=']^]Z_[KV^_^\9.]^N?/WQ2_^_E;
MO9.J(3+!!]4R+[N58N'K6'(GL>#V9AWXQ!`#:$*VKE_\X(MOXG<0#&`>_NSV
M9ON+]MERX4@/X2T#-PBU"+P,]K$CON79\2_FENLL0@=_MK8\QWV+#_?Q``N,
MY'>>`V["@YU8PWGU+!!-:M,887`V#?`(M<D#DRP\6&V3]>\#-G&ZAO6Z3N&/
MT\6LJ+9+FJYB7!0X/$57YBNB)WQ:3'73A!S2ZW:15NJPEI1-YEW0=S9E5\.S
M638P!^9(JF5<+!;]A@H'IDPJ:Q2:[T=W9Z-3OK(RZY(T?*X>@!U.+HL.=-V*
M_CTR\76..#GS@-:.QYA4+NFSKI?GQD?'L[?:@_U%^RGP+!^)I8,:^S4W)G.!
M)U]\YGI6(DA%SD56>\A'E\51?8_TTZHBZH%BL;*GJH%_F9NWX'_'=;.:=F!@
MU0=';F^@O([LT#?A@Y:\?WS;0,WGPTP``Z<3_Z[FUT^A]=;K,X[$&FP#UUDA
MBJ<YJS23D7Y^=6_.[YE>@DP418E0TYR/6A!Z/YO,Y2.=3R:RA?9->$D6^GZ(
M+\E"3?AO+HW3)-<;LD!F\K3(P9EA]W(TF4S&O:OQ>#PQ!CW#8"0ODHAV_)7]
M:N-D41I-101#0#`9C"=7?0#2-<9,U5D1#`#`:#@<#WN3O@'_LU35/@+9G`YU
MU5XE"!1YE2!0Y%4V.>E(R/Q)3X%U&L5]E2!0Y%6"0)%71Y(S\$BY5PD"15XE
M"!1YE56I$OLJK'\J[JL$@2*O$@2*O"JM^$PR\$2Y5PD"15XE",[MU71:-;^_
M-]D"2[$R*Z^/V4P.YHZ+(%S!R:/TC$AO"/.V^-CMC6NO(Y@EAL[3,_Z-@@W\
MNPBB"$ZUW-ZL'.LI\"T7WG;2%NG?BI9P,@K..TWUZ-E9OH`R;L4@QANK:$M#
MEHD,K/"-D=$=&</^53R)DJ3:LU?.SBM:E^D^&"M`(W);;SCAT,^4).&0K[=U
MT`N)^P1;,%<S3PLV@)A(0T*PA0P;\[5G41M)"S$;20-!&TD+41NAZQSJ7"F3
MJV`'YT'W'6R:XVXW7N83U5,MD``_$#&'09`V13YKFQQ@M+9-4ULAOQ3ZQJR/
M+U:Q'K"TID71SIH&!ZRL:2%J(Q\WJ7<YX=ER`J;G`TCV^.9^?AP,4!0W3/'L
M)<$D/^'IA_@$A'"Z.VQNK7AB-4AH-EP)VT"4I&WVJ%5I=PJIEJOC7)Z*K[68
ML%3BBJ2$@(ID:;ON)ZP1_K[.RA)8?;N]>5V3'16PS06W'."&#7P+2]S)V[@$
MB3^`KK)&_=)&FK79N&\/.V]AAR;;^\)4L*.XE)Y_FK':*?_\WG6>?,]FZX=Z
M+.;',(CL9<3VYK`S&&5X!B5X>HD@$3RGZ(<-)`=)!)Z$^3A%/ZQ/'=0/O"C5
M#\$EK%]F/.`NI"2HP04TJ*OPR$0`JQ`I`G"""@2X:RKA`,)3!0*8W:4(($!S
M!`"G(BI.Z0<]DLT@!G*5H+\ME9!C4BLYE2U:699^07^%E2:7?D^BF>1;"/2<
M9OA0`>`DE64I5E6*(6Z'GI93`!\J*#!AU)4SY,%:0Q9WP$$.0!DA).ER@"`-
M5#$B+RI)S@6=HHS,)-8A)"@P%:F&`'"40"".Z"D:?WL4@Z(1F$:#HB&80N#&
MX.HL(;5/4$]P(Z0B#(!'2:_(\W6/&S'.2`.!H"I#DFCHJTJ1%(.J')F[HJ\J
M11((JC(D]82J%$DQJ,J1Q!6J4B2!`(PHR9#4$ZI2),6@*D?FKABH2I$$@JH,
M23PQ:#E%=NBR:;R(2M9/1\>MGVJOZ]J%U%[9I`G\GC:/9T_QS!%\P>929"J-
MUZE9Z=JI]AR$SB\PR<3KU9:PF&J'.E[?&#E+>N1+:&T>[5>8BL:GPE[7>VN]
M;':9K!"+8^2765.LYT4.Q-4O;>]Q6\IFSARLP>M:+6U$N3AK@OR<@`5A)4N!
M\)9+[7R0E1)1:SD-&&%UA^/E>!"X+%5[6F//][(QM!D"DCHWYAS5-,'PKAP#
M=14,]6)=1+"W4E?AV7(^>6BX!1Y7`MEUHIU"^B7(<)+T=2+KR>:L-LFT24L3
MY3A_E^J3)LI;#8BT9&@$"(HS96P(]X[24>6$<55Z'`AFC?AB@*\Q:P@@(^>.
MP'D5Q<@1F?:H\"T#A"OX?'G$(YHE)P[2.K<TPJA7CT%(PVRPOU)3A=!DYU8:
MX:L8JTJF"B5)N0V@3;)2.6EP&X]*O_*L"7OYJP9'0Y!MQ6/;^*HR".5/>C\]
M*<I:1=:<G#8"7:*[\`1<58YH/;ZYX)&&ICE#TNNF)AU>NG)J_S%C2K]LU*L9
M]%H;Y$H!?97#,!?4,B@[->_4L73DH$;#[%2(-33Q"(7B+!Y&*@KX;)Y=4KM@
M)TA7.<F<CD_IQ7KA\)H17QWRY@AGV=,(EQZ6X@S7KV24CMMUL2N;/"&O%Z*U
MN=.%8OC47E4WHAX9A[6#FQ")17#-693M?7#LH3ZOL.N4)"<1H#TX:7Z>ZJ[$
MWQQM130B[CZ3@_FD#KBK>.-[36E'/K:7\*P5*G05K!'_-BC%6D-Z3$W[ZQI@
M>L`X'X(B9/*!>::NPX=K`3=?^)P)$]^=ZTH(:;0U.@<,O*U;/N^**M(*5O;Y
M&%J+5JS8U%=^K<Y^3T*F]!Q6:;X"I_*9@>]AQP]')%IPUZ%8<+:A7+AG""H7
M#-7Z2JLT5(NS0![:"6FO/J>0P5D\:$2&D])0HH2*35&^3N9(Q%/F^-&CIK_Q
M@X=,RM"OAP:(8FT@(=B.*:FH4]OFK"*1U_?;<N<6YZ`\E[QW3^C&<+UT]4Z.
M7Y6WH4\LV`E.W,/82O(3CD<L[M8*-BRQ7:&P#Y1<5<]?4Y_M&M7P#L/P1(3N
M[[4+[?T2+<M.,F*)L=@Y+MS""ZG$';W+W1;N5#.+#R9[,*MD91-$G)E163#[
M;RH+),2U11]W>1-<L/[95%:V^#``:XDLN.%`8UFP\S[&-<`]^#DN`W:K-<4%
M31)9//=#0>Z-0W[$5$APH<DBN*BLW(_`')4%)C>5E?L1'$=E@<E-9>5^!(1$
ME@%*FLK*_0A>H+(@W)K*ROQH\-P/!;F_.NA'/E9Q:[D(+BHK]R,?JP/!6*6R
M<C_RL8HF-\65^Q&D4N[ABZ:R<C_R><(0S!/4QMR///=#0>[W,RH?\7W!B(^E
MY+Z#=X0CK&Y$.(JEY%[CHWP@&.6QE-Q??'P;@O$=2\D]!?*(109\(6Y1YJ,!
MSZXAR.[,6J59EP\8'&=$8,!=XI<[%YYI%.`3D=BE$UAV$(-PRBHDZ=E>OFAS
MN!-.)HCO#SB,B@BZ?]VXEF]%0?BFX>42F3C>Z4-!<7\*@HPC7D(?/HH`^@&>
M'P6/IM*`EV00YPC":PZ:B,GZ`D\/7CO=1`RTCM'P\8<E>1,QT#H6PR=5K)]$
MQ'SP-[O,0WPNQ:%;1,1'QW^Q5WSD\%FB#R!%)#W8NRBTLOCCNU1?D)@'O']2
M)H-/$?$#'=*;/27UYP/<+BDE$2_(('T':V@1X'_9181&;$6$P"W,A80\.A'<
M>2_MQ)P(A"6"XS&`2Y@R$7L915#&WZS0Q]["==V]&"VQ*+\@#*K_U6M^+RW&
M>X1/6&-WV<KF`T#4REY;.S=ZS+Z<ZOG[/[-[6D(P);_ZT?D<1$S$5,_??\2;
MA4(OAJDDI)N/6[@!)?S5=J$SU?][/QM-[N[-_L6X.QM?&`-[>#$9SNXNAL9\
M=G=G3KK][OQ_0!D^CNX:GF=VPN/>V&/IX)*PGG&]=>&A<&%B;`+^4WYLJI,/
M,7RVM1!@PW0X-:*SS1Z7=_M_````__\#`%!+`P04``8`"````"$`\(^@?D,W
M``#HL0``%````'AL+W-H87)E9%-T<FEN9W,N>&ULY)WK;AS)E>>_+[#OD!!D
MC!J@V+Q(E-1N:T#=>N3I;G%$R8/!8#\4JY)DN>M"UT5L&O[@A]@O`^P">H)]
M"#V*GV1__W,B(B,CLTA*W=Y9[`+38ZHR,N+$N=\B\MM__'DZJ3[4B^5X/OO=
MG=WMG3M5/1O.1^/9V>_NO'_WZO[C.]5R-9B-!I/YK/[=G:MZ>><?G_[7__+M
M<KFJ>'>V_-V=\]7JXINOOUX.S^OI8+D]OZAG/#F=+Z:#%?]<G'V]O%C4@]'R
MO*Y7T\G7>SL[!U]/!^/9G6HX7\]6O[OS:&_W3K6>C?^TKI_[+_N/]^X\_78Y
M?OKMZNF+^7`]K6>K"C"JE[/5>'55O9[Y_(#][=>KI]]^K:$^?+_Z83Y;G2\9
M.JI'Y=,?!HOM:G]WJ]K;V7U8/@R3OZW/QLO58L"2/PZF=3GJU>&[E]6[?WKY
M]O#HY?MWKY\?5Z]_?%X."E,]!^[%8`*\H_KGZI_KJW)<VMR[JXO.2KL[]_]E
MXPM']6(\%T)&U8O!JO/N(2@;&=I>309GY2S/UXL%H%6OQLLAX/U;/5ALG"EN
M);SRMKZ8+U8P2'6\&JS6RW+J?ZL[/X497HTG]:)Z#K!G\T4'$X?#8<USGHX`
MB[_*B2,<\^ET/F/Q^?"GK>KX?+"HE]6;]<K8%+#*UQ*&\[V^@J<Z8)8C`X9[
MQ_[+;KG.\SDTGBV!GK^6\\EX9%MY-I@,9L,:0.'^977O_?&+ZNY7Y<NO9]6[
M\_EZ"8LOMQ"%2;U<5O/5>;VX'"_K:GE1#\>GXRX[OZB'B9T?E)-&(@^62Y;^
MIO-XL#PWF1KJC_I/Z_&'P02FZ.#E:%%?#,:CJOX9T5Z";0FB`5<-`U/X$N4*
M[^8KF.OZ,4<+%,8"D=:D`N)"3+M5S>I5.=W;&JD<#\4@`KE\_$;HJJZ#I/]9
M1--D/#@93\:K<=W%%<PIQ;2L+@97@Y-)5]J&P\4:N"**2MCB&B8Z<._\M!K5
MIS5".*HDB.5XA&R]&)X/H'T$ZZI"Y<$:'\""5@)5PMKE8#'J4.S[^>SL_JI>
M3%GE!&1&$H3ER]7:=(H+@H=RX(OK8"X7A8+:YPUK/T><QRO1W/EJB/)&BK%"
MK%_=^W&^JJL''7GY]/'3QQ(XTPCG\\D(<_8/U4O#3X?IX>6`]J4KD+L[VSL[
MN]!U4<'^Z_JWU6"].I\OQG\&R4O3+O<?;NWL[.B_:K"JL"##<YD061#C6H2P
MGI[`>\&N//AM-9N'=ZOQ<BG&@'3SS3I*2(`K;@]2=;_:?6@@?198`1B3WP::
M".I]C.+6P?ZCK;W=1_T[Y?G#@R=;^T^>Z'EGWR5%#D<CQ&D^0PE(@=P?SQ#<
MBS%*H3-RB(U?3TQC(ACCX;@C$LZDAJ)$9!>"<C(?F;&Q4>DV;]Y2AQ]A<W`Q
MZM48X_G5)IW^19.5>^GP:V+4ZA[H',TGD\$"M03W&;-V)*4S@?-TQN4W+AFX
MQE^\<73&YH&QRE?:W/ZY&VJ_W1'6ZQ8+PGC=D*U<3#?"WVOIY0[5KLA0>V\@
MR4#,[VH-J"\6]3GV<_RAKKZ?8]YOY0K4/P_KBQ7>`RQ7X5$,/L<[R)W=CG<0
M`,2/BT:KHRPQN#B&:#LIC%']H9[,S3J7"/RNGK'9B0T;C*;CF;G/*W9:CG31
ME,4'-]G2Y3A#T.EB/JW"6/!8CG%[/R9<F=;5O;")KSJ;>#W#$&(S*Q]9SI(>
MAPG*YP%B\RW"D%[GY$>LW41D%:X`*:.V?BZG3<,EN0PW]2\B;U4G@^5XZ"@?
M3]:R];>3]'^MQV?G#+\_(*`;G-6M:9?56J[I:FZP,6O/,C+8MH6D36QEE_N.
M8MF@WMI2\%RNY:O)_'(CNS=L.!C",>9^;4)6^?OAZ(_K9?`=V-FBQGD8$CK(
M>?2=\*O^-@_7$(#.;+BO6;'#-2]J"#@<FP0[7T\5]?S9?BCA.)8K<1^Z@6&1
M'BGO'7>8S6$N(-&7NY4N8"<P*>Z"Q0O#^;+KB?_(_H31<>3I#4R;`S0%(=B^
M&?P`?YT%]YV_<;*8J#H=C(/K(Y#0-_9$3NXF]6<#EGK7'6K#3V9N.\@\VAQ`
M]+ODI;OM%+C!QY9(W4CHDG2OS9^6*FJ8H1QS%%UQ\'/1&ZZ4;W1`&=]BF5?C
M&92_'I37D3WD6+><1K$Y/X+I`*UKHA8_E6`>#:Z"O9HA+GG(4(Y,&V+_'\8C
M^/SDJKH7).JKZO06H-L4B>N,4*8JQ<_RXS8$G\_UO&^@/-`3,C6SF5#&UE'1
M\H-(BI307SL':9+KWWZS.!O,@N0;),?KZ72PN-);Q^.S&8'Y4+FBP+2"YHCP
M7_%+"<CN]J\X63Y5>Z$%:3-EY[Y97@R&9.U09<MZ\:&^\_05+@J9!NS#1;W&
M?5UN??KX>D8.X9ZP][>__H_GJ*_![.IO?_V?7U67`PGY<+X@;#3/'(G7,#(M
MS,+N7]03Q9_\/:L.+Q;CR:>/>X^46MLA?@"MQ*_56$'S@FG&%W@(C367^C@>
MS*H78[)!6V2%)F/BV]EXL"WXR*$8'.C#:E`-)[@4N-KW61FE=3*>7Z#*INQ-
M>U"*(8RN9V<,&&EN`9JY+`(7WCU;#*93:>EZ,B'<6&A8PH4%V'IO1;K2S(K>
M6N+WR"P#7WU_=:Y'M;'<B,P,*G_9!EA[/EF/)Z0KB0)QF:H+PAIE*V5\`P@&
MW>EZAL4#=4+5:4"I`%M63D[(J/\[XO^-OR:]^6=%J&1I=^[PK^%\0DP)M%,(
MO*M?%J\(G7W(N_$4/?]C?5F]G4\',ST]'6`(KL(,^N%KFWCUE+SDA_&'>6?)
MO\]R_6R)<R*Q"51E9V=X0-/Y2!'A?+'<JI;K(5I@62VG@\F$)Y-ZN,:LM5#_
MM[_^Q[*:D&@6ED?KH:S!;&1IN*WJ:#'_)]+3G_[7EK'4[/\_%&?<KT3]:GXQ
M'RN"[96%K>KR?`S*$;^0OX%WD*HHB2W14EZJ(S:^1J`DPGUFQBUX'PLI#7(\
MMCYR-%\H::,%+G"<+!>T)L9:G,W%%FUPR7Y-#6;$=#!;(ETS]!%RU&(&H_)D
M.8^`:IX.B_^_+E4;22Z-,[V:0X&<_AVQ4=`@Q)D.E]I;W6?,JK84['B&C*%*
M+R;KQ?B"7U$^&6WJX?E,@GRUG=">%6D.R6Z?-JDTJ\9L&1-%Q2\]BOYF7M)P
MZQ,T/WE!A)^4)QJ`EP54?0KO\;^N64WF,YV_52T&8]M`R#J9II5R5GT+;CM=
M#,@HHRG6L&,T6+/YREC33=X"[3];P[86C!HB8+B9]MUCU,)>FV+4ZQD!#0;J
M:'V"1U"].27YR-J.DF;8FUGU9KB:DT/\]/&!U:;VV]B0@9O4PH5`P!K:K!<^
MZSS,FHSXZZ,W;L`Q;C6.VAC*D!>M'FT='!SPWZ/@V0N-S)Q2CW*I!E4Y*QNE
M?L'0NP>D2IM4TW;UW4(!+RPQK.M10)$400+HDO6KNP]X[]-'S,_$I/3PE("\
M.B/6@PA0$'82`4W@+Q?LC)_1"1X9D;L&0+S8E$D)A0>YA18CX?)B)<`,<^2+
M6Y3>`!=`V=E^V(!2DN$]Z7;V^7*Y&J,@N^[;N\8Q,6-#N-D4>H(/#+'-/PH9
M;?:/]T6.2Z3#U%-'6(PLP+L<K\ZK]U"2)\?RJ):![8S'*89=Z(E>6%M&/#(<
M9J^ZAZ?VW>'AD:CL:L\7,3VH+0@109)N">E"/CA^HI@%3$X'/]45<:,CPH2#
M4&T]O?"4UNH<5AGCHHEVK,46$43!._6`%A@\M)/CE.HJ2&24)XE;B%X]4M$T
M(CL9"(DC$X!>+P7`E5;",C"RZ831S]^I5A9:S<$4LR'QT968$G57R\RI;U#P
M16LY;PJAK-BJ$&U7AQ/J#.NS<VT!QFM6DG'T9`+.8;F_GV;SRTD]P@T6AD+Y
M34A%+_C.G$*0<3JX<JE:B9@!_M.UM-T6\*S6\"H47T]XU<9.G-SH6+'_PM7M
M:"SUXOJO`ZE0V;!%1_T=N8X4RP(M&:,@+@AS*7OO(/_-\D0<,5F/\-`9'43#
MILZP9%B0EI35&(_&@P6!V%9ED<_SP6PP(H7:"8,^??Q^-=K&-^P)=X*,_C.L
M,II/P1R;?B%JS5J1E`=2W2GBFNY0*::"R\'#!]<(OU^3F:&4]``YQEL![Z[Y
M!V=GB_J,?^8Q$TAT$N1[(\PBI0P3$P[7%)$R[C6&P%Q:OBAPO+M-RG;$W/2)
MEZB7/I%-4D_&I'%9W;160Q<I\))R*;JV/U1W^^Q0/I)UZ,DMN'(P4K0R^#`8
M3RP517/)\"<)J[:T',AVP.^N'*$N)JP6URY^(@T2?[:QK2>$7*-VT&`\1T(#
M[U-^Q3DI5-:=T(I"P=NS-J[)35T3KU(9).>`Y"`B.#Z48(THB[H6$.H[P1N&
MX3-S**)J5,S,2!V<P.U%YJ.#V/>SP9H"&C2P)/5X2E^$>=&L?DT#C"1)*$CZ
MS:C/VY`Q="@T!&7RC89K'=<W$X.*2C\X0WWFE,:FQET7UUC$[S!K1KA32EOS
M2Y%<PAW,4RJOZ+>V\3PF))3W@*X1C[P,B4R9P>`_F-D\?OG<?",%+1$Q;KU8
M"J5LM30JTD*[N20L/V?O"\6;>"/T*@R0_-/Y?&5V0^1VEZ3!(YZE=3\A+;PM
MIPJ-/M-/LNUA*Y9"L]T2IAH_)/)H2@=A6X7NUS.8;49B0[LW<SZ_P`6<SUQ3
M=*G20)*Y(CWH#^9E29.3E0/`'+ZTV"?P7>]$PFX46,G,H,G"I[`QJ.GYC/WZ
MQMFVK)6)</["C.+Y<JET6@PC+2$-BRS9[4:'IH'L8KZ$ZFS%X$+O1Y.&Q&7I
M)CV53#1%N%2MD;$P83RU0H7@\#RB?%L#HQY%$<@0.J*V@-+-4='X+P+#'*J&
MS()@B<7'$4?ZI>)X5T+YQY@(,ATC_,.S%Y:%(Z/1[#1;6W.U9-QY,:'0V[JN
MU-95(_0R6$6/@AQK\#M6*`,8Y:J'LYG<@[?FURF_]TH9+!K2_CG1Z;K9@1HG
M14GB;.(J[0\AU)S>2K&[Y]UXAF+PX@Y)W(HR;DFU^E[\M=C$%X1K1:''.4F&
M@^"4Q*`JD*Z>A6^?5SZGQ:]Q@=,U/'R:(0SR@_L@U%%%.$-(V/7,G:C*,)"X
MI:._W[JO"Q*'<]+$8M+2=KYKB`V$-NS/*+#D)5]2,3;#=#I?HQ3<L6\TXQ"%
M)S_-<#"M5]]0L/OJTT>`I8IDE>9:V7KUG[D>8C+<"E,D>-^4:9>_Y16],\+D
MD^@,YDQ1B^703)E^S1Z50"8.E).`B:-=0[U+]K+>%I67I"XEWAXODCDZ'?\,
M#_#NB,AU(7^"HA+]-?#NO?$'WAJBXB&&AP<031L?+.D7.8&$\BM98B-6!PO2
M/ZX3E\Y9-)"LQH3)%7V$3?B%YIQ<J9D'JQL!J4EOU<#L>:LT/"CB$:&I9`;:
MT\:CX$T&?`T%S=<,[H6VRMYZ)YJN"2,0\C"4N<1M(&Z`>S8[`T3-)GHVDSG[
M!\G'1Q0,KHT3?#<#9'KAXF(B*RB:#/3WT#RHP%.1S4QE)OYAH_6`?%_@L+@B
MWJRS7.`.-A(?N;-H+5/"K!:CI7)%+1X^A<T4!<^H1:MOV(U+FBRC'#@VAUZ8
M43Y0700X6.>AEH6'-0/@B4MR6*8+B_OD;5!A9%/C(![CB0"$K<FF&Z?G>U&:
M$V]8?B`_P_HGAC)ALYU[D@;KT992I8OYI,.KKX#!LI31W<:DV1)&201%S^=R
M_^E(C@12B(!=G:._`"92)N"]"0S%C0DU61'75,;\Y(\(EM2?]L`P8G`)1M0&
M("-[Q30!:QF3H@T3C=DJODE&K^WJ-3P[BR.L1$0L@Y1O(+GX(ENIS5_VND:X
MRO#ZM(.A7P,8V]6_2@OJER@=0A%NC[8D_,!JI-=("&4K:2\]E.970U`V$IAZ
MF>(<`RT#;RYK6J,>M2F5VCC7)"MPAG+T6<ZI`8*U?5"V.-D=]P<2Q5!]24T%
MDF!Q^B#LL-NS5`Z%<&VFLK*4PL/-G(6?*APCD:2>Y%`%8F7D#_E@#4NLUU;[
M&*%SNM(]/T0ES'HBC#G,D-_'/U\092'H]!5=19,?!+QWJI28LCF-+T):"N%L
MF1R1W+18DI4LCT*&9#1?W`^=U,,JX;L1"F75_G#\YJ7%!RT)B7XM@8([A*Y=
MNVS;6MX8#36/=C$9B:8$"L\76RYMC2B)U:Z(7D]J69;B!??T?;V,%>5@-:%!
M$!1M0;3+N`P(-'T*IS7=>#&ZCVDC@$U:00AX=]2S?ZNF6$I2,D>/',8,0#%R
M_&<I0BW8I@9KKM40@UJ>U:A-Z&Z0$0Y4+&)3?@CA/7'73=,UGK-I:BH-U!N2
M0]E0$SBB^`B/XA='&^SM*1C]E!2)B5]4T=':1?XQ^35*D(I1N5B4ZU5TIF8#
MB`.5G4+*#>T4+'Q,3@"]-\6:9X79,4^_X<M33`4ES[8W(.D5`5OF`SQF:3JJ
MI79"`$C@B<(3RE6X)\8(3H1`-SX['4T27==,]C<Z64H=QB`(9T-'!*K36L&R
M9*6O?U!=].:@D;A)W4G-;R'#WV1_FT=FS>97`QP]/!S1@MT&5Y6TD!*-V'#L
M'II3W8-#]<>>J'T!A58@-?.W9_,9?>'H6#,I^2:<Q7)?QET>"!+M==";R$'P
MLG,&$^74#+;4Z0VS#CCG**K@DV"VR/$)-O=A,I@Z4-!8VW*J.H"@]&&G$^7M
MI+Y-.(2?W'9L6+W-;AD4@QN)*+<VHH)^AU`*UMD#1%&H:-$@BS]XS_PF&%ZH
M"84#I4I@&L)24S.+>CP]62^61ABO]V@$_&8!B+IA(;BMDR(;:6N\K$VSF_YP
M3P_VQTOWY9B3?01+!$M=J-\/-#+&E$A&MA3:9XLWCG:"XQJD=M@^6ACW1&/9
M8WTA`,`AOOF8:%)"([0.,KD!;+F"/*%\L[J"CQIZ\"S`KJ-B_*O1@`T$+!FF
MEQN'B@N.=#-B:D>7Y-KD`0.8RU"9_.0/M>T;)9`&1^T@6%+P&F)5_1:G<;YU
M`QB(DJM].G=FQ(0*QHRW@U71#$&?6W(L9W'3OX8Z0T2S)92GWJMG=*21&0EX
MU4\N5H%W":]UAB8&#*#6!`+UZF1HW(GU"MF+:099'M,_7P);C,CU[LV8,98E
M^*8E!M*QWPMJVLI?1273BM%OG@^JIB`\\_*$2.@?4"%I=/L55'-%6#.U!@Y!
MG5F-/-S7HX8".653Z%4PLYE5HG)WPVG\.J6YT<(B#X5C7T"(<U#C&1N"O"GR
M`VE1_(?HP:AB4&^UF0@2\NJV-3,855@&^T:+AT,A_B$Y8)K]*CH:.1?&^8(N
M-562!$(J3`]H>T'SR6918E/H&=\*8I]/*-*E4X6A9$,^4:*YT7P;#YY)*\^,
MQ6E_4YT0B4^KFY/:TK)-518HHZ+-]*Q-(F4BSR8O9HN^S@=!>GRD'5'K@'AL
M/=//+#[0-C?U3/LXCR-$T#@N%H_9R47ND\M&1,OCZUOY)7.&`:ZFFV)^15Z1
MA,7P)]+$1IZ`G4`QI8R2/3.-3YY962[+@X4,<5S)C^&I(Y:LJ>005.B@GC@#
M643[?F7>"@O2DT)^XSZILI07";V[T9>VJ.\4[4;^"]9]!:_UP:EPQ_5Y7`FZ
MPO^*_$T1-#H@]*8GX</;$(2!TBU^R+:L,]K:0+'E@?5OZ'TZR.2$Q^B\,%(:
MD5;4&BFO$I1OIJ2DZ-PMMORBA=S1*'TY!D[P)'-5V$&#Z9=0-4P0@)QK$8/K
M8-KC%Z`EVWD)TR]"U#M0'G1&BLP\5&WS?Q\[>:N7B/9L,N`XP_&08W9RLETX
M%$2)&8@SZ@G>BKI7--@/*,E10J[:@G03@WXQ>9SKI43-6%.HLRZO087W1D=C
M'7$J4#N*)\=1B,U(51<RYL8-\8L'CAUC0<S1_)B:^U&+Q#8YH2/#,[G7Q1PF
MWO:SZ@$YGSFS-MF6:70)G608"DZKNL,415;G.(+.,37\Y8)S#7_^?51'MF"F
M"M`9,99'&8/U$ZM+>'(6=FLIG)#8(]_2Y+K<:^[6$'06X7OK72-V0&#4`7>L
MTU??%I=)8)]`MO1S.AB%$=+PI89+6.D_IQ?9G!*R,9:WC_Y`>B_4P2[+$UJS
MM9T;9BLVG947XOQNF;)3NN)1L1BX@@=<!!43MGTZC6I-H3(DO.)N$%5Q]<^$
MZ%BSW0*F#`9C1^T<W\@:A)NJLDZ:,'$*67#@,83US_5BJ"L,M,?,V+H8V'2-
MQ0IEM<C$"O;3>?>.+*YTN8`P_?#QUH.'^Q&#>NGQXZV=!^F7B+=;5!)Y5ZTX
MEKE0F1`]/R%)^2*<PTOTA`2_-@-LHEGK/&K<BK-`+AR-]M;A!:*D*PY+R+?Q
MA&S8`_O9R!RF`QO^RFK?<@*MZXJS'NY`)CBRDU'Y!CR9D?^2M%]^/+@)GY][
M&LSBMYQ-Z"X>T-C]"J96^.'[SD`S/\;ED"/WWJIFY<X0^78$S%*2:)(DM5:;
M&IHC0,N1';>,LICQ_6AME0:A)P>U88C0A-"Q-H)<;]W(?.Z1A<E1[_"V/%`.
MD43E@P3=?;3]1#Z5-]*:QC*=X>W7L5^/78C0RZ8AQF2%V?:W=^/KB=RW@,SI
M+UES`X]+09P9:;^_O9,FC:AK]Q5_,5:0Q`SEUV`E08"Q=?4$MFZ+E;WMAVD#
MD;-OP@J078^5O>T':=);8N4M<2G^]*%WM0G=1XOYC'Y:3U!T3I.]GE6'Z[,U
M\8XK+:'J5>H0RZ8YMAN<N">D>C;GNI#4)_[J\/B9%3N"[NY]Y?V%!5"J#1P>
MO[?A6N[^[L.8L]*%#6HC:2H1)L=H;,+OY=@N5;'41/!96M5W%]X4M@_(,<S7
M'(0E:XMM&U`?(;&UXD#:?V`RFJDP>@172*6E9/R<"+\-B71-EL6@?E01KG'K
MW#3GD`XX?F](8Q<*O@U\$U/E+7N`L2*J]?/(<+$HY[Z6%E*+8>B9-YML+C!A
MG?6%-&%2[/_3`L)T7H[NZ^ZAR+H"ZK`<6[*.LP9\V5XJ>5TP\4;0DI1SS!LI
MDE5M-P'Q*,@E3:O-*0G1[)1("#H25]**Y6DRC?`,_>T@LL)3@LIR@]49W96&
MA1.2(#JJYL<`I+6$S]2/EQ1^<]#3T9K:F<2%L.-!B$C<Z1B,8M"BMA.U\OFR
M4;N.YBSI.24Z)5@TE1;3F^"'$ADM^1'22[2N]SR0?`47ZHZ.'?"X@TK!/L\S
M-(T@(GWA7HB.'D2"?Z!ZDHDO$FD\@C@E'MUY$B5MB%VP9'EH(]F"R5%#:GH)
M,4],((4DAN4U+&3S/=HNEFO8E=)<;`Z`\O1'S`+NV*;U`TC_O-\^YI2'.C+[
MYHVXV?9;V521L?E3`B6]I621^(T&#X=C5%]PD9.'IE9](_\EZ3F;S]%2L$`(
MKLW2Q+X2N-,T@N?Q?"+*-FHA\IG:+(X*:-+=KD4LL+?1GOB7:E&?&D,!6DE!
MY;7B&?A@(M7]V8'+&<HQ&Q2-8`!`6TFX\$PW75"RQ:OZ8FD9[TK]6*OQJ>>(
M@)CMDZ_Q8DUJH=FRKJSV6(B&<'0*1X)8FB5.9:^.OVJ<0WL:2YP*U*T>JF$?
MOI*^L$:3_D%"C.;>L+2[>?>8ID-R]]G"4:(3>:?2(A$W;M8C_Q#6]6D!V,5/
M*%@E!FYT)4M306ISV*@,I*3(32&ET_0:&R'/V3TF:)6DV4K!2HBI6<MT-:59
MI=)`P&WTPA=K@4,=;L'LHW5#*RN2\`=9E-8!@^HU![7+`'5O^Y>\_08/`FZ8
M?/IHQ[9W=]K^UD`@*2W=!49=R4..C:ME0I#*+X`=X+IT2XQLAM]"<J$JY#D-
MKW]:TW`0&J"J-ZL5^92MZ@UMJ-HKO'9&QE%I9?$*_[2ZEB)6M3)"GU`2==):
MZZ`8!/&#,U;$::^MG98^4%-[*44E:XWBZ,&O;]<"CG"GE)20[S8HA%'U)-S]
MI90/YQ&E%QN'+CM6DMRJV'IN-4MW1\UM,O5@/07A`)_%Q\/FO@TK:NSN$\\>
M[&5KB`&#Z3(W"&&Q#(3%=W"ZCD>GK*\&P\8Z]AR2<M&!6'(C@30/"0T>TC.*
MC!AOMVN+<?@%"`CG[ND5;OYB<87T(%X3-/Y+2O4NL58JOT8U:FB065]?B*B/
M'S_8.MAY>,O]=1C^$"N`NE$SKVA5XH:CCTJT=T]3/GB\L_7H("4%>EYMH=7)
MY"F-T=K:UK64VG!)?`8^%@#8[GW%0JF0I&'(#,G!2`#]TL,3;D(L-*LZ<>I-
M\'6R+?&X0WBQ9SUWE=NH$[K4YX83H;0!HFXEH\_D0:@Z@+2Z[)'E/Q/37MI)
M::-63H\P,GB_T;I)X!M.ZW#'BX94MXC@?&G8113:L'`F!MG"LGP8!2]9`)+)
M[.<Q%^Z6@B:S5,9GEG52XPX*1FJPXFK"!^FP:KB]1Q($"7F9;EV]FRO<4+9H
M.[O6GJ,%2I`/'F[M/WIR2SEL.OEZ<)4AHI].8CUWA]P)^O31$+8;%Y=VZ)DW
M$G\3#;QS?8_FV8?[CV\Y5]1D&3$-C\RE1O9=`HK]QSNWG2PIPW@_3,.;X=**
M%%I,!S^/I^LI#3#Q8-\7";UI4]@#1'<,G1NNW-`1P01]VQ&50_=L,`66G"W8
M/^LP<2.9%3:"BLFH'NPAJV'-N&,J>-37LZFA78ZC5<'%\8T\%==%=H!_I4NK
M_J#[.JL?+-WI#?^E=[2_?<N![U``0[*;5LJ/?0+L$U_$SS/3YV"8E\CQHQWE
MS4\B*Y,-26(+.5)Z(C,`YX9C3`0!CC<`Y\>07<[J1?)KAP/RD]&LT2"Q6/DM
MKG1T40OV!PI'QC/=6Z#\PW*[HD8!PH,6H]=MX:?FU"<#/=0F9<YM:OZ4"I&P
M!9?"HIS)7,&_>4Q+3G[:S3CJZ(B!IRC;[&Y0?2\WK]H#D`ME:52G6=+=<`(@
M)]P2>-GV(_E)878(D+1VFYO:=T_IT,)BCK#8!N0#)LK(/Z\[S"#B!4))=Z:P
MPA,[:)YTPQF579Q2ZQ4'&BX6TIZ\E92[(*;UY7SQD^%C:DREV9J7C5]1L;``
M^VU.JDMY6=_O=/!'_@S>)GP2^>.*#?B=UV3CE9N7VE_E,T.\T,PDWT8TT]),
M9HV)\=^8JS'T-I8V3*C\%+-7RO8H=*7^%>*[Q'V:2TC/X^;+V'?.<MX,`U>H
M@5>S^!98WJY]%KOHII530G1*K.$TOWH^-5;2JT)/'F">U*M+]9J'RKJZC"D>
M@SCKQ"&9Q&T^]#\GLF@?R@_H]&ZLW392#>Q@JVD7RDJ"R8`#<?MN@IZE*]^S
M)`S0A20A)M]NVAL)0D%D"#=^B,RO-\)=1&E!Y_4^!FPSFSDDW@"?;3WUPD=1
M`S#.&'/5H,F+8$7$8B\U..WES,:\EBK0)77WF^K-R9+6E6`^;,IXJ=*?UG;+
MBK&-]7`1]2IIX3A<_K9_RKUOB+<T#WV:<)<E=MR3NF$^X0N"2F/.&Y@"_X^(
M-X>*Q>$^'>+S?UD763\8^]]P#CB;)Z`+"J?D#PO!8-SL3:['A2IRIN*@B/>0
M]31):1*0EK&PY'5PM"PHG5^:D$26ZVBD)OEGHL3U"AOE/A=XY[>@E*(9:$5^
MY9%Q\2EFY0=S!YL3D2B?F"'%U>)L49-A3+HT:`/>+@^BV[&<N_L/M_=C!2/B
MJ*69,R:65;2;#<)!/YD!LTKFU@<6#)R\S5UO'-7)RM*217A-YS:C0L:>D:#.
M#_6'H_N?O=]HY;@(S%*^BO,1^JMDPF`T!W`_"V8#V1*CPH:A6:_4VQWZ=9CA
M1YV`<]L?;:Z%\<HG-.%S6!%HHA92#A&^O6YI3<'S8"^,?;:K'QM]+9_"5?%$
M!CO<\!!/;U998!MS:\%AZ3EW^<68]W-4B%Q(FN?[^PRYZ.#U,+AA+\-G";9H
MZ>`.RW<JX;RP:^^A?>MN^>?Q2$'?W8R_<+H.>`^V?^&,I;XKIRN?/W=7+[FG
M(1H,GAM5PL"#J0.;#+`4=OCL1/?F9-,JIC_*I5K*I7P8X<1EYDRDIXG<0L2&
M*;AR1M&M>[_MW7*NAP=[W8O^N7I_G\"X'!O731$>O5N$YKT7Z3YX\K@[P8-=
M[H;:-*OMH'SXZ.!1]XV#W=WNC[M;C_=ZQNYM[1UP-U8Y[V>D,:A_R;>+:B[D
MA7:?;#UY>!"C6`AO;G2>-\2KB^$U$8KZF6G5&5KG@)F4?-)!X_U[5E$N+T7/
M<$+"^8JX1E8&W6II^Y/Y#$]KB2<%"\02;(RL++LV"/)KD\D^IVNB%%`P:>2R
M]%T%?%^[O0A'M0UQ9:O%!F\PHMMKSI2DH2KM)Q*9+_:JR_/``=$.U39OOCQ'
M)T*Z5#][F5P@F`/">:PH/`'/YB"Z&ZN^%/9'[8#:O<.A)CR/7FRIF_;9MMX=
M16):#=U)ZB#,U)'LQH`"LXWB$)HYKMJ-C`QI<C]S94>SY.'/=;LUAMJ"/MTN
MT(["^L%(RK7DV`9(?7'$$,\!7;_OFD44+BF0QBV@S*QK!`PSR6V]E2HJU\2Q
MX<+9G>YWG"+CE"^T@>P\5=7!H(_0^A5RH%06%D\P<GSYYKW=@T?E;YW[TN_M
M/^I\,Z@-4%HNKE_.^;T@+&`18[8I5[YU;W_KP>Z3SJ\DS1X<E+]&&Y*)]O63
M][S00F&Y`*C:+W_[VU__>_E3S[1M.'KOX'\SJWZ_GEQALBAD-2YOU(U0,-2>
M4'[$??:)+,7B:(FWBM4D#M^3";%?PGU"5]5ANC$C7I+<##X^M,J.R=`Q'P_"
M?U5::L)E5,\&LY]224C_\!*9G88#CM#?16=HUL>!!RQU`DDS]>NM+W8!GCK3
MU8JG,#1J;Y4Y>VIA[Q#\'$Z48ZW$A39+_DF;]:+Y-1O>LOO(0)"IO]\/4.P+
ML&LM%VI*X'>;56?UV(BFCOYF!K_]KG^W,&++)M0*-]O<DMDNH^3PNYFS*>R`
MG:48[99"SUTI2\$:D=:>G&ARK6C(<`5U$_=X/>KN'E\`2FEV78O#)4%TK%H(
M8M>ID(G?S<?8(1>$;C`CB:$>1C#DYD27%XHVEE2-W&(Z\]`8RYA%:/+,=5&V
MZZ1@TV>_4OVMR5J[3=5B[9T;MQS1`EVC&YOWW!>"L8[\(F2(UV1;8<>I[4=5
MU]!5&Y#3WKCYBQC/F,*.<:';\P_QLC84/5<A1"W<1*!\I8,]LK1N&C>T/$MH
MV:8.G+VR1X-=CP2KUP-TL^718G`9DYYVA4]!(^\M'539,AV3)AG)J),8-7M'
M88NE7E$MD?\]GGYLPW5]'U4#`_9QNV\XR`-7,%DG`C)G_2N88UV+$[L;D$/)
M^\'VDP>_L3<>;>\\^DU[)E6V5Z@N9C@A1\PQPYB.AB`6O:-V2*`1WNCV.D\C
M-%T2DHO3\8*W1S0;L9AG*S4:'R&_9<UF`-PF=V(,GE@ZOBO>3Y<`M<M-%K&&
MM@'(9!+:@!:=$"9*2+$SIUDHZJ`2MG)%8KQ3KPVFA*X7)O?XV"_%3#NE5$!#
M7@<,"!^9/D`<$RS.-88?VZ,Q_-@N2:#F2^DQH%@)>#2U9>!#JL-(H&L55E?W
M'8_!_7&769_'Y#YS/QS;J"G%]QUL=1PV$>W1]D/8@L'>]4YQD!"&5+UZ@4G!
MN<F(ZL@.4YL#:'L)3TM>S_D<\(47F"R6)HSS=<&AM!F._#MCHZXK*6\Z.*88
MA(3*X*0V9^C@8(Z(!E!<:;LQ:BI`C8V/,T97MR.[A]$9BS-2,RBN(<ZW:QJ*
M@,1TA[.!@]#?C_Z]&#Q9)Y-+F%G,8Z7*!>EP)4E!FFXZ<%WL<PN);;N%X0DF
M6P6'F)'0BP*]7>2UA'LX+1)-6=#O,GTD=^ADN7:GB(!QONW1.E19Y'.W6NP/
M-8]$57<?9RS7EOHL)Y\*GBT(A)8"J7;/D3O<]<^J>M/^="Z(78KA`$4,8-50
MSOLY/3&X>?XQ\57JKS43K#D64A6<XBA=3`QA'[^X10H;;EF_C?U%41UE4O;I
MX[-/'[7?WNA<R'!/!MT3LH,*T`>G7)NGJ(RX:,TQTOOA](PE[=/A"S%B[+V7
MKQJ-L;CI"2=?]F]=TX\>RK^&<QWNGF"F5$A2DP^E$A3ET!GUP?;.8S73>5;!
MZ1_?9/P%H;),1S3[F.^]71_5@)C1+&`KS5#DC]GE"2S7:H%H#KG<?$319%9S
M-OE3$-R.[Z+_D.M!J22L1A.Z`LCU.BTJH'R6!M*FLSG-$H[DE`PI_1IEOB5/
MM%+9+>G>GKIR1\#+NQG+<86."9@VD(/BB(23]]V_V-W;WNGX%Z](Z(@K;VJ:
MP?77L`AFPBUT.DC62%S0D#QM.QJ$F`P",,UEL!X:N3*PNV?:$Z/P7N+__8.M
MG4</LCQ7!EU/KQRLG0Z\<1L241@-BCVL_FA[;[=A=?C!CK:Q+>*[3M=%H=86
M?%R#D;E=\?BIG>9!I^H(+=TF],*)9L2LCPZ>B)FL+G<9SUIQPDZ^C@F8NQ)F
MCX7DX)'*47YB<Z3C('MXI(TI[]%^KP9\*$W&_7LJ4YUCC^\R&O-%%?)X*=SD
M;G\I!$$<;M;A6\Y\H%@MY-8[IIO_.'CF_911-B+#1*]<A0ON=1AR-$.7N#6?
M9+/53-,ZNI3>D?EA_]SXI%!+%$8&TO4R]H9+,G++]4F^+VG&)L+AF(?Y9`IY
M%W;I^K'NU[?3ERSQR/643\4L66"63>*]+9Y7&WHNE2R6"M?B<=W,['CQ9+?E
MG3?:#%NJ+4SM](3Y]?>+;,&8--0'^K6%,QS0V0A7@<]"@`XAFA8^&M+$&,)1
M$^<BG+NQDF>)2\:6S!B.7NK;C6I2"GZZ;MD;66FW0R-+X-W-CDYU#.SK%H,6
MFJ/8+`AWY%LRN*%;R6).IS1:BKKE)B@C@>QAI1`5I,8G%;.Z@;+R=DGZ]VF/
M<6((8]V,F[#2)]".$+SRA.I2P1\W<I$^4'R;,1W,/MS.IT+/A:\=]TX6SNR!
M*(KZDO@@@^29%'GP@]!C,AN'^E$@DP-]Z<P/(J9<;>?S?C_:*>9/'^>G)0!O
MK`>V<W`M?:FR''_H*OG3QR-Y'<73_D]'/0O?5\<AC)Y'EG"XU13?X>[*S[S5
MX.>FM;JCG][;V]W?.MC?N=4L+X-[U5GTZ;T'C[8>'^S=:I9L[VUY+K?R5`J=
M>%5'/4*9PP@>FFU09LV]*B:!,$<\ZBGN4.H!B@A)SBCA(@3)7^*+FW+X[W23
M\Z>//RB$7G[Z^%+:_%;;))SJ[W<MWGZZO]-3%GQXT*WJ];/2YL_8=O"YOX.[
M4RY_L--35'S\J*<:>&CQ2IMF;@QRMR%2P`-(<+^[M[?UB.94U!M4LI-`@8)Q
MJ(B7^EX0^=:M8;(*W5?C:7NBR@^</Z$CKFSEF''SH'N1C+'+%TJW?N-%.RRY
MU&7'6H0-1#`1UO;FO>6$C_-L5)Z;4;;F[KYP<[9?\9ZN"+*[@#)WLP^Y?#@X
MAN=^T;^Y95TTX?EYM_?2/XQX]\%V.HIM&A19D(<;\Y,$+QE82$ET?^VVCJR1
MAH2=3E#KS&C7Z97<=FYHH'@7.X_"%9MN\6\1%$'&%%J8E]`-R%*1OF42PMU(
MGNA-(M\Q!6_'RY_NGR+G3<RD0*64E%U%"^6/ORE_(%#ICGH9<?QA/D&9R8<M
MWWN,5])]\<F#OE_3=.92JB'""-&IWMDGK,J%#K9[9#O-.+(KO-&>5^-Z4FJZ
MIU90*"?\3R"W//%?0O)^5;J!#SIZ='>[I[]CK^?'_F42KAMFZ"SQ^%$/E?JG
M>VNAF_Q&I)V&5O]$4L$9G04>]K'IP7:WVZ-_T;2'-K]TECGFLCL<-ASGZJ5]
M[JEDGH/M&X>\\?/&7ENYWB/'Y+O1M1`D7J'J<1^^F2YYM3J<I1AC(BEE3"V3
M9)J4`LF\=8QQBV+&T$\.ZIF-1"VE8['%)SYE>3`[Z!\^H(HVY+_XP5;]CJ+V
MJV!/*?UJMO_PSZC1<(R_0P9MQM=Z:E(F)$6(8?%K>*G]<=!EM_`HDJ>48MK4
MEBUAUPO9UBV7'`L*,<(E_%A?$`BK6R!T7!!NW85)HFDS'&I7,8FWN[43CAB&
M<Q2\H*V&*7OS&.1B6]_B*YFA+*6VJ&@S)@++VV]'HG:*VPQ8N,&!<%.>Q9((
MD\X;Y$-.8:28_MTF&K%V_'2KXM+Q=`II[%.@ZL>""$LK'#*K<<>FY82#_'B3
M%E7<[<</XXD;%N@2V9=T7K$^RO1=+T%;(K<!=[N/Q,KO;JK+M_`:8RP__4V+
ME)TE]^.K('"]N&\W0R3,FV9IZG2A!-,D^RR''9@AXT*3JQBIASIB"MAAK&Q[
M1K:T7DA49YO44'?*)&>>8['WS2NR+XBDMPU:BPY:J975Y=QM9N<8:L;_A@ER
M)/(O5?E(A3K3M+K(@S0_:!9UV#"BRX/LZN8<LUFIL$D*(;`AH_9+$%-*T?N4
M&<C0GZ-75XV9:P3\QLLMDG.<9#*Z1$YH;G.5"9)CWX8$@YR_4D>=]HW\<IF-
M@T@X^-=-P5O(T;1PIB2&U5^Y)'D)QL/I#KQP=K"X5'*__OEB,B=E%#[%NT%C
MEL+DR6WT`8%)^#CX]3K`V_A!T4`'O*E#1QQP:D@?!E9HL%K3+'8_ZTLC)A\#
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M-PJ8VHN+@GI+!KK$'_[%X99V-,.4.M_*_>Q4GC_DRJ%N^O`IUSYL5SL>WG3:
M3(_]8KBE#@"A?<(='"AC^S1W_&9UN>!1^W&HARM1,)*#0F<X(8@7(#O;[OL^
M]BV7[?9YW/+%7X..U=Y&2K[E')&N77OK*3?+)O_[X8FNM1ZN_EN)O%?J*T^W
MGA.'03-S2:/A<&.AK^/]69;&YBXGH0?SF9#,#1N?\TF[9XC.EW_2[IEYP7*9
MI.V]"0(K=\,G[9Z9UXI;$F^JXQ7=JW'#)^T"9WHF4AC2ITNB=DAUZLYU`5QV
MS)'KM0XTF]FUZ#%TH\5XH$3F$4<]<:SDZ=&4W[TI4HSM46B'FUVAF;^40E<?
M*@,CRXRN<97D;@T[8;:++U_Q\#,N1JKNW:2$N.D(Y1`N.BKQDMV^5#X*ICOL
MS%L!0,`-%[Y`S.9B'T=3.?';F&*1R_%"!_3F%Y9."8Y`.?X'OT&B_/EEOM*Q
M*SGO6"A'_J'W3JER5#:%%^<MBK7-B-#1DY&1*U]]H4]+\NU=O]HD'UG]&]X0
MTDY6X;6AL'PU,:;\4[N+1LSCB+,&C#Y8^K;N!T]AQ:+ZD17R&]?Q_S@4,?*Y
MP$<.3F[FR?ZG@?-_%2R=%$^B5XF??H:N_D)UR2Y;*<>_ZK\VY&;=82_ZG0OA
MR*H$M5/8?J?&R5/\`86D=F+#=;F=OJUV)0#^9UG??7K]FWO-FYTS1/F;^1DZ
M,R*?M_"&UZ];?1-&\0_\5'))@N^;8W[EHTUSX<,B+?W3\:QSB+J<MSTFVV0Y
M\'F\`>9MK0-0:+)#;Z3.('O17/SQ%[^*@_,^Q34T\HX<7%@Q>]?O2PC'S3N$
M+(_%E]#]XC#Q)@.Y>ZUOS<FJ;36IV;&,$K9X7HMN'`ME22Q9*-L9U_(2W)8B
M%.5YSHY@64!L"4@%E>F@G+"L@@@^!HG%<K&7J64LM(M9-U`Y*K6&E0]$CR]I
MP"KG>8/OFG<C3:WMK!P53K;&[.4F_XT2C_<TE3U._;/&ILERM?B[],J-SIR3
M"8OJP;URN.5\L9_EL\*C!,1?JO0GKL]8V&(UTB;Z:EEH<K0>QW__P7#7B3/2
MZ]?.Y-V1:DNN-DWT3ISBC;2=+?;WX);#;`9O(K_F$7HAPER.,GUAIL8J4)>Q
M#[3?I8MG&`]Q(?$G5Y9+]8Y4Y;&DA]3BE=+7&W<N9VV\,O>3-%P)U&%J,B_;
M>3LCF4)1WF<#M-EJTPS6.KOW:RYI&`+<%SJUO(DKO,%-1IT0QXY89:6-B)`2
MJMV]T'):/FAFL\,\:<[6F2+DTD^I$'K&S4/0J%\W+;I/@M7ZJ\I%OYA/(,LU
M0O&:Z@4)8K*L,%YUC_RKW85.L:.;^5-*XR@>NKC5(17%12066F=M?O6-]<OJ
MJ_+,?+EN9P"[#Y^P;')#G1CZ%Y/!H=TL*[_6`O(JN6&RT91:TIN#2TQ8NC-<
MG_L/H1/U9H\Z]8"&GD]8H]OR^?2=M>%:Z-W7JQC<C!*B%%A+"66!=3DN-OQI
MV.%(IE=Y+-U]58Y,*50-O75.M9'TD#LII\T:.)7#SDK!W@&`YR`3>$U2YKO0
MNWK-$.]8U37GUPR*!OS:006X*'KI1$%^,Z#%N]=M]3:)5>_8U89N'MU&P,WC
MV[BX>7RQM7ZTW#S-^U_2QUAREE)(UHI(Y*3TJGE4@4K0[/J>R7*R?2_PES_?
M3BA0''_`0BB-^HR3)".=\\:UHR)J#:SEI(VG804-/TI_FJX*+(<G-1)/\^3-
MD1C1IGS2S"&F]6R>MSYTHHU-W6O7V[>$\JP9[?HW#OKQ&GY&^9HMKPYT;KL#
M9%JNZ!N[?LG-+6XE9A]>#QS'',S1H"FY%[Q.+]K-)J%\!<YYWFX"0>'$3@KK
MP#)W%0^$9JV_>/_%NZ8]C%+3Z]FPW-;[HCD+^:!6K>1B.=+RH'[VR\.:<D`R
M,X*@?/B@'WVM=[SAIB^>VNM_.Z0C&IBMF%+4^X64!IJOE\O5T_\M`````/__
M`P!02P,$%``&``@````A`!5VJA3I`@``9PD``!@```!X;"]W;W)K<VAE971S
M+W-H965T,RYX;6R4EEUOVC`4AN\G[3]8OF\^22B(4!6Z;I,V:9KV<6T2AUA-
MXL@VI?WW.[93((8RX((0_)Z7Q^]Q;&9W+TV-GJF0C+<9#KT`(]KFO&#M.L._
M?SW>W&(D%6D+4O.69OB52GPW__AAMN7B25:4*@0.K<QPI50W]7V95[0ATN,=
M;6&DY*(A"F[%VI>=H*0P14WM1T&0^@UA+;8.4W&)!R]+EM,'GF\:VBIK(FA-
M%/#+BG7RS:W)+[%KB'C:=#<Y;SJP6+&:J5=CBE&33[^N6R[(JH9YOX0CDK]Y
MFYLC^X;E@DM>*@_L?`MZ/.>)/_'!:3XK&,Q`QXX$+3-\'TZ788#]^<P$](?1
MK3SXC&3%MY\%*[ZQED+:T"?=@17G3UKZM=!?0;%_5/UH.O!#H(*69%.KGWS[
MA;)UI:#="<Q(3VQ:O#Y0F4.B8.-%B7;*>0T`\(X:II<&)$)>S'7+"E5E.$Z]
M9!S$(<C1BDKUR+0E1OE&*M[\M:*PM[(F46\"U]XDC*XVB7L3N.Y-HMLD3-+_
MH_AV6B:E!Z+(?";X%L'2`W#9$;V0PRDXZWAB"/ET/)"+KKG71:84U!)Z^CP?
MW<[\9VA#WDL6QY)HJ%B>4(0[B0]X.T:([7I&793A$49[QLG.WDQC826VZWI>
MRX,O!@`0S/4`N@C"/`!(`@?`2F#YZPC#3S?Q<'SY_O@`#R9YB'>^=UKL8.UC
MM[E8R=A0)8%Y.6#G%`,T>$8N1]-B!\U9-`LK20R:D^;R]-@`)[T&1XL='*=!
M"RLYC7-Z;(`S'N)<]O#I(@=K-&S/PDK>7U?OCP_P]!EXL#><7U=:[&`E#I:5
MV'45]@O+;>)YS0!O<@V>%CMXJ8-G)18O"M)X'(7CH60YE"3I))[L-Y4!'(1_
M17A&[>`YO[WH-6?Y',U)0'M4VD.@(VOZG8@U:R6J:0E;9>"-X3D2]J"T-XIW
M9K-?<04'G/E8P1\:"CMFX(&XY%R]W>BC>/<7:?X/``#__P,`4$L#!!0`!@`(
M````(0!>%;1["P4``#P4```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL
MG%A=;ZLX$'U?:?\#XKT!&TA(E.3J0M7=*^U*J]5^/!/B)*@!1T";]M_OF'&#
M/31IV)>FX./Q\7R<,5Y^>RN/SJNHFT)6*Y=-?-<152ZW1;5?N7__]?00NT[3
M9M4V.\I*K-QWT;C?UC__M#S+^KDY"-$Z8*%J5NZA;4\+SVOR@RBS9B)/HH*1
MG:S+K(7'>N\UIUIDVVY2>?2X[T^],BLJ%RTLZGMLR-VNR,6CS%]*4;5HI!;'
MK`7^S:$X-1_6ROP><V56/[^<'G)9GL#$IC@6[7MGU'7*?/%C7\DZVQQAWV\L
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MX!<UY[N:U$T%=`,Q?5VS^=)[A3#D&I(@!*KH`N$V(OT$P2X0#^A=.(+;QG-4
MDVR.W+^8[[:1(*1+ONY%:KRP"(!C3`*WG:/`*S<T=TZVGB`$TTTY-#5>6`N#
ME?L75F"(GKEP0':,D'D7LI`'(8E::HW/F7\E()#Y)JW[DD9-(O1"0@\A$=(+
M"?G4')W-KE";VM1NATJ!":6(4$+(3'ML-B>A3*WQ>3SKQZU`SL;04F!":TIH
M(01IL2@DCDRM8>@XE]D6*=7CC-J_[2L%)J1F%[-83PC!\#'>>P*+Z]JH16D^
MAI("$THQH800I!101N8@N^(C!F)XOY,Z-*%$:BS1&)U283CO5T9'68"(<;^/
MKN4K1K3[=OPZM*U+`5DYT1A#F,PW]N)$E+]8')75U*:@+V#,'H88G=/<*'#M
M%AS'6$[#OE!M7DI*[TYJAL)K\2)9DFB,YA5SDO6I-<[YM'>J36R4EK.AF`=$
M#Q.-08=PHA"I-1I?\];_4G)U?B*%%_0YJJ-IJC6EGFH+2/UJ*$=I.1N*>=#O
M6I,RU3K@T<!GYCC(:C]NAW*4FK.AG`>]84W,%.QIR$BH4VU#:T84][5C$QNE
MZ&PHZ0%)[D1C,%#,:"2Z)DU1CZZQ&B7J;*CJ5+@3C4%6<!*W13^UAIEQR+&<
MQ4<I>X>VE3V@S49CM%)`&$E1I#8@]N,^SC8UHNSW';`XGJ@M,:/-1V.@."_G
M\K`7+`SJ;8Q-=%07X*C@(&W]XGW.8"5HC-&"S#?VXD3JE9>F7WZ[\*'DAR2!
M$HVY[26T<P5C$R72KXC.OR8Z;`'T2)QPQ.@60'R97ANUR2FAOKMAJB]-(OWT
M\)EHC"Z#D$5^G^8ZP]#*!\*?L9ZZ36Y4"^##%F#T%IU?IL0_P.&*SP;L;`CC
M@7'JM^F-:@1\V`B,#J/IF8V`PQU#[QCM.@L0!T;UVM1(*[A30H8M(:0M`6YK
M5`KHC\A/SJ\6X+/S*U[6X#5$*>J]2,7QV#BY?%$7,1R^M2YO\9(H88N$JQL5
M\CY5ET?=]<]E`.YN3ME>_)[5^Z)JG*/8@4E_,H.,J_'V!Q]:>>IN!S:RA5N;
M[M\#W-()^!KW)P#>2=E^/*C[I<N]W_H_````__\#`%!+`P04``8`"````"$`
M!<#UH/\"```X"```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R,5=MN
MHS`0?5]I_P'YO>&2$$@44C54W:VTE5:KO3P[8,`J8&0[3?OW.[8#P:2W/"0!
MGSD^<V8\WEP_-[7S1+B@K$V0/_.00]J,Y;0M$_3G]]U5C!PA<9OCFK4D02]$
MH.OMUR^;(^./HB)$.L#0B@154G9KUQ5911HL9JPC+:P4C#=8PB,O7=%Q@G,=
MU-1NX'E+M\&T189AS3_#P8J"9N2698>&M-*0<%)C"?I%13O1LS799^@:S!\/
MW57&F@XH]K2F\D63(J?)UO=ERSC>UY#WL[_`6<^M'R[H&YIQ)E@A9T#G&J&7
M.:_<E0M,VTU.(0-EN\-)D:`;?YW&R-UNM#]_*3F*T7]'5.SXC=/\!VT)F`UE
M4@78,_:HH/>Y>@7![D7TG2[`3^[DI,"'6OYBQ^^$EI6$:H>0D,IKG;_<$I&!
MH4`S"T+%E+$:!,"WTU#5&6`(?DY0`!O37%8)FB]G8>3-?8`[>R+D'564R,D.
M0K+FGP'Y)RI#,C^1P.^)Q`\^2^(:03J_6RSQ=L/9T8&>@2U%AU4'^FL@[A,S
M,H94W\H44E0D-XI%<T$2`JKSM`V6T<9]`DNS$V9G,'`@!HQO(](>H2H!\@:-
MX-I4XQQ*^+KYO2059$L*5_9^NTM(8"/22\32&R"61O!NK/%];0J<H,7(BF`9
M#[S:TIW!F&92'J>C%];.0#/>655P]:$[*@B:T%(PM<=@H#^'@@71.7NM,NTQ
MTY)!U%34XLWSTI=,!4U$19,>V1E,I'LLC!?AW+8M':_'L;<XKUNF+6U][Y=+
M@6U=46AONS.0E99U%<7Q1'9JK2]7\=E'2U9DRU*U_+C359`M+X@FC;PS&&/;
MW/?4Q\X@'2."T$98&M65-ID8'Y=6!4TUGDMC.MY@3AJU@*G&,2)8O*;13'`S
MX1K"2Y*2NA9.Q@YJ.OM0G^&MN3AV<''H,>L."S"X.UR2!\Q+V@JG)@6$>K,(
M6HN;T6\>).OT@-DS"2-;_ZW@AB9P6+T9@`O&9/^@SL=PYV__`P``__\#`%!+
M`P04``8`"````"$`H17P'\P$``"J$@``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q-RYX;6R4F&^/XC80QM]7ZG>(\OX(#I```DX7DFU/:J6JZI_7V6`@VB1&
M27;9^_:=\9C$=K:PN1?'\O!X^'D\]@1OOKZ7A?/&ZR87U=9EDZGK\"H3A[PZ
M;=V__WKZLG2=IDVK0UJ(BF_='[QQO^Y^_FES%?5+<^:\=2!"U6S=<]M>UI[7
M9&=>ILU$7'@%GQQ%7:8MO*U/7G.I>7J0@\K"\Z?3P"O3O'(IPKK^3`QQ/.89
MCT7V6O*JI2`U+](6^)MS?FENT<KL,^'*M'YYO7S)1'F!$,]YD;<_9%#7*;/U
M]U,EZO2Y@'F_LWF:W6++-X/P99[5HA''=@+A/`(=SGGEK3R(M-L<<I@!IMVI
M^7'K?F/KQ&>NM]O(!/V3\VNC_>TT9W']I<X/O^45AVS#.N$*/`OQ@M;O!Y1@
ML#<8_217X(_:.?!C^EJT?XKKKSP_G5M8[@7,"">V/OR(>9-!1B',Q%]@I$P4
M``#_.V6.I0$92=_EZS4_M.>M.PLFBW`Z8V!WGGG3/N48TG6RUZ85Y;]DDC/J
M@O@J"+RJ(&PQF?N+<#DFRDQ%F?=1_-$H`"WG`Z_C43Q*CLQUG+;I;E.+JP,%
M#--O+BEN![:&R+<D4TJZM/]?UB'=&.0;1I&Q(*$-E,K;S@_G&^\-EC=3GN@#
M3\!,SYX\L(.[.)8COCEPO?&KD_MA/9AF-U=81'NN,RC+CPOJ-C4<9$YML3*I
MHZ'%#WS3L__`8SKBH2.8FI9D:/'#1><QY@HEI\_U_AS1O'6A.KNT^V'0Q95Y
MCLA#&PT3O[>%V!8233#8X(MT-JRY.=3>?48<!%O88`PM1O*$L@#GRVD8S$S#
MG@S])&);2#3!8`8^G?D^*YIMUJ6)$I&G1]F3L"+X16#Y8_-CWZJO1`MG<`=C
MN-%L<]O%3AZ-VQ9B6T@TP6`+Q["A^5&-DD=CLX78%A)-,-CP*4([%^^O-YJM
MO"VMO1N11V,C@8IUN9P'TWXGRQT7VR,233!85V-8T6RS6H=L1!Z-U19B6T@T
MP6!C<,!^/I'2_6B5E4G#&RCQ0$ETQ23$#O+II6;4;XQS:+#6RJ03TK!>B0>>
M1"E4$:LI_NO.#),8^X!&C`?HXT;&J'N8Y-8Q$BE3S[D?*/%`291"Y&P&Q=S'
M-<FQ)8PGQU%VS5I'>\3(I)/;2JP\Q(F85I!$#V*"8U_0P.^?!XRZ"'R_UE"M
M`SU2)AU8:SYT!"B/:@I:/:AG'VV`B8OM0,/%"@D>/NK@T_4@SX/'.*W32(J]
M&J:R&BQFH=4S8N7HIYKHBDF.S6(\.;48(^%+ZSR-F-:'%#DI?3U8!V$\&)+H
MB@F.G60\./4?$]Q^]&):DU+@I!"XS]AB9E57/!B3Z(I)CGUE/#EU(Y/<?B!C
M6LM2Y*00N03O#SGIB`=C$ETQR;'K:.0/=B7U*)/8REO$M$:FB&TE'G@273$(
M_5'M3[H?M3]EZC?3?J#$`R71%9/0:G^?:R;^1VVP/_1EYB)ETDEI&*W^AP\]
M@S%XQX"GDHQ"Y'1E0#]C2UZ?^)X71>-DXA6O`Q@\07<J757LV1I^..)E0_<!
MW!1<TA/_/:U/>=4X!3_"T.DDA-.MIKL&>M.*B_SU]RQ:N".0?Y[A3HC#+Z#I
M!,Q'(=K;&_R"[I9I]Q\```#__P,`4$L#!!0`!@`(````(0`:A,^[;0P``'H\
M```9````>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*R;VV[C.!*&[Q?8=S!\
M/[%U<MI"DD$LB92`66"QF-V]=CM*8G0<!;;[]/9;%$FI#FS;R<[-9/I354E5
M+%(_9>GF]Q^[E\FW=G_8=J^WT^AJ/IVTKYON8?OZ=#O]]Y_JMT_3R>&X?GU8
MOW2O[>WT9WN8_G[W][_=?._V7P[/;7N<0(37P^WT^7A\RV>SP^:YW:T/5]U;
M^PI''KO];GV$?^Z?9H>W?;M^Z)UV+[-X/E_,=NOMZ]1&R/>7Q.@>'[>;MNPV
M7W?MZ]$&V;<OZR-<_^%Y^W;PT7:;2\+MUOLO7]]^VW2[-PCQ>?NR/?[L@TXG
MNTW>/+UV^_7G%\C[1Y2N-SYV_P\1?K?=[+M#]WB\@G`S>Z$RY^5L.8-(=S</
M6\C`E'VR;Q]OI_=1WF31='9WTQ?H/]OV^P']_^3PW'W7^^W#']O7%JH-XV1&
MX'/7?3&FS8-!X#P3WJH?@7_N)P_MX_KKR_%?W?>ZW3X]'V&X,\C())8__"S;
MPP8J"F&NXLQ$VG0O<`'PW\EN:UH#*K+^T?_]OGTX/M].D\55=CU/(C"??&X/
M1[4U(:>3S=?#L=O]UQKU&0U!8A<$_@:"G'!,G"/\=8[1Z3.ES@'^>H?Y>+DG
MS@3)]'G"7^>87EU'\V5R#>2$W\+Y70]^V47G@_G5GP_^ONM\2^<'?WV"P8K,
M[#CV;5&NC^N[FWWW?0)S#:P/;VLS<Z,<@OA^L"D.'?*K!H'.,$'N393;*5P\
MC/T!NOK;79PE-[-OT(D;9[.2-A&U*+R%:3L3MN2@XD!QH#FH.6@0F$$1ADI`
M-_X%E3!13"5\#BL/4&E8VM["NY0<5!PH#C0'-0<-`B1MF$LX[?!"X,?9&-].
M838-XQPM^3A;F\RN'F88"T%*02I!E"!:D%J0!A.2)UPTSM,V^I69SJ=3-GXP
M.6AOIW0(5]8HB8=A+P0I!:D$48)H06I!&DQ(SI`<SOETHL:X3]3WX<H2G)4C
MR9!G:4D,DPJUQ#4M3R7<E"-PY<AM2=WT8.2OJ,:!2*:P[N),T>@>G[>;+ZL.
M3@/7&*A``LN57<1,#%H`2W`!'$$%L"2&Z84R^40SJ82;<@02&MQ`"E$W/1@-
M!<"!2`'@AO.+`@1RAGNU3]KXT:0M6=A;=C]_G4TZCKJS&?N]$C;*V8Q>6I`:
M>Y%T8+I]*!WC1].Q)"'S=\[O/-8H'J^UM"2-[<TLC;/E@K5G)9R4<X(_PZ!&
M6<P&U;DM^\C)U2>V?M8X+*D)W)X_5!/C1VMB24J;CUUGX=Q032Q9F!GS[>YZ
MF8C<*N&C+$D6O4]Z]8DM#7HX/K0XCD'RCT#M?J@`O2.M@$.L+=A0%,X*]X5'
M<)7#&,=S=C^HG%5*.N&:A5?.:F%FX[>[["IE':9'@Z$Z_OS]L-#R&&'#I1R(
M<[C0BY=`(Z=9KSC$FB6C35UX1]0MWA'?&N+Y@CI6WA'W8B0K9:_+M5%TE;$P
MVH4!@[%2+I=`I8P6^G\K9?44Z`)_PE5D40P2!+4&:_C"6^%*6<<T[?L@7F;7
MBYBU0B7=E$.TR<1RXQWM>I->S5D7UMX@4"<CIGY=IS^[-YA4P9LJNL%$5I&1
M0EF$[ZO."J%2HDHB)9&6J):H(8A.)*.G4-JG;Z"155\D/XL6_5:\UQ:%LT*H
ME*B22$FD):HE:@BB^<%<>T=^QKI?/%%79VS^K\PS!+#*Z++(9%`Q6OE)4TI4
M2:0DTA+5$C4$T2H8*85&&4G&,P-N-1@9<"?+1CU41`*5$E42*8FT1+5$#4$T
M52.S4*IG\G.B#*]L%J'9640.(27L$1;U\5PL9,YQ7/_4Z.C;0DM42]1XU%\$
M3=FH*)0R&MUWW`VM%",C;1&IA$.X$@Z1FQJ_NU<0U\R99-PI*XFT1+5$C4>!
M2A@]Q2OQ7EG@-!EN"8?&82PBA\9[<.G0PMY\XGG$UHUJ-/!#KV08/5KUCY;F
M$=-;]6C@PS0D#.F-^*,ZLG>D.M(AO%OR5F-E2F\UHDHB)1VUM*HE:H@C3=5H
M(#[XV05//<R&G@E!AZB\B=B6M?!68ZJE0Z=U2N4=H8E&]12QC9KR5F-X?5'X
MVCO2\&S/TWBK/CRMY%^@&<U#`EY4IQEA4419,XE6>,<QZ](A^*T`.[)R5:.5
MGQ=*QM*C%8[%Y]AHY6,U)!8MUVGI>-'S&--IO%P6+:X'U5TX*[Q'<R@%XZ&H
M<J_JK!:P"@]6,5^@E`RO+PI?A\.S?4M#PM,*,A7:W\'&=?LR\0U5$26T"-_!
MG!5"I4251$HB+5$M44,03?M=XM3\Z,1;Q"*DM`MGA5`I4261DDA+5$O4$$3S
M8[+SM!:+G8K$+<KWOBMGA)^X2U1*5$FD)-(2U1(U!-&,C>!#]Z`S&5MYB#6D
M_(DAMD8D8X%*:55)I"32$M42-031C(VP0QDC\7DF>:L(C9@;EZ2,/4%8Q=8*
M3=="HE*B2B(ED9:HEJ@AB&9O9"#*_DS*3C0B:1E;1/)S"&EL;X4[1>XV1BM_
MTU(2:8^D>DY^K14OWT?T0:AN=`CGZ!'*T:/3^XC1:LA1(NU1(,>02!SO-!?=
MJQ.I%ST:14OA$=HA.+2P#X@#.P1G<#T^3%'"ATD53<Y#FA,*3IKSXJG9.[(Q
MM-H-:W]O->9<.K08GPU4TDI)*TVL:!(A<76)JD^DHG*(/@B/N:IW5G#;]BU6
M>@0S<URK8BY`G171_G',9+<*QV(J6)^+16MD9`Y:A2X?:*N/8`WVJ:X2B^@C
M\)@U7>&LX+F;=RP=,FLEJA'?`WM'/,L#-;(7P6(Q/:G/Q:(U,E+I0S6R&HO4
MR"+61^S65<"S#J/72!\Y1/N(/3FLI*/RB#JRQTW:6_6C0K-G2NSR#K&BC&1O
M$>V01,PBYX@[Q"(ZJHF81<X12H7Z2,RB2V)I^(FDE\R_BD5KQ+3;Y36R<HS4
MR")8UOS\*!*!2HDJB91$6J):HH8@FJI156@RG)8MIL_9QL,AM,LH)"HEJB12
M$FF):HD:@FA^1D)=GI^QAF>3N.$R-BE7B37",ERB4J)*(B61EJB6J"&(9)PR
M[79Z1'OK<^\V.2.<L42E1)5$2B(M42U10Q#-.*3D+A$&Z2#?T`(C-A[."L]@
MB4J)*HF41%JB6J*&()H]TW9GQMNJ-[Q"P=L>?=.C%<HC),H]@OOQN!B+GSE&
M*[_:*8FT1U*4FX=7>+JBE??RC4<?A(I6A\@86E4(\LI?:NFM\$TB$C]@C%;>
M44FD/0KD:"0-6I+Z'-^Y\8`?S?E"[-%XFRT\0AL/AWZ]\7`&>.,A?)@&U.0\
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M1$HB+5$M44,0396)MM,SP/S@QWK`(;SQD*B4J))(2:0EJB4R'RV9Z[(78?.S
M'R'9KTUV[?ZI+=J7E\-DTWTU'QAEYHG?@.W73ZMTGAMY"W*"';E/H_P>SB&/
MK."($86!(QE$@[J'C@R?6;'SK.+KW#S9ES[W\:?\'E89>00>R(-/\$@"T6#+
M&?!)P"<<+5G"D67`YS[*\GOX92D0#8Z85YU"1Q9PI)<](M,4KKI?$<01B!8^
M3PS1X)<>>1[X;NV^E\T\%A0Z.#8Q!`K$6260?(#?I_F]%3?\!)!%,(D((L$[
M?O)25Q&XA&/%RWP%S\FE3P%'BN"1$HZ8GQ2D3YG,<Q7T@=\;<O,\7OJLTCA?
M@6"61PHX4@2/E'#$["VD#\AX.!**!AN/W`ASZ0/O5$%U0LT,+_/DYGT=Z0/O
MY^3F%1QY!-Y\R<VK+O((O-J2FW=9Y!%XM0%\0OG`BPK@$SJBKG/XND#&4E#H
MT'7!J]>Y>;LZX!%%<"38LE"95;`R\#)<7@2/E'#$O+@FSU-&G^!(J,ZK+%^%
MIEB1Y46(5UD.WY?(,Z@LAR]H`GR1PX<EDM=97O=\-DPQ^/+S;?W4_F.]?]J^
M'B8O[2,LW//^]:&]_7;4_N/HW@3^W!WAFT^X^\*'A/"-;PL??\'GEM/)8]<=
M_3_@Q+/AJ^&[_P$``/__`P!02P,$%``&``@````A`(TO%.F[!```W!$``!@`
M``!X;"]W;W)K<VAE971S+W-H965T-2YX;6R4F%UOJS@0AN]7VO^`N$_`0$*(
MDAP=J+I[I#W2:K4?UY0X"2K@"&C3_OL=>PCV.$V3WK0-?CU^/#-^B;OZ]E97
MSBMONU(T:Y=-?=?A32&V9;-?N__\_3A9N$[7Y\TVKT3#U^X[[]QOFU]_69U$
M^]P=..\=B-!T:_?0]\>EYW7%@==Y-Q5'WL#(3K1UWL/'=N]UQY;G6S6IKKS`
M]^=>G9>-BQ&6[3TQQ&Y7%OQ!%"\U;WH,TO(J[X&_.Y3'[ARM+NX)5^?M\\MQ
M4HCZ""&>RJKLWU50UZF+Y8]](]K\J8)]O[$H+\ZQU8>+\'59M*(3NWX*X3P$
MO=QSXB4>1-JLMB7L0*;=:?EN[7YGRRR8N=YFI1+T;\E/G?&WTQW$Z;>VW/Y1
M-ARR#762%7@2XEE*?VSE(YCL7<Q^5!7XLW6V?)>_5/U?XO0[+_>''LH]@QW)
MC2VW[P^\*R"C$&:*&(6H``!^.G4I6P,RDK^IWZ=RVQ_6;CB?SF(_9"!WGGC7
M/Y8RI.L4+UTOZO]0Q"34&"08@H1`/XP']P;Q$$CM[R'O\\VJ%2<'F@:6[(ZY
M;$&VA,#GC2'&N-5K.P4Z&>2[C*)BP28Z*,_K)@Y7WBMDM!@D*4K@0(P21A79
M62$+`70C(NS;1@RA@A_G_DPD)U&BP*?KI1](J"*[5,QU$,((J3,9/V>3XK4;
M&:F(([IRBA+5T2K#F?&`+`Q1[E]8BJ'US(5GUL(H250-)_%B81>)C,^3Q95\
M0%>;6+*M;M=,3K+R,K?P4&+DQ7A`\C*G`)\71(JMO,36PBB9J;RP8$%',SJJ
M6Y\@Q5]!DF(+R5HT10DBS7UK-#-'%[$N(T&2[R?K]-\NDYQDH24T'RE*$"VR
M>CLS!S4UX4HHU^?5DV+*8W2E.CTI2H;JS6T@,GJEH1DXCIFJSY&4FC*%=D<-
M&H2:,+TN'G@ZK!-,\L0^L.\(CL0-.G1:TP?L<YZJR&O7.&GC$VGO8:R-@Q)9
M;GV#!!T63&5\*RP"JY<8:DP2XPE=7+JDT<\W%D=/)6G01Q<;AZ$&BQ3ZUG!F
M#>O&HEC2-`VL^]R0H=42/+W`@(<:Q`OFNDN&'C*'(PU/Z:2%&G0WDH:&2ZAT
M*PQ4J(GQ)3(W>V7@(H)9,-,1*-J77)RA"\.>=3/9[X]!8S;3V;OMKQWL2WZM
MU/3$+RY.O.G)DVAF=7HVQ!@<(4RNF".S7/M&P2[M>J$##P4S+?DC,#)^'>Q+
MMLW0=DFYK`9.!XU9KK-9V^4*+(.^[Y"I6;1LB>7$Z:#!LAB^A[U,1B>ZI*21
M`\NG/R^94EM0^@6.)1LT1F;&)]*?)S-?;X.B6`9]9Y[0<LUCG^B]#DAG6U;?
M__61'O)DC@*>GDWQI.$:;G0GGIQE94S;W8"'FK,KQ1?'+Z`"=LV5`NFJ7T=$
M+X8U1G=*;#M7D=<N(D8)\ZVJ9T0PB_Q0^QO-HN7I=V;QTML3JXRIO*]"IO&"
M$`5A9!U9>0TW!.0&@8AXR<9+:,W;/<]X575.(5[D!9K!2V-\BI?[%"[WZB;L
MC0-PMS[F>_XS;_=ETSD5W\%4?QK#VBW>SO%#+X[J$O@D>KA5JS\/\%\4#G=6
M?PKBG1#]^8,TE/'_,IO_`0``__\#`%!+`P04``8`"````"$`AV=+:>4%```:
M'P``&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)R96V_K-@S'WP?L.QA^
M/[$E7W(<)#EH5W0[P`8,PR[/KJ,D1F,[L-W;MQ]%7QK14N*CEZ)A1/Y%D?Z%
MB=;?WHN3\RKJ)J_*C<L6ONN(,JMV>7G8N/_\_?CEJ^LT;5KNTE-5BHW[(1KW
MV_;GG]9O5?W<'(5H'8A0-AOWV+;GE><UV5$4:;.HSJ*$=_957:0MO*P/7G.N
M1;I#I^+D<=^/O2+-2[>+L*KGQ*CV^SP3#U7V4HBR[8+4XI2VL/_FF)^;(5J1
MS0E7I/7SR_E+5A5G"/&4G_+V`X.Z3I&MOA_*JDZ?3I#W.PO3;(B-+R;ABSRK
MJZ;:MPL(YW4;G>:<>(D'D;;K70X9R&-W:K'?N'=L=1]'KK==XP']FXNWYN)_
MISE6;[_6^>[WO!1PVE`G68&GJGJ62[_OI`F<O8GW(U;@S]K9B7WZ<FK_JMY^
M$_GAV$*Y(\A()K;:?3R()H,3A3`+CMO(JA-L`/XZ12Y;`TXD?=^X'(3S77O<
MN$&\B)9^P&"Y\R2:]C&7(5TG>VG:JOBO6\1P4UTLW-I#VJ;;=5V].5!O6-V<
M4]D];`6!ASUU$<9=FC8)NY-![F24C0N-"OH-G.SK-HG7WBL<1M8ON>^6P-]Q
M"1M7>+"9<4>PB\L=Z4]G$):+I3"<.^[DOC-<RG"]3*#*R,0#*.EU.>FT<<.+
M)"9Y=DNP?DI:X'29EM3CL2ST#4GI!\6Y>K;]FLNLDZ4^;="CVV#18GES&](/
MMS&>=&_AV%Z7!8Q5B>LG*A>K<7L+G./8*<E7?3)+5:EKWAG)2#]5M+>$DV0D
M?,GSP1,X[^M922]5H+?`H7UFE>BS2J:2LTHD_531WC+-BD&GT[26RQG=B(ZJ
MR&"Z3(WYOCXW)C%`SG-6<NA(A&4L,&G2^R&&L)X9%Q093)=-R'P#L)A\Y*UR
MZE@!S_;X4&$L?4X:@#"?S^AV."#:&(-)K9F!E/(SRBX_Z4AJUILT-?LA;+`I
M-P:36K/`T(>VZ&!3=@PF34XZ>D1S<"MY3X].@Q#FAX;\;"'"IA093-/\.,'(
M=2CB:K4=!I-:LTB?$[=E!SH282,[.&$'?JB$L/Q&<E.(8"2051^RS[E(&0^X
M+430D237<T53,`*1&SE-P<%[DUHPPZPAAQLK<*`CR<D(#D[`(0N6W)SDT(M(
M]$Q1ZV48/;@M0-"1"!NG#TX`<J->4VA@`%!3ZV48/+@M--"1Y&2</>243;LB
M]),%G/[U]-!151E,2LF88?8(;/F!CD2XYT<\&1@#PH\;.4VQ@0%HR9AA]@AL
ML8&.)"<C-@*"C7F/&'H1B1X?:KT,<T<@'WF;N0H=B;",!:8I$@,-/K@?SIBK
MT)/(Z!#"##-(8(L0="3"1H0$!"'X>;9,9LSZZ$ED=#,(,\P@@2U.T)$(&W$2
M:G`2L&0!!;_^Z*&CJC*8U/8TC"-R)K!J3W0DPCU.INT9$IS(\LVB)3H2E1XV
M:GJ&@22T)0LZ$F$C64(-62(VX^%#1Z*BA8MA-@DE$&S@@HY$6,8"DZ9Z!"XW
M.K*GQ\7WP;`WP0&.OQLP9IA)0EN@H"/)R0B44`.4(.`S@(*>1$8+%,-\$MH"
M!1V)<`^4Z0=XI`$*B^&7UEM`04=593`I3QPWS">1+5#0D0@;@1(1H%QO25Q-
M0O<445J2&^:3R)8BZ$B$C12)-!29UY+H261T&.&&&26RQ0@Z$F$C1B*"D7GS
M%WH1B1XG:C\:YI/(%B?H2(2-.(DT.+G]]0V]B(0.)=PPFT2V*$%'(FR<36*"
MDNO/&JY60P\F]5DS#"2Q+3_0D0@;^1$3?LA>G/&+.+H1#=TXP@WC2&P+$G0D
MPD:0Q#J0^/&,>00]B8P6)(9Y!"X>E7GD1JOTJ+B8%#``;&#Y^8VTNXGLKOL*
M41_$+^)T:IRL>I&WC!SNZ4;K>`-ZA_<YU!ZN[KJ;46]\!VXFS^E!_)'6A[QL
MG)/80TP?3ZKN[C:[%VUUAEW!_635PITD_GN$.V@!UX:^_$S=5U4[O)"WI^.M
M]O9_````__\#`%!+`P04``8`"````"$`:3/:R`4#``#Q"```&````'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;(Q6VV[;,`Q]'[!_,/3>^)JD">(4Z8IN!39@
M&'9Y5FPY%FI;AJ0T[=^/E!S'CMTF+X;-D.?PD!*9U=UK63@O3"HNJICX$X\X
MK$I$RJM=3/[\?KRY)8[2M$II(2H6DS>FR-WZ\Z?50<AGE3.F'4"H5$QRK>NE
MZZHD9R55$U&S"G[)A"RIAD^Y<U4M&4U-4%FX@>?-W)+RBEB$I;P&0V093]B#
M2/8EJ[0%D:R@&O)7.:_5$:U,KH$KJ7S>US>)*&N`V/*"ZS<#2IPR63[M*B'I
MM@#=KWY$DR.V^1C`ESR10HE,3P#.M8D.-2_<A0M(ZU7*00&6W9$LB\G&7][[
M(7'7*U.@OYP=5.?=4;DX?)4\_<XK!M6&/F$'MD(\H^M3BB8(=@?1CZ8#/Z63
MLHSN"_U+'+XQOLLUM'L*BE#8,GU[8"J!B@+,))@B4B(*2`">3LGQ:$!%Z&M,
M`B#FJ<YC$LXFT[D7^N#N;)G2CQPAB9/LE1;E/^ODFZ0LEDGM@6JZ7DEQ<*#?
MX*UJBJ?'7P+P,2>+T&;Y7I*0'8)L$"4F<%"!7T%E7]9^<+MR7Z`:2>-S;WW@
M>?)I/5S(IDT)TNBF-%Z>(S,Z(S.6"U.YMX8N33!.$_9I4'D(/?V8#H-B$G5%
M#(1:']/!GBZ(ZNI"PF"&K;[`B7'0GH^KVSAU=?O!8EPY,)XGXD\G\XN)8)Q)
MI"UV8PG,$>OV<#:D"+SH"@X,[',T%J`Z'9S0&U<V'])>I0SC^JR-9390AM/X
M_,+,X!Y>ZB+&]2D:2U^8/RYL,<)Z3<LPKL_:6**!,!\._[FR((+#_/&-,&%]
MBJ.IK^R=:^CC7#@OZ#723.`9,6*!:43<V5#!RS>++G?-;\9)9\`<37UUX7C?
M8)_TU%VHI1T=<-7;&V8`0-+\U"^[8.P4+YG<L2^L*)23B#TNCP#&;VMM%]O&
M7-%S>[3<V(7GMK_`PJGICOV@<L<KY10L`TS/7%QI5Y;]T**&K&#M"`VKQKSF
M\->"P0CVL*R9$/KX`6+<]L_*^C\```#__P,`4$L#!!0`!@`(````(0"Z4:0G
MAP(``(P&```9````>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;)Q56V_:,!1^
MG[3_8/F]<1)(4A!0%57=*FW2-.WR;!R'6,1Q9)M+__V.;4BYM!TJ#R0FW_DN
MYSAF<K>3#=IP;81JISB)8HQXRU0IVN44__[U>'.+D;&T+6FC6C[%S]S@N]GG
M3Y.MTBM3<VX1,+1FBFMKNS$AAM5<4A.ICK?PI%):4@M+O22FTYR6OD@V)(WC
MG$@J6AP8QOH:#E55@O$'Q=:2MS:0:-Y0"_Y-+3IS8)/L&CI)]6K=W3`E.Z!8
MB$;89T^*D63CIV6K-%TTD'N7#"D[</O%!;T43"NC*AL!'0E&+S./R(@`TVQ2
M"DC@VHXTKZ;X/AG/"TQF$]^?/X)OS=$],K7:?M&B_"9:#LV&,;D!+)1:.>A3
MZ7Z"8G)1_>@'\$.CDE=TW=B?:ON5BV5M8=H9!'*YQN7S`S<,&@HT49HY)J8:
M,`#?2`JW,Z`A=.>O6U':>HH'>905\2`!.%IP8Q^%H\2(K8U5\F\`)7NJ0)+N
M2>"Z)TFR:)AFQ>T5+"0X\@$?J*6SB59;!)L&-$U'W19,QL#LD@W?3`:17,V]
M*_*E@#8PC<TLS483LH$6LCUF_@HF3WH,`?G>`^B>>QC`C%[O[L&#*SKSD,<]
MO_<Y?PV3]I@3#X-3#^]K.S#T":,^?Q*_9`O:`>-WPXD05!V'?5_(@6&S'`FE
M^:`/$(0"IO!C*'+W*7K$B3*,]5C9C?K_;79%YPZ&/7]P$#`C[R#OGYUHYQ_1
M=D7GVEG/'[0#)F@/WQ`O/B+NBL[%7_B#>,`DL4\^C*,7<R%\.%#"^];1)?].
M]5*T!C6\@N;'40&=T^$X"0NK.K^G%\K",>!O:SCU.;QTP(Y1I90]+-R!U?^/
MS/X!``#__P,`4$L#!!0`!@`(````(0`L69_3B`,``(,,```8````>&PO=V]R
M:W-H965T<R]S:&5E=#@N>&ULG%=;;]HP%'Z?M/\0Y;T$)P$*`BJZJMND39JF
M79Y-XH#5)(YL4]I_OW/L$'*C9'V!YG#.]_D[M[C+NY<L=9Z95%SD*Y>,QJ[#
M\DC$/-^MW-^_'F]N74=IFL<T%3E;N:],N7?KCQ^61R&?U)XQ[0!"KE;N7NMB
MX7DJVK.,JI$H6`Z_)$)F5,.CW'FJD(S&)BA+/7\\GGH9Y;EK$19R"(9($AZQ
M!Q$=,I9K"R)92C6<7^UYH4YH630$+J/RZ5#<1"(K`&++4ZY?#:CK9-'BZRX7
MDFY3T/U"0AJ=L,U#!S[CD11*)'H$<)X]:%?SW)M[@+1>QAP48-H=R9*5NR&+
M>Y^XWGII$O2'LZ.J_>VHO3A^ECS^QG,&V88Z806V0CRAZ]<831#L=:(?305^
M2"=F"3VD^J<X?F%\M]=0[@DH0F&+^/6!J0@R"C`C?X)(D4CA`/#I9!Q;`S)"
M7\SWD<=ZOW+]<$3"\12\G2U3^I$CHNM$!Z5%]M?Z&$$5AE]BP'>)$4Q'D]DX
M(-=!/'L>(^^!:KI>2G%TH&>`4A44.Y`L`+A?#PA!WPTZKUSH:3BK@B(\KTD0
M+KUG2%Q4^MQ;'_@\^U0>'I!6S,`VG!F=D1DSBT>YMX8ZC=]/$_P/#3JOW+!^
M^(Y`ZV.*W-`#4</UH#.D_.U4EDYUD228],N$-JJSV_X<S2ZVZ*FD&&<.4F6V
MM/AF'NH%F_90^+?8[U?:!@.;'*4%(L]=$DS[E<UZ:"<#E&%<D[6TA!UEN*5K
M0X#)\T.H\]O3@%%-@M+2E#7KES7O<I(ALC"NR5I:NK((K+F.KNF`@IG`)LG)
M!&2UDMWV:R.X!%H)'23.!+:($0OJ8?=SO1]):X-@V29D0&>8P!9+N4^:\N87
MY+5VRN!A(W9WP-A7TU::^N2U%@JR3,/1U6DCU6XYDY2FAKIP?$$=,+RO>!C8
M2JLU]:GKVR:38$CUNNN$].V3D%S0]]Z%0KH;Y63JF;V>G3*L.;MK!5\3F%A(
MYGGVP@OO.X+KX%VSAX&M\I6FKCRH:(<E`.^W-Z:):E*<3$UM07_I_-9>N<)F
M-T=]V@P`'&!V?@78*Y^]$V5,[M@GEJ;*B<0!KW,^W'(J:W75W)B78]L>+C:`
M#T/G5;_`%;"@._:=RAW/E9.R!##'ILFEO43:!RT*.!7<!(6&VY_Y<P^7?08W
MG3%.?"*$/CT@0?7OP_H?````__\#`%!+`P04``8`"````"$`1PBEC*0,``!7
M/@``&0```'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6RLFUUOXSH.AN\7V/\0
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M1N!KUWU3ILV#0N`\9=ZB'X%_[4</[>/Z^\OQW]U[W6Z?GH\PW!EDI!++'WZ5
M[6$#%84PDSA3D3;="UP`_#O:;55K0$76/_O/]^W#\1G^MYPLLBR=+VX@S-?V
M<!1;%7,\VGP_'+O=_XR5B:6CQ"8*?)HHR7R2W<R2"$YZRC$QCO!I',\XI,8!
M/JT#_/?$I<'Y^P3ATSA$L\E--%LF*K\3CG/C>.,<(;T3#C"E^C/!Y^?.M#2.
M\&ES"E[:5(]=WPKE^KB^O]UW[R.87S`XA[>UFJU1#D%L#^AK';KBHZ:`;E!!
MOJ@H=V.X>ACN`W3RC_MHF=Q.?T#W;8S-*F"#+0IKH5I-A2TIJ"@0%$@*:@H:
M#TRA"$,E8(3^@DJH**H2-H>5!:XT,4G;6EB7DH**`D&!I*"FH/$`2ANFCY]V
M>/+;<5;&=V.8-=XXISB=E;;)](JAAK%@I&2D8D0P(AFI&6E\@O*$B[X\3V4,
M,^)T0VNC#":[5XT,5Z,8C(;19:1B1#`B&:D9:7R"<H<EP<]=3_*)6L1.#[?R
MZ\M@+WZE278S]'?!2,E(Q8A@1#)2,]+X!"4(8^`G>#HK98RSTB2#]<\;R3D9
MR<'(%J-DI&)$,"(9J1EI?((2A1W%3_3BD51^.&=-DMB-)",E(Q4C@A')2,U(
MXQ.4($PY/\'3(ZF,<5::^%D9TNLHO:MH$L,^X(WV#1[MBKD)0V"2>6Y+["8'
M(]LDM1\(90K=YF?J#>7Q>;OYMNK@-'"-@0HDL,/J?5?%P`70Q"^`(5X!-(EA
M1_`R6>!,*N8F#(%).+B!8L=N<C`:"N`'0@6(0+%^4(%`TB#N;-:](T[;H'GD
MVME:I0,JK95K^HI;"6OE'"5'-7+$>2F%P335!<MMI*4);#NV>"N#$N@BK^@1
M+GIAK&)WQ:5!:=RKL3B-L^6<-&O%W81U\\\7942Q2.NX[(,GDP71>K4UZ"\(
M%T?ID*N*HP4,*HY&*>Y(<K%%9!S]XF@T5Q/IQ_W-,F$I5MQ+&)3,>Z]TLB!K
MAG0&=OQJ%`870BF5JPJA)0XJA$:D2\B@%)&V0EUB$,Q1K[V(HJN,8XJ:XH:$
M%\9JKN;IC_MLDI)VD\[`E<>_)%P>)69H>>#&$"[TXM4QTH((54HCTC)4M%E'
MOV6,H[]KQ#.B$2KKZ'=DQ"NE8YE&BB89"2--&#!PE3*Y!&84G.Q/5TK%("NJ
M1C&,D-<:I.4+]7T!.**>TBA-^SZ(E]G-/":M4'$W81!N,K[RF//IE2>=S$@7
MUB@R[B@EJC[NJ#^ZMX_V6W_KT<H,M91&_I8;,51R5'$D.)(<U1PU".&TE=3R
MTCZSM6IAAO+3"*GC>$;D0A$-5K9E2XXJC@1'DJ.:HP8AG++27%[*GK0ZD[UR
M)--`(S2Z#)50+^7H654<"8XD1S5'#4(X5:6NO%3/Y*>U&(2S@[2*C#QSDJBP
MR%.,%L$BY"T&;%:;6&[9%,[1GE%R5'/46-1?!$HY_E@V7KXU]$'P2!ODC6%A
MD5<)BV`=&BH1T:VN<E8V;<&1Y*CFJ+$H4(F0T/SD'JEN@TC+6^2&L;#(;4BE
M07.]$L>SB&RBE3-P-3`G<V&DLU*J`<(0\5$[`QNF,0C6/$"X-Y2P\Z;#Q3-?
MW0S1,AB1Z-U26"M7F=*@N4,51X([2FY5<]0@1YRJDDY7I:HUE[\(J$T>LL=[
M?41N[0IKY5(M#3J]:5?6$9:'8<[$$;F)$=;*A9<7A:^M(PY/;@,::]6'QY54
MTHI6\K/3R,@S;V4%3=07%39&+VNB5PIC!8K/MG=I4(:D)BU7Y:RLH^"QI+/R
M+X+-,7VI<$8;JT&Q<+F4!/NSY=(R#O6@1G/OJT7U>XYJ2[\V&J6^*N4W;\9Q
M#KNR5WJR0`D>7AIT.GP=#D]$?(/"XPK^%4HTYDK4(+2#<27*K2J.!$>2HYJC
M!B&<MI*(I''B3-W2??+7IEAK3=0]@_ST1YS>K1A'D+*VSTN.*HX$1Y*CFJ,&
M(5P-)1E)-:+L@F^)8JTU4?9,?A;&RNN%DJ.*(\&1Y*CFJ$$(IZIT(4GUNH'7
M`A.EKA&^.XGHW4D\6+F!9ZCB5H(CR5'-48,0JD;RL7X]K=Y[1ZQ9#?)&N>"H
MY*CB2'`D.:HY:A#"J1*!>B8_+D43C<CHDON.PED-H\M1Q9'@2')4<]0@A%.^
M5H'"&%(%:A`:76WEH9);51P)CB1'-4<-0CA5HD#/C"Z7G8E&<`8[;H5%WAV7
M1:!1W&8^(SU0.2L;2W`D+>+W4HF20&2-,LOQY7>5?1`R0[6T0CD:Y.=H$.R%
M0X[\KM*$3]Q/ZX(C:5$@1R6>:(Z?%+IP<M:F!CF95E@K=Z-7&C37WYX'[A>-
MP4W_T%+_\Y9@/D2X2G0>W)PAC77)]@I?NK($-?)_7+)6+N?2H+GKYHI;"6XE
MD15.(J"8+M(("5=(!N'?"&)ZCV>L?,EM$>R70V_&,;E[JXP5NA.,8W(3)L*Q
MR#V1/!<+U^A:':4J06[Y#<*_#L2DZ0KKZ(^]CJ4DD%<C<L-164=_E@=J%(Q%
M[B[DN5BX1DKKT(E_T630(LD77(E&ZOQ>JE1I&RO41]I1"2//D2BUBCL*B[`C
MV0"DM>I'!66?7BNX>D>\G!N$.R2AL\@Z>AUB$.Z0A,XBZWBZ0RZ*)<_%PC4B
M2NWB+\Y2+MH,@KW6;L4%1R5'%4>"(\E1S5&#$$Z5*+33L@5^0*>KA$%8E"9D
MJ2N<E:U"R5'%D>!(<E1SU""$4R9*[?+1Y:)-?3<"RZ8O:#@J.:HX$AQ)CFJ.
M&H1PJD3'G1E=K;O\]0U^MV3Y&>0:NK16<,0M9DR4.BO;`X(C:1$7;&J9^6#=
MOER4]D'(*J85&QI#@_P<#8*/(4<N2DUX4&(NQ\'1(FFM`CF&A-HG16G*-9M%
M;@DN+/)$J4$?BU)CX(M2YD/T@43GP<UYK9Y+N9XSR!>EULKE7%HK3Y1R*\&M
M)++"22A]<HV84-J0""Z#L)A(B!XLC)4O)BQ"FB`A(U$9*_4Q=#`77.%81+S)
M<[%PC936N:I&RI%,5HW4#')))$0/%JEQ],=>(R(YB%*KK",*SX2[L<*Q8G(1
M\EPL5*/L6EG6.^(:&43ZB&C+PECY?601E,HK+M&6E;5RQ146(<>4"$%IK7I'
MG/VU@DO]+$0ZQ"#<(2G1EH5U=$F4!N%19:+4.I[ND(MBR7.Q<(V(4KM8MF1<
MM!F$GES75AXJN57%D>!(<E1SU""$4R4*[;1L@;?"6`]H-'??GA3&RD,E1Q5'
M@B/)4<V1>EM-79<^H\Y/OWVF7SG:M?NGMFA?7@ZC3?==O5D&;XG<WPY8O_:V
M2N)<?>L(VH$>2>&-.!#VH2/@`_HW="2!([WLH-$R\($1"?ADX`.Y!([$\US]
MPA4Z<@-'^A\OZ7GB!1SI?QAF1Y9PI/\QBAY)9E"#?BS9$:@!?/W,KP!>%_P2
MS`8<0O8K2#]H#\F'<O^2YE_"14FAPH$+6F50Q1"'&@9+"!4,%C`"!_VP!RM&
MDJ_@^TY>#/@B.2^"1THXHKX:YCYEDL*14#3XWCA7WZMRGU6:YBM8>/F1`HX4
MP2-P\Y"K^P#N4Z89'`E%@YN$7(EH[@-/2L$XAEH%'M')U5,XW`>>NLG5@S7\
M"#S/`CZAMH`'5L`G=`0>6`"?4#[P^`'XA([`0_:Y>JJ>7P$\9@U'0N>!)XSA
M2&CD1`35T8]0T`Z!ZJR"U8''W'+U@!>_@A*.J$?2`D?B&>03\EE%T+SP1"+W
M644P_?4-)KVV1;X*G:58Y$6(5XN\"G&QR.&]$WYFL<SA=0S.ZT5>]WPZ7!"\
MUONV?FK_N=X_;5\/HY?V$19G>-<5MOR]?C%8_W$T#\E^[8[P/B]H,'AC%%[@
M;N$MOYGZ(?^QZX[V#SCQ='@E_/[_````__\#`%!+`P04``8`"````"$`\,_3
M[8$(```5)```&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RL6MMNXS80
M?2_0?S#\OK%ULQTA3A'=!;1`46S;9\56$F%MRY"4S>[?=RB2$F=&<=QN7]:;
MPYDCSN%P.+1\]\NWXV'VM6S:JCYMY];-<CXK3[MZ7YV>M_,_/R>?-O-9VQ6G
M?7&H3^5V_KULY[_<__S3W5O=?&E?RK*;`<.IW<Y?NN[L+Q;M[J4\%NU-?2Y/
M,/)4-\>B@S^;YT5[;LIBWSL=#PM[N5PMCD5UFDL&O[F&HWYZJG9E5.]>C^6I
MDR1->2@ZF'_[4IU;S7;<74-W+)HOK^=/N_IX!HK'ZE!UWWO2^>RX\_/G4]T4
MCP>(^YOE%CO-W?_!Z(_5KJG;^JF[`;J%G"B/^79QNP"F^[M]!1$(V6=-^;2=
M/UA^;GOSQ?U=+]!?5?G6&O^?M2_U6]I4^U^K4PEJPSJ)%7BLZR_"--\+")P7
MS#OI5^#W9K8OGXK70_='_9:5U?-+!\OM040B,'__/2K;'2@*-#=R&KOZ`!.`
M?V?'2J0&*%)\V\YM>'"U[UZV<V=UXZV7C@7FL\>R[9)*4,YGN]>VJX]_2R-+
M3&H@<14)?"H2ZV;C>>YJLP:2"XXPVC\=/I7CZL9REROQ[`MN*^4&G\/SACE?
M\%LK/_A4?O88ZP4_V"S]-.%3^6VNF>:M<H//:Z:YD$O3KW14=,7]75._S6#[
M@/CMN1";T?*!2RRQ`XDB)SPL^GMK#NLD2!X$RW8.(8!["XGZ]=[VEG>+KY!<
M.V43<!L+6X3:0BR_H(TH$%,@H4!*@8P"N0$L0(1!"<A2JH1(]G^IA&`12N@8
M`@T8TI"PM85VB2@04R"A0$J!C`*Y`:"P'1ZV2(#I/:[76SAMY[`EA_6V7`^'
M%4@;KZ]/_7*&#(D8$C,D84C*D(PAN8F@>&'2YC)?CE,8P\[`B4W2-I!&'NP>
M0XT-5B,<C(959DC,D(0A*4,RAN0F@F*'=+X^=F'<QZYG'$C$L8?D#A7B#$BD
M$)B"(<8M%B,>C#1UPHC2P<8@HC4E&XPT46X2H=BAGINQR[/L1IPAW4NU^Q+4
M,%\H#1/YX$!!DV5.<&!))&)*HA!#$H5XLBXN+;)1XF%<!Y$PCG2PZ6OKTG*Q
MHMDPKCERDP,)`0<4%<)>B0-\*G:`=?#"#P<O$1NVVKC6'MD=H3)RQQ11B%!>
MGQ:69^.`8F4$41A&#C9*&'=Z#7<VR4T4S4UNI!\4`ZJ?Y?6)-)$[AG["#^LG
M$1N>9,1(LB-4;H9^$G&P-"LL33P8Z81(&%$ZV)C/7V.B;##21+E)A)2!"LB4
M@88/PKMZAPD*+))$2)+1ZJJ,#)$DXF!M:1T:C'1L"2-*!QM#I!7I;;+!2!/E
M)A$2R8+#]4=5ZCFP3`I"R>20315J/T,G!8DCWTA"XAAK*RB0H]6*;/6$TZ?:
M\2)]IJTP/9E$CNBQIJ*G(UVL-6;>Y_H,8GU4WRQ!0D25D%G>E94!11R*.91P
M*.50QJ$<03ALT=,985^N/Y;L`*&9T4D:*&C57P-EC\:AB$,QAQ(.I1S*.)0C
M",<GFKCKXY,M'VG62!(%EFH,87\:F4RJ9SA:::TB#L4<2CB4<BCC4(X@K()H
MYZY7039_:)4E9*1L:"G(Z%(T!".&,.0TB$<K+4RBH9$KU1#F(M4W&ZTT5ZZA
MG@NK`,>(J<)_ZM_$?8YN<0DA<10T!A0I1P=&#''(*12/5CJ@1$,C5ZH@;]GW
M@_!="._F1A--E",BK(SH](S\,)3YH"#(%A&EBH0<..+'.-?DM`LM:66;QXB"
MD$"LJ5..SJUJA9=+0IUPZE1#%ZFS#ZESS=//&BLH>CVBH&J)K^]<+-DP(C4E
MY*+#;TU.S5`[FFI*1P^.'V,92"F+E2-8Z2Q)-!?2:DW:YG1T-.E)`YR-5IH^
M_X@>JRKZ1**J<2A?=>$2Q9QN6`F1%*5=LW)$*2H=/;M//NMVXQ!=8N4$%CKB
MA/.DHY6XBUFW*YL5MN%)FB='/%@FT2G^J$RRVX2'Z`<&EH1([K%S3CF:N2<A
M#]WJUNP<&*ST$Q/U1%&HC*0E&J?*BM"32IJ-5IH^_X@>B6K_#TUVSX'[006A
MW'/(W$-E9*:>@ERD*:N.VLJ5";IRZ2T_X=2I=KI(G6DK1;U9;LBZY(@::RF:
MX/<3]+KFVN;-M8)<G"]D+X7:T<A0[0A'SIAH7$WY1'<MCUG7(LP)9TZO8LZT
ME62VX%4$OC+GB!EK23KV_JP>+RI7U42;]_$*0GEI;<C9&BHKE)B2"U^3-^2$
MBC7]>B@OB8)<J'3C&K"#1EEYJ`_<D',L&ZV&S:X@.56LH.C?W\_&ZQ04'&1G
M2P@G(]TDH?@60CB:R2BA#^[/RM&5C8]C>R1E$LZ<*N@R<X:9IY+1G#.64EP"
MWI?RRHTM2(B6$C);:EA(865`$8=B#B4<2CF4<2A'$`X;"HX9]N4F67PO2N.3
MD'EK5E8&%'$HYE#"H91#&8?$>U\Q+_E$&9]\CRO?[AW+YKD,R\.AG>WJ5_&.
M%CJ!^[L!EB^0`PO>(,/W"[#OV(@-(WTC1$8>+,=_@*=/^3C@T]]TB$]@N_"F
MNM\U;,33[[#)2&3=^C$<^OPYT$/XHD/@(Y%M^Z):\9$41D2AX2/P$OUA"@^$
M-!/V`0@S:0_!3\7^X/H/DT(&H,F4)'![AO"F1SP8F9(>+LXPVZF1R%J#C'WE
M)@+#-0#8ID8B:P,^?3/)?#;@,S62PSJN)N2*@&K*/@6B*3R"59]:VA36?`H/
M(/)@,G+XDL,/)T<B&!'?9/!D@(L^C$SI"%]S^.(VSWT"SP^F(@\]/YS"(WC$
M%$^T\N%5$.=//!]>"'$\A628XDE7/KP.`OO%L'CPHXQS\5S^5C3/U:F='<HG
M*`C+_IU%(W_6(?_HU!>ECW4'/\>`J@X_"("?WY3P+GXIOL=_JNM._R$>,/R@
MY_X?````__\#`%!+`P04``8`"````"$`SAMIC>$%``#I&@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6R<65N/JS80?J_4_X!X/P$;2#91DJ-L5]L>
MJ4>JJEZ>6>(D:`%'P%[.O^^,,1=?"#0OJ\UD+O[F&W]V8/OU,\^<=U96*2]V
M+EGXKL.*A!_3XKQS__[K^<N#ZU1U7!SCC!=LY_Y@E?MU__-/VP]>OE87QFH'
M,A35SKW4]77C>55R87E<+?B5%?#-B9=Y7,/'\NQ5UY+%1Q&49Q[U_:67QVGA
M-ADVY9P<_'1*$_;$D[><%763I&197,/ZJTMZK=IL>3(G71Z7KV_7+PG/KY#B
M)<W2^H=(ZCIYLOEV+G@9OV2`^Y.$<=+F%A^,]'F:E+SBIWH!Z;QFH2;FM;?V
M(--^>TP!`;;=*=EIYQ[(YC$*7&^_%0WZ)V4?U>!_I[KPCU_+]/A[6C#H-O"$
M#+QP_HJNWXYH@F#/B'X6#/Q1.D=VBM^R^D_^\1M+SY<:Z(X`$0+;''\\L2J!
MCD*:!8TP4\(S6`#\=?(41P,Z$G_N7`J%TV-]V;G!<A&M_("`N_/"JOHYQ92N
MD[Q5-<__;9R(6%232RSM*:[C_;;D'P[P#=[5-<;I(1M(W*ZIR="M<FR1L#I,
M<L`L.Q<&%>I7T-GW/0T?MMX[=".1/H^-#_SM?$CGX<%JNB7!,H9+LK>GK8S.
M6!G;A4MY;`S#,M1>)E#+(/(`.+U=#H-V;C@`L5YVZ9L%-"Z"0`46!,V'A<Y`
MR;"CQ._[U5223E"P;^G`2:D.$S*LWO"\6(V.7]M?C!,+Z1HL+:$8JR%O2TL)
MG\ZH@8%J#6F!4@-D(SRNU+*W^4-GM92TK`PX*+N#G7$[+SH;?`7:9$@GE:_>
M2>%KK5:?S1?&J0"EQ>2+P+0/$6(-&D4S"!.1:I76I%(6=AU0P!'4@MF]%=Y:
M-2DF)FOD?ZF'\#9XB[I5-_NL]5*)Z[U4;+C_!]AF,T<P4(,I31;N-#4154+H
MRNTQ)9VN=-NY-:G$]:*F@L/-/P`W40V]-4329"%.DX^)U)UF#!5BI1,GO53B
M>B\5FR8D\XDS185(DX4X35:PRGKRV,&#0.^D-*F\]8>NBDV3DXGFFB)"I,GD
MC6HJ<CNU\-8W'-$/MM9+X6W@I6"CFIC,YDT$JN/9FDS>J*8K\W@345H)>4%1
M>",C9QM%`1CLM_G8I'(,+T;29,%F$1/JAS,.`FKJ26M2\8V<<GAQO0\?!FJ-
ME28+/DU:1!=7:[QE3^@E[62FT\O6!+']W82,''3T7DT1@1J^44VA%DT)R'HQ
M#<^4%9$+"JOP1LXZJLG*_/$T%4;D@L(F?7@KUX<D]-<+X.:VV(A`M8FM284W
M<MH%]RJ+"-0*RQN+!9Y%62(R8_,%4DD&>[PUJ?!&#KQ`$Y>)9IJ*(A(`3/-0
M"#1%F4C=J<AP2_5'F?Q=);U@'8.-UWLIAT(`'=!GALRYVHI`C3K,!28+=19A
M"0(Z0U@"4UA:D\K=NKO2J/CN%99`JLAP:*1I:?P$"BS"0I;PT&%RYYG"(G)!
M%Q5XU!^!IPG+Q/R8:A)(DSF:H:8FMU,+;S$._=#1L"=%_A#'G."EC";M;S4*
M=7A+OVLT1:!82W<8M29S-$.+JLP;31&IE;'=6>C(G2749&7VH2`"M<)2="SX
M-(7!*M/WZ+!3FKZ%TJ3.Y<A])02O^[C#0`V;-%FP661E!C934D)I4K&-W%5"
M35(F-H:I(R(!8+3L.4U')E)WXM'O.7C$V2F%W'/22]USO9>ZYS0]F3^3IK2$
MTF3R%FG2@E7H&N;K-EX1ILY&:U*)&[FF1/<*B@C4"H]>4R*;H/C+&?<4$:F5
ML0K*R#T%GLDKFVZBFU(R!@><2*`.9O.0OGD2GK/RS'YA658Y"7_#!_!K>(3=
M6>7+@2#<'.!4`=W0OPG]S0%FW_;-P^;0O%'08\CF0*T1FX,U$R2"QV"6$H3"
M-^)ALU%B"=]8%TQAP7!W@VQ>%P0O&J[QF7V/RW-:5$[&3M`'7[!;-J\JF@\U
MOT(GX74#K^$5@_CW`J^4&#QZ]_%><.*\;C]@@>XEU?X_````__\#`%!+`P04
M``8`"````"$`M.+J41\-```>0@``&````'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;*R<VVXCN1&&[P/D'03=KZ7NUL$6QK,8=S?9!#9`$&R2:XTLV\)8EB%I
M9G;?/L4F*;+JYVAD;V[BS,>J4M>!9+$/^^'7/[;/@V_K_6&S>[D=%E?CX6#]
MLMK=;UX>;X?__EW]<CT<'([+E_OE\^YE?3O\<WT8_OKQ[W_[\'VW_W)X6J^/
M`[+P<K@=/AV/KXO1Z+!Z6F^7AZO=Z_J%1AYV^^WR2/_</XX.K_OU\KY7VCZ/
MRO%X-MHN-R]#9V&QO\3&[N%ALUHWN]77[?KEZ(SLU\_+(UW_X6GS>@C6MJM+
MS&V7^R]?7W]9[;:O9.+SYGES_+,W.AQL5POS^++;+S\_D]]_%)/E*MCN_P'F
MMYO5?G?8/1ROR-S(72CZ?#.Z&9&ECQ_N-^2!#?M@OWZX'7XJ%F9:#4<?/_0!
M^L]F_?V0_/_!X6GW7>\W][]M7M84;<J3S<#GW>Z+%37W%I'R"+15GX%_[@?W
MZX?EU^?COW;?N_7F\>E(Z9Z21]:QQ?V?S?JPHHB2F:MR:BVM=L]T`?2_@^W&
ME@9%9/G'[;"D'][<'Y]NA]7L:CH?5P6)#SZO#T>UL2:'@]77PW&W_:\3*KPI
M9Z3R1NAOQL@9Q8E7I+]><7XU+\8WU9Q^_(P>C?9737^]7DDFSBC,O`+]]0J)
MEV?TYEZ/_K[I`FEZ]1=(?R^[P!NO0'\ON<"12V-?%<WRN/SX8;_[/J"I1HDZ
MO"[MQ"T69"N4@W/Q5"`_J@\J#&ODD[5R.Z2+I]0?J*B_?2PFDP^C;U2(*R]S
MEY'A$G60L%5GS382M!(H";0$G00F`2,*PBD25-'_ATA8*S82P8>[`&)H2N%V
MD`@JC02M!$H"+4$G@4D`<YOFH'2[HE4EOQZ$?%NEVR%-H23?4^[6G9.9ND7$
MIK,&T@!I@2@@&D@'Q*2$^4L7G?I[WD\K3#/C?&$[H2DM%4DT9CP:]4GHE&4@
M+1`%1`/I@)B4,-]I^4M]=Y/]RJZ=Y\-@]?HPA(N_<V0Z/]5Y#:0!T@)10#20
M#HA)"7.0<I`Z>-XK*\R]<F3*TST7F3P)A6`T0%H@"H@&T@$Q*6&.TOZ2.GIQ
M)JT>]]F1JHR9!-(`:8$H(!I(!\2DA#E(.4@=/)])*\R]<F1*.UHR)Z]%)D]"
MITP":8$H(!I(!\2DA#E*EY@Z>G$FK1[WV9$TDT`:("T0!40#Z8"8E#`'"]I-
M4@_/I[*7YGYYE#H64-\H^U[!_@QUH[3X)2F_X2EO@^+D5.XJH&A+!\1L3<?<
M5A>E0OV8@'I;/`JV[8!&JU][CT^;U9>['5TUR62B4U%#Y=LLU[O0?A1^\:YP
MB`7'H^A0$Z2F?6]6C@NQ6;=1(%A6`44S.J"3&='C=5$@F#$!94)B6Q(1DG)F
MCQVY*!`^A<'U,BP,#I6T[<?L3PN>L;KP4C'[34#THXFB:-':($7K<2)5<?,J
M2$7S.J"SYKL@Q<V+X)H@U9OGQ66['1')8GK!QEZX-HE%TJ&25N;$55$O=5",
MKC8>5=P)T0>U42I4B$);.DJE%R%VXBY*!5N&V>(QLEV1C!$=ZLC-R^>?ZZQ8
MN!P2A2=WFL)+I>%RJ.)QAO7J)!5<5&A+>\1MS6"]`EN&V>+AHL#\Y7!9&V(M
M=XA55R5F6VWO1UB]-%H.V9-)4I5"L?6*%2V`46HF5@&%YG50/&N^"U+<O+@(
MP\SSF-IV[L<E^/ON]4=;0+KX62,BJ`Y5<:6N"T`-HA:10J01=8@,0]QMV^0)
MMZOK?IU_ZVT&URZR^><0[_1F8F6NBY-4F$8-HA:10J01=8@,0SP<MA44X;AL
ML78])//>(;;[`VI(HV^-8H_?(E*(-*(.D6&(NVJ;PL353'.35K9K(<E<2-)=
MX9#(KM@8ZR@5%!M$+2*%2"/J$!F&F,NEZ'8O[N=[13ZO/4JSBZA!U")2B#2B
M#I%AB+MJ^\R+LUNZKC3-KD?\O#V3K4:4.F4748M((=*(.D2&(>YRIF6]:.Z6
MV+)ZQ++KI!+4H%2+2"'2B#I$AB'NJN@IS\]=V_^(7<DC,7=%/UA'J9A=9XL4
M`VI12B'2B#I$AB'NLFV0DH*^?.ZZSHK5MF^VXII;VT<.%".674`M2BE$&E&'
MR##$7;7]5.+J3[+K&[)D9;:G-.Y,'5!L0YJ`R,VD(1-]?!NE0L)50-&6#HC;
M$@US%Z6"+1,0GD#+7$/FSDV7'PIZ(V+A]MU7FGQLR+QB19%,@B..#FV4"@ZI
M@-+@.//3<7_`IX=QXT+LDIW7(I%@R#!#O#XR/=ME"QVV:+;9MZ5"74CT<RY.
M)[67HI(-E]<$Q`(T%?UV&\S?^'L;X[$PK8*=:%H'=-9T]U/3)MCI3?,(VJ8K
MF6%V,?%W-]Y06ZYS8PN+0Q-V5)F+,TY=>L7H<N/1E)U>YA!-ITA2(0TJV&*Q
MFHL66^?-0Q&">?,S\SRJHJ/LE^@WGN)+[#,]$B4*G8A39"7J&]2R+[[BYKH2
M<6F]Z6E<"Y1'B1T=I?J'IS>S$A:VTR^%Q!AFAX7)GI-E\15O#%-O@Z]K'HG:
MDUMZ4$QJSR-ZL2%=`N0^$*6"BRK8.E][43$U+U;2+DH%\^9GYGE01;_[GMJS
MMR9$G^01J[U*7'OMA9*2:3R:L)C"ZABD)JY`9Q.Y+R@TK8/26=-=D/*FK\?7
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MWZZ]%`Z1>=F61JDP-1I$+2*%2"/J$!F&>#ALERK"<=&YL7+M+?/>H22GM9=*
M4(.H1:00:40=(L,0<]5VP=+5]SW6Z"WQY<XCD7FQP-=1ZI1Y1"TBA4@CZA`9
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MLD'4(E*(-*(.D6&(N_S>!HX.B^`]-G!>*DEX@ZA%I!!I1!TBPQ!SE9Z$P`KV
MO@:NM\0;.(_X@GXC;H+44>J4>40M(H5((^H0&89X.-[;P-G61]2]1TF::T0-
MHA:10J01=8@,0]S53`/WK@6=[NJ#ZZ=.+)WRXO94[163?JU!U")2B#2B#I%A
MB$=#M'#G5SE[#U]FVZ%9?+)8>ZD$-8A:1`J11M0ALA]-VNMRO^C\<Q]!NL_=
MMNO]X[I>/S\?!JO=5_N!X\S>:CUA]_7EW=1^?MD_^X*1DD;Z-A1&JO#)IAR9
M3!>VK:"Y#2,S&IEE1^8TTM\4!9UK&NGW"!BYH9'^=0DY,AW3M?5YD2,5Z=#A
M-G=MI$/GO-P(18>.1;D1B@X=$G(C%!WJJ7,C$QKI[WK*:RM)AU[3R.B4I.-N
MX$J=BF)-]^<R.A7%FNY5Y48HUG1K)S="L::[')F1@G3HY;[<".FXKE9>6T&Q
MIE?&,CHEQ9K>L,J-4*SI1:3<",6:WMO)C%`(LA&@`&3])U>RGI`C6=_)C:P7
M!?T`O?^)5]14XT5+-YMQ1-.(?2*'(TU5D4XN^YI&[(U]U*&OIC]E(T)!S,>0
M0IBQ<T>%E[4_67RB!09_^,[6<(;3VRH+^RX*:NAR1B.Y8-&+*G15N1%Z=K]H
MZ3EYSMHU6<N--.4-Z>3210^;22<W0M^O4+QR`:.W^Q?VW?W,%="(?1,?1YIB
M0CK9Z-!(EQVYHQC<96-`KQ<MZNP(O65$GN9BW5"L[0LT>&WT@M'"OD>#(W<4
M`_M5#8[4-%)G1QH:L9\6H0Y]>4,C.6OTW='"?F.#.O3Y$44G9XT^P*&17F=T
M6F/HZ_S7Y>/Z'\O]X^;E,'A>/]#F-N[O0._=]_WN'T?_>OGGW9&^RZ=NE;[V
MIO\.PYJ^S!W;FQ@/N]TQ_(,N:G3Z+SM\_!\```#__P,`4$L#!!0`!@`(````
M(0"TGV?P^`(```@)```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;)16
MVVZ;0!!]K]1_0+R'F[$=(^/(:92V4BM552_/:UC,*L"BW76<_'UG=H&`(2EY
MP3#,G#-G9MCQ]N:I+*Q'*B3C56S[CF=;M$IXRJIC;/_^=7]U;5M2D2HE!:]H
M;#]3:=_L/G[8GKEXD#FER@*$2L9VKE0=N:Y,<EH2Z?":5O`FXZ(D"A[%T96U
MH"35067A!IZW<DO"*ML@1&(.!L\REM`[GIQ*6BD#(FA!%.0O<U;+%JU,YL"5
M1#R<ZJN$ES5`'%C!U+,&M:TRB;X>*R[(H0#=3WY(DA9;/XS@2Y8(+GFF'(!S
M3:)CS1MWXP+2;ILR4(!EMP3-8GOO1[?^PG9W6UV@/XR>9>_>DCD_?Q8L_<8J
M"M6&/F$'#IP_H.O7%$T0[(ZB[W4'?@@KI1DY%>HG/W^A[)@K:/<2%*&P*'V^
MHS*!B@*,$RP1*>$%)`!7JV0X&E`1\J1_SRQ5.=Q=.W[HK<#;.E"I[ADBVE9R
MDHJ7?QN?!LE@!`T&_#88BY6S7'L+__\@KLE'R[LCBNRV@I\MF!F@E#7!"?0C
M`)[6`T+0=X_.L0TS#;E*:,+C+@B#K?L(A4L:GUOC`]?.Q^\\7"#MF(%M/C,Z
M(S-6%E.Y-88^S4LB`YK%>VC0.;;#7O)C@<9'-WE`!%'S]:`SSL";3(W30&2X
MF*XFC%&?W<RGLWYU1-N68IQ.I*ML8PGT]]!OV&J"(H3DWIX9C!H2-!;@Z48D
M",-I6>L)SN4,61@W9&TLX4@6'M&]+P`K%RSG<&#@D*.Q#)4MIY5MQK3^'%:,
M&[(VEK$R'XZYD30OG%$^'3ED:4U#<:MI<3Z,Q27S+'4Z\((8L<`TH>_B",'6
M;4#SVP/I-T='[S!I34-MZU>TO>M$@:5TV:_6M'X91;-WS,%<4G&DGVA12"OA
M)]PI`1RUG;7;=WO]A5[:PVAO]J#;O8$]5),C_4[$D572*F@&F)Z>`F$VF7E0
MO(8RPSKB"E:0OLWA'P>%X]9SH#09YZI]P%W9_8?9_0,``/__`P!02P,$%``&
M``@````A`%.C3OAT`@``\08``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($`2B@
M``$`````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````G%7;3N,P$'U?:?\A
MRCND+6BU0FY0%XI8"012`CQ:KC-I+!([>)RJY>MWTO22LJ:KY6WLN9TY,QZS
MRV55!@NPJ(P>A\/301B`EB93>CX.G]*;DY]A@$[H3)1&PSA<`8:7\?=O[-&:
M&JQ3@`&%T#@."^?JBRA"64`E\)34FC2YL95P=+3SR.2YDG!M9%.!=M%H,/@1
MP=*!SB`[J7<!PR[BQ<)]-6AF9(L/G]-538!C-JGK4DGAJ,KX7DEKT.0NF"XE
ME"SJ*QFA2T`V5KE5/&!1_\@2*4JXHL!Q+DH$%NTOV"V(EK1'H2S&;.$N%B"=
ML0&J=Z)M%`8S@=#"&8<+8970CF"U9MUA+9<U.AN_&/N*!8!#%I%!=[D6^[9]
M69W'H^':@J1#RS9"AX04AQA3Y4K`A_Q16.>#/.QC7J/H$'>`MEWD-!M\JAWQ
MQ7_KKMO*])'O:K@RU&B-D'&2T)0J$XX.OT0IM"0V=X8M+UV6XRY=S1N"_N63
M.,I6_5>:C8L_S8.="ZW>US.U)B%IJDK8%3<Y3Y2WF@DB.#Z1;XU"U<YB:_L,
M5AF>%GYD-S1/_%F4#?![$-A8*D$?3L:N\(F4MB%"ITMZ>@C([XR>IV`K?@TS
MYT64."-?"U-FM`'XE'"YE=^NF2&\-92:3Q>?`CA.B9_&XZ#]/A[4/!4SFF8O
M^..P1E_P.?/Z'&^OOY1/^DL=<T+1;MHU=_\FCC/F+\?'6)?"3UGRL=\;0`?6
M![OEPS:Y4_H5G^K47-.KVZ[+PTN6%,)"1HMDJ]]?L%O:E+9L@UP50L\AV]K\
MK6B7.SVB]@>+A^>G@[,![>W>'8OV?U7\!P``__\#`%!+`P04``8`"````"$`
MIY^\]Y4```"I````$````'AL+V-A;&-#:&%I;BYX;6P\CD$*`C$0!.^"?QCF
M[F;U("I)%A1\@3X@9$<32"9+)HC^WGCQTE`T5+>>WCG!BZK$P@:WPXA`[,L<
M^6GP?KMN#@C2',\N%2:#'Q*<['JEO4O^$EQDZ`86@Z&UY:24^$#9R5`6XMX\
M2LVN=:Q/)4LE-TL@:CFIW3CN5>X"M-I#-7@^(L3^`2']4EFM_B/V"P``__\#
M`%!+`P04``8`"````"$`2IIZI3,!``!``@``$0`(`61O8U!R;W!S+V-O<F4N
M>&UL(*($`2B@``$`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````G)%?
M2\,P%,7?!;]#R7N;ML-_H<U`94\.!"<3WV)RMP6;-.1&NWU[LZZK$WT2\A+.
MN;^<>U)-MZ9)/L&C;FU-BBPG"5C9*FW7-7E>S-)KDF`05HFFM5"3'2"9\O.S
M2CHF6P^/OG7@@P9,(LDBDZXFFQ`<HQ3E!HS`+#IL%%>M-R+$JU]3)^2[6`,M
M\_R2&@A"B2#H'IBZD4@&I)(CTGWXI@<H2:$!`S8@+;*"?GL#>(-_#O3*B=/H
ML'-QIR'N*5O)@SBZMZA'8]=U63?I8\3\!7V9/SSUJZ;:[KN20/B^GT9@F,<J
M5QK4[8YOWWR3(&XJ^ENKE.S3,>E!!%!)?(\=TAV5Y>3N?C$CO,R+BS2/YVI1
MYJR8L/+FM:)'US#/1Z`9`OR;>`3P/O?//^=?````__\#`%!+`0(M`!0`!@`(
M````(0#ZB>44N0$``+P/```3``````````````````````!;0V]N=&5N=%]4
M>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L`````````
M````````\@,``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`&>`@8:C`0``
M7PX``!H`````````````````&`<``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L!`BT`%``&``@````A`!NH_A:E`@``H`<```\`````````````````
M^PD``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````(0#X4E2`D@,``(\+
M```8`````````````````,T,``!X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"+0`4``8`"````"$`+%,7,B,&``!C&P``&0````````````````"5$```
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M`!0`!@`(````(0#,^4VN
M7PH``)XW```9`````````````````.\6``!X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L!`BT`%``&``@````A`-TVU6)A`P``^0L``!D`````````````
M````A2$``'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"+0`4``8`"```
M`"$`\FS%ZI<#``!R"P``&``````````````````=)0``>&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L!`BT`%``&``@````A`%,&5*=O`P``'PL``!D`````
M````````````ZB@``'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4
M``8`"````"$`^V*E;90&``"G&P``$P````````````````"0+```>&PO=&AE
M;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0"OJ(6?.PP``'1O```-````
M`````````````%4S``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`/"/
MH'Y#-P``Z+$``!0`````````````````NS\``'AL+W-H87)E9%-T<FEN9W,N
M>&UL4$L!`BT`%``&``@````A`!5VJA3I`@``9PD``!@`````````````````
M,'<``'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0!>
M%;1["P4``#P4```8`````````````````$]Z``!X;"]W;W)K<VAE971S+W-H
M965T,BYX;6Q02P$"+0`4``8`"````"$`!<#UH/\"```X"```&0``````````
M``````"0?P``>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(
M````(0"A%?`?S`0``*H2```9`````````````````,:"``!X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L!`BT`%``&``@````A`!J$S[MM#```>CP``!D`
M````````````````R8<``'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M+0`4``8`"````"$`C2\4Z;L$``#<$0``&`````````````````!ME```>&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`(=G2VGE!0``
M&A\``!@`````````````````7ID``'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+`0(M`!0`!@`(````(0!I,]K(!0,``/$(```8`````````````````'F?
M``!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`NE&D
M)X<"``",!@``&0````````````````"TH@``>&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+`0(M`!0`!@`(````(0`L69_3B`,``(,,```8````````````
M`````'*E``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"+0`4``8`"```
M`"$`1PBEC*0,``!7/@``&0`````````````````PJ0``>&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+`0(M`!0`!@`(````(0#PS]/M@0@``!4D```9````
M``````````````NV``!X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!`BT`
M%``&``@````A`,X;:8WA!0``Z1H``!D`````````````````P[X``'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"+0`4``8`"````"$`M.+J41\-```>
M0@``&`````````````````#;Q```>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L!`BT`%``&``@````A`+2?9_#X`@``"`D``!D`````````````````,-(`
M`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`4Z-.
M^'0"``#Q!@``$`````````````````!?U0``9&]C4')O<',O87!P+GAM;%!+
M`0(M`!0`!@`(````(0"GG[SWE0```*D````0``````````````````G9``!X
M;"]C86QC0VAA:6XN>&UL4$L!`BT`%``&``@````A`$J:>J4S`0``0`(``!$`
M````````````````S-D``&1O8U!R;W!S+V-O<F4N>&UL4$L%!@`````?`!\`
*0@@``#;<````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Expenses, Long-Term Debt, Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Accrued Expenses, Long-Term Debt, Commitments and Contingencies.</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock', window );">Accrued Expenses, Long-Term Debt, Commitments and Contingencies</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">4.</font><font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Accrued Expenses, Long-Term Debt, Commitments and Contingencies</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Accrued Expenses</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Current accrued expenses consist of the following (in thousands):</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 78.00%;margin-left:64.8pt;">
			<tr>
				<td valign="bottom" style="width:61.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accrued payroll and other employee benefits</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>562&nbsp;
				</td>
				<td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,234&nbsp;
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.84%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accrued clinical trial costs</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>498&nbsp;
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>415&nbsp;
				</td>
				<td valign="bottom" style="width:01.28%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accrued other</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>767&nbsp;
				</td>
				<td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>611&nbsp;
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.84%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,827&nbsp;
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,260&nbsp;
				</td>
				<td valign="bottom" style="width:01.28%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">During the three months ended March 31, 2015, the Company issued 19,956 shares of its common stock to certain senior executives of the Company as consideration for a portion of their 2014 annual bonuses. All related amounts were accrued for as liabilities as of December 31, 2014. Future senior executive bonus amounts, timing, and method of payment are at the sole discretion of the Board of Directors of the Company. As such, all relevant bonus estimates are accrued for as liabilities as of March 31, 2015.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Long-term accrued expenses consist primarily of accruals for the final payment fees associated with our long-term debt.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Long-Term Debt</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Long-term debt and unamortized discount balances are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:68.4pt;">
			<tr>
				<td valign="bottom" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;">31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">31,2014</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Long-term debt</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,000
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,000
				</td>
				<td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Less debt discount, net of current portion</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(167
				</td>
				<td valign="bottom" style="width:03.24%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(371
				</td>
				<td valign="bottom" style="width:01.24%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Long-term debt, net of discount</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,833
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,629
				</td>
				<td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Less current portion of long-term debt</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,419
				</td>
				<td valign="bottom" style="width:03.24%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,546
				</td>
				<td valign="bottom" style="width:01.24%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Long-term debt, net of current portion</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,414
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,083
				</td>
				<td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Current portion of long-term debt</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,419
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,546
				</td>
				<td valign="bottom" style="width:01.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Current portion of debt discount</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(163
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Current portion of long-term debt, net</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,256
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,546
				</td>
				<td valign="bottom" style="width:01.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On July&nbsp;30, 2014, the Company entered into an Amended and Restated Loan and Security Agreement (the &#x201C;Restated LSA&#x201D;) with Silicon Valley Bank (the &#x201C;Bank&#x201D;), collateralized by substantially all of the Company&#x2019;s assets, excluding certain intellectual property. The Restated LSA amends and restates the Loan and Security Agreement, dated as of January&nbsp;5, 2009, as amended, by and between the Company and the Bank (the &#x201C;Loan Agreement&#x201D;). Pursuant to the Restated LSA, the Bank agreed to make loans to the Company in an aggregate principal amount of up to $20.0&nbsp;million, comprised of (i)&nbsp;a $10.0&nbsp;million term loan, funded at the closing date (the &#x201C;Term A Loan&#x201D;) and (ii)&nbsp;subject to the achievement of a specified clinical milestone relating to the Company&#x2019;s Phase&nbsp;2 clinical trial of ProHema, additional term loans totaling up to $10.0&nbsp;million in the aggregate, which were available until December&nbsp;31, 2014 (each, a &#x201C;Term B Loan&#x201D;). On December&nbsp;24, 2014, the Company elected to draw on the full $10.0&nbsp;million under a Term B Loan.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Term A Loan and the Term B Loan mature on January&nbsp;1, 2018 and June&nbsp;1, 2018, respectively and bear interest at a fixed annual rate of 6.94% and 7.07%, respectively. Interest became payable in cash on a monthly basis beginning the first day of each month following the month in which the funding date of each loan occurred. The Company is required to make a monthly payment of interest only during the first twelve months following the funding date of each loan, and thereafter is required to repay the principal and interest under each loan in thirty equal monthly installments based on a thirty-month amortization schedule. The Company is required to make a final payment fee of 7.5%, equaling $0.8&nbsp;million, of the funded amount for each of the Term A Loan and Term B Loan on the respective maturity dates. The final payment fees are accrued as interest expense over the terms of the loans and recorded in long-term accrued expenses.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">A portion of the proceeds from the Term A Loan were used to repay loans outstanding under the Loan Agreement and to pay for transaction fees related to the Restated LSA, including a commitment fee of $0.4&nbsp;million paid by the Company to the Bank. Net proceeds from the Term A Loan, after repayment of loans outstanding under the Loan Agreement and transaction fees, were $8.8&nbsp;million. The Company determined that the repayment of the Loan Agreement was a debt extinguishment, and accounted for the Term A Loan at fair value as of the issuance date accordingly.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Proceeds from the Term B Loan were $10.0&nbsp;million. In connection with the funding of the Term&nbsp;B&nbsp;Loan, the Company issued the Bank and one of its affiliates fully-exercisable warrants to purchase an aggregate of 98,039 shares of the Company&#x2019;s common stock (the &#x201C;Warrants&#x201D;) at an exercise price of $4.08 per share. The Warrants expire in December 2021. The aggregate fair value of the Warrants was determined to be $0.4&nbsp;million using the Black-Scholes option pricing model and was recorded as a debt discount on the Term B Loan and is amortized to interest expense over the term of the Term B Loan using the effective interest method.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company determined the effective interest rates of the Term A Loan and Term B Loan to be 10.3% and 12.0%, respectively. For the three months ended March 31, 2015, the Company recorded $0.6&nbsp;million in aggregate interest expense related to the Term A and Term B Loans.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Warrants to purchase 36,074 shares of the Company&#x2019;s common stock at a weighted average exercise price of $7.21 per share issued in connection with the Loan Agreement remain outstanding as of March 31, 2015, with 5,305 and 30,769 of such warrants having expiration dates in January 2019 and August 2021, respectively.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Facility Lease</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company leases certain office and laboratory space from a stockholder of the Company under a non-cancelable operating lease. In March 2015, we extended the term of the lease on this facility an additional 15 months through September 2017. The lease is subject to additional charges for common area maintenance and other costs. In connection with the lease, the Company entered into a cash-collateralized irrevocable standby letter of credit in the amount of $0.1 million. As of March 31, 2015, future minimum payments under the operating lease are $2.5 million.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In January 2015, the Company entered into a sublease for additional laboratory space. The sublease is accounted for as an operating lease and expires in September 2017. Under the sublease, total future minimum payments as of March 31, 2015 are $0.8 million.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accrued expenses, long-term debt, commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/<F=A
M;FEZ871I;VY?86YD7U-U;6UA<GE?;V9?4VD\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y!<W-E=%]!8W%U:7-I=&EO;E]O9E]697)I
M;U]4:&4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&
M86ER7U9A;'5E7TUE87-U<F5M96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D%C8W)U961?17AP96YS97-?3&]N9U1E<FU?1&5B
M=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K
M:&]L9&5R<U]%<75I='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=6)S97%U96YT7T5V96YT<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?4W5M;6%R>5]O
M9E]3:3$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!
M8V-R=65D7T5X<&5N<V5S7TQO;F=497)M7T1E8G0Q/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>5]4
M86)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y/
M<F=A;FEZ871I;VY?86YD7U-U;6UA<GE?;V9?4VDR/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$U
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N7V%N9%]3=6UM
M87)Y7V]F7U-I,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-BYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D%S<V5T7T%C<75I<VET:6]N7V]F7U9E<FEO7U1H93$\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y&86ER7U9A;'5E7TUE87-U
M<F5M96YT<U]$971A:6P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y!8V-R=65D7T5X<&5N<V5S7TQO;F=497)M7T1E8G0R/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S
M7T5Q=6ET>5]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N='-?1&5T86EL<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%
M>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K
M<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!
M8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0
M<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO
M>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL
M/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@
M<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0
M(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V9F,V)D-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D,V5D
M8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F9C-B9#0S,5\S,C8U
M7S1C-3!?.#AD85\Q-C$Q-#0R9#-E9&,O5V]R:W-H965T<R]3:&5E=#`Q+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%4$-!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U
M;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%Y(#`U+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT(&%N9"!%;G1I
M='D@26YF;W)M871I;VX\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^1D%412!42$5205!%551)0U,@24Y#/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C`P,#$T,S0S,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C$P+5$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%
M;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^36%R(#,Q
M+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A
M=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N
M=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G;W)Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!8V-E;&5R871E9"!&:6QE
M<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PV.#,L,S0U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U
M;65N="!&:7-C86P@665A<B!&;V-U<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^,C`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^43$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V9F,V)D-#,Q7S,R-C5?-&,U
M,%\X.&1A7S$V,3$T-#)D,V5D8PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]F9C-B9#0S,5\S,C8U7S1C-3!?.#AD85\Q-C$Q-#0R9#-E9&,O5V]R
M:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%44%!1SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D($)A;&%N8V4@
M4VAE971S("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W
M:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&%S<V5T<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@
M8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T,BPS-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0Y+#$P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H
M97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<W,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,BPW.3(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.2PX-S(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N
M9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PU-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L-#DP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$L,C`T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C<Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D
M(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@R
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,C8P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#=7)R96YT('!O<G1I;VX@;V8@9&5F97)R960@<F5N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5P=7)C:&%S92!L
M:6%B:6QI='D@9F]R('5N=F5S=&5D(&5Q=6ET>2!A=V%R9',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M=&5R;2!D96)T+"!C
M=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L,C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PU-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#0Q,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-3@Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E
M9"!R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;VYG+71E<FT@9&5B="P@;F5T(&]F(&-U<G)E;G0@<&]R
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-#$T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L
M,#@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<R`H3F]T92`T*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y.CPO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R
M960@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[(&%U=&AO<FEZ960@<VAA<F5S
M+34L,#`P+#`P,"!A="!-87)C:"`S,2PR,#$U(&%N9"!$96-E;6)E<B`S,2P@
M,C`Q-#L@;F\@<VAA<F5S(&ES<W5E9"!O<B!O=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[(&%U=&AO<FEZ
M960@<VAA<F5S("T@,34P+#`P,"PP,#`@870@36%R8V@@,S$L,C`Q-2!A;F0@
M1&5C96UB97(@,S$L(#(P,30[(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@<VAA
M<F5S("T@,C`L-C,W+#(Q-R!A="!-87)C:"`S,2PR,#$U(&%N9"`R,"PU-CDL
M,SDY(&%T($1E8V5M8F5R(#,Q+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30Q+#4P,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,"PW,3$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$R,"PR-S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,3$R+#,Y,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C:VAO;&1E<G,G
M(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L,C4Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C@L,S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@
M97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0T+#0Y
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-3$L,C`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P139.04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N9&5N<V5D
M($-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E9"!"
M86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;"D\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P
M87(@=F%L=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S
M=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K
M+"!I<W-U960@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E9F5R<F5D('-T;V-K+"!O=71S=&%N9&EN9R!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL
M('!A<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!A=71H;W)I>F5D('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,34P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L-C,W
M+#(Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(P+#4V.2PS.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@;W5T<W1A;F1I;F<@<VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PV,S<L,C$W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C`L-38Y+#,Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?9F8S8F0T,S%?,S(V-5\T8S4P7S@X9&%?,38Q,30T,F0S961C#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9F,V)D-#,Q7S,R-C5?-&,U
M,%\X.&1A7S$V,3$T-#)D,V5D8R]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4R14%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;F1E;G-E
M9"!#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS(&%N9"!#
M;VUP<F5H96YS:79E($QO<W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X
M8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/
M<&5R871I;F<@97AP96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#4V.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PU,C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E
M;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#<U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,R-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.3,W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3&]S<R!F<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<L,S(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#8L.3,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!I;F-O;64@
M*&5X<&5N<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#4U."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@T,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!O=&AE<B!E>'!E;G-E
M+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4U-RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@;&]S<R!A;F0@8V]M<')E:&5N<VEV92!L;W-S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B0@*#<L.#@Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-BPY.#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<R!P97(@8V]M;6]N('-H87)E+"!B87-I8R!A;F0@9&EL=71E9"`H:6X@9&]L
M;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#`N,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@P+C,T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960M879E<F%G92!C;VUM;VX@<VAA
M<F5S('5S960@=&\@8V]M<'5T92!B87-I8R!A;F0@9&EL=71E9"!N970@;&]S
M<R!P97(@<VAA<F4@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(P+#4U-"PT-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,"PS-#8L.#4V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14):044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED871E9"!3=&%T96UE;G1S
M(&]F($-A<V@@1FQO=W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S
M<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!A8W1I=FET:65S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L
M;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#<L.#@Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M-BPY.#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%D:G5S=&UE;G1S('1O(')E8V]N8VEL92!N970@
M;&]S<R!T;R!N970@8V%S:"!U<V5D(&EN(&]P97)A=&EN9R!A8W1I=FET:65S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M97!R96-I871I;VX@86YD(&%M;W)T:7IA=&EO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@W,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO
M<G1I>F%T:6]N(&]F(&1I<V-O=6YT<R!A;F0@9&5B="!I<W-U86YC92!C;W-T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VYC87-H
M(&EN=&5R97-T(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$969E<G)E9"!R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@;6EL97-T;VYE(&-H87)G
M97,@86YD(&-H86YG92!I;B!F86ER('9A;'5E(&]F(&5X8VAA;F=E86)L92!S
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#:&%N9V5S(&EN(&%S<V5T<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@
M97AP96YS97,@86YD(&]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S`S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R
M=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L,S<U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L,C4U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY);G9E<W1I;F<@86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T
M>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@T-3(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,SDX*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@:6YV97-T:6YG(&%C=&EV
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0U,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S.3@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D9I;F%N8VEN9R!A8W1I=FET:65S/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO
M;B!S=&]C:RP@;F5T(&]F(')E<'5R8VAA<V5S(&%N9"!I<W-U86YC92!C;W-T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT
M<R!O;B!L;VYG+71E<FT@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-3`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y("AU<V5D(&EN*2!F
M:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(&-H86YG92!I;B!C87-H(&%N9"!C87-H(&5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#<U
M,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@V+#$U-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@8F5G:6YN
M:6YG(&]F('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0Y+#$P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4T+#`S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!A
M="!E;F0@;V8@=&AE('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`T,BPS-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0W+#@X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?9F8S8F0T,S%?,S(V-5\T8S4P7S@X9&%?,38Q
M,30T,F0S961C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9F,V)D
M-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D,V5D8R]7;W)K<VAE971S+U-H
M965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY/<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O
M9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]R9V%N:7IA=&EO;B!A
M;F0@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T
M>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,C0N-7!T.W1E>'0M:6YD
M96YT.B`M,C0N-7!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SXQ+CPO9F]N
M=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M
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M;F<@4&]L:6-I97,\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P="`P<'0@,'!T(#(T+C5P=#MT97AT+6EN9&5N=#H@+3(T+C5P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
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M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C(W<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[)SY&871E(%1H97)A<&5U=&EC<RPF;F)S<#M);F,N("AT:&4@)B-X,C`Q
M0SM#;VUP86YY)B-X,C`Q1#LI('=A<R!I;F-O<G!O<F%T960@:6X@=&AE('-T
M871E(&]F($1E;&%W87)E(&]N($%P<FEL)FYB<W`[,C<L(#(P,#<@86YD(&AA
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M;R!P<F]G<F%M('1H92!F=6YC=&EO;B!A;F0@9F%T92!O9B!C96QL<R`\+V9O
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M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HR-W!T
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M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X
M="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
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M.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[=&5X="UI;F1E;G0Z,S9P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D]N($]C=&]B97(F;F)S
M<#LT+"`R,#$S+"!T:&4@0V]M<&%N>2!C;VUP;&5T960@:71S(&EN:71I86P@
M<'5B;&EC(&]F9F5R:6YG("AT:&4@)B-X,C`Q0SM)4$\F(W@R,#%$.RD@=VAE
M<F5B>2!I="!S;VQD(#<L-C8V+#8V-R!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M(&%T(&$@<'5B;&EC(&]F9F5R:6YG('!R:6-E(&]F("0V+C`P('!E<B!S:&%R
M92X@1W)O<W,@<')O8V5E9',@9G)O;2!T:&4@;V9F97)I;F<@=V5R92`D-#8N
M,"9N8G-P.VUI;&QI;VXN($%F=&5R(&=I=FEN9R!E9F9E8W0@=&\@=6YD97)W
M<FET:6YG(&1I<V-O=6YT<RP@8V]M;6ES<VEO;G,@86YD(&]T:&5R(&-A<V@@
M8V]S=',@<F5L871E9"!T;R!T:&4@;V9F97)I;F<L(&YE="!P<F]C965D<R!W
M97)E("0T,"XU)FYB<W`[;6EL;&EO;BX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS-G!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT
M+7-I>F4Z,3!P=#LG/E5S92!O9B!%<W1I;6%T97,\+V9O;G0^#0H)"3PO<#X-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
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M:6]N(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;G-O;&ED871E9"!F:6YA
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M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD
M.V9O;G0M<VEZ93HQ,'!T.R<^4')I;F-I<&QE<R!O9B!#;VYS;VQI9&%T:6]N
M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN
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M<F%P975T:6-S)FYB<W`[3'1D+BP@:6YC;W)P;W)A=&5D(&EN('1H92!5;FET
M960@2VEN9V1O;2P@86YD($1E<W1I;B!4:&5R87!E=71I8W,F;F)S<#M);F,N
M+"!I;F-O<G!O<F%T960@:6X@0V%N861A+"!W:&EC:"!W87,@9&ES<V]L=F5D
M(&EN($IU;F4@,C`Q-"X@5&\@9&%T92P@=&AE(&%G9W)E9V%T92!O<&5R871I
M;VYS(&]F('1H97-E('-U8G-I9&EA<FEE<R!H879E(&YO="!B965N('-I9VYI
M9FEC86YT(&%N9"!A;&P@:6YT97)C;VUP86YY('1R86YS86-T:6]N<R!A;F0@
M8F%L86YC97,@:&%V92!B965N(&5L:6UI;F%T960@:6X@8V]N<V]L:61A=&EO
M;BX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT
M97AT+6EN9&5N=#HS-G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/D-A<V@@86YD
M($-A<V@@17%U:79A;&5N=',\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
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M=F%L96YT<RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MT97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T
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M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\
M+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
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M05`@8V%N(&)E(&-O;F1E;G-E9"!O<B!O;6ET=&5D+B9N8G-P.R9N8G-P.TEN
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M;B!W:71H('1H92!#;VUP86YY)B-X,C`Q.3MS(#PO9F]N=#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SYF:6YA;F-I
M86P@<W1A=&5M96YT<R!A;F0@86-C;VUP86YY:6YG(&YO=&5S(&9O<B!T:&4@
M9FES8V%L('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,30L(&-O;G1A:6YE
M9"!I;B!T:&4@0V]M<&%N>28C>#(P,3D[<R!!;FYU86P@4F5P;W)T(&]N($9O
M<FT@,3`M2R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,30@
M9FEL960@8GD@=&AE($-O;7!A;GD@=VET:"!T:&4@4T5#(&]N($UA<F-H(#$R
M+"`R,#$U+B`\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
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M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
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M/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)
M"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS
M-G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!R979E;G5E<R!W
M:&5N(&%L;"!F;W5R(&]F('1H92!F;VQL;W=I;F<@8W)I=&5R:6$@87)E(&UE
M=#H@*&DI)FYB<W`[<&5R<W5A<VEV92!E=FED96YC92!T:&%T(&%N(&%G<F5E
M;65N="!E>&ES=',[("AI:2DF;F)S<#MD96QI=F5R>2!O9B!T:&4@<')O9'5C
M=',@86YD+V]R('-E<G9I8V5S(&AA<R!O8V-U<G)E9#L@*&EI:2DF;F)S<#MT
M:&4@<V5L;&EN9R!P<FEC92!I<R!F:7AE9"!O<B!D971E<FUI;F%B;&4[(&%N
M9"`H:78I)FYB<W`[8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U
M<F5D+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
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M;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MT97AT+6EN9&5N=#HS-G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^1F]R('1R86YS86-T:6]N<R!E
M;G1E<F5D(&EN=&\@<')I;W(@=&\@,C`Q,2P@<F5V96YU92!W87,@86QL;V-A
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M.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
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M<V5Q=65N="!T;R`R,#$P+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS-G!T.V9O
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M=VEN9SH@*&DI)FYB<W`[=&AE(&-O;G-I9&5R871I;VX@8F5I;F<@96%R;F5D
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M;B!T:&4@87)R86YG96UE;G0[(&%N9"`H:78I)FYB<W`[=&AE(&UI;&5S=&]N
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M9"!A<R!D969E<G)E9"!R979E;G5E(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T<RX\+V9O;G0^#0H)"3PO<#X-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS-G!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F
M;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI
M;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
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M+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB
M;VQD.V9O;G0M<VEZ93HQ,'!T.R<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N
M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN
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M=&AE(&%W87)D<R`H=7-U86QL>2!T:&4@=F5S=&EN9R!P97)I;V0I(&]N(&$@
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M<VEN9R!A(&QA='1I8V4M8F%S960@;6]D96PN/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UA;&EG;CIC96YT97([9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN
M9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^5&AE($-O;7!A;GD@86-C;W5N=',@9F]R('-T
M;V-K(&]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@87=A<F1S('1O(&YO
M;BUE;7!L;WEE97,@=7-I;F<@=&AE(&9A:7(@=F%L=64@87!P<F]A8V@N(%-T
M;V-K(&]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@87=A<F1S('1O(&YO
M;BUE;7!L;WEE97,@87)E('-U8FIE8W0@=&\@<&5R:6]D:6,@<F5V86QU871I
M;VX@;W9E<B!T:&5I<B!V97-T:6YG('1E<FUS+B!&;W(@<W1O8VL@;W!T:6]N
M(&=R86YT<R!F;W(@=VAI8V@@=F5S=&EN9R!I<R!S=6)J96-T('1O('!E<F9O
M<FUA;F-E+6)A<V5D(&UI;&5S=&]N97,L('1H92!E>'!E;G-E(&ES(')E8V]R
M9&5D(&]V97(@=&AE(')E;6%I;FEN9R!S97)V:6-E('!E<FEO9"!A9G1E<B!T
M:&4@<&]I;G0@=VAE;B!T:&4@<&5R9F]R;6%N8V4@8V]N9&ET:6]N(&ES(&1E
M=&5R;6EN960@=&\@8F4@<')O8F%B;&4@;V8@86-H:65V96UE;G0@;W(@=VAE
M;B!I="!H87,@8F5E;B!A8VAI979E9"X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT
M+7-I>F4Z,3!P=#LG/DYE="!,;W-S('!E<B!#;VUM;VX@4VAA<F4\+V9O;G0^
M#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT
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M<F5S=')I8W1E9"!S=&]C:R!T;W1A;&EN9R`U."PT-3,@<VAA<F5S(&%N9"`X
M."PP-#,@<VAA<F5S(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H
M(#,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E;'DN($1I;'5T960@;F5T
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M;&]S<R!P;W-I=&EO;BX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/D9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$U
M+"!T:&4@0V]M<&%N>2!R96%L:7IE9"!A(&YE="!L;W-S(&]F("0W+CD@;6EL
M;&EO;BX@4VAA<F5S(&]F('!O=&5N=&EA;&QY(&1I;'5T:79E('-E8W5R:71I
M97,@=&]T86QE9"`S+C$@;6EL;&EO;B!F;W(@=&AE('1H<F5E(&UO;G1H<R!E
M;F1E9"!-87)C:"`S,2P@,C`Q-2P@:6YC;'5D:6YG(&]P=&EO;G,@=&\@<'5R
M8VAA<V4@,RXP(&UI;&QI;VX@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN
M9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D9O<B!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!R96%L
M:7IE9"!A(&YE="!L;W-S(&]F("0W+C`@;6EL;&EO;BX@4VAA<F5S(&]F('!O
M=&5N=&EA;&QY(&1I;'5T:79E('-E8W5R:71I97,@=&]T86QE9"`R+C4@;6EL
M;&EO;B!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q
M-"P@:6YC;'5D:6YG(&]P=&EO;G,@=&\@<'5R8VAA<V4@,BXT(&UI;&QI;VX@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT
M+7-I>F4Z,3!P=#LG/E)E8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S
M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN
M9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^26X@075G=7-T(#(P,30L('1H92!&:6YA;F-I
M86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@*'1H92`F(W@R,#%#.T9!
M4T(F(W@R,#%$.RD@:7-S=65D($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T
M92`H)B-X,C`Q0SM!4U4F(W@R,#%$.RD@,C`Q-"TQ-2P@=VAI8V@@9&5F:6YE
M9"!M86YA9V5M96YT)B-X,C`Q.3MS(')E<W!O;G-I8FEL:71Y('1O(&5V86QU
M871E('=H971H97(@=&AE<F4@:7,@<W5B<W1A;G1I86P@9&]U8G0@86)O=70@
M86X@96YT:71Y)B-X,C`Q.3MS(&%B:6QI='D@=&\@8V]N=&EN=64@87,@82!G
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M96YT)B-X,C`Q.3MS('!L86YS(&%N9"!R97%U:7)E<R!A;B!E>'!R97-S('-T
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M871E;65N=',N/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C(W<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY)
M;B!-87D@,C`Q-"P@=&AE($9!4T(@:7-S=65D($%352`R,#$T+3`Y+"!W:&EC
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M9"!&:6YA;F-I86P@4W1A=&5M96YT<RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`^
M/&9O;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9F8S8F0T
M,S%?,S(V-5\T8S4P7S@X9&%?,38Q,30T,F0S961C#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V9F,V)D-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T
M-#)D,V5D8R]7;W)K<VAE971S+U-H965T,#<N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY!<W-E="!!8W%U:7-I=&EO;B!O9B!6
M97)I;R!4:&5R87!E=71I8W,@26YC+CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T($%C<75I<VET:6]N(&]F
M(%9E<FEO(%1H97)A<&5U=&EC<R!);F,N/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%S<V5T($%C<75I<VET:6]N(&]F(%9E
M<FEO(%1H97)A<&5U=&EC<R!);F,N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA
M<F=I;BUR:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P
M="`P<'0@,C(N-7!T.W1E>'0M:6YD96YT.B`M,C(N-7!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US:7IE.C$P<'0[)SXR+CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#L[9F]N
M="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT
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M5&AE<F%P975T:6-S($EN8RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P="`P<'0@,'!T(#(R+C5P=#MT97AT+6EN9&5N=#H@+3(R
M+C5P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
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M,3`L('1H92!#;VUP86YY(&%C<75I<F5D(%9E<FEO(%1H97)A<&5U=&EC<R9N
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M97)S(&]F(%9E<FEO(')E8V5I=F5D(#DP,"PP,#`@;F]N+79O=&EN9R!S:&%R
M97,@;V8@1F%T92!#86YA9&$@*'1H92`F(W@R,#%#.T5X8VAA;F=E86)L92!3
M:&%R97,F(W@R,#%$.RD@=&AA="!W97)E(&EN:71I86QL>2!E>&-H86YG96%B
M;&4@:6YT;R`Q,S@L-#8R('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[
M<R!C;VUM;VX@<W1O8VL@86YD+"!S=6)J96-T('1O('1H92!V86QI9&%T:6]N
M(&]F(&-E<G1A:6X@<V-I96YT:69I8R!D871A(&%N9"!T:&4@86-H:65V96UE
M;G0@;V8@8V5R=&%I;B!P<F5C;&EN:6-A;"P@8VQI;FEC86PL(&-O;6UE<F-I
M86P@86YD(&9I;F%N8VEA;"!M:6QE<W1O;F5S+"!W97)E(&5X8VAA;F=E86)L
M92!F;W(@=7`@=&\@.#@T+#8P-2!S:&%R97,@;V8@=&AE($-O;7!A;GDF(W@R
M,#$Y.W,@8V]M;6]N('-T;V-K+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\
M+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,S9P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/D%S(&$@<F5S=6QT(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS
M($E03R!O;B!/8W1O8F5R)FYB<W`[-"P@,C`Q,RP@-#@P+#<V,R!S:&%R97,@
M;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]M;6]N('-T;V-K('=E<F4@:7-S
M=65D(&1U<FEN9R!T:&4@9F]U<G1H('%U87)T97(@;V8@,C`Q,R!P=7)S=6%N
M="!T;R!T:&4@<F5D96UP=&EO;B!O9B!T:&4@17AC:&%N9V5A8FQE(%-H87)E
M<RX@5&AE('1O=&%L(&YU;6)E<B!O9B!S:&%R97,@;V8@=&AE($-O;7!A;GDF
M(W@R,#$Y.W,@8V]M;6]N('-T;V-K(&ES<W5E9"!U<&]N('1H92!E>&-H86YG
M92!O9B!T:&4@17AC:&%N9V5A8FQE(%-H87)E<R!A<R!A(')E<W5L="!O9B!T
M:&4@25!/(&AA9"!I;F-R96%S960@9G)O;2`Q,S@L-#8R('-H87)E<R!O9B!T
M:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O8VL@=&\@82!T;W1A;"!O
M9B`T.#`L-S8S('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!C;VUM
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M#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N
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M)#`N-"9N8G-P.VUI;&QI;VX@8VAA<F=E('1O(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!E>'!E;G-E+B!4:&4@0V]M<&%N>2!M87D@:7-S=64@86X@861D
M:71I;VYA;"`S-C4L,S<Y('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[
M<R!C;VUM;VX@<W1O8VL@8F%S960@;VX@=&AE(&%C:&EE=F5M96YT(&]F(&%D
M9&ET:6]N86P@8V]N=')A8W1U86P@;6EL97-T;VYE<R!A<R!F;VQL;W=S.B`H
M:2DF;F)S<#LS."PT-C$@<VAA<F5S(&9O<B!T:&4@86-H:65V96UE;G0@;V8@
M8V5R=&%I;B!P<F5C;&EN:6-A;"!M:6QE<W1O;F5S+"`H:6DI)FYB<W`[,C$Q
M+#4S."!S:&%R97,@9F]R('1H92!A8VAI979E;65N="!O9B!C97)T86EN(&-L
M:6YI8V%L(&UI;&5S=&]N97,@86YD("AI:6DI)FYB<W`[,3$U+#,X,"!S:&%R
M97,@9F]R('1H92!A8VAI979E;65N="!O9B!C97)T86EN(&-O;6UE<F-I86QI
M>F%T:6]N(&UI;&5S=&]N97,L('-U8V@@=&AA="!T:&4@;6%X:6UU;2!A9V=R
M96=A=&4@;G5M8F5R(&]F('-H87)E<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[
M<R!C;VUM;VX@<W1O8VL@:7-S=6%B;&4@:6X@8V]N;F5C=&EO;B!W:71H('1H
M92!697)I;R!A8W%U:7-I=&EO;B!I<R`X.#0L-C`U+CPO9F]N=#X-"@D)/"]P
M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^
M#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\
M+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT
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M:60M:6X@8V%P:71A;"X\+V9O;G0^#0H)"3PO<#X-"@D)/'`^/&9O;G0@<VEZ
M93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9F8S8F0T,S%?,S(V-5\T
M8S4P7S@X9&%?,38Q,30T,F0S961C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V9F,V)D-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D,V5D8R]7
M;W)K<VAE971S+U-H965T,#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<SQB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@
M5F%L=64@365A<W5R96UE;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$
M;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,C0N-7!T.W1E>'0M:6YD96YT.B`M
M,C0N-7!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SXS+CPO9F]N=#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF
M;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I
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M92!-96%S=7)E;65N=',\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P="`P<'0@,'!T(#(T+C5P=#MT97AT+6EN9&5N=#H@+3(T+C5P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
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M92X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT
M97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/E1H92!A8V-O
M=6YT:6YG(&=U:61A;F-E(&1E9FEN97,@9F%I<B!V86QU92P@97-T86)L:7-H
M97,@82!C;VYS:7-T96YT(&9R86UE=V]R:R!F;W(@;65A<W5R:6YG(&9A:7(@
M=F%L=64@86YD(&5X<&%N9',@9&ES8VQO<W5R92!F;W(@96%C:"!M86IO<B!A
M<W-E="!A;F0@;&EA8FEL:71Y(&-A=&5G;W)Y(&UE87-U<F5D(&%T(&9A:7(@
M=F%L=64@;VX@96ET:&5R(&$@<F5C=7)R:6YG(&]R(&YO;G)E8W5R<FEN9R!B
M87-I<RX@1F%I<B!V86QU92!I<R!D969I;F5D(&%S(&%N(&5X:70@<')I8V4L
M(')E<')E<V5N=&EN9R!T:&4@86UO=6YT('1H870@=V]U;&0@8F4@<F5C96EV
M960@=&\@<V5L;"!A;B!A<W-E="!O<B!P86ED('1O('1R86YS9F5R(&$@;&EA
M8FEL:71Y(&EN(&%N(&]R9&5R;'D@=')A;G-A8W1I;VX@8F5T=V5E;B!M87)K
M970@<&%R=&EC:7!A;G1S+B!!<R!S=6-H+"!F86ER('9A;'5E(&ES(&$@;6%R
M:V5T+6)A<V5D(&UE87-U<F5M96YT('1H870@<VAO=6QD(&)E(&1E=&5R;6EN
M960@8F%S960@;VX@87-S=6UP=&EO;G,@=&AA="!M87)K970@<&%R=&EC:7!A
M;G1S('=O=6QD('5S92!I;B!P<FEC:6YG(&%N(&%S<V5T(&]R(&QI86)I;&ET
M>2X@07,@82!B87-I<R!F;W(@8V]N<VED97)I;F<@<W5C:"!A<W-U;7!T:6]N
M<RP@=&AE(&%C8V]U;G1I;F<@9W5I9&%N8V4@97-T86)L:7-H97,@82!T:')E
M92UT:65R(&9A:7(@=F%L=64@:&EE<F%R8VAY+"!W:&EC:"!P<FEO<FET:7IE
M<R!T:&4@:6YP=71S('5S960@:6X@;65A<W5R:6YG(&9A:7(@=F%L=64@87,@
M9F]L;&]W<SH\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MT97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`T-BXP-7!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^3&5V
M96P@,3H@3V)S97)V86)L92!I;G!U=',@<W5C:"!A<R!Q=6]T960@<')I8V5S
M(&EN(&%C=&EV92!M87)K971S.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@-#8N,#5P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P
M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@-#8N,#5P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#LG/DQE=F5L(#(Z($EN<'5T<RP@;W1H97(@=&AA;B!T:&4@<75O=&5D
M('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T<RP@=&AA="!A<F4@;V)S97)V86)L
M92!E:71H97(@9&ER96-T;'D@;W(@:6YD:7)E8W1L>3L@86YD/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`T-BXP
M-7!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB
M<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@
M,'!T(#!P="`T-BXP-7!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^3&5V96P@,SH@56YO8G-E<G9A8FQE
M(&EN<'5T<R!I;B!W:&EC:"!T:&5R92!I<R!L:71T;&4@;W(@;F\@;6%R:V5T
M(&1A=&$L('=H:6-H(')E<75I<F4@=&AE(')E<&]R=&EN9R!E;G1I='D@=&\@
M9&5V96QO<"!I=',@;W=N(&%S<W5M<'1I;VYS+CPO9F]N=#X-"@D)/"]P/@T*
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@-#8N,#5P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
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M87)C:"`S,2P@,C`Q-2!A;F0@1&5C96UB97(F;F)S<#LS,2P@,C`Q-"P@=&AE
M(&-A<G)Y:6YG(&%M;W5N="!O9B!C87-H(&5Q=6EV86QE;G1S('=A<R`D,S4N
M,R!M:6QL:6]N+"!W:&EC:"!A<'!R;WAI;6%T97,@9F%I<B!V86QU92!A;F0@
M=V%S(&1E=&5R;6EN960@8F%S960@=7!O;B!,979E;"`Q(&EN<'5T<RX@0V%S
M:"!E<75I=F%L96YT<R!P<FEM87)I;'D@8V]N<VES=&5D(&]F(&UO;F5Y(&UA
M<FME="!F=6YD<RX@07,@;V8@36%R8V@@,S$L(#(P,34@86YD($1E8V5M8F5R
M)FYB<W`[,S$L(#(P,30L('1H92!#;VUP86YY(&1I9"!N;W0@:&]L9"!A;GD@
M3&5V96P@,B!O<B!,979E;"`S(&9I;F%N8VEA;"!A<W-E=',@=&AA="!A<F4@
M<F5C;W)D960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<RX\
M+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT
M+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
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M;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI
M;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.W1E>'0M:6YD96YT.C(W<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY!<R!O9B!-87)C:"`S
M,2P@,C`Q-2!A;F0@1&5C96UB97(F;F)S<#LS,2P@,C`Q-"P@=&AE($-O;7!A
M;GD@:&%D(&YO(&UA=&5R:6%L(&QI86)I;&ET:65S(&UE87-U<F5D(&%T(&9A
M:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,N/"]F;VYT/@T*"0D\+W`^
M#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V9F,V)D-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D,V5D8PT*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F9C-B9#0S,5\S,C8U7S1C-3!?.#AD
M85\Q-C$Q-#0R9#-E9&,O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-C<G5E9"!%>'!E;G-E
M<RP@3&]N9RU497)M($1E8G0L($-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC
M:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^06-C<G5E9"!%>'!E;G-E<RP@3&]N9RU497)M($1E8G0L($-O;6UI
M=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S+CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D($5X<&5N<V5S+"!,;VYG
M+51E<FT@1&5B="P@0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4]
M,T1M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`R-"XU<'0[=&5X="UI;F1E;G0Z
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M<'0[<&%D9&EN9SHP<'0@,3AP="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M
M<VEZ93HS<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SY!8V-R=65D
M($5X<&5N<V5S+"!,;VYG+51E<FT@1&5B="P@0V]M;6ET;65N=',@86YD($-O
M;G1I;F=E;F-I97,\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P="`P<'0@,'!T(#(T+C5P=#MT97AT+6EN9&5N=#H@+3(T+C5P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
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M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO
M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS-G!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^0W5R<F5N="!A8V-R=65D(&5X<&5N<V5S(&-O;G-I<W0@;V8@
M=&AE(&9O;&QO=VEN9R`H:6X@=&AO=7-A;F1S*3H\+V9O;G0^#0H)"3PO<#X-
M"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\
M9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P
M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L
M;&%P<V4[=VED=&@Z(#<X+C`P)3MM87)G:6XM;&5F=#HV-"XX<'0[)SX-"@D)
M"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M-C$N.#0E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/CPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP
M,RXQ."4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C(V)3MB;W)D
M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*
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M.R<^,C`Q-3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3@E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ-2XR-B4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
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M1'=I9'1H.C`Q+C(X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E
M;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-
M"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C8Q+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^06-C<G5E9"!P87ER;VQL(&%N9"!O=&AE<B!E;7!L;WEE92!B
M96YE9FET<SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C$X)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+CDV)3MB
M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A
M<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU-C(F;F)S<#L-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#,N,3@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO
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M<W1Y;&4],T0G=VED=&@Z,3,N.38E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB
M;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
M("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N
M.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL
M969T/CPO9&EV/C$L,C,T)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C(X)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C$N.#0E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T
M(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[
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M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C(V)3L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^-#DX)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3@E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XR
M-B4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y
M;&4],T1F;&]A=#IL969T/CPO9&EV/C0Q-29N8G-P.PT*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C(X)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C8Q+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E
M;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^06-C<G5E9"!O=&AE<CPO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`S+C$X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,34N,C8E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
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M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$)W=I9'1H.C$U+C(V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB
M;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG
M;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z
M;&5F=#X\+V1I=CXV,3$F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,C@E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HV,2XX-"4[<&%D9&EN
M9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@
M,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/D%C8W)U960@97AP96YS97,\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S
M+C$X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O
M=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C$S+CDV)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D
M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#@R-R9N8G-P.PT*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C$X)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N
M,S`E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C
M,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S
M+CDV)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA
M;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO
M870Z;&5F=#X\+V1I=CXR+#(V,"9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C(X)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M/"]T<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY$
M=7)I;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2P@
M=&AE($-O;7!A;GD@:7-S=65D(#$Y+#DU-B!S:&%R97,@;V8@:71S(&-O;6UO
M;B!S=&]C:R!T;R!C97)T86EN('-E;FEO<B!E>&5C=71I=F5S(&]F('1H92!#
M;VUP86YY(&%S(&-O;G-I9&5R871I;VX@9F]R(&$@<&]R=&EO;B!O9B!T:&5I
M<B`R,#$T(&%N;G5A;"!B;VYU<V5S+B!!;&P@<F5L871E9"!A;6]U;G1S('=E
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M<F-H(#,Q+"`R,#$U+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS-G!T.V9O;G0M
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M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS-G!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[
M/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z
M8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/DQO;F<M5&5R;2!$96)T/"]F;VYT/@T*
M"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO
M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS-G!T
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M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT
M/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E/CQT86)L92!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93IC;VQL87!S93MW:61T:#H@-S<N,#`E.VUA<F=I;BUL969T
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M='EL93TS1'=I9'1H.C`S+C(T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L
M:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,34N-30E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L
M:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="US:7IE.CAP=#LG/DUA<F-H/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HX<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C,Q+"9N8G-P.S(P
M,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`S+C(T)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,34N-30E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M8F5R/"]F;VYT/CQB<B`O/CQF
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M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)
M"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV,2XR,"4[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/DQO;F<M
M=&5R;2!D96)T/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#,N,C0E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P
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M.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C(P+#`P,`T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HP,RXR-"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P
M=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT
M.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D
M97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O
M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ-"XR-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P
M,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O
M='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^,C`L,#`P#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C(T)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L
M:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C$N,C`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#(P<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[
M)SY,97-S(&1E8G0@9&ES8V]U;G0L(&YE="!O9B!C=7)R96YT('!O<G1I;VX\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`S+C(T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-30E.V)O<F1E
M<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG
M(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I
M=CXH,38W#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,#,N,C0E.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4T)3MB;W)D97(M=&]P.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#,W,0T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`Q+C(T)3L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@
M<W1Y;&4],T0G=VED=&@Z-C$N,C`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N
M=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[)SY,;VYG+71E<FT@9&5B="P@;F5T(&]F(&1I
M<V-O=6YT/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#,N,C0E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XU-"4[8F]R9&5R+71O<#HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT
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M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4T)3MB;W)D97(M
M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,3DL-C(Y#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C(T
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)
M"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C$N
M,C`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M="`P<'0@,'!T(#(P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N
M=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[)SY,97-S(&-U<G)E;G0@<&]R=&EO;B!O9B!L
M;VYG+71E<FT@9&5B=#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C0E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ-2XU-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L
M:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF
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M.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^*#$L-30V#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,C0E.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)
M"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV,2XR,"4[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/DQO;F<M
M=&5R;2!D96)T+"!N970@;V8@8W5R<F5N="!P;W)T:6]N/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#,N,C0E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ-"XR-"4[8F]R9&5R+71O<#HQ<'0@<V]L
M:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X
M="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$
M9FQO870Z;&5F=#X\+V1I=CXQ-BPT,30-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#,N,C0E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M-"XR-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ."PP
M.#,-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#$N,C0E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y
M;&4],T1W:61T:#HV,2XR,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D-U<G)E;G0@<&]R
M=&EO;B!O9B!L;VYG+71E<FT@9&5B=#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C0E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP
M,2XS,"4[8F]R9&5R+71O<#HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M-"XR-"4[8F]R9&5R+71O<#HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA
M;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO
M870Z;&5F=#X\+V1I=CXS+#0Q.0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(T)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT
M;W`Z,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)
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M;W`Z,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N
M;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^
M,2PU-#8-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T1W:61T:#HP,2XR-"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)
M/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV,2XR,"4[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D-U<G)E;G0@
M<&]R=&EO;B!O9B!D96)T(&1I<V-O=6YT/"]F;VYT/CPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#,N
M,C0E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O
M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XU
M-"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#$V,PT*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HP,RXR-"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CLG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SXI/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-30E
M.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ
M<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US:7IE.C$P<'0[)SXF(W@R,#$T.SPO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q
M+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-
M"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z
M-C$N,C`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
M9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY#=7)R96YT('!O<G1I;VX@;V8@;&]N
M9RUT97)M(&1E8G0L(&YE=#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C0E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P
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M.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P
M,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N
M.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL
M969T/CPO9&EV/C,L,C4V#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C0E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G
M/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR
M:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SXD/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,30N,C0E.V)O<F1E<BUT;W`Z
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W
M<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C$L
M-30V#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#$N,C0E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV
M/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,S9P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/D]N($IU;'DF;F)S<#LS,"P@,C`Q-"P@=&AE($-O;7!A;GD@96YT97)E
M9"!I;G1O(&%N($%M96YD960@86YD(%)E<W1A=&5D($QO86X@86YD(%-E8W5R
M:71Y($%G<F5E;65N="`H=&AE("8C>#(P,4,[4F5S=&%T960@3%-!)B-X,C`Q
M1#LI('=I=&@@4VEL:6-O;B!686QL97D@0F%N:R`H=&AE("8C>#(P,4,[0F%N
M:R8C>#(P,40[*2P@8V]L;&%T97)A;&EZ960@8GD@<W5B<W1A;G1I86QL>2!A
M;&P@;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@87-S971S+"!E>&-L=61I;F<@
M8V5R=&%I;B!I;G1E;&QE8W1U86P@<')O<&5R='DN(%1H92!297-T871E9"!,
M4T$@86UE;F1S(&%N9"!R97-T871E<R!T:&4@3&]A;B!A;F0@4V5C=7)I='D@
M06=R965M96YT+"!D871E9"!A<R!O9B!*86YU87)Y)FYB<W`[-2P@,C`P.2P@
M87,@86UE;F1E9"P@8GD@86YD(&)E='=E96X@=&AE($-O;7!A;GD@86YD('1H
M92!"86YK("AT:&4@)B-X,C`Q0SM,;V%N($%G<F5E;65N="8C>#(P,40[*2X@
M4'5R<W5A;G0@=&\@=&AE(%)E<W1A=&5D($Q302P@=&AE($)A;FL@86=R965D
M('1O(&UA:V4@;&]A;G,@=&\@=&AE($-O;7!A;GD@:6X@86X@86=G<F5G871E
M('!R:6YC:7!A;"!A;6]U;G0@;V8@=7`@=&\@)#(P+C`F;F)S<#MM:6QL:6]N
M+"!C;VUP<FES960@;V8@*&DI)FYB<W`[82`D,3`N,"9N8G-P.VUI;&QI;VX@
M=&5R;2!L;V%N+"!F=6YD960@870@=&AE(&-L;W-I;F<@9&%T92`H=&AE("8C
M>#(P,4,[5&5R;2!!($QO86XF(W@R,#%$.RD@86YD("AI:2DF;F)S<#MS=6)J
M96-T('1O('1H92!A8VAI979E;65N="!O9B!A('-P96-I9FEE9"!C;&EN:6-A
M;"!M:6QE<W1O;F4@<F5L871I;F<@=&\@=&AE($-O;7!A;GDF(W@R,#$Y.W,@
M4&AA<V4F;F)S<#LR(&-L:6YI8V%L('1R:6%L(&]F(%!R;TAE;6$L(&%D9&ET
M:6]N86P@=&5R;2!L;V%N<R!T;W1A;&EN9R!U<"!T;R`D,3`N,"9N8G-P.VUI
M;&QI;VX@:6X@=&AE(&%G9W)E9V%T92P@=VAI8V@@=V5R92!A=F%I;&%B;&4@
M=6YT:6P@1&5C96UB97(F;F)S<#LS,2P@,C`Q-"`H96%C:"P@82`F(W@R,#%#
M.U1E<FT@0B!,;V%N)B-X,C`Q1#LI+B!/;B!$96-E;6)E<B9N8G-P.S(T+"`R
M,#$T+"!T:&4@0V]M<&%N>2!E;&5C=&5D('1O(&1R87<@;VX@=&AE(&9U;&P@
M)#$P+C`F;F)S<#MM:6QL:6]N('5N9&5R(&$@5&5R;2!"($QO86XN/"]F;VYT
M/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)
M"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS
M-G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^5&AE(%1E<FT@02!,;V%N(&%N9"!T:&4@5&5R;2!"($QO
M86X@;6%T=7)E(&]N($IA;G5A<GDF;F)S<#LQ+"`R,#$X(&%N9"!*=6YE)FYB
M<W`[,2P@,C`Q."P@<F5S<&5C=&EV96QY(&%N9"!B96%R(&EN=&5R97-T(&%T
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M)#`N."9N8G-P.VUI;&QI;VXL(&]F('1H92!F=6YD960@86UO=6YT(&9O<B!E
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M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS-G!T
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M;F-L=61I;F<@82!C;VUM:71M96YT(&9E92!O9B`D,"XT)FYB<W`[;6EL;&EO
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M#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N
M=#HS-G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^
M)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[=&5X="UI;F1E;G0Z,S9P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/E!R;V-E961S(&9R;VT@=&AE
M(%1E<FT@0B!,;V%N('=E<F4@)#$P+C`F;F)S<#MM:6QL:6]N+B!);B!C;VYN
M96-T:6]N('=I=&@@=&AE(&9U;F1I;F<@;V8@=&AE(%1E<FTF;F)S<#M")FYB
M<W`[3&]A;BP@=&AE($-O;7!A;GD@:7-S=65D('1H92!"86YK(&%N9"!O;F4@
M;V8@:71S(&%F9FEL:6%T97,@9G5L;'DM97AE<F-I<V%B;&4@=V%R<F%N=',@
M=&\@<'5R8VAA<V4@86X@86=G<F5G871E(&]F(#DX+#`S.2!S:&%R97,@;V8@
M=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]M;6]N('-T;V-K("AT:&4@)B-X,C`Q
M0SM787)R86YT<R8C>#(P,40[*2!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D
M-"XP."!P97(@<VAA<F4N(%1H92!787)R86YT<R!E>'!I<F4@:6X@1&5C96UB
M97(@,C`R,2X@5&AE(&%G9W)E9V%T92!F86ER('9A;'5E(&]F('1H92!787)R
M86YT<R!W87,@9&5T97)M:6YE9"!T;R!B92`D,"XT)FYB<W`[;6EL;&EO;B!U
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M#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N
M=#HS-G!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^5&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&4@969F
M96-T:79E(&EN=&5R97-T(')A=&5S(&]F('1H92!497)M($$@3&]A;B!A;F0@
M5&5R;2!"($QO86X@=&\@8F4@,3`N,R4@86YD(#$R+C`E+"!R97-P96-T:79E
M;'DN($9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$U
M+"!T:&4@0V]M<&%N>2!R96-O<F1E9"`D,"XV)FYB<W`[;6EL;&EO;B!I;B!A
M9V=R96=A=&4@:6YT97)E<W0@97AP96YS92!R96QA=&5D('1O('1H92!497)M
M($$@86YD(%1E<FT@0B!,;V%N<RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)
M/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V
M<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P
M="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US
M:7IE.C$P<'0[)SY787)R86YT<R!T;R!P=7)C:&%S92`S-BPP-S0@<VAA<F5S
M(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!A="!A('=E
M:6=H=&5D(&%V97)A9V4@97AE<F-I<V4@<')I8V4@;V8@)#<N,C$@<&5R('-H
M87)E(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($QO86X@06=R965M
M96YT(')E;6%I;B!O=71S=&%N9&EN9R!A<R!O9B!-87)C:"`S,2P@,C`Q-2P@
M=VET:"`U+#,P-2!A;F0@,S`L-S8Y(&]F('-U8V@@=V%R<F%N=',@:&%V:6YG
M(&5X<&ER871I;VX@9&%T97,@:6X@2F%N=6%R>2`R,#$Y(&%N9"!!=6=U<W0@
M,C`R,2P@<F5S<&5C=&EV96QY+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO
M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ
M93HQ,'!T.R<^1F%C:6QI='D@3&5A<V4\+V9O;G0^#0H)"3PO<#X-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
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M(&$@;F]N+6-A;F-E;&%B;&4@;W!E<F%T:6YG(&QE87-E+B!);B!-87)C:"`R
M,#$U+"!W92!E>'1E;F1E9"!T:&4@=&5R;2!O9B!T:&4@;&5A<V4@;VX@=&AI
M<R!F86-I;&ET>2!A;B!A9&1I=&EO;F%L(#$U(&UO;G1H<R!T:')O=6=H(%-E
M<'1E;6)E<B`R,#$W+B!4:&4@;&5A<V4@:7,@<W5B:F5C="!T;R!A9&1I=&EO
M;F%L(&-H87)G97,@9F]R(&-O;6UO;B!A<F5A(&UA:6YT96YA;F-E(&%N9"!O
M=&AE<B!C;W-T<RX@26X@8V]N;F5C=&EO;B!W:71H('1H92!L96%S92P@=&AE
M($-O;7!A;GD@96YT97)E9"!I;G1O(&$@8V%S:"UC;VQL871E<F%L:7IE9"!I
M<G)E=F]C86)L92!S=&%N9&)Y(&QE='1E<B!O9B!C<F5D:70@:6X@=&AE(&%M
M;W5N="!O9B`D,"XQ(&UI;&QI;VXN($%S(&]F($UA<F-H(#,Q+"`R,#$U+"!F
M=71U<F4@;6EN:6UU;2!P87EM96YT<R!U;F1E<B!T:&4@;W!E<F%T:6YG(&QE
M87-E(&%R92`D,BXU(&UI;&QI;VXN/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HS-G!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^26X@2F%N
M=6%R>2`R,#$U+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!S=6)L96%S
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M/'`^/&9O;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9F8S
M8F0T,S%?,S(V-5\T8S4P7S@X9&%?,38Q,30T,F0S961C#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V9F,V)D-#,Q7S,R-C5?-&,U,%\X.&1A7S$V
M,3$T-#)D,V5D8R]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET
M>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y+CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I=B!S='EL
M93TS1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#(R+C-P=#MT97AT+6EN9&5N
M=#H@+3(R+C-P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HQ,'!T.R<^-2X\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O
M;&0[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T
M.C!P=#MP861D:6YG.C!P="`Q-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US:7IE.C-P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/E-T;V-K
M:&]L9&5R<R8C>#(P,3D[($5Q=6ET>3PO9F]N=#X-"@D)/"]P/@T*"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,C(N,W!T.W1E>'0M:6YD96YT
M.B`M,C(N,W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
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M(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@<W1Y;&4],T0G8F]R
M9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W=I9'1H.B`X-BXP,"4[;6%R9VEN+6QE
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M='EL93TS1'=I9'1H.C`R+C@X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L
M:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,3,N.#0E.V)O
M<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#LG/DYU;6)E<B9N8G-P.V]F/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$
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M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$S+C@T)3MB;W)D97(M=&]P.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
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M93PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#$N,38E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HV-2XT,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#(N.#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HQ,RXX-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF
M;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#(N.#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,RXX-"4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N
M,38E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T
M;W`@<W1Y;&4],T0G=VED=&@Z-C4N-#`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
M9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY"86QA;F-E(&%T($1E8V5M8F5R)FYB
M<W`[,S$L(#(P,30@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N.#@E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,RXX-"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,BPT,C4L.38Y#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`R+C@X
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C$R+C4T)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV
M('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+C@S#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C$V)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT
M<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C4N-#`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P
M<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@
M+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M9F]N="US:7IE.C$P<'0[)SY'<F%N=&5D(#PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N
M.#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
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M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$S+C@T)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-"XX-PT*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`Q+C$V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L
M:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C8U+C0P)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
M=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^0V%N8V5L960@/"]F;VYT
M/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#(N.#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,RXX-"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^*#(Q,RPV,S`-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N.#@E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$S+C@T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXU+C0Y#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C$V)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)
M"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C4N-#`E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T
M(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[
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M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S
M+C@T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI
M9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T
M.FQE9G0^/"]D:78^*#0W+#@V,@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C@X)3L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
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M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^
M#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HV-2XT,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG
M.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@
M,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/D)A;&%N8V4@870@36%R8V@@,S$L(#(P,34@/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N.#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,RXX
M-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#DU-RPV
M,CD-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#(N.#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
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M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^
M)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/E1H92!A;&QO8V%T:6]N(&]F
M('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!F;W(@86QL(&]P=&EO;G,@86YD
M(')E<W1R:6-T960@<W1O8VL@87=A<F1S(&ES(&%S(&9O;&QO=W,@*&EN('1H
M;W5S86YD<RDZ/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[=&5X="UI;F1E;G0Z,C-P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\9&EV
M('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E
M;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P
M<V4[=VED=&@Z(#4Y+C`P)3MM87)G:6XM;&5F=#HQ,3@N.'!T.R<^#0H)"0D\
M='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C0Y
M+C0X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N
M,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0U
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HT-"XW,"4[8F]R9&5R
M+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^
M5&AR964F;F)S<#M-;VYT:',F;F)S<#M%;F1E9#PO9F]N=#X\8G(@+SX\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF
M;VYT+7-I>F4Z.'!T.R<^36%R8V@F;F)S<#LS,2P\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`Q+C8P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT
M<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#DN
M-#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/CPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP-"XR
M,B4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)
M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(P+C(V)3MB;W)D97(M
M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^
M,C`Q-3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HR,"XR,B4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)
M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#$N-C`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HT.2XT
M."4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT
M.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N,C(E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR
M,"XR-B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#0N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR,"XR,B4[8F]R9&5R+71O<#HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG
M:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N-C`E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z-#DN-#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N
M=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[)SY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@
M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,#0N,C(E.V)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
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M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M."XY-"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^-38U)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C8P)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-#DN-#@E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[)SY'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV92`\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`T+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,C`N,C8E.V)O<F1E<BUT;W`Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
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M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(P+C(R)3MB;W)D97(M=&]P.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ
M<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,S`V)FYB<W`[
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z,#$N-C`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z-#DN-#@E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V
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M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,R)3MB;W)D97(M
M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$X+CDT)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
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M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
M("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$X+CDT
M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P
M,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U
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M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"3PO=&%B;&4^/"]D:78^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MT97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^07,@;V8@36%R8V@@,S$L
M(#(P,34L('1H92!O=71S=&%N9&EN9R!O<'1I;VYS(&EN8VQU9&5D(#$R,BPW
M.#`@<&5R9F]R;6%N8V4M8F%S960@;W!T:6]N<R!F;W(@=VAI8V@@=&AE(&%C
M:&EE=F5M96YT(&]F('1H92!P97)F;W)M86YC92UB87-E9"!V97-T:6YG('!R
M;W9I<VEO;G,@=V%S(&1E=&5R;6EN960@;F]T('1O(&)E('!R;V)A8FQE+B!4
M:&4@86=G<F5G871E(&=R86YT(&1A=&4@9F%I<B!V86QU92!O9B!T:&5S92!U
M;G9E<W1E9"!O<'1I;VYS(&%T($UA<F-H(#,Q+"`R,#$U('=A<R`D,"XU(&UI
M;&QI;VXN/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL
M93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C(W<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY!<R!O
M9B!-87)C:"`S,2P@,C`Q-2P@=&AE('5N<F5C;V=N:7IE9"!C;VUP96YS871I
M;VX@8V]S="!R96QA=&5D('1O(&]U='-T86YD:6YG(&]P=&EO;G,@*&5X8VQU
M9&EN9R!T:&]S92!W:71H('!E<F9O<FUA;F-E+6)A<V5D(&-O;F1I=&EO;G,I
M('=A<R`D-"XY(&UI;&QI;VX@86YD(&ES(&5X<&5C=&5D('1O(&)E(')E8V]G
M;FEZ960@87,@97AP96YS92!O=F5R(&%P<')O>&EM871E;'D@,RXP('EE87)S
M+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E
M>'0M:6YD96YT.C(W<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G
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M:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W
M:61T:#HQ,#`E/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<]
M,T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW:61T:#H@
M-S<N,#`E.VUA<F=I;BUL969T.C8Q+C)P=#LG/@T*"0D)/'1R/@T*"0D)"3QT
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M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,R!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,S0N,C8E.V)O<F1E<BUT;W`Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E1H<F5E)FYB<W`[
M36]N=&AS)FYB<W`[16YD960\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#LG/DUA<F-H)FYB<W`[,S$L/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XS,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C8Q+C(R)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C(E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ-2XU,B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
M1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT
M.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,34\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP
M,RXR,B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ-2XU,B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H
M.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT
M<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C$N
M,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N
M=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D:6YG.C!P
M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-3(E.V)O<F1E
M<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE
M("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S
M+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,34N-3(E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)
M"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C8Q+C(R)3MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\
M9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+C8F;F)S<#L-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#,N,C(E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO
M=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR
M+C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)3PO9F]N=#X\+W`^
M#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG
M;CTS1'1O<"!S='EL93TS1'=I9'1H.C8Q+C(R)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M17AP96-T960@=F]L871I;&ET>3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C(E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
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M9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXY-"XU)FYB<W`[#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#$N,S`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)3PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A
M;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV,2XR,B4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D5X<&5C=&5D('1E<FT@
M*&EN('EE87)S*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C(R)3MB86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
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M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A
M<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV+C$F;F)S<#L-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,#$N,S`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\
M+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W
M:61T:#HV,2XR,B4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
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M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^,"XP)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C(E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^,"XP)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,S`E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"3PO=&%B;&4^/"]D:78^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HR-W!T.V9O;G0M
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M<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HR,RXP
M-7!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB
M<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E
M/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE
M/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW:61T:#H@-S<N,#`E.VUA
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M1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,R!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,S0N,C8E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I
M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E1H<F5E)FYB<W`[36]N=&AS)FYB
M<W`[16YD960\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DUA<F-H
M)FYB<W`[,S$L/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XS,"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P
M-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C8Q+C(R)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N
M8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M-2XU,B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US:7IE.CAP=#LG/C(P,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXR,B4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB
M;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ-2XU,B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L
M:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z-C$N,C(E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T
M(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^
M#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S
M<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-3(E.V)O<F1E<BUT;W`Z,7!T
M('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT
M.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L
M:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D
M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-3(E
M.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L
M:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C8Q+C(R)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[
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M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
M='EL93TS1"=W:61T:#HQ-2XU,B4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T
M.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL
M93TS1&9L;V%T.FQE9G0^/"]D:78^,2XR)FYB<W`[#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C(R)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XU,B4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,BXR)FYB<W`[
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@
M<W1Y;&4],T1W:61T:#HV,2XR,B4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^.#<N,29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
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M=&]P('-T>6QE/3-$)W=I9'1H.C8Q+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI
M;F1E;G0Z("TQ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^4F5M86EN:6YG(&-O;G1R86-T=6%L
M('1E<FT@*&EN('EE87)S*2`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXR,B4[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\
M9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU+C`F;F)S<#L-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,#,N,C(E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[
M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XU,B4[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-BXW)FYB
M<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$=VED=&@Z-C$N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY%>'!E8W1E9"!D
M:79I9&5N9"!Y:65L9"`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-3(E.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X
M="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$
M9FQO870Z;&5F=#X\+V1I=CXP+C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT
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M>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXP+C`F;F)S<#L-"@D)"0D\+W1D/@T*
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M"0D\+W1D/@T*"0D)/"]T<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#(R+C-P=#MT97AT+6EN9&5N=#H@
M+3(R+C-P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG
M/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@
M/"]F;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B
M<V5Q=65N="!%=F5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`R
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M.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,39P="`P<'0@,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HS<'0[)SX\+V9O;G0^/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US
M:7IE.C$P<'0[)SY3=6)S97%U96YT($5V96YT<SPO9F]N=#X-"@D)/"]P/@T*
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,C(N,W!T.W1E>'0M
M:6YD96YT.B`M,C(N,W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D]N($UA>2`T
M+"`R,#$U+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!R97-E87)C:"!C
M;VQL86)O<F%T:6]N(&%N9"!L:6-E;G-E(&%G<F5E;65N="`H=&AE("8C>#(P
M,4,[06=R965M96YT)B-X,C`Q1#LI('=I=&@@2G5N;R!4:&5R87!E=71I8W,L
M($EN8RX@*"8C>#(P,4,[2G5N;R8C>#(P,40[*2!T;R!I9&5N=&EF>2!S;6%L
M;"!M;VQE8W5L97,@=&\@<')O9W)A;2!T:&4@=&AE<F%P975T:6,@<')O<&5R
M=&EE<R!O9B!*=6YO)B-X,C`Q.3MS(&=E;F5T:6-A;&QY+65N9VEN965R960@
M5"!C96QL('!R;V1U8W0@8V%N9&ED871E<RX@4'5R<W5A;G0@=&\@=&AE('1E
M<FUS(&]F('1H92!!9W)E96UE;G0L($IU;F\@:&%S(&%G<F5E9"!T;R!P87D@
M=&AE($-O;7!A;GD@86X@=7!F<F]N="!P87EM96YT(&]F("0U+C`@;6EL;&EO
M;B!A;F0@=&\@<'5R8VAA<V4@,2PP,#`L,#`P('-H87)E<R!O9B!T:&4@0V]M
M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O8VL@870@)#@N,#`@<&5R('-H87)E
M+CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E
M>'0M:6YD96YT.C(W<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G
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M(')E<V5A<F-H(&9U;F1I;F<N/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T
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M;RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT
M97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D9O<B!E86-H
M('!R;V1U8W0@9&5V96QO<&5D(&)Y($IU;F\@=&AA="!I;F-O<G!O<F%T97,@
M;6]D=6QA=&]R<R!I9&5N=&EF:65D('1H<F]U9V@@=&AE(')E<V5A<F-H(&-O
M;&QA8F]R871I;VXL('1H92!#;VUP86YY(&ES(&5L:6=I8FQE('1O(')E8V5I
M=F4@87!P<F]X:6UA=&5L>2`D-3`N,"!M:6QL:6]N(&EN('1A<F=E="!S96QE
M8W1I;VX@9F5E<R!A;F0@8VQI;FEC86PL(')E9W5L871O<GD@86YD(&-O;6UE
M<F-I86P@;6EL97-T;VYE<RP@87,@=V5L;"!A<R!L;W<@<VEN9VQE+61I9VET
M(')O>6%L=&EE<R!O;B!S86QE<RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`^/&9O
M;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9F8S8F0T,S%?
M,S(V-5\T8S4P7S@X9&%?,38Q,30T,F0S961C#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V9F,V)D-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D
M,V5D8R]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$571T%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R
M>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A0;VQI8VEE
M<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY/<F=A;FEZ871I;VX@86YD(%-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@
M06-C;W5N=&EN9R!0;VQI8VEE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);FET:6%L(%!U8FQI8R!/9F9E<FEN9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I=B!S='EL93TS
M1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HQ,'!T.R<^26YI
M=&EA;"!0=6)L:6,@3V9F97)I;F<\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY/;B!/8W1O
M8F5R)FYB<W`[-"P@,C`Q,RP@=&AE($-O;7!A;GD@8V]M<&QE=&5D(&ET<R!I
M;FET:6%L('!U8FQI8R!O9F9E<FEN9R`H=&AE("8C>#(P,4,[25!/)B-X,C`Q
M1#LI('=H97)E8GD@:70@<V]L9"`W+#8V-BPV-C<@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!A="!A('!U8FQI8R!O9F9E<FEN9R!P<FEC92!O9B`D-BXP,"!P
M97(@<VAA<F4N($=R;W-S('!R;V-E961S(&9R;VT@=&AE(&]F9F5R:6YG('=E
M<F4@)#0V+C`F;F)S<#MM:6QL:6]N+B!!9G1E<B!G:79I;F<@969F96-T('1O
M('5N9&5R=W)I=&EN9R!D:7-C;W5N=',L(&-O;6UI<W-I;VYS(&%N9"!O=&AE
M<B!C87-H(&-O<W1S(')E;&%T960@=&\@=&AE(&]F9F5R:6YG+"!N970@<')O
M8V5E9',@=V5R92`D-#`N-29N8G-P.VUI;&QI;VXN/"]F;VYT/@T*"0D\+W`^
M#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E5S92!O9B!%<W1I;6%T97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F=#HP<'0[
M;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^
M#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG
M:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/E5S92!O9B!%<W1I;6%T97,\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-
M"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^5&AE
M($-O;7!A;GDF(W@R,#$Y.W,@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S(&%R92!P<F5P87)E9"!I;B!A8V-O<F1A;F-E('=I=&@@56YI=&5D
M(%-T871E<R!G96YE<F%L;'D@86-C97!T960@86-C;W5N=&EN9R!P<FEN8VEP
M;&5S("@F(W@R,#%#.T=!05`F(W@R,#%$.RDN(%1H92!P<F5P87)A=&EO;B!O
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M(&QI86)I;&ET:65S(&EN('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;G-O;&ED
M871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!A;F0@86-C;VUP86YY:6YG(&YO
M=&5S+B!4:&4@;6]S="!S:6=N:69I8V%N="!E<W1I;6%T97,@:6X@=&AE($-O
M;7!A;GDF(W@R,#$Y.W,@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE
M;G1S(')E;&%T92!T;R!A8V-R=65D(&5X<&5N<V5S+B!!;'1H;W5G:"!T:&5S
M92!E<W1I;6%T97,@87)E(&)A<V5D(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&MN;W=L961G92!O9B!C=7)R96YT(&5V96YT<R!A;F0@86-T:6]N<R!I="!M
M87D@=6YD97)T86ME(&EN('1H92!F=71U<F4L(&%C='5A;"!R97-U;'1S(&UA
M>2!U;'1I;6%T96QY(&UA=&5R:6%L;'D@9&EF9F5R(&9R;VT@=&AE<V4@97-T
M:6UA=&5S(&%N9"!A<W-U;7!T:6]N<RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`^
M/&9O;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')I;F-I<&QE<R!O9B!#;VYS;VQI9&%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z
M,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SY0<FEN8VEP;&5S(&]F($-O
M;G-O;&ED871I;VX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG
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M<R!D:7-S;VQV960@:6X@2G5N92`R,#$T+B!4;R!D871E+"!T:&4@86=G<F5G
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M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#
M87-H($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="US:7IE.C$P<'0[)SY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]F
M;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF
M86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^
M#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N
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M+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV
M/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E=F5N=64@4F5C;V=N:71I;VX\+W1D/@T*("`@("`@("`\
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M:71I;VX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
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M97)I82!A<F4@;65T.B`H:2DF;F)S<#MP97)S=6%S:79E(&5V:61E;F-E('1H
M870@86X@86=R965M96YT(&5X:7-T<SL@*&EI*29N8G-P.V1E;&EV97)Y(&]F
M('1H92!P<F]D=6-T<R!A;F0O;W(@<V5R=FEC97,@:&%S(&]C8W5R<F5D.R`H
M:6EI*29N8G-P.W1H92!S96QL:6YG('!R:6-E(&ES(&9I>&5D(&]R(&1E=&5R
M;6EN86)L93L@86YD("AI=BDF;F)S<#MC;VQL96-T86)I;&ET>2!I<R!R96%S
M;VYA8FQY(&%S<W5R960N/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,S9P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE
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M8G-T86YT:6%L;'D@=VET:&EN('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;G1R
M;VPN/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M=&5X="UI;F1E;G0Z,S9P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY&;W(@=')A
M;G-A8W1I;VYS(&5N=&5R960@:6YT;R!P<FEO<B!T;R`R,#$Q+"!R979E;G5E
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M=F5R960@96QE;65N=',N/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,S9P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X-"@D)/"]P/@T*
M"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD96YT.C,V<'0[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)
M"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P
M<'0[)SY"96=I;FYI;F<@:6X@,C`Q,2P@<F5V96YU92!H87,@8F5E;B!A;&QO
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M9&5N8V4@*"8C>#(P,4,[5%!%)B-X,C`Q1#LI(&]F(&9A:7(@=F%L=64@:7,@
M86-C97!T86)L92P@;W(@82!B97-T(&5S=&EM871E(&]F('-E;&QI;F<@<')I
M8V4@:7,@=7-E9"!I9B!N96ET:&5R(%933T4@;F]R(%1012!I<R!A=F%I;&%B
M;&4N($$@8F5S="!E<W1I;6%T92!O9B!S96QL:6YG('!R:6-E('-H;W5L9"!B
M92!C;VYS:7-T96YT('=I=&@@=&AE(&]B:F5C=&EV92!O9B!D971E<FUI;FEN
M9R!T:&4@<')I8V4@870@=VAI8V@@=&AE($-O;7!A;GD@=V]U;&0@=')A;G-A
M8W0@:68@=&AE(&5L96UE;G0@=V5R92!S;VQD(')E9W5L87)L>2!O;B!A('-T
M86YD+6%L;VYE(&)A<VES(&%N9"!S:&]U;&0@86QS;R!T86ME(&EN=&\@86-C
M;W5N="!M87)K970@8V]N9&ET:6]N<R!A;F0@8V]M<&%N>2US<&5C:69I8R!F
M86-T;W)S+B!4:&4@0V]M<&%N>2!H87,@;F]T(&5N=&5R960@:6YT;R!O<B!M
M871E<FEA;&QY(&UO9&EF:65D(&%N>2!M=6QT:7!L92!E;&5M96YT(&%R<F%N
M9V5M96YT<R!S=6)S97%U96YT('1O(#(P,3`N/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,S9P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
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M92!T:&4@9F]L;&]W:6YG.B`H:2DF;F)S<#MT:&4@8V]N<VED97)A=&EO;B!B
M96EN9R!E87)N960@<VAO=6QD(&)E(&-O;6UE;G-U<F%T92!W:71H(&5I=&AE
M<B!T:&4@0V]M<&%N>28C>#(P,3D[<R!P97)F;W)M86YC92!T;R!A8VAI979E
M('1H92!M:6QE<W1O;F4@;W(@=&AE(&5N:&%N8V5M96YT(&]F('1H92!V86QU
M92!O9B!T:&4@:71E;2!D96QI=F5R960@87,@82!R97-U;'0@;V8@82!S<&5C
M:69I8R!O=71C;VUE(')E<W5L=&EN9R!F<F]M('1H92!#;VUP86YY)B-X,C`Q
M.3MS('!E<F9O<FUA;F-E('1O(&%C:&EE=F4@=&AE(&UI;&5S=&]N93L@*&EI
M*29N8G-P.W1H92!C;VYS:61E<F%T:6]N(&)E:6YG(&5A<FYE9"!S:&]U;&0@
M<F5L871E('-O;&5L>2!T;R!P87-T('!E<F9O<FUA;F-E.R`H:6EI*29N8G-P
M.W1H92!C;VYS:61E<F%T:6]N(&)E:6YG(&5A<FYE9"!S:&]U;&0@8F4@<F5A
M<V]N86)L92!R96QA=&EV92!T;R!A;&P@9&5L:79E<F%B;&5S(&%N9"!P87EM
M96YT('1E<FUS(&EN('1H92!A<G)A;F=E;65N=#L@86YD("AI=BDF;F)S<#MT
M:&4@;6EL97-T;VYE('-H;W5L9"!B92!C;VYS:61E<F5D(&EN(&ET<R!E;G1I
M<F5T>2!A;F0@8V%N;F]T(&)E(&)I9G5R8V%T960@:6YT;R!S=6)S=&%N=&EV
M92!A;F0@;F]N<W5B<W1A;G1I=F4@8V]M<&]N96YT<RX@06YY(&%M;W5N=',@
M<F5C96EV960@<'5R<W5A;G0@=&\@<F5V96YU92!A<G)A;F=E;65N=',@=VET
M:"!M=6QT:7!L92!E;&5M96YT<R!P<FEO<B!T;R!S871I<V9Y:6YG('1H92!#
M;VUP86YY)B-X,C`Q.3MS(')E=F5N=64@<F5C;V=N:71I;VX@8W)I=&5R:6$@
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M)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
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M;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P
M/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I=B!S='EL
M93TS1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"@D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HQ,'!T.R<^
M4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]F;VYT/@T*"0D\+W`^#0H)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y
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M:7-I=&4@<V5R=FEC92!P97)I;V0@;V8@=&AE(&%W87)D<R`H=7-U86QL>2!T
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M;6]D96PN/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[=&5X="UA;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y
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M:7IE.C$P<'0[)SXN/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4]
M,T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S(%!E
M<B!#;VUM;VX@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I
M9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF
M;VYT+7-I>F4Z,3!P=#LG/DYE="!,;W-S('!E<B!#;VUM;VX@4VAA<F4\+V9O
M;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"3QF
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M960@<F5S=')I8W1E9"!S=&]C:R!T;W1A;&EN9R`U."PT-3,@<VAA<F5S(&%N
M9"`X."PP-#,@<VAA<F5S(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA
M<F-H(#,Q+"`R,#$U(&%N9"`R,#$T+"!R97-P96-T:79E;'DN($1I;'5T960@
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M970@;&]S<R!P;W-I=&EO;BX\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^
M#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
M"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#LG/D9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R
M,#$U+"!T:&4@0V]M<&%N>2!R96%L:7IE9"!A(&YE="!L;W-S(&]F("0W+CD@
M;6EL;&EO;BX@4VAA<F5S(&]F('!O=&5N=&EA;&QY(&1I;'5T:79E('-E8W5R
M:71I97,@=&]T86QE9"`S+C$@;6EL;&EO;B!F;W(@=&AE('1H<F5E(&UO;G1H
M<R!E;F1E9"!-87)C:"`S,2P@,C`Q-2P@:6YC;'5D:6YG(&]P=&EO;G,@=&\@
M<'5R8VAA<V4@,RXP(&UI;&QI;VX@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX\
M+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#MT97AT
M+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D9O<B!T:&4@=&AR
M964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!R
M96%L:7IE9"!A(&YE="!L;W-S(&]F("0W+C`@;6EL;&EO;BX@4VAA<F5S(&]F
M('!O=&5N=&EA;&QY(&1I;'5T:79E('-E8W5R:71I97,@=&]T86QE9"`R+C4@
M;6EL;&EO;B!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@
M,C`Q-"P@:6YC;'5D:6YG(&]P=&EO;G,@=&\@<'5R8VAA<V4@,BXT(&UI;&QI
M;VX@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX\+V9O;G0^#0H)"3PO<#X-"@D)
M/'`^/&9O;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G
M:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/E)E8V5N="!!
M8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]F;VYT/@T*"0D\+W`^#0H)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HR-W!T.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^26X@
M075G=7-T(#(P,30L('1H92!&:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R
M9',@0F]A<F0@*'1H92`F(W@R,#%#.T9!4T(F(W@R,#%$.RD@:7-S=65D($%C
M8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`H)B-X,C`Q0SM!4U4F(W@R,#%$
M.RD@,C`Q-"TQ-2P@=VAI8V@@9&5F:6YE9"!M86YA9V5M96YT)B-X,C`Q.3MS
M(')E<W!O;G-I8FEL:71Y('1O(&5V86QU871E('=H971H97(@=&AE<F4@:7,@
M<W5B<W1A;G1I86P@9&]U8G0@86)O=70@86X@96YT:71Y)B-X,C`Q.3MS(&%B
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M8V]N<VED97)A=&EO;B!O9B!M86YA9V5M96YT)B-X,C`Q.3MS('!L86YS(&%N
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M+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P
M.SPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E
M>'0M:6YD96YT.C(W<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY);B!-87D@,C`Q-"P@=&AE($9!4T(@
M:7-S=65D($%352`R,#$T+3`Y+"!W:&EC:"!C<F5A=&5D(&$@<VEN9VQE+"!P
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M<RX\+V9O;G0^#0H)"3PO<#X-"@D)/'`^/&9O;G0@<VEZ93TS1#$^(#PO9F]N
M=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?9F8S8F0T,S%?,S(V-5\T8S4P7S@X9&%?,38Q
M,30T,F0S961C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9F,V)D
M-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D,V5D8R]7;W)K<VAE971S+U-H
M965T,3,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY!8V-R=65D($5X<&5N<V5S+"!,;VYG+51E<FT@1&5B="P@0V]M;6ET;65N
M=',@86YD($-O;G1I;F=E;F-I97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-R=65D($5X<&5N
M<V5S+"!,;VYG+51E<FT@1&5B="P@0V]M;6ET;65N=',@86YD($-O;G1I;F=E
M;F-I97,N/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-C:&5D=6QE(&]F(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@<W1Y;&4],T1M87)G:6XM
M;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[=&5X="UI;F1E;G0Z,S9P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D-U<G)E;G0@86-C
M<G5E9"!E>'!E;G-E<R!C;VYS:7-T(&]F('1H92!F;VQL;W=I;F<@*&EN('1H
M;W5S86YD<RDZ/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP
M861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[
M9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT
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M=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T
M.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
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M96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@
M,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I
M;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S
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M="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T
M.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY
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M<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ
M93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E
M;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P
M<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M
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M9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O
M;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X
M="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T
M(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N=#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.W!A9&1I;F<Z,'!T(#,V<'0@,'!T(#!P=#LG/CPO
M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y
M;&4],T1W:61T:#HQ,#`E/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW
M:61T:#H@-S@N,#`E.VUA<F=I;BUL969T.C8T+CAP=#LG/@T*"0D)/'1R/@T*
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M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C$X)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N,C8E.V)O<F1E<BUT;W`Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DUA<F-H
M)FYB<W`[,S$L/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
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M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C$U+C(V)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T
M('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
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M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#$N,C@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z-C$N
M.#0E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI
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M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@
M;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
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M;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
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M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR
M:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,RXY-B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[
M)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D
M:78^,2PR,S0F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,C@E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HV,2XX-"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/D%C8W)U960@8VQI;FEC86P@=')I86P@8V]S=',\+V9O;G0^/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`S+C$X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS
M1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C(V)3L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^-#$U)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,C@E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\
M+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z-C$N.#0E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@
M,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P
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M)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M-2XR-B4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C
M,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`]
M,T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-S8W)FYB
M<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C`S+C$X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,34N,C8E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y
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M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^
M#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C8Q+C@T)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI
M;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^06-C<G5E9"!E>'!E;G-E<SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3@E.W!A
M9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG
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M.38E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C
M,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L
M:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A
M=#IL969T/CPO9&EV/C$L.#(W)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,3@E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@
M.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG
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M<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N
M;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I
M9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T
M/CPO9&EV/C(L,C8P)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,C@E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*
M"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F
M;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\+V9O;G0^/"]P
M/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(&QO;F<M=&5R;2!D96)T
M(&%N9"!U;F%M;W)T:7IE9"!D:7-C;W5N="!B86QA;F-E<R`H97AC;'5D:6YG
M(&-O;G9E<G1I8FQE(&1E8G0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA<F=I
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M;W5S86YD<RDZ/"]F;VYT/@T*"0D\+W`^#0H)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@
M,3!P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N
M="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP
M861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[
M9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT
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M=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^
M/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I
M>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T
M.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F
M;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z
M,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
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M96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[<&%D9&EN9SHP<'0@,S9P="`P<'0@
M,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T.VUA<F=I
M;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\+V9O;G0^
M/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T
M.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY.E1I;65S
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M="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ93H@,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E;G0Z,'!T
M.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P<'0[)SX\
M+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M9F%M:6QY
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M<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O;G0M<VEZ
M93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X="UI;F1E
M;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T(#!P="`P
M<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T.V9O;G0M
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M9&EN9SHP<'0@,S9P="`P<'0@,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/CPO9F]N=#X\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[.V9O
M;G0M<VEZ93H@,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[=&5X
M="UI;F1E;G0Z,'!T.VUA<F=I;BUL969T.C!P=#MP861D:6YG.C!P="`S-G!T
M(#!P="`P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#L[9F]N="US:7IE.B`Q,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMT97AT+6EN9&5N=#HP<'0[
M;6%R9VEN+6QE9G0Z,'!T.W!A9&1I;F<Z,'!T(#,V<'0@,'!T(#!P=#LG/CPO
M9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE
M.C$P<'0[)SX\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M<VEZ93HQ,'!T.R<^/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@<W1Y
M;&4],T1W:61T:#HQ,#`E/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L;'-P
M86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93MW
M:61T:#H@-S<N,#`E.VUA<F=I;BUL969T.C8X+C1P=#LG/@T*"0D)/'1R/@T*
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M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(T)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N
M8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-30E.V)O<F1E<BUT;W`Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DUA<F-H
M/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7=E:6=H=#IB;VQD.V9O;G0M<VEZ93HX<'0[)SX\+V9O;G0^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US:7IE.CAP=#LG/C,Q+"9N8G-P.S(P,34\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S
M+C(T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$
M,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-30E.V)O<F1E
M<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG
M/D1E8V5M8F5R/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V1I<W!L87DZ
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M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S
M='EL93TS1"=W:61T:#HV,2XR,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT
M.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/DQO;F<M=&5R;2!D96)T/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,#,N,C0E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
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M;VT@<W1Y;&4],T0G=VED=&@Z,30N,C0E.V)O<F1E<BUT;W`Z,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L
M:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y;&4],T1F;&]A
M=#IL969T/CPO9&EV/C(P+#`P,`T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXR-"4[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S
M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-"XR-"4[
M8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y
M(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,C`L,#`P#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C`Q+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T
M.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T
M<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED
M=&@Z-C$N,C`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P="`P<'0@,'!T(#(P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY,97-S(&1E8G0@9&ES8V]U;G0L
M(&YE="!O9B!C=7)R96YT('!O<G1I;VX\+V9O;G0^/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(T
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,34N-30E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O
M;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV
M('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,38W#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C0E.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$U+C4T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL
M969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
M;V%T.FQE9G0^/"]D:78^*#,W,0T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C(T)3L^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R
M/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-C$N,C`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ
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M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ-2XU-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L
M:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A
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M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$U+C4T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^,3DL-C(Y#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-
M"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N
M/3-$=&]P('-T>6QE/3-$=VED=&@Z-C$N,C`E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#(P<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY,
M97-S(&-U<G)E;G0@<&]R=&EO;B!O9B!L;VYG+71E<FT@9&5B=#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#,N,C0E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XU-"4[8F]R9&5R+71O<#HQ
M<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I
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M;VT@<W1Y;&4],T0G=VED=&@Z,34N-30E.V)O<F1E<BUT;W`Z,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R
M87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#$L-30V#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#$N,C0E.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^*3PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S
M='EL93TS1"=W:61T:#HV,2XR,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT
M.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93MF;VYT+7-I>F4Z,3!P=#LG/DQO;F<M=&5R;2!D96)T+"!N970@;V8@8W5R
M<F5N="!P;W)T:6]N/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#,N,C0E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO
M=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M-"XR-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE
M(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ-BPT
M,30-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#,N,C0E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS
M,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P
M,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-"XR-"4[8F]R9&5R+71O<#HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H
M=#HQ<'0@;F]N92`C1#E$.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[
M=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE
M/3-$9FQO870Z;&5F=#X\+V1I=CXQ."PP.#,-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,C0E.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*
M"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T:#HV,2XR,"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P
M<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P
M=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/D-U<G)E;G0@<&]R=&EO;B!O9B!L;VYG+71E<FT@9&5B
M=#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#,N,C0E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HR<'0@
M9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT
M.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P
M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-"XR-"4[8F]R9&5R+71O<#HR<'0@
M9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT
M.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#0Q.0T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I
M9'1H.C`S+C(T)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#$N,S`E.V)O<F1E<BUT;W`Z,G!T(&1O=6)L92`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXD/"]F;VYT/CPO
M<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,30N,C0E.V)O<F1E<BUT;W`Z,G!T(&1O=6)L92`C,#`P,#`P
M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,2PU-#8-"@D)"0D\+W1D/@T*"0D)
M"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP,2XR-"4[<&%D
M9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M
M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O
M;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-
M"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL
M93TS1"=W:61T:#HV,2XR,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP
M861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P
M="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M
M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF
M;VYT+7-I>F4Z,3!P=#LG/D-U<G)E;G0@<&]R=&EO;B!O9B!D96)T(&1I<V-O
M=6YT/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#,N,C0E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ-2XU-"4[8F]R9&5R+71O<#HQ<'0@;F]N
M92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M
M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L
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M;VT@<W1Y;&4],T0G=VED=&@Z,34N-30E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXF(W@R
M,#$T.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C(T)3MB86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA
M<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO
M<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L
M:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z-C$N,C`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[
M)SY#=7)R96YT('!O<G1I;VX@;V8@;&]N9RUT97)M(&1E8G0L(&YE=#PO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,#,N,C0E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HR<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@
M;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS
M1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXD
M/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T
M;VT@<W1Y;&4],T0G=VED=&@Z,30N,C0E.V)O<F1E<BUT;W`Z,7!T('-O;&ED
M(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E
M<BUB;W1T;VTZ,G!T(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W
M<F%P/CQD:78@<W1Y;&4],T1F;&]A=#IL969T/CPO9&EV/C,L,C4V#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#,N,C0E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HP,2XS,"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR<'0@
M9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y
M(#MP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T
M.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O
M;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SXD/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G
M=VED=&@Z,30N,C0E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O
M<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,G!T
M(&1O=6)L92`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z,3!P
M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W<F%P/3-$;F]W<F%P/CQD:78@<W1Y
M;&4],T1F;&]A=#IL969T/CPO9&EV/C$L-30V#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,C0E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^
M)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT('-I>F4],T0Q/B`\
M+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%4DI!0SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`H5&%B;&5S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K
M:&]L9&5R<R<@17%U:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@<W1O8VL@;W!T:6]N(&%C=&EV:71Y
M('5N9&5R('1H92!0;&%N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR
M:6=H=#HP<'0[/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M:6YD
M96YT.C(S<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL93TS1'=I9'1H
M.C$P,"4^/'1A8FQE(&-E;&QP861D:6YG/3-$,"!C96QL<W!A8VEN9STS1#`@
M<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.W=I9'1H.B`X-BXP
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M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C@X)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z,3,N.#0E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L
M:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A
M9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[
M9F]N="US:7IE.CAP=#LG/DYU;6)E<B9N8G-P.V]F/"]F;VYT/CQB<B`O/CQF
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M"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C@T)3MB;W)D97(M
M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P="!N;VYE("-$
M.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E
M<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#MP861D:6YG.C!P=#LG/@T*"0D)
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M9V4F;F)S<#M0<FEC93PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,38E.W!A9&1I;F<Z
M,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HV-2XT,"4[<&%D9&EN9SHP<'0[
M/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$=VED=&@Z,#(N.#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ,RXX-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG
M:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N.#@E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ
M,RXX-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#$N,38E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT
M9"!V86QI9VX],T1T;W`@<W1Y;&4],T0G=VED=&@Z-C4N-#`E.V)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W
M(%)O;6%N.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY"86QA;F-E(&%T
M($1E8V5M8F5R)FYB<W`[,S$L(#(P,30@/"]F;VYT/CPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N
M.#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ,RXX-"4[8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N
M;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,BPT,C4L.38Y
M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M)W=I9'1H.C`R+C@X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*
M"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$R+C4T)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+C@S#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C`Q+C$V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)
M/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$
M=VED=&@Z-C4N-#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[)SY'<F%N=&5D(#PO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#(N.#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S
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M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C@T)3L[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG
M:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^
M/"]D:78^-"XX-PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C`Q+C$V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-
M"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C8U+C0P)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI;F4M:&5I
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M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1"=W:61T:#HQ,RXX-"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS
M1&9L;V%T.FQE9G0^/"]D:78^*#(Q,RPV,S`-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N.#@E.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^*3PO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$S+C@T)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A
M<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU+C0Y#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q
M+C$V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-
M"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z
M-C4N-#`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
M9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY%>&5R8VES960@/"]F;VYT/CPO<#X-
M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W
M:61T:#HP,BXX."4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$S+C@T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@
M.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^*#0W+#@V,@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C@X)3L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
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M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T
M9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HV-2XT,"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M:6YD
M96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US
M:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D)A;&%N8V4@870@36%R8V@@,S$L(#(P
M,34@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N.#@E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HQ,RXX-"4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HR
M<'0@9&]U8FQE(",P,#`P,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H
M=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\
M+V1I=CXR+#DU-RPV,CD-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
M;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#(N.#@E.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
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M0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A8FQE/CPO9&EV/@T*"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QP/CQF;VYT
M('-I>F4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE(&]F(&%L;&]C871I;VX@;V8@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N
M(&9O<B!A;&P@;W!T:6]N<R!A;F0@<F5S=')I8W1E9"!S=&]C:R!A=V%R9',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^(#QD:78@<W1Y
M;&4],T1M87)G:6XM;&5F=#HP<'0[;6%R9VEN+7)I9VAT.C!P=#L^#0H)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C=P=#MF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG
M/E1H92!A;&QO8V%T:6]N(&]F('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!F
M;W(@86QL(&]P=&EO;G,@86YD(')E<W1R:6-T960@<W1O8VL@87=A<F1S(&ES
M(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD<RDZ/"]F;VYT/@T*"0D\+W`^#0H)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[=&5X="UI;F1E;G0Z,C-P=#MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N
M=#X-"@D)/"]P/@T*"0D\9&EV('-T>6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@
M8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D
M97(M8V]L;&%P<V4Z8V]L;&%P<V4[=VED=&@Z(#4Y+C`P)3MM87)G:6XM;&5F
M=#HQ,3@N.'!T.R<^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1'=I9'1H.C0Y+C0X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT
M+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)
M"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z,#0N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D(&-O;'-P86X],T0U('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W
M:61T:#HT-"XW,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
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M='1O;2!S='EL93TS1'=I9'1H.C`Q+C8P)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M
M('-T>6QE/3-$=VED=&@Z-#DN-#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F
M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HP-"XR,B4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@8V]L<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C(P+C(V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S
M;VQI9"`C,#`P,#`P(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\
M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L
M9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N,C(E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A
M;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR,"XR,B4[8F]R9&5R+71O
M<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$
M.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M
M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q
M-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T
M=&]M('-T>6QE/3-$=VED=&@Z,#$N-C`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)
M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E
M>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^
M#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HT.2XT."4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#0N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
M"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HR,"XR-B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG
M:'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P
M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L
M:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#0N,C(E.W!A9&1I;F<Z,'!T
M.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HR
M,"XR,B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN
M9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ<FEG:'0[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#$N-C`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB
M<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z-#DN-#@E.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z
M,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@
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M/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
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M#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B0\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ."XY-"4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-38U)FYB<W`[#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C8P
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)
M"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M-#DN-#@E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
M9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY'96YE<F%L(&%N9"!A9&UI;FES=')A
M=&EV92`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`T+C(R)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS
M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,C`N,C8E
M.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T
M(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P
M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL
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M="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@8V]L
M<W!A;CTS1#(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C(P+C(R
M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUL969T.C%P
M="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUR:6=H=#HQ<'0@;F]N92`C1#E$.40Y(#L[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^,S`V)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N-C`E.W!A9&1I;F<Z,'!T.SX-
M"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N
M-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R
M<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*
M"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED
M=&@Z-#DN-#@E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP
M<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P
M<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N
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M(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)
M"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I
M9'1H.C`Q+C,R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D
M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D
M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@
M.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^)#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$X+CDT)3MB;W)D97(M
M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R
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M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P)3MB;W)D97(M
M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C
M1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R
M9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)#PO9F]N
M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T
M>6QE/3-$)W=I9'1H.C$X+CDT)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P
M,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T
M=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE
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M<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"3PO=&%B;&4^/"]D:78^
M#0H)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@
M3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)
M/'`^/&9O;G0@<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16UP;&]Y964@4W1O8VL@3W!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U
M;&4@;V8@=V5I9VAT960M879E<F%G92!A<W-U;7!T:6]N<R!U<V5D('1O(&1E
M=&5R;6EN92!T:&4@9F%I<B!V86QU92!O9B!S=&]C:R!O<'1I;VX@9W)A;G1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/B`\9&EV('-T
M>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUA<F=I;BUR:6=H=#HP<'0[/@T*"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*"0D\+W`^#0H)"3QD:78@
M<W1Y;&4],T1W:61T:#HQ,#`E/CQT86)L92!C96QL<&%D9&EN9STS1#`@8V5L
M;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S
M93MW:61T:#H@-S<N,#`E.VUA<F=I;BUL969T.C8Q+C)P=#LG/@T*"0D)/'1R
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M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(R
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A
M;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)
M"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!C;VQS<&%N/3-$,R!V
M86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,S0N,C8E.V)O<F1E<BUT
M;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R
M+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/E1H
M<F5E)FYB<W`[36]N=&AS)FYB<W`[16YD960\+V9O;G0^/&)R("\^/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US:7IE.CAP=#LG/DUA<F-H)FYB<W`[,S$L/"]F;VYT/CPO<#X-"@D)"0D\
M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T1W:61T:#HP
M,2XS,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G:6XZ
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA;&EG;CIC96YT97([9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)
M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^
M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C8Q+C(R
M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[
M;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C(E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D)
M)FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ-2XU,B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R
M+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N
M;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E
M;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X
M<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O
M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,34\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1"=W:61T:#HP,RXR,B4[8F]R9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ
M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z,7!T(&YO;F4@(T0Y1#E$
M.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ8V5N=&5R.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ-2XU,B4[8F]R9&5R+71O<#HQ<'0@<V]L
M:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R
M9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P
M="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,30\+V9O;G0^
M/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T
M<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$
M=VED=&@Z-C$N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT
M97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N
M-3(E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T
M.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y
M1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z
M,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG
M:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S
M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C`S+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,34N-3(E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-"@D)
M"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$)W=I9'1H.C8Q
M+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q,'!T.VQI
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M,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@
M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3MB86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS
M1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+C8F;F)S
M<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4]
M,T0G=VED=&@Z,#,N,C(E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D
M9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE
M+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF
M;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)3PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H
M.C$U+C4R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR
M:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F
M=#X\+V1I=CXR+C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#$N,S`E.V)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G
M;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I
M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)3PO
M9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)"0D)
M/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1'=I9'1H.C8Q+C(R)3MP861D:6YG
M.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P="`Q
M,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*
M"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ
M93HQ,'!T.R<^17AP96-T960@=F]L871I;&ET>3PO9F]N=#X\+W`^#0H)"0D)
M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z
M,#,N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE
M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*
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M<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#$N,S`E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY
M.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^
M)3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"3PO='(^#0H)"0D\='(^#0H)
M"0D)/'1D('9A;&EG;CTS1'1O<"!S='EL93TS1"=W:61T:#HV,2XR,B4[8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\
M<"!S='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H
M=#HQ,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE
M<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/D5X<&5C
M=&5D('1E<FT@*&EN('EE87)S*3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C(R)3MB
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
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M93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3MB86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H=#LG(&YO=W)A
M<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\+V1I=CXV+C$F
M;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,#$N,S`E.V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8[
M<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO
M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@
M<W1Y;&4],T1W:61T:#HV,2XR,B4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ
M,#8N-C<E.W1E>'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.
M97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE
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M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3L[
M9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E
M>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS
M1&9L;V%T.FQE9G0^/"]D:78^,"XP)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\
M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#,N,C(E.W!A9&1I
M;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE
M:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)3PO9F]N=#X\+W`^#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U
M+C4R)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,"XP)FYB<W`[#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N,S`E
M.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P=#ML
M:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA
M;CMF;VYT+7-I>F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M<VEZ93HQ,'!T.R<^)3PO9F]N=#X\+W`^#0H)
M"0D)/"]T9#X-"@D)"3PO='(^#0H)"3PO=&%B;&4^/"]D:78^#0H)"3QP('-T
M>6QE/3-$)VUA<F=I;CHP<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N
M.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/'`^/&9O;G0@
M<VEZ93TS1#$^(#PO9F]N=#X\+W`^#0H)/"]D:78^(#PO9&EV/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]N($5M
M<&QO>65E(%-T;V-K($]P=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F
M('=E:6=H=&5D+6%V97)A9V4@87-S=6UP=&EO;G,@=7-E9"!T;R!D971E<FUI
M;F4@=&AE(&9A:7(@=F%L=64@;V8@<W1O8VL@;W!T:6]N(&=R86YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX@/&1I=B!S='EL93TS
M1&UA<F=I;BUL969T.C!P=#MM87)G:6XM<FEG:'0Z,'!T.SX-"@D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#MT97AT+6EN9&5N=#HR,RXP-7!T.V9O;G0M9F%M
M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O
M;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R<^)FYB<W`[/"]F;VYT/@T*
M"0D\+W`^#0H)"3QD:78@<W1Y;&4],T1W:61T:#HQ,#`E/CQT86)L92!C96QL
M<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V)O<F1E<BUC
M;VQL87!S93IC;VQL87!S93MW:61T:#H@-S<N,#`E.VUA<F=I;BUL969T.C8Q
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M93TS1'=I9'1H.C`S+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N
M.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE
M.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!C;VQS<&%N/3-$,R!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z
M,S0N,C8E.V)O<F1E<BUT;W`Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6QE
M9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@
M(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N
M="US:7IE.CAP=#LG/E1H<F5E)FYB<W`[36]N=&AS)FYB<W`[16YD960\+V9O
M;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DUA<F-H)FYB<W`[,S$L/"]F
M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@
M<W1Y;&4],T1W:61T:#HP,2XS,"4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S
M='EL93TS1"=M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UA
M;&EG;CIC96YT97([9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)
M"3PO='(^#0H)"0D\='(^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL
M93TS1'=I9'1H.C8Q+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE
M/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"3QF
M;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N8G-P.SPO9F]N=#X\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$=VED=&@Z,#,N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4]
M,T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI9VXZ
M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z
M(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D
M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XU,B4[8F]R9&5R
M+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@
M(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R
M9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M
M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG
M/C(P,34\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXR,B4[8F]R9&5R+71O<#HQ<'0@
M<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO;F4@(T0Y1#E$.2`[
M8F]R9&5R+6)O='1O;3HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M<FEG:'0Z
M,7!T(&YO;F4@(T0Y1#E$.2`[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y
M;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M86QI
M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I
M>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)
M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-2XU,B4[8F]R
M9&5R+71O<#HQ<'0@<V]L:60@(S`P,#`P,"`[8F]R9&5R+6QE9G0Z,7!T(&YO
M;F4@(T0Y1#E$.2`[8F]R9&5R+6)O='1O;3HQ<'0@<V]L:60@(S`P,#`P,"`[
M8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`X<'0G/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP
M=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG
M;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP861D:6YG.C!P=#L^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MT97AT+6%L:6=N.F-E;G1E<CMF;VYT+69A;6EL>3I4:6UE<R!.97<@
M4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)
M"0D\+W1D/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$=VED=&@Z-C$N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)
M"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH
M96EG:'0Z,3`V+C8W)3MT97AT+6EN9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ
M5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0D\9F]N
M="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[)SXF;F)S<#L\+V9O;G0^/"]P
M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS
M1'=I9'1H.C`S+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P
M.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@<W1Y
M;&4],T0G=VED=&@Z,34N-3(E.V)O<F1E<BUT;W`Z,7!T('-O;&ED(",P,#`P
M,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y1#D@.V)O<F1E<BUB;W1T
M;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$
M.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I
M;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6%L:6=N.G)I9VAT.V9O
M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*
M"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D:6YG.C!P=#L^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T
M)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
M9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-3(E.V)O<F1E<BUT;W`Z
M,7!T('-O;&ED(",P,#`P,#`@.V)O<F1E<BUL969T.C%P="!N;VYE("-$.40Y
M1#D@.V)O<F1E<BUB;W1T;VTZ,7!T(&YO;F4@(T0Y1#E$.2`[8F]R9&5R+7)I
M9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP
M('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT
M+6%L:6=N.G)I9VAT.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT
M+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)
M"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C,P)3MP
M861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN
M92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[
M9F]N="US:7IE.B`Q,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D
M/@T*"0D)/"]T<CX-"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T
M>6QE/3-$)W=I9'1H.C8Q+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@
M,'!T(#!P="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z
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M1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN.C!P
M=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2
M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB<W`[/"]P/@T*"0D)
M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T
M:#HQ-2XU,B4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1CL[9F]N="UF86UI
M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ
M<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE
M9G0^/"]D:78^,2XR)FYB<W`[#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N
M/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`S+C(R)3MB86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$
M)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT+7-I>F4Z,3!P=#LG/B4\
M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O
M;2!S='EL93TS1"=W:61T:#HQ-2XU,B4[8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ
M,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I=B!S
M='EL93TS1&9L;V%T.FQE9G0^/"]D:78^,BXR)FYB<W`[#0H)"0D)/"]T9#X-
M"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C,P
M)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^#0H)
M"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W
M)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T
M)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93MF;VYT
M+7-I>F4Z,3!P=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R
M/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@<W1Y;&4],T1W:61T
M:#HV,2XR,B4[<&%D9&EN9SHP<'0[/@T*"0D)"0D\<"!S='EL93TS1"=M87)G
M:6XZ,'!T(#!P="`P<'0@,3!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.W1E>'0M
M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N
M="US:7IE.B`Q,'!T)SX-"@D)"0D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ
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M"0D)"0DF;F)S<#L\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$
M8F]T=&]M('-T>6QE/3-$)W=I9'1H.C$U+C4R)3L[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[
M)R!N;W=R87`],T1N;W=R87`^/&1I=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D
M:78^.#<N,29N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,'!T)SX-
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M)W=I9'1H.C8Q+C(R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I
M;F<Z,'!T.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0@,'!T(#!P
M="`Q,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[=&5X="UI;F1E;G0Z("TQ,'!T
M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0G
M/@T*"0D)"0D)/&9O;G0@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.V9O;G0M
M<VEZ93HQ,'!T.R<^4F5M86EN:6YG(&-O;G1R86-T=6%L('1E<FT@*&EN('EE
M87)S*2`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS
M1&)O='1O;2!S='EL93TS1"=W:61T:#HP,RXR,B4[8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1CMP861D:6YG.C!P=#LG/@T*"0D)"0D\<"!S='EL93TS1"=M
M87)G:6XZ,'!T.VQI;F4M:&5I9VAT.C$P-BXV-R4[9F]N="UF86UI;'DZ5&EM
M97,@3F5W(%)O;6%N.V9O;G0M<VEZ93H@,3)P="<^#0H)"0D)"0DF;F)S<#L\
M+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE
M/3-$)W=I9'1H.C$U+C4R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X
M="UA;&EG;CIR:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$
M9FQO870Z;&5F=#X\+V1I=CXU+C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT
M9"!V86QI9VX],T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,#,N,C(E.V)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8[<&%D9&EN9SHP<'0[)SX-"@D)"0D)/'`@
M<W1Y;&4],T0G;6%R9VEN.C!P=#ML:6YE+6AE:6=H=#HQ,#8N-C<E.V9O;G0M
M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)
M"0D))FYB<W`[/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1"=W:61T:#HQ-2XU,B4[8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1CL[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M<VEZ
M93HQ,'!T.W1E>'0M86QI9VXZ<FEG:'0[)R!N;W=R87`],T1N;W=R87`^/&1I
M=B!S='EL93TS1&9L;V%T.FQE9G0^/"]D:78^-BXW)FYB<W`[#0H)"0D)/"]T
M9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q
M+C,P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F<Z,'!T.R<^
M#0H)"0D)"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V
M+C8W)3MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)/"]T<CX-
M"@D)"3QT<CX-"@D)"0D\=&0@=F%L:6=N/3-$=&]P('-T>6QE/3-$=VED=&@Z
M-C$N,C(E.W!A9&1I;F<Z,'!T.SX-"@D)"0D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P="`P<'0@,'!T(#$P<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MT97AT+6EN
M9&5N=#H@+3$P<'0[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M
M<VEZ93H@,3!P="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[9F]N="US:7IE.C$P<'0[)SY%>'!E8W1E9"!D:79I9&5N9"!Y:65L
M9"`\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O
M='1O;2!S='EL93TS1'=I9'1H.C`S+C(R)3MP861D:6YG.C!P=#L^#0H)"0D)
M"3QP('-T>6QE/3-$)VUA<F=I;CHP<'0[;&EN92UH96EG:'0Z,3`V+C8W)3MF
M;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q,G!T)SX-
M"@D)"0D)"29N8G-P.SPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX]
M,T1B;W1T;VT@<W1Y;&4],T0G=VED=&@Z,34N-3(E.SMF;VYT+69A;6EL>3I4
M:6UE<R!.97<@4F]M86X[9F]N="US:7IE.C$P<'0[=&5X="UA;&EG;CIR:6=H
M=#LG(&YO=W)A<#TS1&YO=W)A<#X\9&EV('-T>6QE/3-$9FQO870Z;&5F=#X\
M+V1I=CXP+C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B
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M;&5F=#X\+V1I=CXP+C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI
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M/"]T<CX-"@D)/"]T86)L93X\+V1I=CX-"@D)/'`@<W1Y;&4],T0G;6%R9VEN
M.C!P=#MF;VYT+69A;6EL>3I4:6UE<R!.97<@4F]M86X[9F]N="US:7IE.B`Q
M,G!T)SX-"@D)"3QF;VYT('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93LG/B9N
M8G-P.SPO9F]N=#X-"@D)/"]P/@T*"0D\<#X\9F]N="!S:7IE/3-$,3X@/"]F
M;VYT/CPO<#X-"@D\+V1I=CX@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P139"04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^3W)G86YI>F%T:6]N(&%N9"!3=6UM87)Y(&]F(%-I9VYI9FEC86YT
M($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I;',I("A54T0@)"D\8G(^26X@
M36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E
M('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@
M,#0L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^26YI=&EA;"!0=6)L:6,@3V9F97)I;F<\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S('-O;&0@:6X@
M:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<L-C8V+#8V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4'5B;&EC(&]F9F5R:6YG('!R:6-E("AI
M;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1W)O<W,@<')O8V5E9',@9G)O;2!I;FET:6%L('!U8FQI
M8R!O9F9E<FEN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T('!R;V-E961S(&9R;VT@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#`N-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9F8S8F0T,S%?,S(V
M-5\T8S4P7S@X9&%?,38Q,30T,F0S961C#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V9F,V)D-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D,V5D
M8R]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R2$%#/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D]R9V%N:7IA=&EO;B!A;F0@4W5M;6%R>2!O
M9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A$971A:6QS(#(I
M("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!E>&-E<'0@4VAA<F4@9&%T82P@
M=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5V96YU92!296-O9VYI=&EO
M;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9O=7(@8W)I=&5R:6$@;F5E9&5D(&9O<B!#;VUP86YY('1O
M(')E8V]G;FEZ92!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XH:2G"H'!E<G-U87-I=F4@979I9&5N8V4@=&AA="!A;B!A9W)E96UE
M;G0@97AI<W1S.R`H:6DIPJ!D96QI=F5R>2!O9B!T:&4@<')O9'5C=',@86YD
M+V]R('-E<G9I8V5S(&AA<R!O8V-U<G)E9#L@*&EI:2G"H'1H92!S96QL:6YG
M('!R:6-E(&ES(&9I>&5D(&]R(&1E=&5R;6EN86)L93L@86YD("AI=BG"H&-O
M;&QE8W1A8FEL:71Y(&ES(')E87-O;F%B;'D@87-S=7)E9"X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!E
M>&-L=61E9"!F<F]M('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F('-H87)E
M<R!A='1R:6)U=&%B;&4@=&\@<VAA<F4@8F%S960@<&%Y;65N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#0U,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X+#`T,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO
M<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-RPX.#$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@V
M+#DX,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!O=&5N=&EA;&QY(&1I;'5T:79E('-E8W5R:71I97,@*&EN('-H
M87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!T:6]N<R!T;R!P=7)C:&%S92!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K(&EN8VQU9&5D(&EN('!O=&5N=&EA;&QY(&1I;'5T:79E('-E
M8W5R:71I97,@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?9F8S8F0T,S%?,S(V-5\T8S4P7S@X9&%?
M,38Q,30T,F0S961C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9F
M,V)D-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D,V5D8R]7;W)K<VAE971S
M+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5/5$%'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D%S<V5T($%C<75I<VET:6]N(&]F(%9E<FEO(%1H97)A<&5U=&EC
M<R!);F,N("A$971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC
M97!T(%-H87)E(&1A=&$L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D]C="X@,#0L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D%P<BX@,#<L(#(P,3`\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06-Q=6ES:71I;VX\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M(&ES<W5E9"!P=7)S=6%N="!T;R!T:&4@<F5D96UP=&EO;B!O9B!T:&4@97AC
M:&%N9V5A8FQE('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#@P+#<V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PU-C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L-3(R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y-87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^06-Q=6ES:71I;VX\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AC:&%N9V5A8FQE(%-H87)E<R!I<W-U960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X-"PV,#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9E<FEO(%1H
M97)A<&5U=&EC<R!);F,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!8W%U:7-I=&EO;CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&-H86YG96%B;&4@4VAA<F5S(&ES<W5E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA
M<F5S(&ES<W5A8FQE(&]N(&5X8VAA;F=E(&]F($-O;6UO;B!3=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,X+#0V,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5E;65D($5A
M<FYE9"!#;VUM;VX@4W1O8VL@665T('1O(&)E($ES<W5E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L-#8S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V
M96QO<&UE;G0@17AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`T,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!O=&5N=&EA;"!I;F-R96%S92!I;B!S:&%R97,@:7-S=6%B
M;&4@;VX@97AC:&%N9V4@;V8@17AC:&%N9V5A8FQE(%-H87)E<R!B87-E9"!O
M;B!A8VAI979E;65N="!O9B!A9&1I=&EO;F%L(&UI;&5S=&]N97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V-2PS-SD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!O=&5N=&EA;"!I
M;F-R96%S92!I;B!S:&%R97,@:7-S=6%B;&4@;VX@97AC:&%N9V4@;V8@17AC
M:&%N9V5A8FQE(%-H87)E<R!B87-E9"!O;B!A8VAI979E;65N="!O9B!C97)T
M86EN('!R96-L:6YI8V%L(&UI;&5S=&]N97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,X+#0V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&]T96YT:6%L(&EN8W)E87-E(&EN('-H
M87)E<R!I<W-U86)L92!O;B!E>&-H86YG92!O9B!%>&-H86YG96%B;&4@4VAA
M<F5S(&)A<V5D(&]N(&%C:&EE=F5M96YT(&]F(&-E<G1A:6X@8VQI;FEC86P@
M;6EL97-T;VYE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$Q
M+#4S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&]T96YT:6%L(&EN8W)E87-E(&EN('-H87)E<R!I<W-U86)L92!O
M;B!E>&-H86YG92!O9B!%>&-H86YG96%B;&4@4VAA<F5S(&)A<V5D(&]N(&%C
M:&EE=F5M96YT(&]F(&-E<G1A:6X@8V]M;65R8VEA;&EZ871I;VX@;6EL97-T
M;VYE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,34L,S@P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6
M97)I;R!4:&5R87!E=71I8W,@26YC('P@36%X:6UU;3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C<75I<VET:6]N/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I
M<W-U86)L92!O;B!E>&-H86YG92!O9B!#;VUM;VX@4W1O8VL\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@X-"PV,#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1E1!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY&86ER(%9A;'5E($UE87-U<F5M96YT<R`H1&5T86EL<RD@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!M96%S=7)E;65N=',\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A
M;G-F97(@;V8@87-S971S(&9R;VT@;&5V96P@,2!T;R!L979E;"`R/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YS9F5R(&]F(&%S
M<V5T<R!F<F]M(&QE=F5L(#(@=&\@;&5V96P@,3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5')A;G-F97(@;V8@;&EA8FEL:71I97,@9G)O
M;2!L979E;"`Q('1O(&QE=F5L(#(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1R86YS9F5R(&]F(&QI86)I;&ET:65S(&9R;VT@;&5V96P@
M,B!T;R!L979E;"`Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<R!296-U<G)I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER('9A;'5E(&UE
M87-U<F5M96YT<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@5F%L=64@365A<W5R96UE;G1S($YO;G)E8W5R<FEN
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A
M:7(@=F%L=64@;65A<W5R96UE;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BUF:6YA;F-I86P@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM9FEN86YC:6%L(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87)R>6EN9R!297!O<G1E9"!!;6]U;G0@1F%I<B!686QU92!$:7-C;&]S=7)E
M('P@1F%I<B!686QU92!-96%S=7)E;65N=',@4F5C=7)R:6YG('P@1F%I<B!6
M86QU92!);G!U=',@3&5V96P@,3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@;65A<W5R96UE;G1S/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@97%U
M:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S4L
M,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,S4L,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?9F8S8F0T,S%?,S(V-5\T8S4P7S@X9&%?,38Q,30T
M,F0S961C#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V9F,V)D-#,Q
M7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D,V5D8R]7;W)K<VAE971S+U-H965T
M,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5+,4%+/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D%C8W)U960@17AP96YS97,L($QO;F<M5&5R;2!$96)T+"!#;VUM:71M96YT
M<R!A;F0@0V]N=&EN9V5N8VEE<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;"X@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&%C8W)U960@97AP96YS97,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C
M<G5E9"!P87ER;VQL(&%N9"!O=&AE<B!E;7!L;WEE92!B96YE9FET<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-C(L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-C(L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q+#(S-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%C8W)U960@8VQI;FEC86P@=')I86P@8V]S=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y."PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.3@L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$U
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C<G5E9"!O=&AE<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-S8W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<V-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV,3$L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,C<L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX
M,C<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPR-C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D('1O('-E;FEO
M<B!E>&5C=71I=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M.2PY-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^3&]N9RUT97)M(&1E8G0\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO;F<M=&5R;2!D96)T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DQE<W,@9&5B="!D:7-C;W5N="P@;F5T(&]F(&-U
M<G)E;G0@<&]R=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,38W+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q-C<L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,W,2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;VYG+71E<FT@9&5B="P@;F5T
M(&]F(&1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M.2PX,S,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3DL.#,S+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$Y+#8R.2PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@8W5R<F5N="!P
M;W)T:6]N(&]F(&QO;F<M=&5R;2!D96)T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S+#0Q.2PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,RPT,3DL,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-30V+#`P,"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M;VYG+71E<FT@9&5B="P@;F5T(&]F(&-U<G)E;G0@<&]T:6]N/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPT,30L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L-#$T+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X
M+#`X,RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-U<G)E;G0@<&]R=&EO;B!O9B!D96)T(&1I<V-O=6YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-C,L,#`P*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V,RPP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0W5R<F5N="!P;W)T:6]N(&]F(&QO;F<M=&5R;2!D96)T+"!N970\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C4V+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C4V+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-30V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AT96YD960@=&5R;2!O9B!L96%S93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,34@;6]N=&AS/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H+6-O;&QA=&5R
M86QI>F5D(&ER<F5V;V-A8FQE('-T86YD8GD@;&5T=&5R(&]F(&-R961I=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D]P97)A=&EN9R!L96%S92!M96UB97(\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY,;VYG+71E<FT@9&5B=#PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=71U<F4@;6EN:6UU
M;2!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=6)L96%S92!O<&5R871I;F<@;&5A<V4@;65M
M8F5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M3&]N9RUT97)M(&1E8G0\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^1G5T=7)E(&UI;FEM=6T@<&%Y;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQO
M;F<M=&5R;2!D96)T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G1S('1O('!U<F-H87-E('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@:7-S=65D(&]N(&-O;G9E<G-I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,V+#`W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@*&EN(&1O
M;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`W+C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`W+C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!\(%=A<G)A;G1S($5X<&ER871I
M;VX@4&5R:6]D($IA;G5A<GDR,#$Y(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3&]N9RUT97)M(&1E8G0\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N
M=',@=&\@<'5R8VAA<V4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I<W-U960@
M;VX@8V]N=F5R<VEO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PS,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=A<G)A;G1S('P@5V%R<F%N=',@17AP:7)A=&EO;B!097)I;V0@
M075G=7-T,C`R,2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DQO;F<M=&5R;2!D96)T/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S('1O('!U<F-H
M87-E('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:7-S=65D(&]N(&-O;G9E<G-I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#<V.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&5R
M;2!!($QO86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY,;VYG+71E<FT@9&5B=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W1I=F4@:6YT97)E<W0@<F%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`N,S`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y497)M($(@3&]A
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQO
M;F<M=&5R;2!D96)T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5F9F5C=&EV92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1E<FT@0B!,;V%N('P@5V%R
M<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY,;VYG+71E<FT@9&5B=#PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92`H:6X@9&]L;&%R<R!P97(@
M<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N,#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#0N,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A:7(@=F%L=65S(&]F('=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M96YD
M960@06YD(%)E<W1A=&5D($QO86X@06YD(%-E8W5R:71Y($%G<F5E;65N="!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/DQO;F<M=&5R;2!D96)T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G0@9F5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@:6YT97)E<W0@
M97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06UE;F1E9"!!;F0@4F5S=&%T960@3&]A;B!!;F0@4V5C=7)I='D@06=R
M965M96YT(%M-96UB97)=('P@36%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQO;F<M=&5R;2!D96)T/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R:6YC:7!A;"!A
M;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%M96YD960@06YD(%)E<W1A=&5D($QO86X@06YD(%-E8W5R:71Y($%G
M<F5E;65N="!;365M8F5R72!\(%-E8W5R960@1&5B="!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQO;F<M=&5R
M;2!D96)T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!M;VYT:&QY('!A>6UE;G0@;V8@:6YT97)E<W0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$R(&UO;G1H<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F(&5Q=6%L(&UO;G1H;'D@:6YS=&%L;&UE;G1S('1O(')E<&%Y('!R:6YC
M:7!A;"!A;F0@86-C<G5E9"!I;G1E<F5S=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,S`@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N9&5D($%N9"!297-T871E9"!,
M;V%N($%N9"!396-U<FET>2!!9W)E96UE;G0@6TUE;6)E<ET@?"!497)M($$@
M3&]A;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DQO;F<M=&5R;2!D96)T/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(')A=&4@*&%S
M(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<N
M-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV+CDT)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F5T(%!R;V-E961S(&%F=&5R(')E<&%Y;65N="!O
M9B!L;V%N<R!O=71S=&%N9&EN9R!A;F0@=')A;G-A8W1I;VX@9F5E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PX,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N9&5D
M($%N9"!297-T871E9"!,;V%N($%N9"!396-U<FET>2!!9W)E96UE;G0@6TUE
M;6)E<ET@?"!497)M($(@3&]A;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DQO;F<M=&5R;2!D96)T/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(')A=&4@*&%S
M(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<N
M,#<E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&:6YA;"!P87EM96YT(&9E93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9I;F%L('!A>6UE;G0@9F5E("AA;6]U;G1S(&EN
M(&1O;&QA<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@4')O8V5E9',@869T97(@<F5P87EM96YT(&]F(&QO86YS(&]U
M='-T86YD:6YG(&%N9"!T<F%N<V%C=&EO;B!F965S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!T;R!P=7)C
M:&%S92!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&ES<W5E9"!O;B!C;VYV97)S
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY."PP,SD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M
M96YD960@06YD(%)E<W1A=&5D($QO86X@06YD(%-E8W5R:71Y($%G<F5E;65N
M="!;365M8F5R72!\(%1E<FT@0B!,;V%N('P@36%X:6UU;3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQO;F<M=&5R;2!D96)T
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M:6YC:7!A;"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%M96YD960@06YD(%)E<W1A=&5D($QO86X@06YD(%-E
M8W5R:71Y($%G<F5E;65N="!;365M8F5R72!\(%1E<FT@0B!,;V%N(%1R86YC
M:"`Q(%M-96UB97)=('P@36EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DQO;F<M=&5R;2!D96)T/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R:6YC:7!A;"!A;6]U
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`Q,"PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F9C-B
M9#0S,5\S,C8U7S1C-3!?.#AD85\Q-C$Q-#0R9#-E9&,-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO9F8S8F0T,S%?,S(V-5\T8S4P7S@X9&%?,38Q
M,30T,F0S961C+U=O<FMS:&5E=',O4VAE970R,"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-0
M0D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I
M='D@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E=E:6=H=&5D+4%V97)A9V4@4')I
M8V4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&]T86P@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C`X+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#<Q+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@06YD($1E=F5L;W!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^5V5I9VAT960M079E<F%G92!0<FEC93PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S`T+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@
M06YD($%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^5V5I9VAT960M079E<F%G92!0<FEC93PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S`T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,P-BPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5M<&QO>65E($%N9"!.
M;VX@16UP;&]Y964@4W1O8VL@3W!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^3G5M8F5R(&]F($]P=&EO;G,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A
M="!T:&4@8F5G:6YN:6YG(&]F('1H92!P97)I;V0@*&EN('-H87)E<RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#(U+#DV.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)A;G1E
M9"`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-SDS+#$U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%N8V5L;&5D("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@R,3,L-C,P*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V5D("AI;B!S:&%R
M97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-RPX-C(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M86QA;F-E(&%T('1H92!E;F0@;V8@=&AE('!E<FEO9"`H:6X@<VAA<F5S*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-3<L-C(Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E=E:6=H=&5D+4%V97)A9V4@4')I8V4\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!T:&4@8F5G:6YN
M:6YG(&]F('1H92!P97)I;V0@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C@S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D("AI
M;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-"XX-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V%N8V5L;&5D("AI;B!D;VQL87)S('!E<B!S:&%R
M92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2XT.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE
M<F-I<V5D("AI;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,2XU-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!T:&4@96YD(&]F
M('1H92!P97)I;V0@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+C`S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@8V]M
M<&5N<V%T:6]N(&-O<W0@<F5L871E9"!T;R!O=71S=&%N9&EN9R!O<'1I;VYS
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#DP,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M<&5C=&5D(')E8V]G;FET:6]N('!E<FEO9"!O9B!U;G)E8V]G;FEZ960@8V]M
M<&5N<V%T:6]N(&-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5M<&QO>65E($%N9"!.;VX@16UP;&]Y964@4W1O8VL@3W!T
M:6]N('P@5F5S=&EN9R!"87-E9"!/;B!097)F;W)M86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYU;6)E<B!O9B!/<'1I
M;VYS/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)A;&%N8V4@870@=&AE(&5N9"!O9B!T:&4@<&5R:6]D("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C(L-S@P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E=E:6=H=&5D+4%V97)A9V4@4')I8V4\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E(&=R86YT(&1A=&4@
M9F%I<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y%;7!L;WEE92!3=&]C:R!/<'1I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG:'1E9"UA=F5R86=E(&%S
M<W5M<'1I;VYS('1O(&1E=&5R;6EN92!F86ER('9A;'5E(&]F('-T;V-K(&]P
M=&EO;G,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4@*&%S(&$@<&5R8V5N="D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N-C`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BXP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C
M=&5D('9O;&%T:6QI='D@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@R+C4P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDT+C4P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R;2`H
M:6X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XV('EE
M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^-B!Y96%R<R`Q(&UO;G1H(#8@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@9&EV:61E;F0@
M>6EE;&0@*&%S(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYO;B!%;7!L;WEE92!3=&]C:R!/<'1I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY796EG
M:'1E9"UA=F5R86=E(&%S<W5M<'1I;VYS('1O(&1E=&5R;6EN92!F86ER('9A
M;'5E(&]F('-T;V-K(&]P=&EO;G,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4@*&%S
M(&$@<&5R8V5N="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N
M,C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BXR,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D@*&%S(&$@<&5R8V5N="D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@W+C$P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDT+C4P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5M86EN:6YG(&-O;G1R86-T=6%L('1E<FT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XV('EE87)S(#@@;6]N=&AS(#$R(&1A>7,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X<&5C=&5D(&1I=FED96YD('EI96QD("AA<R!A('!E<F-E;G0I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14-1044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',@*$1E=&%I;',I
M("A54T0@)"D\8G(^26X@36EL;&EO;G,L(&5X8V5P="!3:&%R92!D871A+"!U
M;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA>2`P-"P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L
M-C,W+#(Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(P+#4V.2PS.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@179E;G0@?"!#;VQL86)O
M<F%T:6]N(&%N9"!L:6-E;G-E(&%G<F5E;65N="!T97)M<R!\($IU;F\@5&AE
M<F%P975T:6-S+"!);F,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<SPO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<&9R;VYT('!A>6UE;G0@<F5C
M96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VL@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E(&ES<W5E('!R:6-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H('1E<FT\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H('1E
M<FT@97AT96YS:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!;6]U;G0@<F5C96EV86)L92!F;W(@<')O9'5C="!D979E;&]P
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?9F8S8F0T,S%?
M,S(V-5\T8S4P7S@X9&%?,38Q,30T,F0S961C#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V9F,V)D-#,Q7S,R-C5?-&,U,%\X.&1A7S$V,3$T-#)D
M,V5D8R]7;W)K<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\]
M,T0B=7)N.G-C:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-
M"B`\;SI-86EN1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"CPO>&UL/@T*
M+2TM+2TM/5].97AT4&%R=%]F9C-B9#0S,5\S,C8U7S1C-3!?.#AD85\Q-C$Q
,-#0R9#-E9&,M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-15-035555-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-15-035555-xbrl.zip
M4$L#!!0````(`,>`IT9C^[GY068``.`&!0`1`!P`9F%T92TR,#$U,#,S,2YX
M;6Q55`D``[;%2U6VQ4M5=7@+``$$)0X```0Y`0``[#W[=^*XU3]WS^G_H+(S
M/;/G`,&\DC"9Z2&O;S.=5Y/L;OM3CK`%J&-L5K*3T+_^NU?R$TP2`@1#W.VV
MP9:NI/N^U]+5T3_N1S:Y94)RU_E0,JJU$F&.Z5K<&7PH^;)"I<EYZ1\?__K3
MT=\J%7(B&/6817H3\H4)P6V;G+AB[`KJ`0!2J00-_WU\^9E8KNF/F.,1,^AU
MQ[UAU.]8<&O`"&E5C7JU`2/'O8^IA-8`3X&I5XWH33B^ZW1(:V]_KUXS6N2P
MTS(Z]7W2_:+;W?>$36!=COQ0&GK>N+.W=W=W5\7'55<,H%.ML<<=Z5''9"7=
MLF-SY\<#S?%U#Z85-K^?:7_74*V-P\/#/?4V:@J`+!ZU3<)M[^F785.+3;63
MS*P.W-L]>(%K;59J1J5A)"'S!=;8!]REFN,#;\@$'3/?XZ:LFNY(X;36B$?A
MTFW6C?V'QM$MP@[`-@-*QU&'/I4]U3AXD;42R;.0"="-O7]_^7QE#MF(5J+U
M`)4).4(D=Z1Z=<GZ1"&]XTW&L$;)1V,;UZV>#07K?RCA8BOAXJKWTBJ1/0T(
M&<MU/';OD2MF(B<K1H(W9O"86Q]*77GSK7]CU&Z:-P"EH2<!;8##N3<)?L%O
M;N&3/F>"J,FE41Y2].3BGZ6/-5A?L]%L&.VCO;A;"'@O!?EHS`1WK<0X"AO>
M1YQ,Q:A5:LVCO?!9""'1YV@O6,R\E35N&@:NK'43T.FF>T>%=0T([=YS>8/X
MNSD#O+H3QKJ.]=5UPE]7GFO^^#9&S'UAHQX3$8C?F?1`E\0`@@=*Q+\YWYGH
MNV*$1-4=UXY5`"79`-52]``>:3'LL/NQS4WNZ;D0BT,[K1F#]712*"E]Q"5U
MGHB3H[W,49XUC01:@TD\@M?'!C_:2V-E`>9K56H-$.7EF,^H!]S77`'WO6(F
M6H*.S8I17X*.I[YV`FZ,FX"0UVZD4^91-7RZ*Z0,'[\8_8!2PCL%!OH8&M4:
M4#!^&C5DCI5HI@4V?/8"A%;BNVLR^Y*"F@-"MY*$GN<E%!*]2D*WGD;HU@8(
M74CT%A-Z_Z91BW1W_".D]"GK>1?@!0@5O\?D[L)/BUG@HUR"NXF1^&>7.O`3
MPB9?P%J[`\$8]ID*`SZ[SL!C8H2`TQQT#4^["&4[F&86,P'G+(J:548#6=@-
MIC6%WG5;I?U*H_8$JZ2;/8^'YP6KGQF$/ETAJ#-0:$ZSV97?L[&!:K4=K#9O
M00%E,U:4]R!O4:)]`^`4H]K=H5K6DO)+MB<Z!JLR%WFG[8LI_RUP)>9)]#GE
MXG=J^^QX\@58W!=JV>>"_>DSQYRD8H2H;:*EO$24"9"0[>"))ZPW#B*>LN#\
M:H.YF;J"YOFE^9)9O=5_&L@[<?.9G'T90UY0=3?C_GE27,3Y&W?UMB/.7[43
ML?&4TW'!BNMDQ>,78<4HDY1/5BP8:^=)O(BVN1;4`6H;4STO,5.4"I&^<(>/
M_%'!1&O53FERK'+TB*)Q$)@B:2$N3S?.#XD)O2_$)"=&?%GQ2)*R$(^"V=?`
M[`7;%=%[GK7MRT3O*V'%C.^X"]OS*\0^KN'L3Q^F?N*.QJZ#J?&4VON#XI?4
M+8FG-F-.'T1DK.M2F,Q[>FB6P7:075X'X1+?RJ(_?P4<4F$.)Y_9+;.S/P]>
M.&/?DZK!=,2<_?GMF$J>YH83P-R$.X-+-G8%J/KNR/4=+^I]RJ5IN]C]2?!?
MQ>?,!TB4\45SED:K5&R/D#F>SX)T7O\<\_DE^`6^_A<27DAX(>&[L=>CF:<#
MKLV5ZJZ\G=U=Y;&[.3L[CGW)'29EUP1G4W+LD3R3"R-=)\Z!7SCF;F6DYBP_
M.CL[;_W;G(#*T3Z3I>WM5]<16VMRGVDW9M><7^?PB5H(Y,H=L2CP_>R:--)$
MD:9ADJ%?T@4.1+_#':L8^7X,&-Z2,P`/+#.F^1/6N0,:886,\7_,`0UM`[ZZ
MUH@[7'H(^I;M'FL\::4[R!QS3I(76B,_6B-7)08*K9$OK9'CL@1%\:*B>%$N
M3%U+EP]33!O]'>4S,:W%Q!@F,OE*1PG6_>0[CT7HF98A<1(52YP):GK7;H#@
M<U=\P^IO\GB2EI,3U[9I+RCJ!_`^<Q,U2/1M'+]FRNGON7Y/JMC&.[MEB8.\
M<]YOA\!DT2-@V;D$66G*8!4T#2:\`%%7^GDZFR]BLY7)&.N6^):JEO>HQ.MF
M2TI\(\M,;3P#.8V1QJ;=_7QA)%>NS)8G7U]!XC,B9/.FC;2K(2&;-_OZ[R63
M\'FG[[J2ZTO1'>NA5FKMQ^BNF^VO.5`M"/]RA,^5YMZ90XB;.^^7@[SDLXB[
M1=NE<U(_[#76P(O"8^S,+'RW'3RS15OLHTAS&L<[4`TO5E4UT%"XG02Y.3]%
MZE,HT67J&X^A)*IFOQ;MK80XV%0MS^['7+?^KF#'8CZOQ2?J^%1,`-3A[IYH
M4(+\$(X"67\RDG;MP$/^G)(EV;KK#WSIU6OUZ:VX!5?/Q5'!U"_E:1?%87;`
M#7O=P>(.Z=%"9ZUQQW7>B9[+G-]+[FXN/MKGG$.+C_8[\M$^O3V]M;H+[C:>
M%5G?J<P\+6TEQ]%:\$\.:8;_7<]AB8TO](4LZ]\JE=\</G/CIH_/$$OX,L'/
M%K^%E<2#8[NO$/0`*MV4DAOI(S0?@TM).[]=G1[MA0]C593=7X$]98X[XLX\
MP*CD>$<.J6!R'N19$$=[B17H1ED+CC.VZ>'&\&=ZL/DPZC,PYN)B/I`Y\\A:
M=A((4/7:']MLFJSP_,Q6)FOZC<6X#E;5^2B;#DC`)I=X:>MCLM*GM@3$S`")
M89_X0N!#+DUJ_P<L\YEFT86&J82J["&(\9BGP<W'NHG.'IW#,[G0H/\*QIL+
M;=Z`.*?%A\/_S1HP@C8[G)[+<Q":U!ES(<X.B)[(0N,8M<J_TB,@B!CPF5*%
M)PP],OO"L=C]/]EDH1&2NG8NQ)D!W='(==0NZRLE4=]\#TT)WKN=&GW*"!*4
M-/5""RFQF,E'(`,?2A=?SQ&M[8-&H]E*3>6!L6;FI5E;G[.']QCB+\A&_T'U
M\!C$Z7'/N<W$"9!\X(K%T-\U36:C%F<645"2@Z?`3H]YR0;JC(3C892PT*#G
MW>LS<OWKV67W^]EOUQ<G5^3BZTERX#1L/;).RYFF\)EU8G.'@VQ="T[M$U=Z
M,L!3!O$3SMT4^>M)^E?`=#2-%K#CT=Z3AEIN5C$V'IW4X<$RDPJ.KTA,*EX'
M245D:>ZI4[(0%&$\!9S%'),S>0W3/+:!UQ<BZ-]M[SW8Y[\/O/<D^)M(;V*#
MCS6B8L"=BLWZ7J<V]MX'OP4?#/6#$O;ZZT]_^0MV'*>[80,2_EMO5EO0'B=5
MX0ZZ91U2"1[V8;*5/AUQ>]*YAH!,DJ_LCERZ(^KH=Y+_CW6(`7"B\=2`^#(<
MT^)R;--)AW`'\,MTQSNF9MIS;2L!R8AFWJPBF#U\A3^7A3D]VP=7ED1%`K<1
MKL?40BVEL&@<Q*C4,U_5O!NK!A@C-^!A$C)QF2`;5Y"/"3)RF218F8!.)BEF
M3DTH9+&]\4LR7'T1AM-8I*/Q>Z<GQ^^?-_T-RL(TN=:\@`W@-LD+C?9:D3V%
MV]"4T`#'+,`QZFD)QI*X?>(-&>F[MNW>H1_TCCOPQ/4ER(7\I;/=Q$A8E#MN
M>4/`3.UMI'4\VH.8"3P9.U!Y'TJUDOHMQ]0,?P?]>ZZPF*B8F!L<2]8)_WBO
M`9/]@RK`3BG3=K-ZD#15:DJ>B'[JWQ:YI38?.#B$Y[FC4GK&;:-ZT'R;5,H)
M@/,)@`BK#+7D&;5VM;W_]GE$69(N:9H$-/*LQ7!0:U2-@]7@0(FB&JMC,LQ8
M/Q\KZ04_88W`,L!8L$CPUAY<K]&JUMMOWP<LY[GCC@&&Q7$=1GX^/<1_2/A2
M,=K<MQJZ>B]=FUODYYKZ3]1`.U2S_3>*ZH,%^>\!*Q/)WQ?\.!"3K&&49]BT
M)\C>DCY(-!PZN(4<%'*0.SDX9:;Z/O2BHM!<@R@8U?H6BX+^+5*_G^D9]*CY
M8R!<W['0.7%%A_Q\<G)V=GZ^*'*B",9X$%-13/-HH#G7DWVF,QL&"F,Z$>!]
MJ<C-Q4^XA`45%$B/.:S//;DVW;LR;*_60UM8!S\F7(W:C-[-UIQ/5KR9[^?I
MW7R@>15,^V;UK&@TJH>S9C$?Y'DB;HTH+-:*5PWTO@3#W`DZ_E#2_Q]%:HDX
MKF^[U.O@LN+L49!$;+7KL2`4HEZ(>B'JNRKJ1KG>:*Y&V+4CF0\NS(5#N:MN
MHQE\_B(>?O^"*%2NT4_<#JYY;D2^2=%O'AZLTLH7A%H;H8S6*C7T=A"J".R7
MT-`JF"]"]]U)G^;3>=QO[Q=Q8L%7*^>KMF$4(4D1DBQ@\%C6EI?7&X:\;*8*
MYDLLU\<]("_Y.;#(2"U-ALUFG@[J*W4?"A$M1+00T56*:+U<;]=>?>I!_\0M
MCM/X"=_.W:JZ_&:(QR1AV_?5GOIX09C:.NL-!6-D!(V&DJCR+T1M-B,-HTQP
M'UA9-<-"'=29$"XE>G[&8?FPU2;Z9!_NPN4>;LK%0T,P#SQ)X;G$9,*C'!XP
MA[L"O$5F^GBYB`RW[89`:;"AUV+ZQ`7I0W-*U.D?^*5;<X'3:1+J.#ZU2<]U
M?'`]JZ1KVT0P6QWFH>J.3TGNF&#1IF$%3!*;TQZWN<=A?*JF$&XF"I?:K))S
MW_.AZ_2,]6@A>,`('P'^RFH+QXAY0]=">&,Z48<5*0[NJ16"UF($*&(*EE@*
M.7:I4%U.N6"FYXIIE,"R))&^.80Q]/K8+070>AYX\\4(%BSU4(^M,TW/ZDMS
MZZN2+'54`^L8S=^S/A9`/`$S0=JH5M26BGIJ*SMW@+M#5NHS147IFEPQ^!WW
MAL3U!;&C<2S6\UX#3=='PL=.>*2/WZQY^J]46I"+E3KU'="RH/?_!]R.BA,U
M+NE1&V_V"?2=#,Y[R.*TQW-/>^S/GO8XJ#97<=JC7BM.>]17=.)E6W:YMYK%
M+O>%@N@GG?:8YLQ5[FJ?`;XL0-R&'_'8VHZ/%()5"-9*CH^L4[9`%-9W:&2+
M!6#!#VK`\-G>Q>O96))VC]>F4;?]2^UFDOO%3O&5)OV;FA7S2)Z-?@RHE6'I
MA8P7,E[(>"'C#SN&^6"^S3N(SW4#ZWEU`YF4.D$:)D3+Q&&J^(T9%,@)/I7E
M.N@N0NR<;31X9[3WEV>-;3!FOSQ+,`HV>AH;-?:-Y8W7[K%1D>]8+M\1&;G0
MZA4)D/4JK"4]\5TX`V$<E@\:C8*C"HY:(4>UZX=%<%<$=P\$=U-A'!H]^V5R
M_]O!/-NHCC;KDI>;QE)*IXCM"D[2.8)RJ]DNPKLBO%M;>/=2.<QM]Z`V\PGL
M&8>G\H'HU_(1;*4$VFBDU`:GI5G(>2'GA9SOM)P?E&L'2^78BHS(*C(B>743
M3XIDR#KLPP/Z8SV;;0HCD&$$7IP*F]3T*\I"%6)9B&4AEJNL`;22E-YVB&61
MIEN!_Y7:?%@DZ'9GWU@^(\1W1GNM>S"VP>SM_);%]4K[#$N^).V4ROCY'D^!
MKJ/`0)'^>-7I#_7AK,B!;$>.O(BV<I$)WVP6I-Y:*MPJ!+,0S$(PBSS(YLNK
M/FN:CW%[[#)O9Q&[;P[YY-N3>`6-FBXGFJZ<JLJL,`L@>2ZA#NF.=+55+'IW
MR:2GZCM^=N$-/KEBIB^X-R'=@6!,U8)\A]#BT.+D?=SKJAL_/WW_BRX3><5M
M;H(#^3NU;38AQ]3Y,0L#GZ;ZEHDJ%@=S!=;'(GR]"9%^#T9R/`Z0)JH@:;I:
M:0S@\+TJ5\FP2"J[-VT?)2,J!`M+9S`7T\,"KF/ACN'YI$JN`5)R+80B:J3"
M@]#/I1KN`>R4B:4KP*J*IY^HXU.1($D+*5([+.-[JA%?QI4AL![S[AASTA5I
MX;DJU)J)-#6/:.@4^JKDNR^DC[5:@<S>U,K*,5"*W2UL-*(_&+CXU)%AEZC8
M+JX66D+3`8#`RJ&.R<>`/%V)%I?JC['7FWJMFJ@9#4QO0^R`M!Q!)\E4L=EW
M_)>X"25OC*P^1,49.)TRZ?N:0W4M6]-V)5(3$3V+$U4?LZM(E.9%1.4[GAP:
MV.F_P`3A:JDYY.Q6\SA61"5RS$S>Y\D[[V!R@$:T'*K4KRI>[,YGP>]#*EFB
M'MGTY7DPS'?A_LI&%#@"M#<&6O@R7#I2P@/^AV$"_&;CBFNNB2A4)G=#;@Z#
M^L.WE-NJ:B.0BMLD\^YR7=/X':.JU.\L1H]G,5HEH'%F@=6;F5H'Q4WSF27H
M'7'UC/L^"/&<12'1L?QR8OSGUI<M[$6&O4!UEY"62-<D\`TZ0=6A!FK,J#+-
M,P>JVR??83-ORJ@T082P<+4=JC@JE/9%=8KR3$F?WROCHXII"Q1I$(IV];#Y
M5O78K];VWZ8A5<E%"*''3-"B6*58\3>(@4GE$*=+=2EQ&+=')9?0$A#NA,7&
M^UQ`;XNJTL?(\[IU4,\U;*6?`5`M3)I?'2O2/6%?E%3BFFK_L*7-2%RF'*;^
MI\]%0L7&4PNK*V/=\G!)K@,OK+@NNIXJ6`;[-BJ/GI[FW#F50Y(*1OL`?GHV
M@L$$%(B$0G>L>"Y:`N,U*C7#P582@(+:,%@'=\"TV#:N12*^4<TC"73CBL9C
M4$Y7%U:7YI!9OLV>@JV92M2XR/UJ"]A"30/7_J96/<@P.X%[$-H/;:RPPK5:
M4_!V6@:2_!^HJ9C]M$2@R4=T2SW_K%K9B8+H8.LCE`95N(E[RW2=;=3U4=5U
MK?.UOV%BP(+$2*3=IFMYOX9ZVYM3D-VIRO_H*IK@+($`"G<TPSO*V/HR*5N:
MGJ[OH=NJA%2+5.1$QEZU$E47F4B78!?0DYKZ%@)DJ/!J@4QO#J0W<'&INOV`
M>TE9`>%HSIK7,>7*J4Y:Z0`X.H95P*KW\(I!ORBUHM8:*K)%ESRUSK)&XYN#
M#'E.*PN+H4@`[5#%!:YA:B89(]ZAVZV_(@-7P>1\+H?:;<?)@'BAA@CN,)C1
M#8!0R@7&XCX+''QL@U=18%5PK8`1AL!U@Z$JI'.-TOD]FS6/$\*8[5BB_X"7
M(#A,LYT*4I.&-&$7XL['\9^:]S-N(XF#*@<M(`LO)*']/L3`*GQ$AW=28?=,
MF%PJI^6."I`!3P5=8U^8&#*DPRV`<GA0KC4.$_><S`TY4I>?S$1'?P2#385&
M*(LDF)3R!DRM.)K5V@&!Z%@/K.4O!(%&""PU&JCH`I-ZK6[H5O'L$S(3S#N"
M@.*8%&,7W+0YVLJ7H;MS;%/S1^7*'+HVHF*L:(A3Q@8CUV+:B4'8D1&-Q3XJ
MY1]8]B3/*-]'DKCN/TSH8<.=<B$"*/%,6;\?.`T1%'U)2Z$8UAW79!J)3(H(
M)99/<`4U=X)&:>C(Q*A7:S.1R7E@-Q:\S2AB5&#^=F9X'\O3#$=.>0;!&J:F
MOYRK6-QD]1C3_9&EQ1OM<FV_N;#65G&Q+NZ-N@L4#AVP+/6\7ZT;L7H.K1#/
MMFY3KI!@(TR%)AVUK%N:RAI`J]RHM11/-6KE_?8A-L1KH6+K-:2W"$,9!1WC
MJ0`)9Q.D#A#>H8+1]0>^])2UF!*@5Z`8U\>2C]T?=$Y-O)!K0CXS3$L6J;2U
MF!P;D2NC;PTN^'XF4VQOTYX+LN&"*.!=.4Q[KE1+/;@S&"9-W4@7YD`=UZF8
M&&3H1"Y^L=#99S6:\FBUW`8RB^K"TW9GVE=1/;3[`\Y./^0)M'AQ!MIHA<8+
M+)GK#X;DBHV]T,DS]K63IT%QO"$NRJ0G@(`2%`.FKQ0+%!RH*4I0\<#D5,RD
M/&5,44$+Z<FYOKD:ZJ$/62KS5YGZ9L2%8+>NJ7"FU%P/Z>-Y&M$F].9>E#R/
M/F6`$39(%"QT,[5B7U_0!ZX%'_FC,/<C$\'N%(U41NA-O=J*(!<"N#H!O$A9
MF=:#C")Q8P!21%U4&+/KM'AJ'H]:8V20R@]@4.',DMFQ@LA(V;YIL?DMXH\0
M<%E_XYG+45E663-3K7JP$#.%7]@U<@&!'TJ&PAZ9OZ<C^46>)'\<[?5!T#K!
M%>QG04(22VN@UXD7U)U$B2C9=:P3@`Y88H[)F;P&1CFV0>M]_.M/A!QI2$K^
M+B&4Y+<HL.!*0XAO^:9WRL`W<,?*;0'=@%QVR?H?2EUY\ZU_T[IIWB!.;GQ9
M&5`ZOCE1-!)C*KS)5SIBW7LN;W"(FT^^XP)-!1TSW^.FO'#,+XHX4=]+)AEB
M&B:<&+6+/LY`^4VX#$%-[]K]S@1PP0BF^0WUESR>7$_&B<%.4!4IC@+Z`+S/
M8`8`19$'AFB24\-?^3W)_O3A[=DM-@D!SGFO>Y=`Z7"-D=_@#Z->@K#'Y"-J
MRP^E2JOTL:7WP-1"DCT%T4G"_'][W]K;-I(L^OT"]S_P9F:`#"!K]9:<G`G@
M./8<GY/$1NR9Q7X*:+)E<X8BM7S8T?[Z6U7=))L4)9$2)5%2G\&>6!+975U=
M75WO0C_ZA?'OT/+IJ,2;E]J,3R%?Z?<V_$?[\>!^[W[O\@]O/HAPF)B.I-`8
MN?T;GFCQF8?JI*)95L72=H"_9OB0=B:^W)_<U6G.G:]-QLQ"NW1E,BHDW,:X
MEH*&M/8@066U[;FZ50\H&>F1.C6)/)%;_LD\R]7DHPYRA;'FC5LI=9W4K7P+
M"B=HJW:RA"'=7ZWT_:P;PN<WOVW)F[A_VEO9EDE/9V*&T,J77!8@\H'B;(AI
MGIEN_AM$A$@8T&Z#0'_5&]JM$^@X,4@'3RBRPS6/Q1#1^D=F3L,.?>[#MCD/
M-Q=%$"T07BD2B2\S0Z,<$9("X"?DZQ&'ALG.6]28@92`%Y=DC<2D<(TVH4O=
MT4U]WMQ[]0-D<+BY2`"^IW?2EE_RG)"M',0.$5?%Y)=(9FIW1XW>H%/>D.&8
M#2T398.1C*8>(2%NS0U2`<@'H"JAV4"/8Q$R,3G1XU/`C8BD:6C27S`Y&DF$
M'QO=L@Y]BL-V(O]2:HTHS/'PFM&HUQBT^F47JFQKV_7#HO4>]B.T@Z5;<G-W
MBWKMK1&XJ8@D'I#4;6B]$1JONJ7IF!\0;EV30S/<T(,3+G@*#H?3H/DO%7@'
MW(9-IK(?.>=8<F6#:P).2`H#FMA*`BI@#*?"NQ&1^9*)N6\DC5U$Y+..7`Y4
M9`KG($O%NFR`M"Z^-'AGW4W@<27QTA9P!D/(YV'JU)^"77%_Y_-3<B16^3W@
M*,;Q0<7X>XIWIXU41(YKGF;0\AP1],P/34.<`5P)R@`+_)#<IL4C/+BJ2&/(
M4H?PRZ2C%2:Z\!)GUS#H-[K#\I[=95B437"YQT%J7?XN'8U+*&U'T$11$"5W
M*1UEVVFW&_WNJ."8.0-&D;ORH.TVH&W4*CIH+!=$\6<RN.3'B$-()OH/LK\D
M#K?-V'$<F)@C%W(Y3Y8++3^2013+VJI(P3<["IF<"_V.Z8,+Z/,Q#-(9$U0!
M6\>9@UF$.\P%^4D#8F36&<6R3BVX-/=GVUMD^)&,0Q\QW`&T)>FQ*_@KF$4Q
MNOZ=&S!*V;@1TL2-\Y5.U.V82R`7"?)OQQ<Q&KXD#*"XG2FVE.7`E9CFZ-SE
M&@*SMC39E';S]?K-!^#7P*X%@G:Q^"WB^I*SQTO!<NN)<+@^X/;8$L(78F`'
M6,_>2?5$/V&_M67T+T;%]O?A+A%BZKD#W1%(9-O=@%P<2*B_M'7?OQV+&)=;
M[QN:9*.(EQL2GQ_<.Q'UPJ>!L4D2ND=!Z!:VV'EAGD\2='G4WF.H,T+,%XN"
M%T"(?B79.2(`*LS(6\.>0&N5ZZL1VM`)=^/X@1>2$RLF1I'Q>>&8410YQ@;!
MQRB=,?919=Q3Z-T+A'<O[>Q"9]9''*4@]L]'K>[Y<6*?\!'-<Q6'0]TA!S`3
MC"U\@F*C,#0JZQO<QB%H#0=J&_*>$-$$J-7M8!_ZW59_R]N0/'$CM-(_`.YO
ML6WR=BP;!X5M,!_?+4`S6CH1X?"!W._=E6OLC8#8NM$JUP%'6DZ:M7T20=U1
MR:+Y(('$$;W46=X%@6?035SE2Z=9"<Y7UUD,4;LC0.JM!*D[;*\"*9EJ,ZC*
MX&E8`5!X;V#\`0]VN1W'F9VYE#?\WFT1RI#RD@^[O>]B/H`O,Q-_$Z?\PUV[
M\R47(XN6N0HOWZ)\IMOQ792B"7"+H)L#1U:WM119Q=:^$(-_.)B*]]'U/,J4
MO=2GN@'07S,&#!Z];=PU7%JH6BX#72R6@;IS'+'5;+>ZN2@H`GS-5KY$^LM=
M>:>:A0,EFE=DRY>NE'^QX,']R/AMN72I/7FIO9WH<LF.KX9=6FKJ.HSN33A1
MY'OA,DNDX,4P+[C`>]\'N-P6KKT'K('^WO;2S^40M+46LQUD+*?Y;SA+BI-]
MX?Z!@JL>P8;'HMVFJ[[A(1K7NN7]B;9HY(;F7Z`M<"Y96'[+(_T"0D@_V;_2
MD,ROXBY\M"WC=CQFM'H7/LSJ%UFXQZA!@2>-(TJ+,*6BQBN-3UL<+")'J&$(
MF<TP\!LCPD2HE#;E.^.*G9D/O[JYN\W4P\):'(\S&`7+VYG:L#$8#.!_0\FU
M.)\*EITG20`;-%LM.3_W=\_U_9RD_?A5GA;=&^2F15]0-O^3Q1.Y*%4275F4
MTO`*HA\5&1&RO<^CK2S?)]8JI7%@`1;*Y<@F)D9`\(:+,9`"I%:S/P_2OCQ?
M17B4Q-+DJ'?:@DK4OG8?[HZ8Y2Z:8STPBNMYW5[[O!047UD0I>9?`_W=B.H(
MN2C=Q,`P%^;>:_5E&:,,'!+XMU$^!R7)78DL*LJDS06VFW\IW;7[D7:S>$1I
M6M!VA$WGLZ4_4DH6Z$!_."^@XX"42*:FBU?=,ZNAK9YTF9>>NF*P2]!BMRJH
MN7-^\:[&226PJRK!Y,-=[U\QVA/4+<`H4?AB<ZU";1JUG3S4QCB4<$R2]$>,
M^T*Q!'[FT"7K^SA+'A&F)CH!#QAZ^3L:D#_!.+'0OHX^Q,=+X>H*1"-WQE`'
M^.HZT2=NBR93;@9/?\(!!68H*Y7T!8%]ZXBM059=*KU)(+%J)&7Q[U\$@6<]
MAE2R]L&='RN9R;^BPJ/,Q.OGGR*=_X)G\Z=]LK=2$O[Z*EN.\MGJ=66\;!OX
M6B$K<R.O=,&,>OU](>N/*4CJ3B`&3C+S5+;C^MF.8BL7H99C7\R$6:RDU-SQ
M0I*)F3F2+2SF`W,S*A'K>UR>7F_NBN$N(7NU.]L"NQ*)=B!$VN5SK`E'";=8
M1SCK2L*1P5PE*.ET!JTL+/GSK`]."<R,.L,-H+G7;=VK"C/M3K>7!TMFDC4!
M*8Z3_F#N4*T&(PX2O=,M\\:YY%'"FS*EUK"=(=S\>=8%I@2A]-K]5G<-6&S;
M-=#@E"\#BA(%5=K$1]FS7@B"+4,=7Y]PW[L3%H>K?,9I(F].],SOS,%B*62_
MQ\H3?H!#OS`Q;9$K%^^&UN#`\9`O"97#0G_0KP,6ELN]\_=F:U0_J/="P[T#
MQT,5-%P)%J1"W[?C:YZ$[3Q=HD\`88L\")5RXC34!2'8`MPE3U^O5P7@U.AD
M,P&@#^)]!A8:M>!,959,^D^AB:HQ=9^/AIV<"?.%JQ7SEEAG9WA><MK8Z(3[
M;+M^Z#'0H#P,G9ISEF3`B9E`/,;'V1>FXQ#(!*X]TJ.-68IAQ,]*3_KRC`69
MQMP:5RPDO?;5.0T\3.+6BR)%TR:595$^>XET:6.43R?!234+W!W2MI+F4GE$
MS3:Q>ZG[>(OB/SC6BVY3?'=PJ7O>#`AXWGR>X4HKG)7(;WNM;EIH+C1I-7`6
MOU=[P]&HO2\P2S'Y=FMO<):Y%+H9ZU]E8.;PW*4HS;LQXC__VX(C#*+D[#,*
MDOF7QHTS#0.?'LBFJN1?0A^Q$4]JK&B1WQ@VVF`FKTR7LY)"XY>XY+Z5N>'Z
M(!;WNZU6@7W+`;VZO5MZV:NMV\_6\;#-*-GR$^/_5JG:G`W:_7Z!!>1#LJ4U
ME%1SS@;#?F>[:U`!I',-W#$2#P/SZ`\)5\<=0MH9[C*$-$8RQ3VR!,FB)Q/C
M/UB.!J1L6M@'+V[':#PSXV\JO`_O^U0_/ZXQ[#>PBA+#PD'>WU0\4!@?\-G4
M+]BUQD\7&P+B]RTJ)H@]4I^!3*AV(0"'I48P0HJ7%J9"-%C#&.B96IC%S<VH
MRHE4RLGU-!MK(L81I5'EE+C7`6^/D<7"/B(X2S&*#&_)2[Z\$HT7[C#L-O[1
M%[_Z[4)7=059HSV9JW;>?,#N#])JUP%]5ZLOG#JT37QA,Z-J\;6XP+7VP[?>
M.9;]VYO`"]F;LLK-/RJ<:-DMG3./2$.ZT[U;CS;!)*D(;F;2ETNMI#>GO;>:
MK99,M*LGK`+"A2C8*H`BBB@,GH&__B=C;5F%NGFK4E+%N\!<FP!5/&:J4IAR
M3%*ED=1I]0?GW?/S)?#DVGL*PU(<-YW6H#OLM(=;`T5%@JTDSY7$66@'%@4<
M;H,ZY^(#UX2J4CHM`E0%-KQ.>]%FY1G!5D]=7#TM.;/CNU$-:Z5VYO3EI&1]
MFV>SI;!UW(KG[EM.&3%RF5SMW(]DYT0)Y<51A0J9Z3%%-7`#:N($6J-%D6<-
MN:Z\^)!?E_]S8#:I`;'K39'I\VJ6.#Z>-?CTO\`V3'?".^Q^HEC_)27^YX>*
M8.!-V*EEJ.7#LE_XS]AZGBH+@PKLDEK*4S>E]JD\_PK3%/G*?99:*[:N8YKC
M8CMYYH`"^N1@(7I=="A&%9IZ+D9]!*26Q5P=?]1M3%<0`]$@S+8FL!]!W(XO
M.01[58F7\*XTETN798BLO=S*NR&;GY,9E\VU$50E;H#*@+K6#;80H'V582E2
MGV3.<MY>@9-DI77&1TE_\QP65E'&86"AO`%F4[P=!_44P-L#7`?&,\LZTG+P
MQSN[[19_;!_H*Y"JO71IK,#*HO".;P`.M\HLJ&Y4$UHI61FJ-3CO+<+/LJ4?
M$\I*EI1J#5O#/:-L[S58RU+9L%\%QL;,\Q@L!.0D:JE:2=SFJ)]A$0MF61^8
M$N+AH!I8JLHA[+=7P+,H\ZXD2"62=N8X>G&0L(^(12H)_&TS83>48Z&KC*=H
M=[H92%?/7S'$):,GVIW1IA#',2U4*S:.W__&*_10?/E<@K-?/[.6W(JQF]>*
ML;M7TU=?-?K<7J//>ZE)HMQS1^,>XLU[>VY,4"<5^$+;H;F\KQU:PUXP;D3T
MJ[=M"@()N''1EQ^%@1V?]XR?P$+(!RFUHZH"#S7:,XGYO5IF\`P(;/T2'Y"`
MAP$QVQ:G\[<WK3?T&1N01Y_%^X_8*LCC'>ZG/GL7_?&>#ZR-L!C<+ZES3Q;I
M]/("+_[(/YO4D?/)P0F"P)V\2<,[Z#=[,*K$/:0!%^\'HNOLF9_H=FO0'`Q_
M66]+-MR5](Z('0K,<CAH=9JC434XJ*CC)\Z:7O"F:VQWFZ/>+^\%D07N]%T;
MN*+C.DS[Z=,Y_J=%/Q)I+?R5CTZ_DZE9^XG;,>('^&T___Y>T3LJ27-+;JQ1
M!#_/,TGVR1W/D>:CI_UCPPLRGHX76_(5^2]8(_!+X*H.AH*IH[#CHQ#51#K;
MZ@D0%9<2TJ`POBT<B':S/3C<`\$_>ZG/NQ$+8FF[O10?L?R]4NDY%;&AUD)"
M/F\KS!IS?]\19Z1IZH+=@Z27#6]513NUNY)J=P$!K>3?/H^Z\?>3YX:.B5JQ
MZ[W3?KJ\O+JZOJ[5O=1:1Y[*&%L^\@@C+`?_B1DLK5=$K=67A`9MR)(J0_0A
M7&X+UUH0T'9LCY+YQ!M@1J^>/OWM#?\WM@%)%J*Q[>K!.V1^B0E56-([C5ZG
MWS@?G*O-+,H/NU5RB(W66@4'^+GZP]WN-/NU)7@XC-W-[\-Z[/_^;\ICNP^I
M3C<SMW?C'09YE+G7]GF8A^?=1KO?.;5M*:L;[7.+>LW14.D?2O]85.4`M`][
MFPSWT&_JPU<QWG;:W<:@V]KF7AZ"I/WK6C1>V@Y62QH`OK:1AJFD[F.6NJ/J
M&$KN7M]9LDLW\EYOD]ZP,1I4(/*K*Z,.ZD&[V1\H]:"T?_QT-`3)0_$%"XEH
MPBO15RI#O5SN`*]FNB$&GA:]1^HIJW8:Y_UA8]!1+A'E$CD)ETBOV5(ND>SM
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MUKIZV4;-\]IZV;JM7D(2BNB5:_D4B+X_Z%=#]%QLJ`<AU$*@.#:QX7?F,$^W
M>6<,<V(YEA]@/=`7MCW!X3"(IB+M]U0"A"N^9X^81O9KS]TOC0RJO)8.@T9.
M3INMJ]'UT*684OIJ/>.+E=X0ZPWUW*!]W@Z#UDAIZFMJZO6D)G7<U7%?>-Q'
MP[:R4:@X^.W'P5]0G]!T%AOO*>I*/9>CT'?18=4$)'4:PU%+F_+^V)@-)T+G
MHT<Q:IYW,>7M6)\M]D(MGJ*.K/.OOE"_U"=MZKDOED^C4`=4ABV@8`$F]2T-
M7.V1X3./2`!-[2'5__0)BR519U1MK%L>GHZ0):U00P<GD<"<3^'#*7]N-?L:
M(-\NVL*TRCU5]$?T$3H>,]PGAYIFI!(R#-</-(]W\T%RR*/4M^P'DBI^%3R[
ML/.O5O"<0W.&"^_1*[_RG>\USZ.=Y\V"?8W]F#)#S`6D)X&E\Q\=&-]]P5X@
M4Z#+']8$(+-G6K?9TF9,]WQ%0MM.Y7F-:J[KO"PZ[(P?3@0MA'[2I_FC#5?A
MV;WQ[%+/;M&FQ;,P(T6;N":S<9=CED/OS#$2C4VFMCMC3$MU>R'>`SR+>:R"
M+B\UV>L=9OD,AW-9/H-VL[-QD@\.LF^KZ=[-/-WCB@WNKK`E=WO[]C<<76SP
MJ23Y=$\\5%FQRZ-AE\NM+_UFO_*@TA/GD5M*[.D>6?BO.@AUPN]!)1*IVWF=
MF^G$?-K5W=['S*)4`HBB%T4O^[V&:G?IY!3X;5<;,E#[L-]OEO_WV=AC#!X"
MP8"AMT$/MM%;LWLZP1@11ZJEN[W=K"CVLDX;6L51^*5ZHJ\U(72:K:KB+HXK
M2:@<(51UYQS;S7(5>9)?7%L/+-L*9DK[*<PR]AJ0U6E6E#6V^]VI]T6PSUT]
M[U6UJ[O7"`Z7JY^.)A'S>PPGH7*P%`_TJU(ECE:"'%0E0:H-K<N&5A:*71^5
M8/_FI*-E]4`V%@!A:C.+V?,!,4J\KZ,@V*J6:Q^W''ARFWJ"PCW_6#;%IB*G
M^JK5JHCUTA'KCNN<[2)J/=VLHMGJJTAV%<E>5_E'1;*?9G":BF2O_SDIJ6<J
M=GG<[%(%\*I(]CK&I:F#4"?\JDCVH[^=523[41A[C^<&J%=DLJ(712_U-FWO
MW_5X.O$G"R+9MU&]6H4KU"-<`4C\^.)/ZNWCK"<A=*HBA#K%K>S=+ZKB71:'
MLF_O6CF^RV.OL>S#JD+:5+1+?795Q;+O@ZV?D"[!)KKE8-")`;]ZNA&$NIT-
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M0=F7H>P7@7)4$91WKFT9LQCQ9:#\('A03`82/Y+#V?$HBL_<;YIB'8OXQEH\
MHA"#R`_B23C&5Q9HGUW?QQ80&A#OQ'4TPE61\[3!2DXJKX6(5',`U7:$:H.C
MVD=48R\-0[>-D'?N>)QQB9+WZ&#)>_!#D)<AXX231QC2'?/AJ'-(-#[/:)$:
M@6#_&=%FQG+-!O7_@-_Q+/@@Q?)#0$^EAF#_#BVX,9%Q-;6K'Z+=S=AS)T5A
MDF#`-8NO>2N<9WA->V3,`53X(0P<3EV>Y<-TSYYI[`?S#,NGK!TY2<?G+8AQ
MN/#Q+Y#&,>5G'`;`BN.N.?A$W-X&7;V>15(['R=P`Y`#X+'^J-'K=R.P\*71
MJ-'JQ=]$>`LP1EX#Q`3/OL8P(C[;*`??1?[;P-E01;!>F#UK:A%O3-%!Q02P
M:,^6D(#<1RCTHSD#C^EPH\W.^%`3!E1BBC5@G^>%$Z4'AT4"$C#ZSHR:)&FO
MNL=3J^)'0\"?SG=7'K=!J$Q3LMAV>3F@6#,^$%Z^NC,C3O'3#]B#\_=^.JD+
MCJK3U*YA8MVVYV&D#CM\/QP7-F$\AD^.P:*<LSFJIH0TH+EX][1'.NL(N"GV
M.^<`F"'#MQ;"G)"(ZU,7'M4I9YO\^;KHV6[(6P;'&U@'M3M*-@Q(X^=ATBJI
MR2]3^G[J!K`T"PAOQFD#SY'/C-"#+89'B!7!:-UF.^ZT5)CK-,3QDGL]`87%
M1PM[+D6#YM\2BL3J0&*]HB36VH3$.DD;M\(DUEM%8IUFKPH2VY*2MD(7R"@.
M(B/XGGDOEL$2Y4U6[[ZZ0JJX@!O-]!\0M_+OJ/=]=8-_,5`PHLYH=W3C`#&(
MK_"Y=@D]Y+N`\#O-^3";LHL?EO]]##?/]PAHT(8`M'@)B/A;VJXO#&^O-Q_N
MNO^2\++3I>X(S=*B_11V+_SOM^-JT9G17SNR_GH&BF/OG()Q=X!Q>=5I1%_K
MEO<GIKU?^#X+_,\,)-+V@TO_=AY`&O-!T/$O)F[H!,OPM7RQW3<?I&66F7,U
MM!WQ9KLR:/LKH5TTYP)H$S.07S\30V*GZS7[\W8Z_N7^S!#=YAQSWV3,++1+
M5R:C0L)MC&O)"*RU1PDJWR?6YPK@[E8]H"1[8-4+(E'M"VEUU&_67T^&JI20
M3DH$Q.HF!NB^,[)*$"<A"4DW#/[W5)]1L0VR:1B&AX80V](?,8@0I3>T%$1F
M&JGKJM!>=1+V>%D3V._$]B!5/?'A#4,/_;C\B?_L>L$9!:LX.IE-Z`=L#&LY
M?N"%$V[Q^<A[&',M^-'U//<55X%!\W#!AAYHR0'(G/J+;MFTAK1V2T*F[>K8
MN1C[S?H6H%OW*$K&;P@CD.7+J],UXKU:!P"9AH%&#8]]P[,>T4+";/<U+2G#
M5]A)&4329SW(*?9BN\X37ZC)'@.Y(ZVO68&?[`R]H92A;9\$0?6(\:?0,K'U
M,.S,&%[QI9UK:"`$`4%9_C,>`$X@/BHYVMC3)^S5]?XFXIH08R/K5K+M>)#8
M#R`/$X@GOIWI>:8#Q4WTO]`2A#<^/1L=MAE00\">7&\FQD5Z#%($Y6C,0EL1
MP.2A?D53PV".ZR2?T18$A^<Z><_RQ2*I1[(.H_RP`JI:Q!K)48Z,<)Q)<(I^
M=4/;%&V6&9QJ.O\^LVT<A2\!II_J%OT0"(D%P$L696'G9HV2NN"LTB.Z06:Q
M1Q:\HO45J.-O&&BJ>X%E6%.=SOZ%K_FA\=R0UV_A9O"G1</H27*S<("!M0B(
M)0/C8\1'Y*I.]'C.U&+-(3&CN+23O-QX;02ESA$NC-><D^`;"+T\84.T7I\G
MP#2QD49\!JS7DY?^#)]1+YY%?`L`<U&__@\Q'\;Y55*K*I\RJRTH56].$XL,
MO4&YPE<;,QI^A;3?:;>//FA;=#.)[1%$H?T[=-%(2T?0IR/"+TU.C_ZNEWQZ
MN]-YI]W0EC0TES@JL`,N9ZS8F@9G'"@5N<GV"K9L6L`G420!7@"G1'QZCVQ>
M[>B6=[3[3OO#<>=.'&P@9YBQCP4X=P"_T[4970"F'N@19_70L>3QTGUP.8*H
MBFP4+TBXS:BX'TSG3DE^<U]3E\J:`MP![?(^C=F6`]>EI=O\)O:72$FR>,1O
M9R'"11I(KO_+T/WGM,OY@E2E'$_K)Q"'T`Z7JAHF6=(S&A>9I#.C:Z]P#_S<
M[3>[D?TZ(L"4EI`1+%])(\E(-N2W%K>.H/NF=IF=#S@:["-L4RS/F@C7Q'78
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MC;DSCL\VB&:><SUV>NU^RL^Z8N[J`%T>T#P/Z+`_6!_0&\?`T#P&K)W^O7$N
MA/_@CKL/<!CN/)`VJDI$][HIZ-<#:.N+*KLI@_,=K.H.M%C=,C\Q8)5PI8H-
MAJ%N42?FKN<JM^JLV^JM6%81D+:^K)*;!<M:18-K+@N9)`5:@"[&PZHN@L"S
M'D/*BWEP+W7;%A$6,-8_HTC6];<LRW`[O4RTR`9@[69]R_<NN[YN:WOKXY6\
MMG"US'&\U$SK@U&2[/O]T=IP?$*GYQIQ9OC>3>P)3J*C+B84(@B[\0V=)J#B
M?79U!S[>\VC#V<63QVA?"TH:@SFZF(,_NT`,D,(9@(3<"8M>J!+C[0Q(^3.F
MX?K,`OC:OQU?`M^Q@MLD[+L"H;R=P=*JR3*@)3<5[A2&BZ%9"`:X^G=(;L\E
M$OAJ\FQW,K?-JODVAJ[X3O9Z/`ZO`N`N>;C#9LCJ]4?M1>"("=8`H#@^!KUV
MM^3\#HO([%HWR.N*#-NB`W'-6`YU[YC'Q`-^=ITG-,SBP.F@S@?X]B..4I`K
MC;+GK1@65J/N#P?]PY<Z]M#)#'''/*Q7C8D]!XW,KHS,FZ_7H$TV6\/^<F06
MPDL&O0#@@P!PLT/9/A]TTFJ`/':I64O<,>>C;G>-22MA0^U^;[!P[GP^4`B$
MXLOO=OH;0/#5=8Q*\#!JC19O0C++FI"4H`9@S+W2@'QE`3J9[CP7*Y&8'V=_
MP"&Z<83)!H0!=)QSWNYBR$L(W]U.1;)GM1IGO]5)@;\9:#M;9DG!<-C?]2*Y
M\+G;O>R>CXHLLR!H.UMF66M"KU^(9*M<IGA\MR>STR]$M05AV]DZRV[GH%OL
M=*Z[3J[\4=&$*K=G0(<M#78RU;I0E$7><)312Y9"\7H1!U$"=AWXT^!^!IY=
MI^IMY%2+1!E62_"FI1&GRFY4YQ:_<;2+\"GT`\GCG80N25MPCS833+/3/KKP
MC_86GTS"*R[?7U_<?TP^?WK_:U2G(G>0/Z8F5@)X*X]P<?]'>@`$Z0SSMGFD
M4105#D@`!0=)(1W>@>D<&"LD0KD#5V/HA\=Y7I^9B)L4875^^(A6(,P#UDPW
MQ&R'1RSQ@>'F%#N7'EI/QC0X_Z/X9%U[<D554X-Y#L438+HOYZ(`$"]6D<35
M-S589+2N>$&46HQI%SE0.684XN='8=V^3Q'D&,*M1P4JW+&&T2]82573QX$H
M]D`X%A$QN!L4P"T^)X$PI.J*)):;()D.EA3HEB.!C[5(F),#)L:ZVS9[L6B]
MA!EX.K1Y+%FJ;`H&<2W80*P\X<\MF?W`$!D_`9.><$4(:Q'0,+8K`:^I86Y%
M',_^R)!S^QH;CZ-<(->30BFC.)U'!J>5:MAR_$9Q(QH2*"Q@P.O$B&HLNAE5
MT\#@MR">-@XY<QF'2^3D)"DY\9NT3P!]#.FK9=L\GDA/PE`L&,\(,-0$(SSA
M<J;V-K0-R3F^3W98!1EMEYM^T6<R*P6F&//!Z.2WSB..AIXX.C`:%I6Q60/#
M'F'+IC83*2,>T`8R&R])$(\:=U/&"Y*$'P*1P<-,'!T`T\"*.)P0X0'VP^)U
M?OYHWC>UWR\N[G+'C0BMJ5TA"T3O,8WO1=G3\5L89XZGV.&AZ`%PLJEE!+XH
MBR/R:H"`GUP\.G">?)[(3=40#+ANX,AY/H9+(4^34G@\-K99-%*:<<";<6QT
M%.#,J+ZH+_+\Z$N;I_V(%"`$E?TPGG7GB8DR#IBX-P<7/YT<LX)]BQ!/%N&"
M)Z,`W\1Z$0&;^N^TMQ;<<DAGUG@604SEK3DKT..E-N#1[+.P:0#0A//D1]MZ
M$G*^J*,3#46OPKOI+NUR9I)(C7IKO?R*V^UB8E;^0U'*X8*I>3&AMS#,W);S
M@D#3$!XVM$>L@80L.<(-)_85+!7(!:M^K\59$2YJ0V1-XM?H+K><-%^UY%1+
M<?U'$9>"519ELI6RU"U%])55+S+*B>N,ZQ1Y]55*#"P??%5\-6DLQ#JN<*-6
MJK(.SKO#E*XX-]LFP)2UR'4[O;6`V9HZOP@YB]3ILA"55NT78F@E1)\QJ,:_
MIL)Z7RS'FH23J(SII[#8`:(A+C!P@TO':5=2>J:"YZ/3SWCG"L*[KT7>PPV#
M#Y198]8!N=X2O2<=+CQ1."9B^?#APC'OXNH!KG,[CN^`Y`I(6`LZ"RVX.<>6
M`5J(Q)N1#UNJZDEI8U!;53W97M43F>A)QKH/)[#(&8I%$AFG3'&"D$^S,LK^
MSH&\5<H`6F&>)BI+H$%X^I2%@67XC60Q<.<WYPV=<ZEE:*K$3$?0W%T/E!N=
M5W+EQ6,"88+[Q&S]E?*P'>T"E#$[F:8S1#6G-:03^*SS6BO"$`":AINX@&#0
M>U"8/UGLR6UHE[IM@6+E6/J<#@2:)ZP8#J]]YE.4S*/E3I]U4/D,6B4,:XBG
MF?,$#\0`BWQALK-AM43/??+TR03KE3/;#JDBC82MI#0BFC*BMWP8Q`.5%.!C
M9U@B`I!`"A[L"-W):8!QS8^A90>48(?YEK!M`6JHPIJ*('"C):@W,;,:"]0B
M8/Z\'K6:$O"W=Q86-S9R:8/]T%ZL%W>-D=/CB)K!8@-<VWT")7KBFE@-U_5`
M>XX*+?@3--=,7!NT(#N#I;2I%(0DS/J',4"C-3"<$174!GI*_IM-=/'PQ=7[
M!I&#4VOT2$3V#,`'[M2U&%!7+LG)I9!B31^(-R+X%`7G4B>?0^P"=;A`>4Y4
MM/;PC#XQA^8'Z*D4#)V\*1Q"2DVF8LK<\)\&UP=QD&#FEA<T9W.A<?Y\VGZ<
MFH_C'.3N(+HF,Q>0)6_5'%'Z@OR)JR$C",[@F8#W!0*>'QI8P,(./8N79I71
MR(QG!W=JINS6NTZ.S6:_8B;_"Q4;D7PLPL`,+^/NLC&<-VZ-C:A`.HP-.%L6
M48*A3Y%PB8"0[U.Y7,L9>SK&9!I48RVZ"]%'\D3)7T%B#O=Y57VB*!O-T&;N
M?7D*1+,_B?0&W0:`[SMN%+[%0O"PD<<MG'8'NSR7MXYV:P1N*CN]1\>SFSZ>
M*,S9C!@J59'A.R/,]:[8F7E1]N;N-B/&HDW]$:XH`!.+80P;@\$`_C=<U#8#
M/3AS\W!?`];@'C1;K:2'0U/[W:.*_9YK,&;Z26^,^-57],__C)5EDA7'1;PO
MR#WP9+U0B1MR+B"OH?OX%<N+<0F3YR`V"%#+]^,>&-QE3)5-#.PW%/OGA5<D
M`J)!=<1C(`5(+;E%;@32KBGJI!C,'[P&YY4?\.HRBK-46UXROZR0[.[*BQ&A
MFC=33!WUN-:(10*]R'D6/&MHI(5?R#KJB[N;!`7#8%/R=B?6I-C=[:=#@=!'
MG>),7(+FT^J)YV[M1<0!)A:QD(G^-U4V%&6,J+ILMOJBY#[D/DQ<BE2BEO)E
M&W)=D$8BKX@RF]RE0V%"J&LG_C4>)H,XH0`7G@XLU]NT6.P97G??>,E<_C(B
M'T2KQ/'MHULRL?@EN-AL4LYB$<51M=X("\#.;6RK]$0.?3^%?H\E53`73OZW
MX[[:S'SBR!-Y!8CO>*W":(*%,V?\E@APG\6*>`^DAB:Z4?-X)9\_:W-0[%D<
M:$/=(O""B"\M?PG%J(MAFQ?#7<(U8.M3WAIU1U1<C'OE"8]:5DGU8OT,<^;A
M&P&/NK1,2_>(.9+I]5)W=%,7'V0[;(*XSX'9;.1:5\55\[_`S4QWTA#UG##6
M:<%0:-&='RJ"@1N6J&@=R(VN_<)__I_0812Y!;S2U;B=C5;[].2Q)S)")B9:
MOG*?I=;*`TIXN!\&*4J,EA@'J-`4W1+99*7`'<Y:'G4;+UA?Z@+';&L"^R&6
M8,B'0'&?;7(?*E6(FT)_7"4U"X^;]^S6(A4C>:X09<1OZ`>@?(_III6JJV\\
M,^/OJ*VAKZ.VZ,>LJ9$N(1ES+#)FYA27?$AIV3P>D8*=M6<@$YC7M@`X/(-1
MX0-1OY_*B%N`26"7$^P;@/&*Q!VD'E)8?!`#Z6)%.(K8CCM&\<C&N6*?RK*U
M3<73T4.3;I8;$7.8Q/W=.!0Y>?RRQG[:'<3*213M"6?.1'W!+*B9AM'>T='U
MI2_6&C*Y;Y>IO!1232Y)BA&.`DZ%DLE'$B)16CN^3_K.X>M74:3R96RZ2NO%
M]U>7:8/=F&IW\W7%D;54$C=./(B;?V+@LX=^Q4:<VC%VW8#40.1$W#Z6H,%*
M2#VI=NO@5Z@-B<51*U9:/X@SQ*IB[.*0(O=!HDQ)%EN8"().,2HQC!B;W\"B
M.R6T1U^?,%%86>>!Y=&`"_7DZ))!/J^;?X6"L\>^1_&SZP`B.$:D.I^I%QP&
M8IN/,361+Y(*A$ZED+*EIHP$Q*C/:2Q-1QHKYOXD`JCH!PL3/,,V8/`U=42,
M7J*;9(Q=%0B@^2JTXMA("#%=$EUEG,AY-W.$0-?N<]*+0X\DU+\B[ST=FH5+
MWMAE6<+\D>P*K`A>H`0JWMDQ#D-/ZL&BB4:GE*UE5I$+'NC^C8XC$N$U1C*T
M6V?_&\^V;!H`Q>;8E%6H&&7``G!,[JQK=[BSKKDYTAZ(87&**M'(V>-Z343F
M%CGC3=!MI%9+\;@\70,/7H3U$(A)1CWE"<P$*TI'_$>_B=[5T>/\QXT$(HH!
M>(=)I\RK\_6\/XGHFTC\D?I4'K?TLS=K?))ZXR?68TIM1+X[=D,O3N",90T#
M1`@T4M)IG+"`$I,2=&!V6*C35<`PL0G%%GZ?PZ!112.>).:_IT2EY%V3V?">
M-XLF%7Y]8J?_D/.ZT%<?E3E_SU.6DE'H%F:VG3@'L061]8,+"5%F$RIO[WD*
MDO4BO6W`0H%MQ"V:$#&Z[^+S,S*Z>M443Z^[R6-_]!D=?ST)VQ=:[@1-Y5/L
M*6-+0CB(=?;L/]RSFN2M24G8R>-":C0MJCN!+!];=I&7AU'@O]S_3S00RQUH
M@DGLC[$-4EPRE(K,DRMIM/1@F9Q<*TK[DX9=#1`)%M.I;8E7Z6^#+!%Y69;Q
M8<7\=.RP)DY6-&-#L\8B$I..'KI,;%G&Y;7EA<\Z2C#DM>:IL"%<9Y@*3@)O
M/)BT<Y$@1^GKW#NG4;H`0N(QN%P=[K9!AB&FF8=%Y.2E0)V)^SC)+1P+"3YG
M+>E6AL!7'N/&CND`(Z2S%4ZHP'-MQ0&VWIM=MDJ3L!0=6&KOAK0"6]*.O9YD
M28\24LV8W@4%)!X^*_(3IAMQ\EO/??Q+Y)#RY&;TA]K2108D)KU"EUAT]#'S
M.3G&=-LEIZ"IW8RINH"`!F&ED)=%!RE6W>)VF=*II=?Y_8BW&VCQWI,DYHJG
MFMH_<4DIL5['>-*H'6C<6T^>:4Q7Y-SYX7S0R<"4>]1XZPKA?$CZ]YGIG3)%
M'6@-^9J=1A_%P"0CP]S\(6ER(U+XXAU#EVG2_&<LQ/<\"-79W>;9_1CG5\,I
M2)]0BKQG7+A<<$Q%60JX--A4ME;(-PH/\.6:GCC':7$/A-)GUQ1Q%+[4XE)N
M(!EWC>37\O*AX@".N'!&Y(PW,R_$K4QCQB-%%P`:3-<[PS[`Z)&3V$W,85(&
MN#_O;Z_2%K@4`TJZL@F#RB*ND`*(SK%%F"$6%(D;U)JO(4Y._#2>Y!G#95#C
MSO0+#6D^Z:2C-2$QM@D^A&O)\,^H6$KD2\'A+,\\PY:CLP4H>;A;AA&*=J?(
M'SX>%:UYQ!K4T7[QA)&,<L`[@XXU1_0J)%@=>!EFHR$C")O:Q:KA$EN4U!HW
MMJ<D.PXO1OPJ;M)$`V"AC;CR1,RY:=#H3HPDH7A+D6'2WGCL">/B<2]S;Q;9
M7$9I`2)&A8?,4&4,X9%"RZJ5-O(!(`GMC@$.U\O)K<$M3=W7V`PXB6N9N":\
MSWCKLZQ`GY;Y43*C=/Y`W/8MQ;KKHGAAX%)DHP4%A"KKCQF/0O,9F>V0;.3T
MF*G(AFY@4S\X0$B4R7<B7C8)2TM^(EG,G>DVN2[()CV+8_Y]'2-SL+$P!E"0
M:Q-5>/W1C>+R4Q0J&3RH,S0Z7DD@DA<A>J)+AR=N$AS=9>(:`"X@55.2CX$/
ML_N<T$&V65H#18)I#@HL$[84$#)V3QXQ.",V=F<EGP6S+\2,OG(390C<%Z$=
M4U4Q<6&G]D`R_.A^7&M&BFA$-1[F<U!*I'I8UN0Q]'SN8*?H:7S"XK5VX9G(
MR<22D1L\G'S1Z)+V)\KWT'3<IR^N?B`I\FGQ\C_9TC6QYT&:/%&^8SB6('6.
M[.7LLH3PJ64E#W!ZQFI=42:9/(#%%1DLB0-*-%S$:8H(XI9_J2:O\@!^-+S)
M'4OB2DF>F#"*"@7BE8T(CRE4QKKS"XM<.?'#<JA6;#W,&`N#N;I+7,X0FR/?
MI1-`@Q^27817/K-BJTRNHBYO'=UNSZ+RF;S&2&-RGG51R2:BWY3>96&.6'*<
M,A7GX)J-!;HPP,(=XD=J,1[%6JP-9-9(6@QG(A06A`(4[%!KUD%LD>;+-9L6
MVHO8'LI2EAORU'$<X6]<;(C8!;*&.+I7NE_R++#I+<K(4Z:0*U+D+V)W'*YV
M:H_6./0,$:R&!K6$2NE)8/SR5RC:P$R\JRW&#PJV(8IZF1@>@]4,`U[IJ_@=
M&1LJ^%TPB^2\7%)8:KU+=WZ5M.>8!Q>-FQ:Q?8!6/-ZG)D_M-LPDDJ>(!SSA
M->G087CB/9SDYJ^DE*6NO21^7[KYI+N'!LD+#XENXC@(A#^)]0!.HNOK_OR6
MU++F["-I^W@28?].('1KMSH*QS&WJ!@2CJ/SDC6&H/28/@@4])BV8[+)U'9G
MC(DT0U&M3QS36(0S$TF79$'?P@N6NR2ERKATP[U2W>&W(=P;J/221,%KU8LG
M?XT4=$]'HCK#!4?&7TP(1*AB$Q/<V6.0=S``AI=&S(-S3#9:E/2BF7CEX;]$
MXJ)T]PO\Q9>L,#A'*)09D[3DB<Y-%9DE)P6`IZX5V9=RQ-<Y^3/VP@@I3!:&
M8NN#9#04XNKZ&'@$'7,I&GA<;M;^T5B.F$CUW``M2V#:"%&R)I)D#\W[%O*0
MF5A9/]HZ'+E[X]FE')AI7.$3'Z`BIHWDYF$_),OMCK:'#XKW)*W(%+#K&@BG
M@94,A*">1.C.?B-KXSR<*-I]G#FO4=5M8'X6*>HBNYLSS<"EOO<13Y8I4:):
M4+T]%RB]J=VO/S*23)I#PLD%-<Z+:KDB&8MSCC,+LB7IZH`8<3Z_L'S98<95
M^X33C--\RHO=!O-L1LF46Y0IOP*OH\*C6->`]V/5J"'K<0N5N^5:(++#J4>Q
MRXY0'=6=>-9Y"P=#MXV0%W!X%,$[$5>*WQ-!M'Q+F7FFHRGD"1X(*>06+]K\
MNA9NTB4T]N+S0]V(C<!ITPP^E1I"3M?!R'XTO9F)]:D`3!(,Q!?YUYR1)>'N
MHKQ\;*/D==_9#^89EC\G3(A`Z#2;%2&U$7/$)T+*9V(YK#MPL>@4/-8?-7K]
M;@06OC0:-5J]^)L24<3P+H^PQAX>4?1`4_MDV2%.G**#B@E@T9XM(0&92R=7
M(=88\T-O=L:'XGYJL09AU,J?*#VX%(L?&VQ?HR;3\:-1>EAF`8W(,RA1LMAV
M>3F)S2+7/)6Z0K'`$K]9A=<D#2-=CY[P'(L4>?(1"\OB'%639Q>[`$2[1SH6
MKR9FBOW..0!F$O.6"W-"(B)-XA0NP3V6S2QZMM-UBN"(V*2WZ\F&89V@8?-<
MB\O\W,<LF1>$BZHOB'/D)SE3Q(I@M&ZS';U>G.LTQ/&BH-*HT(>;'*UNLQ4/
MFG]+*!*K`XGUBI)8:Q,2ZS3[I4FLMXK$.LV>(K&]IK6H3G.[.LZJTYSJ-*<Z
MS:E.<\=T<ZE.<ZK3G.HTE_>0ZC1W9)WF=MT?*=.=";?@@E>0E'J[78JJC_-]
MI]J=XBW:VNENWLOGVA"N$LW:!L,-P:(BHE]=QZ@"2^U6#C29&=8#HCA*NIVU
M8(`?W70;-]'NKM)F=KWN/'`+9ZX,RK(-[OK]'*HJ".:=;IDWSO^"O$-EL3#I
MID($9@AL?K*-@"F)I_:@5Q(:GAGQX%X8I$_<>8C18':'/4"`Z6&90!ZN7R'*
MNN>C#)1%H=@*]"5QW.MWJH'>$Z&W%'9PIWNW'MT\)G7]O&,>&?M*<;^>#.O-
MU^LW'UK-5JLMP5IHSHK@7(C2'8#)#:47(0BS'EE5RZ!Q#CS>C+*U",#L9!L"
MMA!OVX?KABMB&R%K!3A\B@U`*8Z>BB"YE=QYV\2,-,^F0%6&HX(PT;G4?OC6
M.\>R?WL3@+#WIJS<]H\*)EC&Q>?'G\+M*"0&8-.26%:)?#X<MK-G<]6$54!8
MXB++B'YK`,A;C5Q[[N1&&$]%=QW>7"?JK;/@^FT!L-@3!N]?^-"C#RO;YO8&
M\URO(!RKP;\=\\@H'@I8I9S=60ER:NXJ02W;;KM?/:B?7>?I@7F33^QQ@3`V
M_-YMQ7A-/D3ME_'%&P?[;*$DE31>OIB0`Q.H]1LC^[?YV=51N1<E2F<743HE
M[\J<]',&B`(!4;J7,\)Y@:,4[>.<;>2\&@75H"QW>_>%L8\E,-9N%3G"*U"6
M+V-_99L:##KSH"V<:B.@2JAU_5YO39B^L2C[O01%E>1MV5[MB^;,0L83PP'\
M3TE:^!9,'*"P=3+P+9EY.T#&A^BCL`R3KL@COI)S]"<:;A^D#A`WCE'P2/7F
M]F`':RRM.0]&&P`IPCFQQ#Z\@/](30PJLQ?.TTK!>2N$MP1GJ`Q<7B#X2O?0
MSP#D:803'J3ZB8TMP]H0K6?M=J=[GH5UU9P5P%C"Q@B<OS/L;@@B^8*D<K-?
MHH2,+Q17>\UKW90Y51^PSL%//RY:ZQ1$I?<V*H9*(^!;I0NATIN%BJ#*""^&
MP%5H)[_,+/;*E,(W.I)DIQ+\G?:AG]EL')`C77RF,I3O8B=W78/&5"UD50NY
M[/%7M9"/A#Y5+615"UG50CYE#J!J(<_7*Y!.K:J%K&HAU_;LJEK(JA:RJH6L
M:B&K6L@'Q[I5+615"UG50E:UD%4M9%4+6=5"5K60CT^>4K60]Y??MM+UF?:4
MWAN@288VNQW/IV0]((9JZ#+=G^@>1=GJ'%<)]0@E=-Z-]Y:8L1OZP!']7]_5
MKK)(LL#L0$LGE;=`VL1X4Z>ZB2'B^+>&6Z2U^/\$L\D2>-E]V&0`M4ZU3K5.
MM4ZU3K5.M4ZU3K5.M4ZU3K5.M4ZUSEVL<WZ`?#N`9#)YM<S@&=YN_1*_''"G
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M'$15#G=Z%'I;.`KM9N>`CP+_[*4^KRD9/.K&WT^>&SHF"B>N]T[[Z?+RZNKZ
MNBQR(OF.2XX+,24D1NULI8"9$4;+TW)&X!/>-?34>R!]2069XPZ1C\QA8RM3
MK+U*WEL9MJN5T$KSX%6'J]N:X[OYG+,PX\W]?1'?K0>:JR#:GZLGQ7:W>3Y_
M+=9C>PKBEO`C,5Z:Z/T;F.;5TZ>_O>'_QIJ:I,>-;5</WN&R$B50>,G[@TYR
M$-115T=='?5C/>KM1J?;J^:P<T&R'E18"X'R6,5&`YZP#-W6`FIA0<':M=;1
MZZN1[_/H]\Y'5=[R:J.VME'M?I4<^C`V2BGV&W!H4N:5ZGX\YM-Z"H_#P5#I
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M'2QUL"K)'-[FV8*CL+U\X0,^`/QSX5@J(/A\Z>)T8HK3OJBM<=1##])328)'
M$._1XZ18Q^TIB-OMQ(&T&K!T=<;5&5=G7)WQY8)A/8AO_P+BNF)@IZYB(/-]
M'HT411\U-(=1DP%#-"(0C91JK70K%;MF,:9OVX/AYJ1Q")?9KVL=#$5&Q<BH
M.VQO?GD='QDI>\=F]H[XDHMN/64`V2[#VE`2/X;TU_9Y8]3M*HI2%%4A10TZ
MYTJY4\K=$N4NH\;AI6?OQO9_&,1SB.QHOR)YH]?>B.DHW4Y1$K<1-/J]@5+O
ME'JW-?5N5S;,0Y>@]N,"6R-OOAZ(/A4G6*4;M%=-:0!"2T^=<W7.U3D_ZG,^
M:K1&&]G8E$6D"HM(7<7$2V4,V<;]L(1_;"?81ET".9?`SG=AGYR^(BN4.I;J
M6*IC667YQTI,>H=Q+)69K@+Y*Q5\J`QTQQ,W5D\-\6U[L-48C$.X]HX^9'&[
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MF7.$6V55-%[3,)X0ZP5NPS(VJ*C\Z`$42%/L\D38Y2I;?J>5U\MVIRDJ1\<O
MMU3"]`0ILZ,N\HH)<SNE1=7-N<[-N55WTC'?K#7E5I7?HSN/S5O;\[UMH__1
MT\[\3:=HIW;7TT%=1J<3=/B-^0PM!&2[-=D+L]TIFMZ7&/0W9$2''C]3V--:
MF[76U0TZ:IXOC:?::_!`JY>0A"+Z4N$%M5BK(OKR1-\?]*LA>BXVU(,0:B%0
M')O8\#MSF*?;)#7HYL1R+#]`;_D+VY[@<!A$4Y'V>RI%;"N^9X^81O9KS]TO
MC0RJO)8.@T9.3INMJ]'UT*684OIJ/:NF*+TAUAOJN4'[O!T&K9'2U`\P$:`>
MB%;'_<".^VC85C8*E5ZP7GI!Q>D"B[(2DG'O]!EZ4RXP!OX>P^%O>:C\G[H=
M\LE\/YSP[QYPV]9)1?@N(/A.TSS,INSBA^5_'^L!^_[5=>)%)_-_H6Z\NTQA
MZ#9;_?I0V@X#](?#N0!]3*#>.#X?!]FWP6/O&EKWN,+ZNBO,0-W>ODV%1Q?6
M=RKQ^=T3CS)4[/)HV.7*^CJ5QX.=.(_<4DQ^]\@B]]1!J!-^#RH'0-W.Z]Q,
M)^:.JN[V/F86I6*W%;TH>MGO-52[2R>_B&&5WK[:1^Q]L_R_S\8>8_`0"`;,
M#S1/#[82KM<]'4=JQ))JZ2H#$J_&55:G#:WB+/Q2/='7FA`Z51'"L07XER.$
MJBZ=8[M:KGY,&17\>G%M/;!L*YAM[UHYOLMCO]$4S8K"*7:_._6^"?:YJ^>]
M9F6)/+O6"0Z7K9^0+L$FNN7`BBA(Q=.-(-1MC0JE8V''&=,]_U>E61RO0-EO
MMHY/LSCE#1TTA\>G(>S?O'1LC#^6](%L+`#"U&86LTTE[1^&7-BJEFT?MUAX
M<IMZ@K(^_ZC"Y9_RP^6KB&.O=XQ\].V^8N1K0DHJ'EX%>.X_DBA:HXJ'WU^(
MFXJ'K_\Y*:F=*G9YW.Q2A0&K>/@Z1K>I@U`G_*IX^*._G54\_%%8B(_G!JA7
M?+.B%T4O];:'[]]A>4(Q+/GQ\-N3ZP_<)7[X,0[M9D5E1.NTH?7VB]:3$#K5
M>DQ/E1"JNG..[6;)"8=7VL]!A%*,.E7%3:L`F?KLJHJ&WP=7/QU-(N;WF0!X
MI4H<K00Y4/'OQ[:AE545KH]*L']STM&R^G3\NQ+O#T(05.'O1RC=J_!W%?Y^
MB.'OTBC?7-N^=CT*3%\WOGVGM=SK0P0[#%P?#>8"U[N#S</6^\W>OKV,&^Q*
M-<).ISDJWR.S-@$_Q6[*;G,TW]!%A:IO$'WV-<0$G62?W/$<:589F"Z8M2+_
M!6LLW,Q2'87*C\(_Z6=FGFWU!%R\,$]_DK)#[CS+V$;$1+O9'ASN@2AI/*E0
M+#BQ`-#J^&:MA005T'?"]++AK:IHIW974NTNH!SK/;]]3L>%^U&W=<=@FAYH
MGYC!TGI%M]W0,--E&U5N.$LZ='=1J<NMEOZ_3J/7Z3?.!^=J,P_/SUD%!]A&
M#]].LU];@H?#V-W\/JS'_N__ICRV^_!W3W?0S:V4ML+WVCX/\_"\VVCW.Z>V
M+65UHWUN4:\Y&BK]0^D?^?SV$K4/>YL,]]!OZL-7,=YVVMW&H-O:YEX>@J3]
MZUHT7MH.5DL:`+ZVD8:II.YCEKJO?C#/L'PE=Q](1,5>;Y/>L#$:5"#RJRNC
M#NI!N]D?*/6@M'_\=#0$R4-!%3(UX97H*Y6A7BYW@%<SW1`#3XO>(_6453N-
M\_ZP,>@HEXARB9R$2Z37;"F72/9VYA]5BLC3@A21(FD<F1R0.*ODTIU,F>-3
M5L?25(^>G.K1>Z.%CL4?_`/^:(-X:S+#FNBV_]N;L^Z;#Z-A&ZX="=S<&3>&
M*I.`L@JJ06M4$507GJ<[3PPS<C[.\I-TKG7+P^0<)B7F1,F;GT3NYC=L?UT<
M[0LZ2(QAE.]?76=Q!XD,8KHR8@`OK68!M%2XY(/#\.H>'0K#FW5!432\;0P?
M`PT_KI[NL<QT#\R;M'?!'C[<#?[5_C+XE$'?5M93"[Q5U?H(\+8GG%5-VG_&
MI=AJ<^N?]_I;/L_I11\@EBO@FJ>-Y5W=_J!Q*"QO70(8=8Z&EK'Z\K7'V(VH
MO5P;KMSJ=+:$X[PE'QR&JY!C.]N28^N.X9WI8NU3I>&=Z6+MP>%A6)@IKUUO
MS*P@A-%OG#OF6:Y9$=5&"+UPS#($+&/WYNOUFP^==G?0K8))+%YQM2BE</EX
M[-\]U_=KAM+A>;?=KX(K+%YQM2B]#0,_T!UTF/`Z'RF$7OC?;\??VYTB\D!E
M5-GK],\'Y]7A<&Z)N\?@;H_U>7\XZ"@$+D)@/,2?P/=ATF0`\04!>HMG;NQZ
M$PP'*8CY=J<S'%7(4'>'^*BPB2@]$D5(4N&177.$GHS7SIL/F$*W%9PN6W1=
M,+U-SI%%-#KFZX#H=8R?*R?]QB:ZY<#WEX!C3S>"4+?1*MK9A3J,%M[1EW:G
M"M/X^BNM-ZHKTMH^W/6K,*97BN5EI\A?<8RBPQ(+@849R,ZEX2P_P6#;$ORD
M4DQ4O`LYJLWA[`-FPU2X#R5Q4?%.I#6BP]D$3$RM<!.*HZ$(_OF@L,(;!\NW
M62_LSM8=_\ZU+6-6G^JX:T5E%@K)S*_(E\1HTG:?$=XT&7%%@N-J'+>WH@(Q
MU=W='M)S<4PW,9"<%!S'?N#?3//8%'@.'@XM>,;C[0>:.Z:_G_`X:";:+<>Z
MY6$$:<CP1R;.*P""A9Y=(G3^N`\#&NZ3`U"8F@LGAT;RV+]#R[=@()]Y+\A&
MIMQV)V;2\1#ZVMO0APO?GM%W+UQO%$_^JL$,.DSHZ4A49[A@#99E^0W-800R
M/C_1L?+#.&&F30TX:RZ<\)#V^FP9S_%,EJ_YX>-?S`BTP,5Y(TU5X`]V"YYT
M'09S(H01"BV^:,],+UF(,MDEZ^-`/#)U+<#OZS-S.!*,9XN]$*.*\!+/B'-,
M/?>1:D*[XO4$0.0FID6K>]9][9'!D&(X<WT,/+K!\U(T:"#$:4#F?\,&Q!``
M<I8BQ@0T`%B;H&4)3!LAZ@$>1D:D.[.8FOBQ2--_'C)#'Q&(SWZT=3AR]\:S
M"S!%3TWAUL`')J[)[(;V:@%J.0T9C#\!X^YH>_B@<&7Q%9D"=EVS]2"PDH$0
MU.8F'&_SVJ6[9\^=X2[9LTQQNF&X8;3Q,HGQC42'"A`1\C?^HV":0`F.ZYQ%
M/%FF1(EJ]2F<"J#TIG:__LA(,FD."2?7,F"`EZB70'S.<69!MMA:[)`8<3Z_
M@,%-ADN!O33I_#&)TXS3?,KCHUG!/)N9"]XO2S.%CN2VD@?*2[HYHO)""VCK
M>P]%WNXJN1^[&62`6B26^S>^#SR.?@:YGK[+F;K/9TZ4EDL\B\R;ZEXP^ZI/
M)-WE?T+'A7/KZ5,6`KL$?<'(V,"_@4"%>8Z`D4^PY;8[)4TC440B\\:#*^SA
M<#9N@?0\T%#2BM(E-G)X=+E^`.-]AF4`J5\\>8Q&0NN(GYG^/GST0>""7Z]>
M\)&L[SCS>S%5:S2/\CS49G8`CSO<@W#G^U<@`@:SI7;OE6D8G5&WUTK'$L_-
ML`8$Q?-`.NU.OUT>`(XH4/.`#7'E4D8@;/X]9TUE/*^K'2?GYRE342E`2BP"
MKD;Z:1'P+8`9#S5"O_"$SSM]!_A_PX+PQS"4@%M.?TJJ5]3+]=T;C@:=@CC(
M74\6'UQ]^@QWRS>\J"I,W#K/'(OT3!O`43)5JYUE$$L!2;-"OW[=B^+D_DZG
MV<W(JMJ9^')_-IQ!L[P\LV3,++1+5R:C0L)MC&LI9U5K#Q)4OD^R9RN`NUOU
M@)+Q)J9.C9/G>OI-I21T4NK9K:-]T6=:CU>KX,I&;""@(#<37@==0$<EBF0^
MS9`E-M*O;"ZS:7HDM&EO<2#"RT\_8.3+][$\EWSYZ?VOW$R`\J8F"YP-#43.
MIO96'@`?2K\+4&%"5&"-9YH/[-$&A=YF1HA&"=2J/!?TKPDM*4@&Q^]!_PDL
M-%V,M?2PY^]][8DY#)Y#,]T9<V"+&&'A@3J3X=MF"&J;@>X]M!R"WG<7>GZ(
MED28E69#D34RY<0+;_!UHKI$>"(5:ZK/4CC7'2V<CCW<Q2DWW^,X/_>;+=0)
M[0CA^&8(>P%ZBM9NP'6`_]-\NB6CB<60Z<49[F0"8P@M.-!^1JD7]4'^\D;&
MD'4(^*0.6Y9.4@<IO4_Q88-!G?2Q?`4Z0-4<'IF"(&2A=DX&%0.(BLP`2"'1
MR2"S0.IPH-DKM/7`]8A4K,D$R-)VGY#D>?<],J#!@T2OBZ;CELY8]Z-)D;I0
M+--MZS]Z9/.;/T-\2GXF\1A:CN%Z4\*#L.ODTFX"=S/O*(U#@``7NIS^4[S+
M`%7>(E:`2]+1:6#8H0_Z/7P1>F?8*C[9"^H@_\A@.81FEQM3V'C,<!S&'0GS
MQYYXW,1RK$DX@3F<$/`L#K<?D4*TN0A&/!^N"":25HN/"ML2O`B$C$V.A955
MP)V&5BP+Y01\"V8.7ET-EP6[+)F@R"J4,!S"!`SNXTQCQAJ<ZSQSPX+EH$U5
M0$>/`]878M8D.5Y`B0#C=@%L%2!&<:LM<JL_8%(O2\OREB!!/HE2Y$2AJ?/S
MZGJV^0IL*)8.8$<-N'AUB]B"%>#!#X`?,(J"B>[E60/Y@1T2;2U\2-,]BZS`
M80QEB@`;.-M$_QLH-_3A__G(=Y"&B>V\@N*(-E7;M8(5]WV65W';,Q!CFFDM
M9K&FY?&FY/H3K-P/8AR8S+>>''+G!>'$]<YTWW>!=]*S<,B>T%@+A,""^:,*
MRT&>PQFL+A[3'F>T#VDW#^Z2QW!&&%=B$RB8TRGS0SA1V]P)XD'(EQ&+*+=,
M71\-V^G!89LT-PQ\I!CBH2Z2#%^_6"\L(%JB.OE;//GHQV`Z"A]"V!7W?()_
MV!X0'I,CP.3;.9(]+*3L9\\-GYZ%GR)/@4CS%,O7F&T]D90!M`E'AR&UDG/G
M![DK[1F(PRU)'K:B8R*=BC$3SD$#%HEGNP%#/7'X9AE1)>5L@</R2JS"UVSW
M54/"MMF9"1`%FN?.=)OK#2!!Z_#27AT5BPP[:?O/'SZ['5_%KMZZ&'WV:-#Y
MPR<&$^/D^()Q]N'<S8K9#A5IY,$JEJ,[=-+\`+[@XATZJ:8>F^K<PD"^8<\D
MCR2)A6CZA%_N`R);O*,]"IR!Y]B4KDCN3*8`&A`P#6N*>G_*9/#[Q<5=RF3`
M;T8^;:R?+-$55BV"HGY0Y;:"2-Z0PBJ0S>A)[J#@F3`1WN/$#X%WTE(FW"V.
M=[GOTWUO6_HC9GI;R)0\8+].*$84KF`_ELAAHPS;]4./R)K+YT^DD=%8PD`3
M#T?\<H-]<SCJZ65$/@A':`-!Q$XPM`J%&N#]!NJY"2XVF]1C-JI6:(8R#"]D
M"1::VH4-HH*X8OP4^CV*GT)/^9+)_W;<5YN93QQYH><AYMB+M%:^>;##$WW&
MA9P`]UFL:!QB%%9#XZ'<>,>%-KQ*S]I!=&/A/YY%!&Q:H"]ZVMAS)_,@IREF
MG]=+^MY(WRG_U#T*;+APS&\D1DKQ[H6243Z[SA.J@)_88Y!V*Z&W]^-G5\\F
M7=U'Q,`]D+B5<&$C#++?5P"6[WI*^U'@?B-'J^1(6;:L#`+2@;,\R^J398?P
M'7=52:]>F'^%?C#9S!F5A;W3SP*_'DC;7U=QGRZNJ]O>V;INQ_2^]/I'W;<,
M#&G@PU>T72W8K5:W-QC)ONKU(-KZJHIO%JVJW^_UAJ-J5O7_SLZN73?`ZT2[
MYV+\V1G\]%__^/'HV?#'_P=02P,$%`````@`QX"G1N1D],:Q"```]W```!4`
M'`!F871E+3(P,34P,S,Q7V-A;"YX;6Q55`D``[;%2U6VQ4M5=7@+``$$)0X`
M``0Y`0``[5U;4^LV$'[O3/^#FKZT,S6Y<AUH!\+A3*8<8*"G<][."%LA:ATI
ME60@_?5=*79P$E_DD)R(T!<(SFJE;[_5:B6OS?%OS\,0/1(A*6<GM>9.HX8(
M\WE`V<-)+9(>ECZEM=]^_?Z[XQ\\#W4%P8H$Z'Z,/A$A:!BB+A<C+K`"!<CS
M8L$O9[>7*.!^-"1,(3]N]4358-KN3-#@@2"TN]-L[;2AYY?69UB"-.@S:EH[
MS>DW2?^<':'=^GZ]U6CNHL.CW>91IX-./TWE/@&"/BT3#"G[^TC_N(<.T;.D
M1](?D"&^Y+[!<U(;*#4ZJM>?GIYVGN]%N,/%`ZAJM.O35KD2^B\O$?/T):_9
M\@#HLPQJ",S.I.G;HI-$'$8X(_W43F2;]2^?+N_,X#W*I,+,?VD%.FE!+POR
M"Z.*^VD>'A[6S;<UL!Y"QX*'Y);TD;EVI,8C<E*3=#@*M2YS;2!(_Z36!\X\
MS4"C/<'_XYV"2]HWNIP%A`'=\$'RD`::WC,<Z@'=#0A1LH9T-Y]O>S-#TBK5
M@`@\(I&BOMSQ^;"N!>N55!O$5@S4UPMY^JV\[E^/R&0^R5,&0L.1(`-H0!_)
M)9<KMD>5?ITT5A?+P47(G]9HEU07W]`$YU3Z(9>1(*>^+R(2?'@>Z6'*2\X>
M_B!B>$[N8>S#(55FG(8SIB!P0P"G1)X3A6E8V2PKZ_8-F:J+0[_UK0T5=UK9
M3#ZTBT(S3R_AN]@T>DAK"9`I,LBS(M`BF%ZE2G<*JT\#%F\TU0N?IZI16C>*
ME:/*X==`!_`A]V>&%.J5FHM9!XG5&55]+.^-/LAE'C`>Z42@4R>ADLD5[4H=
MK]&,E^8?X\M?3Z5,62#$]R0T&=',E_6-#:P;"0&V+AQ?+/-UK[V[M[=[<-AL
MM/?V#P_@9VKD*7\Z%;,@L/`3_?!QP<5FN8HEZC(:#HTVCX([).W[@@\7S1=W
MQJL,G(N`"$A5:RB2,!X^TGWAL(:>"'T8*//-)FC1JX2>X_#KPS\1?<2AF?6J
MBX48PZS_$X<1R:'+JJVK-!:1M4CP\E!=)?Y&D!&F2?@';-<Z[MK,4HN6VT'Z
MLD!CREON4<XA5U;C&UC.%,#1GCS22]\5R><ZOXFK)&=361&'JQRF7/"*,[]P
MHF;*OB76[`'$=+6+Z!H)R@558\/J)KB[)5()ZD-*F;V<E!)JK^`ML?Q*5#'U
M'==FZB7%]S2D"C9-@.E.<?_O`0]AK%)C4^,<CLN;;1A,<7*P*.B>*]HRDW92
M2URN9GNPV><1S*4;/,;W(2G9AF4*.\UCM<2N`D"'"=6G-];S,E=^NVBM@-'5
M#.^<]`F,.KC59UWPFZIB9G/EMXC9:AAMDL%JS"X>WNHKD+F,(N$/L"0)LO$%
M%Y_9(V0T))@L)J=/6`0YDW,Y)5O`ZPJ!.YO^I<_3BU.F1<DMH+@JNIC'7==X
M7`P]I=NTHB9.,VN=#5=&Z.IB.Y<)@@$6DXA2OJLIV0X/6`'F-W%FDPY?I8Z0
M+;P=A%?`9K,D;YS8@GO<>;>[\EML!\55`=HLV1OGV?K@;5%P.UBUQ!63N>?:
M"GTCXES#X"BZ'9TAZ1Z#EFQDWHRT0N?J@94.+IR5DC@OMD4,6D%S-E$.(,DW
M0[G!-.BQ+AY1I<>5G1%G2V\1F540KOX\:E7W(Q6FC`0?L&"PTDO(X*.A9H`$
ML,&C/LV_#UG6<(N87A*L_;G4<7VN./*;5$Q6*J%.$91;3MFR+:=\Z1GQ/GKI
M&V&F)5.]HXH5W!N80U=$]1B8?,92<]-E3F8C92,3*[.'TL%F2+HWF3.M/E,Y
M8HG"U6QI.OZD/+N,K43./:YLJ2@@L1!<*87>QI972<!0NJ+EG#R2D)N"LQA+
M?H5/?AN'N2UD*&M-K0K3U8GZD3`P0:C//X,A950J;9!'4DQS2:OM(7H9H*YN
M@4PUXA5G?#:@%3-=W,@]HLM7UNJ`7"6T9VXUZ\@SP=!CB@BXDD-EGKA[)"[!
MT2+1E>"Z&IZ301=/TCFIK26T'&7I5/4<VK:FGW"UV:&VE]NAZFY0U2=IG7F4
MZX8(R@/P%T%@7.=D\COO]+62BDU,:%B?].AN!'^DP/'9^#.PUV/3_.34A_1B
M4J9B[E]%<.WEB"%_@_X*I>Z%BV4\(1TIUF`/5Q>(RN<W[K&]!K8R7>*-'J6<
MDY$@/C5HX7-(##FP(1ERH>B_YGIN(5=YTW?J#TN;QM7-P-T`"V)>X:./H"$I
M*'*,;.%WZ@H5C.'JG;#)/;S?*0M*]H"+@N^4=$M#N%J=?:<$U@.`+0JYS2_H
MFQ=[IV1;F:&T&JSZ.7S.8Q<]!H!P>(&I,(44YG3QKVAR6''=__#L#S![(+HN
MU<2F^;QN.27OC/L5&LG5TK+YK5"/Q6]\2,K;,]_\D'N&M(RR=^94:S!6[%S[
MSMW^6\1H4S-O[5TVRO[WKM<:*_:N`]="5WJ;==V_H`PS'TS5Y=+4;NNWO!G`
M>?5YELW?J0.]RCRQRQPZ716?8\;)/9\5'Z-:*G7/U]9TC/H:>[AZ>@*!U=PO
M^8.?^F`J07)?N)2[L;95X)Z?K('GK`WWJPSD;)54CO&F07>5D<A2J7L>MJ9(
M]!I[.'N4)[A/2"`OP(`]*2/]YM;K?NK9B[P`5-;./:]8`ZL9<6<IN[AZ,^@6
M=IGCN'P@_41K;CEFMO@[]85*YG"@E&1U;P4O+R_I-#J-)O+02Y_P1]PM2OK]
M!>F>/=TUTGW_@E*]Q\\_I/I'/\4C^-GMRA.+F;3@+HUVXV"_L[_;[!RT.HT5
MG0QK[3TFE3#_P2/9IUUQ5O#^G;(V[LWU4EO.G>(NA=`J8=SX/G866O(V9MB_
M1P5O9\EO\J:Y7AJ@S:9RXTR_ZGU*:PTOE6/+FP@L<ZA*@LDF(TD.66DP'P67
M1>]@RY-]FQ150K/DY'<U94O^/XE=PM9:=<+F(;_B/TAQ/UW[?SY:SL>53,3"
M+;-3J_#VO`XKA\,E<*PPFA[7)S:-`P5<^0]02P,$%`````@`QX"G1E;&>M[F
M$P``+CT!`!4`'`!F871E+3(P,34P,S,Q7V1E9BYX;6Q55`D``[;%2U6VQ4M5
M=7@+``$$)0X```0Y`0``[5U;<]NX%7[O3/\#ZSZTG:DB7^+L.I.T(_FR=<>.
M/(HW;9]V:!*R.*$(+4`ZUO[Z`B`EDQ)NE$#RR-F7Q))P.9</.`<'P,&'?S[/
M8N\)$1KAY./!T9O#`P\E`0ZCY/'C049[/@VBZ."?__CC'S[\J=?SS@GR4Q1Z
M#POO%A$2Q;%WCLD<$S]E#7B]7E'PO\/QC1?B()NA)/6"HM:W*)VNZ@U)%#XB
MSSM]<W3\YH3U_%)[Z%-6FK4GFCE^<[3Z9=D_3MY[I_T?^L>'1Z?>V?O3H_=O
MWWJ#VU6Y6\;!)#(5C*/DZWO^SP/KT'NFT7L:3-',O\&!X.?CP31-Y^_[_6_?
MOKUY?B#Q&TP>65.')_U5+64)_JFW+-;C7_6.CGN,T6<:'GA,[`D5?5MTLBS.
M**R4_G:R+'O4_^_MS6=!?"]*:.HGP4LMUF:8KBJ6NSCMYS^6BT8:@C::WF"@
M(.GH[.RL+WX]8(+VO`\$QVB,)I[X[GVZF*./!S2:S6/>EOAN2M#DX\&$J;?'
ME75XDHOJSQ<1#6),,X(^ISCX.L5QR.!Z^6L6I8M[_R%&],#CK?\\OJY0PEM*
MIXCX<Y2E44#?!'C6YP7[-BT*_JQ4TW?'X(!2E`X"1@B-./Y&DR^(1/B^Q,5U
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M81:CT>3SU"=(+"F89>/F3OCV`T)\9M:$F1LN7LK<^0O^W>";3T+!Z)*XV']`
ML5@3N6Z_WX%X\OY9+X/GB"I87"NS(O,%L0-2)9B-I&5;Q:#:<J[`A$&.K4>7
MK4T(GC4B^X)ZK.0ZHXP'/.?-^G$WNMJ>R1=>DO`N]I-/_@Q=5&S=.JH;Z:HA
MY&P:63ULI)@OJ[X9[G]'T*Y=_?+NY/3=N],?SXX.3][]</8C^[<-4"T--4!4
M224"`&B7S$7""Y2[(B-!RFW%75U#BZ9\4_JM.KL&0]/@N"E#1".&G92ZN=3D
MW_SR"2>VBK(HWZJBCKM1E(48`(P^HQ140F`K#W2=HIG*$W31<$,P$<&`'4>Q
MM5@JT[H[)W0-.OG:\7V`DY0MUBYCT09;?Z)'_L?+[VR9AL*/!RG).EI$E$3P
M,A[H&,?Q%28K_NX9$T-&Q5?S2LJNE;V8<';%E)THYB3"A"W*!?8AS$`K!E8S
M)2)/48`4\HKC8JMM-!FC`#\FT6],7'PW@I6C*;7'CO/^6D7923<H<RXTN'B4
MRZD\S/C&4,XPI=DL_Z[N!.:DDU:1][9KF[F+I,QP^]"OQE==QUSK[J6:`[%O
M#QF6UP.QHANOU(^')Y[HR2MWY;&^WGA_+;K;FPCM,*,,-926^&,N4^F372#6
MMIDN)B();9K(J[(TQ!AL/>V5IP,EFP`LAXPV_B=!^OB713T@X5`#)$V*6F/J
M-:L,=/S1I1K=AQ45$2B9D53'GW2E(80)K8&W"B7I.`(PDL;<R]/8I]+O'5@D
MU9+<@44J,09%#=KX>:4$$+NR`9X-`4-#NJV(0=L!6[%#W3JZ]9^C63;3ZF*M
M#(2Y7P*@LN#7*`8@9\GD:`K_ZZMT%]BW844>?K"U$.U'YA4.T^5S,.5(XV2)
M*,DUI1D*+S(2)8]Y+$Z$5"H<R7RI+1N"$'.W5?<N?$(+8$IXSH_A73,(,NI3
MFO,U(OQ_SNRGC,NRB+`5O]J/ZZT:AQ`JKSL7N.+='6`4(Y\?Q\?)"L*<DI_G
M.!FC$.51T=&D@G5!G6SD;]D0A&ATK9&_)9^-*_(",7,17OHD$4'U)8W_0^D]
M'B+I0*U1KU4UG3I0DQU;T.;C,:*(R68Z2,(+](1B/.>6O[A&HUI!Z.NTJKEW
M;F9/`TN-CR7S['V'4T91Y,?7";]^2M%U4IW`!\$T8J1SND>301A&.8&W4<RJ
MXT0^A[;3;ZN(^,'!6&Y'+'N'JG-$4B;Q.X("UGD4M(TN??^MHNQ'@"C3BV=?
MT7;>)=1DG;>*LS.X.)/)9F]!QAPV1`)6*_I-'-+H!FTZ*MH-#AX"QIU.2MV?
MH#'<R2^I2WE@YF3SP`QOU1/->N5V]^5LS$HHXN`/OX=_$_D/4<PDCFC!4#AB
M:]H@(SR@Q0I\P@E9?ASZ-**Z0S,.V^]B%;8B?[@H:5=0I=FU--:"<[K&N?[+
MBS>C'`"LLU<TOHQJ/FD.9CCCTX/N.(==52";I99(EJI/R]_KUR'HW=B&]`IU
M\_;<)V3!)IXQFF.2HC`G6L*1=GNW=BL0-H#KH+RL[MK,`E"S'-571&28"1:U
M;>]:33AGB3JPOVNR@*1M&95VT[>N)F@++,6T5(DZ%E^[$O?0!+M0+%0K+%U*
MK^8HK>FUJPK*WIH!;5+K)H-0E5@V+O7U**L-X4"/2U7*>(2DS>%B]>>_(D3X
MYNGBAF^=VCE-VLH=^$V*4SAM^4U:<4!2>QFBFT37MK^:-N"Y4Q:`-PYK-;_?
MHY;WQ=]J4O/@G:_K9)ZE5#!\9&>K936@NEI&?$L5*^,0DLYV,%<;^WD-;+64
M^NCNM'TCPI*B97?G85\SZIS[E)^IX__QK=\G/ZX,N9>@H#*":ET?U`*@*4C5
MD`>TDZ:Y2"2DEB6@@(%E70CG]AN'@*4LH*F?4<=TXB?\W$9)(O9309T&()SQ
M;QP(=00"#0UKPLD=J7LL_C^^)WY")XC0?`O)S@\Q-`'A.D';#H=!)/N`B>."
M^J/M,:%N`L)%A4XPH18)6$R4I++39&'?#H1+"^VAPUXN>P.1;><.^W8@W#CH
M#B)[-(OLY'A:UX9P,:!Y.+AS.1O/9;CCFV`EO2F/:K^5Y#;,N_66_?[=XSWW
M>-<>[_OO7JEWST]"K]+_OASIYJQ<)S0EXDU,W>%L:<G?TT!9'IW6R/GW3$_?
M<::GW_,+M21G)BFCG*ME((2B37*N4@Q`SMQ(IH5Y-CSD)2\*Y[2MY90M9P.@
M*K0;_JK"0.9T':QTR@!T+,.!.BJ'#,Y.WQZ>G,`Y:+&;BJ2L`=#:9[ZF0B$G
M5FL[).4@V&D]Z"I9Z#89:.+F-U\_#6ZPKWG7::,(!$$J<;"Z)[U!=E/B&YK%
M-^Q,?*HLN%;B&[8F/A[L"J9(?A)*7[1+-.HPL"G)=<H!3*=5GTKC',H*PCE0
M;.D:RI@`IP3CVYGJXD"<0S6HU,H`]A2J(Y6`=A!W4Y-[!U%A(P8S$2,>).$8
MT91]$_*YE'T4-BQ*%X-'@L11/;7QJ-\&!!_'!,*5A:G/'H`A]ID3*O(!BNPU
M_`$IG(BM`[45,M3IP"`ICBE9&B0#/P"TM$:8=A94E`5BE:SP5GEN5\[.:U`*
M:+OD1E%0`QC_\?GK>/K@Q5H9"+9("[FR,M9H;\(C*+J@E\_SB(A<97FF=HGA
ML"C?@=%0G&0T&`T+7MJ4MG36L:K1L4&PQI!1Z$Y,0DMB!SGENU9%:XL2%1G_
M]I/,)PM6X4R]&JE1N?/@EAT,C>J1L-:J9<@>,YH>'QYK`HSV=;L,X+I4RB9G
M`/RC&YZPM/2"L&G36EF\`[NN.(UNNW&M9`6H6O0[IIH*0%:$)JB9E`-H1>A0
M/2`=!;<J:\U-&+&YPN>'4`4M:MLC+P=AW6<&ULK,R)EH/'?YYXS-IZQ#@XBE
MQ2!LQ=:0L)0':-<"JM;NQI#W0%FZNPP&!@;4FR-[GE6@RLPR\:CV=H^^"H31
MM;4RUYEIX>&O<O?\[@/O^!-.SC-"T(8*+.M`N+QOH0-+;J#-=>7++RI'JU($
MPA7Z&D.B2GSC0Z#<W4\$4ZJ!OKHLA$OIMI!7<P$9ZFQ(!E+-F`I#N!N^)?S+
M;'1D"VH;@FZ&A.+6]6Y68"_&A5Q!VI(0+CMO.2+`JJ3*SY4?H!I.;+DXA*O'
M6SNP949@:VCY<-68#7^Q^1_>(1*P'_Q'N\NO^@9`//&UM1KUO+5LB?C0O\+D
MSE_P3Z/)DCBS25+7;%<]VZ_Y:S'5C5[&:+XDY8Y$21#-_7B0A,75^=K*LFVN
M70UNO]#?G5-H\RAG<S0Y)RB,^'S/$T<L?DX88>&Y/V>?Q8F=(BG"%4+&:76'
M]MH%P?:1!@>L[@,**L1KW1_KVNUJV$'PPI8Q:/I<\^,,^E.6;E=?VP="C(Q`
MT\\=P0%"(;UBG%Y3FOE)P(!F$0NTJ=BNUG:/D=CPU+@W=![[E(XFQ4&7$1E'
MC]-T>>R%4X7">WR7D6#J4Y2_@<MF!C87X.1SBH.OH^0<)T^(Y*<Y-MTCM^VW
MJ^(=PS%N68<VE*7<73[SAY`I8JX@Q_*2V>)7>J08W5NVU2X:=@\!;<DF-,TO
M2>27I@2-HRREJ9^$ZGS9^BKMZG'W:)&>FY87L+GG/<2$X&^L_Z4+KENS;-U*
MN]O2V\>#MF80VE!;KI^+U'T:!TE:LEU][7XH1,I$X^.I>OKJLLBLR'TP\X&S
M:NEVY;UC.$?'"+1Q<(-2A@RZ7).6YEO]`MU8K5V-.8B]&#F"IKHJS.A5EO(G
ME_-L;T7XEUYDJK":=>UV%;E[B,6:L>[3UHK%R!3'C'6:7V:LEY+V=#,E;;G)
MOWAYH_N29_9S,$5A%C-?7:S9ACX/?.(9MUA^#KO5@50Z7+R4*;0Z^.:34)>=
MUF'[G3RK(_K77SU9*P,GMZUSW58>RJER#6!NWI[)%UZ2\"[V$V.>EV:Z`G(=
M1HKY2K:*1KAOPAF^G,UCO$`HS\.^_)3'HT1/ZGL"UE4AW,YH$OHK%]M:(@#F
M`EM56Y2'<'J]:?U:B*&)X5EW3`(:B(K%3RL#$?SH^X(H7PQH?*9*"3BII1OU
MF"H\P]&2UM%9*P/$0Y'@2R)H0-=R:XL:].7;.N)O[8IMT:L8CB.>V&""R8QO
M0JO-B;$*!-=."IV5*3"R``#\UTF`9VB5S>N&]\0EJ;8.VAIPLLTV:BVT,H"K
M5>T49Z@#Q+I8X-5"48"LCW-5@;9.+M4'-7G@&%'$!,0?*[_@CP3B.:>]V&C4
M/PQE4Q."W;,";>4%*1O.`.CN)Y0@DA\K#V=,NC3E6R=/R$9[EG4AA"QJZ\^2
M-P`:-%I[E;'?V$.K&U:V:+B[?!GNQ%()-KMSLO8U(<?6@LT#0^4#76,<QU>8
M\!]=8]#0&80YJ2&$-B0Q:&<?'/+Y*=,]V>2^'P@.3;.CN"%`+@7XVK#X4WYL
MO4B`*3)N-(1&:4][/1FVCD>I"%\;(IG\)BCBYZ96G#:$2&E/>[%Y!@:14A&"
M0R3?&\QOYEQD_/GYG-#\;DYIXY`N+VTH`;=%0Q`27+6(IRTD!`XN[J3U'\0O
MDJ!P\,16](^H<BF(2W+2U@K$FI"]GO[:6IU82_,[A7:W>'YUJYR:LT@'H-]#
MI"MC9%)?NPFTNZ3@E:VCFD2\2[&_.M1+_/DNH%^;C+UV6V#AO[;L7]T@6/+7
MZ1"H2<0K6V9V.0!J2AX:_`>Q:!R%<D$4N\BJ*UR6E?<:;MIEHJT$FG_&8UOV
M[G'JQ\*+N6#M7/D1^>+'&U=Q&^H#0JYQM\!H2%#0IHW510I$GMB\)F?X$\]<
M1/E4R'FC@KGR[^>8II]P^C^4CE&`'Y/H-S:.2E$_TZ6C9ON&D&R]F4FK)0%^
M-YC-[;[(@RJ^XN546:[:)@)"ZOH]0[%"DM#@O+545V9E0&DVRT?K(`EO43K%
M(8[QXV+PP$\1!JJ,*JWT#"&S/["MA3KB>]5H'4?TZQ5!J)S<O0VLROO=Z_V#
M^I-!8U"62_=5`YFO#P-FG;[@F#7#,RRW!655SWN]-0`(S"KY@H3S@YGIA]I1
MN#'B*N=I%G$B9)[Y,4\L=ZR#=]N4[/5.@`.XMRWO5P-_W9CGO*K6?TUVN-=A
MUH[`;"%6D)AU;:<NHJ<H1$G8MO]1[7>OX\$`O8^J=`%DD<P>*/HU8Z1?/O&]
MM7HY)-])<DBN&O3R%O<F@615$MI<D-*BG<P\:Y3H$SPJ2P-*]:C10F5PJEB!
M8`XV:=,G8527!Y))P@`S@V(`99!PIAK0F2-<J`MJQH@U@K59!A1E080'34#4
M*`E0!@%YKHJ2C[1<<-[C(J?3%28C[I30X<)@K1RU#2@IGZ5M<\3X?L/#.#4[
M:AN(A74ZD!R!"9CM!@\FT#X!;("UEEWQ',=,]9CD:_DDO(D"?AYP\$B0()9'
MF*@ZTV*MZA#\#*>#YN4-O3IB@!:M.^<OLB`R]TFZX,F)-2Z(O"B@Q(V6'H6<
M#P"Z&*-Y\=+B"COKM!KF;>OZ0`R]#GW5:=6:L^])CZ!MK'/=MF86_YTE^+X4
M*KY.`K41U!2&8?)J8G%EUC2,03-B:S/_C2DAG[)XAVGV#"SHPE1=Y<%3#)^?
MYXRU)"TV@<8H0-&39/_`4!;$21\+I1C8@#942F\WYWE,\OPF2I=/41K$P90:
M0T;)"#3]E*D3=_+80D1\I]OUEI<'<=ZBSK2F9J7Q^VG+E:'J1=7J[R#.`=C.
M35726Y6D>+`U7[KI15HJ".)>TS:R+?'0N)#SAU1?[,P5)G<$AUF0EN(:,J%;
M5@1Q+<=6"98\;76\Y$,_%V&4'\5@W_P?4$L#!!0````(`,>`IT:%SU[%GD(`
M`,LI!``5`!P`9F%T92TR,#$U,#,S,5]L86(N>&UL550)``.VQ4M5ML5+575X
M"P`!!"4.```$.0$``.U]:W/DN)'@]XNX_X"=O0CW1)2F'^/QWLS:NU%Z>;6K
M;BG4FIEU=%PX6"1*19M%UO"A[O*O/R0`DF`508(LDDBJ]X,]:@G(%Y&)S$0B
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M,\;HE\3[AC"QAPG';8`D'\XHK(S^_'T^]NWK_WY_^Y$3?^:'2>J$;CF+P?0;
ML!R-/Z)*XGG[XX\_ON9__89)CY`_QE%`'^B:\-_]E.YW]$_?)/YV%P`L_KM-
M3-?UJ(,X?@WS7X?T"3XI2.A'D-#;/X"$_EG^^M99T>`;`B-_?KC1<O%C!9:<
MQ-DQ$N]KP8]8#S#YEOU488M^26GH42]G#-`U@.;4E)("V)%;`1C`&HOBJJ#6
MC/HS6*IOOA<+Y9_A-W^]E(JT#+VK,/73_4VXCN(M7Z/+59+&CIOF@#CY`I+I
MO(YB`F8`R3*N<N3$;DX$^[%%0'+$:S=B*V^7G@7RD_'IZSC:=F-!D!%UF/37
M8-5CB>2\5QB/:1)EL4L[K0V5WZ[?K*"=S00[3<.SGS]V8.;?<B3$"3TBT!`%
MSQ\%>9V6KL3*,:Z=9,71L@WDR7%V8'U__YH&:9+_!A;Y[\_>O)7V\)_EK__Z
M,64R`,H>G55I1:1\M(.0+N!FIF"UUH]`N#1;".V[#@MPY!,'^/\0K#QF^ND-
M^S%I$X$Z<"XK\(BYVE58C)K#2CPF=H#5"$`)AWKRDDRH^]U3]/S:H[Y8C>R'
MPT7(?O57888?Z),/1CY,/SC;0P/8,`SI`FQC#):?;@S"Q==*:M^E)_?@$BH!
ML-,NO0NV\F,GN&%N[I?_HGLMZ\?CT"\^#6O5U7<P"/7RT]%ZXOJ38`F'2QC@
MJ59@[I`^,K`U3!_\&?%ZJV,D7V;JWY"NKEH23XXR`-K4*^F>QG[$0BCODFWJ
M#9P>CIO!VJIE[7"1508A7VWUM)Z\[`18%M]Z!`!/M0*7#+D'!%P'SE,-UX=_
M1[SB:EG)5UKECTA76#V-?5=6`8T`N*G6TT46Q\"!G[A.\!?JQ'JCUC`4\2IK
M8S!?<+IQ2-=>*[E]EZ$$3`1D`J`G-W+2#164/-!=%*=^^`01=':8.#$8CGAQ
MFC!Z$$?4CD6Z2(U(/C6JD.NU`$\$_&G7ZK4?T/B"J<A3%.N#V\-1Z%=F+5O5
M!5D9@GH=UE-ZXO+C0$D.=6(#&6VW4?@QC=R_?]PX3&!W60JGK7"^KM?&YDGH
MEZ0)TP<FLV$&Z@5K1/BIYI/C(!S)@@@T1,$S=61=.C37[#=UN[U^).*UV\+>
M87Q],`SI*FVC]N086_5!.6@[JU&$^F;KL3IV-BNRAL7Z-:D,G,6JK*-WJ'4I
M4T"#K,P!SI;OUM=^Z(2NS[B.$K^A?J?C5*2KN(\`:D^D&^8A7..]R.^=#8A"
MCX90,,E^2J+`]WB%Y+D30%$?\Q<H31/RZMZ!&&Q#4Y_IQ;?V=&&9)(R>EE5_
M-`CY^JYG2EW)U1&(UZR&T-XI4PZ.?,H!'I53#,)02N.$WD[-E6TEDGD5(UTZ
M'CL+E=*P>*Q9!P/1*YB.WM-6Y*+(M>%0N*&YS+ES./2?["G@A9-LEJ$'_[GZ
M+?.?G8"1E2S3"R>.]RPF_\4),EWYJNE<Y`K:202JPAI-1*S`W>COO=09>%Z>
MS7]0$"V(DY(<%^'(1E'Q77XHWZ3F$\O"A1]HB0A$0=GOHS5AKBT1)(\H#>;0
MQRER>:SHDQ^&L#;&ETKK-F!9'O8VB/N8[AS?N_JR@]B,B>".?8JXLBMJ1&8V
M$_GFT(%]=6LPF(9X8^A"?=^E+G$0B82O>HZ&''B`=O1]2A%0@23A,HBX#-R*
M?X@D/C/QD/%K=*ONSD5+AUV,DVA=E#J!<;!U,DN/@`Z-*MW'$7-@TOT]XX9?
MBF2[^PYRJA^H?@=MG()<T4P8KNZ9^O&(U="([/Y;A`"^(!R\N.::(U@0AL+6
M]C@!TYQ;6G(;'G,[G?H^T"2-?3>E7GTH\($I1.,VV0D`<M7N+@Q5T<UG(U;[
M'DSTU8<2%6E(II0([9@$.P*!0-F>45""@E;]UXU%KNJ-+*I:73L0L0(WT]MW
M:59#6-LZ.2:/MOUIP59C((%?NZI,'$>AB/7G@,!A3Z"G##<'BC-MZ\.M[ZS\
MP$]]FK#-EQ?9;J+`8R8"-N%TWW*ZWF$Z<IWJ*@A5ZTSG(M;+SBST7?8*HB(N
M94&;[0-[:_RKJ'XGI8'"')B5US1.F(_*&Q3:Z$?/0ZV'+D910..INQF1WYS%
MH$1AL0)GZ;I1QN+C>V</G<-:SEIT@Y$K:#.3%;^W=B1BQ6PAN+=?+,$2"=?R
M>>C87.X$7*MJ&&?4.S8[>H%HQ^-7QF96#_2Q?C!NE6RA^83U"I!)W99I33%'
MYC4O3[`4HUOC;SK;<TG7E/'D/3"V+MA__;39]C2-1VY[6EE5;8]V,&+;TTYS
M[RN!$C(!T$3`MFQ\QF,V]]%YHXTHA!)0+^>_CM\3FI(_T!T3S(:AS8W,_CJ*
M?PZ?:9)23R8-/CNQI_$(>@-!JJJG":7H7=X9@F6ESA]YX(W#!_G$`YQS[A@G
MO!X:ZI_=O%;^&8J-%\1)\LKHE;PCF<`=20+W)A?PI[B@N(AU]V0=Q2231//J
M"BBTX&0OR.>-[VZ(G_`]D9^OIA%94<++%.'1"Y]I8DC)'F[)OV*``#D4:SB\
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M\NJ?VI,AV\9A>L$@.5%1`XA6RZ`=C-P"-#.IB^UGH=$M!`\5X5]]<8,,6L].
M%NNWECV-S7@1VT/(WQ(#3Y_>F))ENU$_-$/V4SAP@#+5BRB$##H-7;;R-')J
MGH'<5AFP6VFMI!^.V&J94-V_.V8!6UP`5*%;ZHDS(;NN"IV\^A"EE/S>8O?/
MSO<KYGRCHML=BEG>FACQGD#=O0"R3-/87V4ICQ_2B(BNMF-771NDWB<6A,7"
MZ_M89C<X74V-#NM'(E?:!O8..E4=#D.LIDW4GM"&26:YY,L4OXCRBILD8<&L
MM?93(_*9"#[_SYOOWKQY2W9.+"I*_I4X6;J)8O\?,(8_SW'VP^+-FS?P/^C(
M]YXMOPWY_NT"BJCXMGQ)7;I=T1A^24#/_I6$D9Q+?"Y`$L4D&NZ1C],\;OG$
M26-7T^-AR#5=Q]BA0ZV.0:SC6E)/\27+=V<0:/=8')KK-3DC;W]XTUFWI4;S
M/G6E2I<PW[U9_.'[?UF\>_LO]2#9WW_XPX^+[W_\$?Y^A,#B"8/G\<<,G.#>
M\;V;\,+9^:FC3:MJ1R.W%"UL5@X'ZH<BMAMM%/?.:A=P"0`F?D@D:$M)_?'Y
MA'K/,\:G6\_GE%VW4L</J7?EQ-`).%FZ;K;-`G@8Y)*N?=?7=]LRF(A<6\V9
MKW;7:IN%6(<[$-^_+%6@(#D.\DK!0B2:H]32-+H]`?\JLYZ`B2F-9IR6P*^_
M>N::TV6(];.!V`G28W;.IT;@693$)17.*9Z&(;5]4W2G=^W3D*NI*>-=^@0A
M5F%CTH?M"V2]G'4<9H4F!P<LX]+L:C*1F=*[F#_HY_'DPSV-^5.\1IG(ALG(
MM;R;$/09<MU,Q!K?D8'!\N@,$R1_!2Z1=X-W3,7+SQCRZA.(0J;DBEP<><7"
M:B\*`B=.X$$;D3NS>)!=E8AXE'M9I`N-Q%@S:5;&0,>TW@@<SIB-\FL)'TSI
MY;/N)0H,BCXBVU+!90K<T;)M5Z/%:4<'61439JC)56;;M%B,GID&'Q`]M/;B
M.?H>B5VIM?(\2R@O+HV]*\_7.@BJ.FN&NEO#=IL"*U-FIL5UE`^MRG?ZT@M[
M^CP.XU*ICT^F4=2<=(R[S68BU_`.[&N*5688;G>A?IB2%H2!]H1"0!]B*[(P
MC*^;9\Q'Z4TBZX;A\U#RP8/+JG(C":@G8%@J\E&Q&B+-;8RC]:/GIK'Z"%HS
M=$Z:.E`P6:>E:,I*Q^"4JZ<,F1&I9'N@W#)E;LK9$B(WC9^3F@X9(];KJO70
M>`J>$0;%-Z$;;2F/"+;M[]+H1R-7W!8V59W5#$6LKFT4]U^UH0>]0_@%YR0*
M?(_'M`4BWO+V3G2<90/D5>CM+J8;-LU_IN0V2BRN[;N\&>Z5[('2LKJ;QB-?
MWZVL5EX'U0U&O,;;:>Z[R@O()`=M_;VE*9C-^P)9O/3[0!,*UY*6H7=)GVD0
M\;?%)<\:T;3-0:ZG1BP?O,^MGX!87\WH[G]O0$"7=^,*^+D*6WMU>RJ>O1*^
M/?W],PV9-0F@DYFW]4,?;%3*MOUF#6Z?A5R'#=E6M;AE"F(]-J6\[ZJ6\$7;
MO@H&N[H\)=].!0,B?]G4/<&OLUK6&OUBQ'JIIW4X/]C.-8'A.1/W`J(CUQ>!
MIHG0'<+D-FE41LY%VX[9J]6W<M@<-*Z&VM-U3@`EKP#L2/==C15O0`8!"('%
MD:M?%%I4NP]1&%69E#:F)3%D,@^Y2AJSKBIHZR3$ZFI.>]^UK6(H]%<B^=9Z
M#FE\_N_2#8V)+QF7F^JW%O-)-_PM*XB)!<,W(9,2^XTV;:X=CER9VQBM'F?4
MCT6LNJTD]UVQ)6"IKPN2P[:CI"-R*@!)];2IDX*0YIS0\2CT&EC+5E7Q*D-0
MZUL]I2<OOE$R.#\*AD+Z!*>1S=HU$E^TGJ\)XT?8>K4[O,Z_;YN$7.?,F*X$
MF(TS$&ND(>&G>6Z-_JNE$'1<OF4BB',O=;CV:<4)(U*:MJ:`#L<@5]-:EBI1
MI3H`L1+6T]D[6J1I-<DS:5^EUFAQ<%Z#FM*?:8S(.+S(EP_4ZJ8Z%J<S'7E;
MNOP*S[F3^"X</?M!EFKKXMMG(3<OAFRK!J=E"F(39$IYW\5=M%TL;J@M",<A
M"BL$%CL6:6S6"[V&6VFNK,\5$E@5$O`$,G2WV'ZE_M.&$;9\9G[2$_V00>OF
MNS47E%*W;&82>@-#;BE.$Y)J0/I!0FQ73F2HK\[E:(G$2P1B*",^OB&/QA)9
M%M:9(X6E&JF$9%"7S;Q&<$D8OAJC%:H6CL_B=DS,M_I<DZP?OUM?.,GF.H@^
MMU5FMTQ!;HA,&*YVH=6/1VQ4C,@>]2X"H"4<K]6('LBXCZ-GWZ/>^?YG1O1-
M6!RN+]W4?Q9ONO-GU#+VN_(.1=M!]%#`D6O,L$(\2#X,`!FQ%@[,X"GN-5?'
MG!"RVI-70`OQPV])6?A2TK,@)47JM2+K)^DX)%J*S"D0VGRDY6^9.+GDCU8S
M^=PP0YP\1@\4]-L/:"4-\Q@9BK#%`$Z`%KEIG$KPU?=GQL6)V)Q.QGKO)R1*
M`L4;]V!T.8T+"`\*,LEQ`IK]N:.)MFZ+Y_0Y0+YQ(?XB&F._A9_Y=\J$L)7:
MY-*V6RRDNJ0[1KC/-S#V<T#A![@*L86WR?_!?Z_Y0(93D1O9+@)0#:7)/,3&
MKA/Y?35$1;(@!1IQ`TA!9,?`3"X"<0.H@>\)$S,RSTX]N,7/HNTF1=<.1J[:
MS4Q6TC"U(Q&K;PO!?5<K!WL&/XOV#CE@.PHZ%I/0FD4RZ38P.6&$I=B$N_6U
M'SK,D0B?+J(D37B:.7&CC+D9.D_)?#IRC>TJB$KD8C@7L59W9J&WZZH@@FQJ
M@8IP7/(@1F*SY/[;DH670Y:W[U<I;[[&T,.Y3'(LCPD;EO.'1__+#[V6^PZU
M`Y'KOIZY2B?RHU&(];F!V-YMM\43L6<`U/*-AA&XRY,:/IKRZX]I[,#A[*T?
MT@<6ZFL/Q(Z&(5<W'6/5T\GJ&,2JIB6UOY<H`!*`2!X&+]<TO]LP.&N7>>?^
MNB)4$]5:,Y)!87YX\[U4%_C-7V]"/_6=X-KQ8]YQG'?4R'-D=^NK+^Z&$4RA
M"%;4@!PPW!L(4E4[32B@B/T@6%93+W(S(*TNI7`B0_T;*NT8&)&IW5"VO7`"
MR)I1()O7\Y)?CA:2M.H?ML(99)XA50C+:W.\+`:W&:#N:.Q'WG>C;,9UIL^2
M+"5&`BCEHP>BHT^.%42EXI4%7],Z*9:$H^86MG[`7)B([1X,3?PDWRBM763U
MB\MJJ]B8,B8NJ?BO<I!RX>S\U`G:N\>:`T!JOOL+XZ#'K.%LQ-Y5#R;ZFQ>!
M@KS*D7T+RE(>44J$UL\G)Y3)!;<,"<C!21(J4Q/*Z\=6.S$<BN$^ICL6&N9>
M9MZ+(O3XE;\E9\!8IH;`9F="N@BIV9R80)J5:>G$T,!F1N+.K[-S/1-7:`5>
M>_?;K4@I%T?>1HW+0URJ=6KE8=/N+%V1M[UW]N!$@;/GNG'&!%L:2F/Q&@*;
MG=WI(J1FNV,":59VIQ-#`]N='#>1R$5()=`3!3\65V<2615"V2E"<:10['=V
M/*U86"/JDX$BMTC#"&VX,G_$%FH@QNR7]5OK#6!;?*V%G^B,E^A2-M+=I>[`
MYVG,>@K1P*AUA#P_X]:7P9&,7$'.?.\N32W14F08S!SS3WF!_F.T='_+_)@R
M\3">T_T]8R]E;NL5^RU_6T-;Y-`!`')SU5T8U<H;T]F(S4X/)OI7ZNR+NR$2
M&<FQ+0C'M^`138'25G)I2J$P\C<0_D9KLI-8N!"H3@AS<8E&L<KX;<HP0AO.
M]4%L>P9BS+ZK@RJ>FU)\E7C.1^7H:*13U$V/$<]U!SY/8]93B`9&K2/D^1FW
MO@R.9.3*>PZSC>>FEF@I,@QFCDG#I=1+KIG>WLA;&7=KY4%OG8MK,`^Y<3)F
MO1*TM4U";%+,:>]_O"TPB&>+<AR\O93R<KVEVQ6C<Z_RZU9>K8>F!>R7,=W)
M<$T<_%>N0=E\2W@G`]:[]6T4/CW2>'M)5SKGI6$X<HUO8[3Z>'#]6,3ZW4KR
M"=7>>>Z%K6(`?<;4;4L`N*T<RVC,%FDFIKY!P:I7P^I<@I%1_"'\VCZ,T(8+
M.A!;CH$8LQ]DH,JD3"D^GDG9J>++<O&M404<(*AEZ,%_(`O^[`1@;._Y59_#
MLBB-N#N"0&ZF^@A$-4I=YB,V0;W8Z%W_#]H"'CC_0<&W(`(CJ2DKM&-;)I4+
MMR3%?2HWEQ+_@9;8+3[>%3\YH>PM438S%FVF[L6-Q&J#"R<HVQRW)&6'@HW<
MW@PJPLJ+84,`1FRAAN6O=RM;A0JNG!^S[=:)]_PA`/\I]->^ZX1I7@`-V_X]
MH]2UNNF?)#KH3!-$219#5;3"8LEASN`C_9*>!_JDI04R7K(Q..'##&8W>M#P
M4DW,*:(8PAHM2(5D;IQ4HI6^6$Z@OCY0$BX,6K,5(Y^`?,+IMW22-.O/-,&F
MH6EGPN_0\8JHQ.?2JO?'VL8B-:E&+!8]2'0#$1HG,WI[WTD"P$2!#&OR%PAO
MR..&QLZ.9JGO)A"0'74"&7`MZER'UL%S6HVUVW#S2.RM;]H)[[LPV>HC##-4
MF7KE!K6.8F9`Q65=XBBK%AJ?!A3>U3GJ8+.`E^2##!ZZ(BO'_?M3S(PL^VWJ
M;_E;76"0H=DYL\/_8//K.Q),W`9G/+D>*[R]#7UR5H>U;<,$9T4WG](S:4N5
MM$Q!:A.[,*P&*$WC$>[7G<CN7<54-JMZ3QV`O;6;&:SCMBT?T#9GANNX,=)N
MG#"SE3R<E5:6L@(?09@Y&=NG:K#.QQ:=!60GE42MTH"R*U\\]0*'&_Q4](F&
M$'`J\7%3?#@<;*1:/HH(2X=_(,#HXX.A^>S?B9EX=,T;94(.YMGQ`VC!,;5;
MCT4<>2N6G)*%*"M[S,O*%D2A1QS5JA0-F@KH)9/FA,')(%^>46I(/IP&[V6:
MH$D2&0>M?Q8'!8\+7L:L*J';J(08;=>`T?QI)LM&9N-E26S"1_P*/>$W!(H7
MC1YH`'7)_,T4WN"8-R;.*X9;DB8G`T6Z)PPKM,J3@"=!1!S0#L3824VU-U'@
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M5TGJ;YD,=!?/CP8A-6G-3*FN1'4$8O]!0VC?]?>S:#Q9`%P4RB?_:]V%&)EA
MB_>HU7L'S=Z%X13D6FC"<.5>=,-XQ!IJ1';O>\\J<'S*.BKO]VQG=/U=0!.1
M@5-0H>N&8*;.AG.QZW47$1@T/IB/IG>B?XQ6!]C4WZY`;#9@>Z9A1A_$'1#S
M#=UD'G+M-V:]VINM91)BK3>GO7^W-HZ!*"CPZ;H5,5C,P1<G8^K9V=U.7AJ^
M87H2IOXSA0<"I,73Y41[04)N!4X03R6CWQT,8DMQ"C>]\^+*X;.*=4$$7KYQ
M%ICYHQL).MMB17#\G?KS(\'9,SE73ASZX1.TBN(",7,IVF<A-R6&;*MFHV4*
M8A-A2GG?59W#AZYHHC`%GR<QM@R@)]IME`@9Y&VL`9'-=K"?E6XA<12R'UUQ
M?4MP;Z;K/<`@5_Z^@JDV>>T&`[%YZ,U*?UWY7.DA4T&)SW1,+A\6B]"#-CL5
MK!8#%'=#O2R@=^OC=Z<?X:)::]50%P#(S4AW852B$./9B$U'#R9ZN\X2%:3E
M:UYH)Y\X/OO6PI)(\+S/7@H`+N_<A$D:9T:E^$839V,3VIBOMP6Z6;.P`:W$
M#['0J^]*$`4?0A,PB42JMS%Y[B4+G6T4I[Q1%-SF!#^"K)P`GI%)R"OZ)6\T
MQ9;T,V4#06XP^ZA]]0D5CA<E['LVCL8Q]7@"!#H:*G7ZEW3MNWYJUM%A"*!(
M;<BP0BL*)T^&B-#V#,S8"[EM4IB=^M3F,HZA9SNW1.?[HULXR\].['$+VFK6
M3H>/5`5'$V7];G\B<(2*.1Z/0^R4NG,+HI(#SZ+4W*XCG";I8QPY%M-IN1`-
MP[+\XNM*9P_'(->V6I94C:D,0+SJZ^GLW1>!+S@`1SX!0(N+KK\2ER()/3A)
M^^!LZ66T=?S#"Q(CHT*N`F,*N/WL^S0\B!5R5'9/.CTGQX?`U5WH7.Y"<F!U
M%U),PQ+ZYS-*"%!(/@D:41VI?X7BGO#\?KL+HCVE/!01Q0OOZ79%8\TG:AJ/
MW$:VLEHYK=<-1FRMVFGN?4(O(8N7E?,JG4\"NJT3^6FY'3"Q]2$*3=7.9#Q2
MM3-FM<@T-0W&?C77B/;^![H[\=Y+PE\%*/<=\GE#8\H"3H>$47A&\X7K)[P7
M7QJPK2B-H.T_A4(Z/^3O!:RS-(,:FR1;_8VZ*8QXI@D_*(;D;\3&Q&Q.DL:^
M"UPD"^+2.&4;%0DS8`ABX01VNR0'R;$Q,E)&2;*CKK_V&>H=`\#P.(EH2LI?
M"N7#G:>8<@8FOC$\ZE=BP`DF0VF18\21ILZ#O&7K\R:E6UU.9!#`2$WU\,+K
M%#.V0D7L<PW(W-#5U&J`TI*4!&((IP9KY#>!&`T.8P81QC.-5]&+$(>5LZER
M%TL>HB"XCN(BV6]>(6(*!;O![B<6S6F2"0C,IK@G)X.<#"G.3T(`)Y%($5:5
M3"2>\O''A$LGDG=[6$SQ#,%"%C+;PL,!2(AAL"V%ITSC9Q:Y:*QPP&GA#V\^
M%.^IB:?2>7]*<RLT/+[9V*N11%UOV09&-@L;.!;/0UC+,F84Q&D/UA>DI!`F
MEC020:1H9XO0QF(6OU.1*3?.4O:N&C[PMQO81A;)74T\("FR0FRL,.H.[!PH
MJH7K'6)UKX-GJ(3<DR3;BM]U]1N'03(;,SVD4-MJF/ICF(5!'I31H:N9*OF`
M1=6=79"",*)0AM#HHA/Q9^H_;9BQ/'-8T.\\47AUMY!?EHCLO$>A^!HR,#PY
M#P_F/?,'\PX]YR<6_H_?0[:I>KIM`E*[9LYL<[M8[!7-9D0/W0GU4XX!30/4
ML5FVZ.Z`/;AA1H1ZE_P!<.$L<L.7?*"?^9^T1QBFDY&J<3\A5-P.HYD(U;LG
M`R<E?XG`0P0B&7#)ET.84P"WL`6Z4=1^%\%CYL_-._]$TA!'W4D4\`-L3?-K
MRV>>]W#6WG2<D`_`KMQ'S!R=)?*_8E;28R)/*S[DL"P>S`W#RWU57T1U"'G%
M-,J+@L")$[*CL:@KZ76-<!AENH\CEU(ON6:K$NP'7'FL=3(T`NLR'[DJ=A:%
MJJG&DQ$K<G<>^K<-%I@(?`&2XR*&_N=4Q]+3R>//,?1"VE6D,N"^JRO,I&E?
M]>\S'ZGZ]Q9%6<C983+ZPLX^O)S2!0R!*=#73WZ%PFBIKYQ:(J/9Q&'<I^..
MNRV/%C9.0&HAS9EM[B>-.)_8@>@!6R<WY!)M+N'W?D"3-`KI>YIN(N^:T1?%
MNBQ;A^FS6][-@FA>[/5S9[7T6U@8M)5Z@8L(9`LBT6'II#Z2,*X9[<2-?4:1
M[Y"0;774XZ4(4#CAA'MYGT742K"?.%D#Q@`BV;=,T]A?92D_&HR.SQ65JY]7
MO!D2]6#[_U6>]RW%<=\'?EM&GDLF=UF:I$[H:8*'J1`C-3K3"[\(5R;!BCW.
MF58(`]R$@\-R>0F-2E*$3PQ_.#IX/[JX%I54$4?A&NP+'T)$9<1.5D8XZFUO
M/\P;H$EHGS>^NR$;AHVL*`V)+XY.LETD[\<Y<;!G=-+8]9.CDWU16P4XE2MY
MXI9>Y69>%L*_Z'$9UL37Z.:Q5N2QS?+@X]9>TU<_[E5E->7D$DDO^5"L)(E`
MH=E"`#JK;U%5U%Q)B59)#1338NUAK?0N_2!COSL2X=+[6Y:D0+'&P^H/#>F.
M/I"8U*BB)RC$0<:I'/552)U9DZAK;!LIL=L)06R)ZCY*X7J[$[`=W`-T<)4^
MH6X6B\[1<((I[)7%8\N;T(VY?7<"\7I$W;YPP7B0A9#+T/N5NS2I+H]Q&D3D
M-FD`<:EVZ01PB&W3$%SUK[PK<%>>0SGVYRYSE;Q:K\%UAF=7X=K"G>):YV39
M,5PVY9A+@0EJQQC;L%\6$=`:[GN`9$4L(H(:T:1C-P>;5Q9^GV>)'](D6;J_
M97["TU/)^5[YEUE?6F,PR*U;7\'4W]`P@X'8CO5F98@K`#E*HN)<0#\&Y1?V
MV\+62*:A0:Q^-'+-:&%350#-4,3KO(WBOLNY;@E;;RE;QRS\&-/F_K`F\V:X
MB&M9;UO.E4DS6]CUM`^ZQ',<EKNB8N7^A$.V7Z!._W'#XO@=9;ZEFS`76=__
ML'$T4ETU9+,X@](/Q7YP9$#Y`*<]?KB.XJVXA+H3S0@A)\7"&HZ?J`3`T\$3
MGXB,*(1Z_FSV%)R<68NU0'!LTN`(JW]':HFTK%3*=?(_(O8"CFGL;5<`DG4/
MEE/1V&R[.F(.ZTO?4%OY,_8U-M3N)5:9U2;9T_$SG=Z\=[[XVVS;J#F'8Y#K
M3BU+JO94!B#6GWHZ^ZXX"<VR#HW"$ZK$R6U+[^.6*<B5RX3AEDS)[5%;57RJ
M9T3VL"G`6]MM@T?E60$Z8.KCZHN[@8T4\OV-_0O4\X*Z**PO(*3:>KIPBEQ*
M+RC8TRRG,=7[QME1V>P:BO@*2O*C8U'NZHE.(5#PNA/M&7=9#!?B>$&KHQ`V
M<7K&CO!4K*324L536ZH4A0T*[JEO>*.1DGQ5A"-&Y2.)#N@W(=N3:)(F0C1W
M,;_PR2BOELZ*OYIO6OV`([7DXPBQQ4/K`7E>OMPI#`[I]2WD6P`D)R6W:5%,
M<F(61T7R:-Q#&V)4C!HW<LQUSO=07JTFR]O`X@[H:,I2L]R.`^:?=U'X0#TJ
M.E#>K2L&GQ-9MRWT!834/)TNG,+1[`4%NZ-Y&E,#7>PJ;X*H)8I5'8)Q<4'5
ML6<JM.[()YW8];0C3M6F%&997$=[J(BLQONRXGM:%5,EB%%#EN,EQB_S'2^S
M`>WV);R,YUTY<<B;Q>=2^0M-'Z-S6NM9=IF'V2IW8;TPPB:3L-O<3CR,9F*%
MP4PW3DH^,_>(>)PJN+L*3S>NLI2$49JKR6JO//PXL4V=1%P""1%8*DX:88C`
M.JRH]'T'U/YVE[6XCL2O%3!2;\*JU[IT-SY]YA<.[M9+S^-`G*#HUU#KY$V$
M%[/UF5+TA?6:`BEVZS>I#`:RGLXVRD)^V:BX*I/?V/<EC:3NO=S<A>!F\W=)
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MKW6O-Y#(R]CT#QE]>;O_B)]R$C?@Z`N]4']@Q.\TG6.@5R=[A>#7CA_#F^%T
MF20TA<Y\M[ZS\@/>!>\]DP:S-=Y=^`"=\?C+PZ'W(0KC_)_G3N(G3;WGAH2/
MU`$8391J1?A@P!$7A0_/8^\W.N"->DX*D7AY)^X%*7#SKILJ=OL=[@KQG>\5
MHKE4&AI\M,^:B]HULUVK3/53YJ`B+93WOKQ=`B4<JO4F(@7'EW[B!A%0![=?
ME]PS3AH[X1E.G<OZ-A!`[2)OF#>'E6Y"_@!VOD3#+WP3B<AR:SSL4IC.#EPX
M<;QG^RR+D*,8FN1SRFKDT]@VI3L4Y-:AIUA40]$1!&*;T9>3WK<K)#Z2(Y3Z
M0NHURFZ7%]S"0>!@5%RJZYC^EM'0W7=VG0]G(C<@'=AO=Z$KTQ`;BB[4#^%*
M%Y#QN--U?)MYTXTSY[+:V]FO7>WZ:7-8[0;4#YLQ41<^#C\:HPCL:G]2Y+0:
M/6?#J3/4?YT`V@S`X;R960`M^0,G396<J5T'&(<0D"F_FL+NKO^UL^=H`O1B
M:+4"QU/G9@@:.!A:#:HG)OC,@251(#`*Y_OBQ__P:<P4:K._I<],+XT"X.;)
M<S$)1D+0A,$-,^=@$,P8.%T)%J0`CS(83H[%T#DL;H(Q%U7H(I+6/5('8`Z*
MT8F/H3<)Y?>*VJ`+I9$+QH)%N0EW69IP`_K6S*^NG3$7:Z%GM]8V'`^?@R5H
MH'J`Y2V@$P$>BV\\'<OD+0*M/:'P[+;EB8&A<<S%,@PITJ$+(@L$<[`^@_(Y
MA!\O".*%D`I)^3;-*Z$;RB5E==FM[1<6$,KWF1O'K>+NV"R[23:,9?@/%/(S
MTBKN7GF`KZTZ,)^/W*1U%D6UR,9P,F)3U)V'_K4CR8:;#/Z#@FQA5CTR547-
MI/*@)0Y[]D!8R1H>5:.HD9?I7.1VH),(5!M@-!&Q_G>CO_>K1!R+1M$7C6GS
M:=1^&C$P8&=K/W1"N#!&'([3GMHS:@IB%/_(W`_H!`"Y`>@N#-4*F,]&;`IZ
M,'&"(I1ZH`8:TWD"#;=>[0A$L0Q!B0Q-`D7DBQXC_M]WC[$3)FMF547]KUD<
MU@8"N8GH(Y"&[$;C?,1FHA<;P^4F%GEJ$7H>B!_?D0+M0A:DH\@[C"N:'![O
M)RO2-K!>25"*1_SX#I<->2<%\K:_#6D`,4,;TB:0-ANBFS\S&]+*QO`VY%UI
M0]YBMB&CB:;9AKPK;0B&@QS%!3O)&>D`9R[6I*MH:DV**9`YV)7.O`QA7!2D
ML_!2)A.2:F:4V`:QOW(HFKY.2P<X<[4UO=P74R!SM#63.#(UM@:U-S.9D`QL
M#1*_YJ3<J_EL[':E?];5<"IF&S)1>O':<K*UW4Y,)(A;#)G52[I*;\(DC7FK
MTZ9.>_4CD6MT`WNJ]M8,0ZRI3=3V78P?W0WULH`WG[R-PJ<SIB9;`IA(B2JQ
MWX1NZ;IQ1M4:JHLLCAEMRQ6CTG%U7K#)/.1KV9CU2DU`VR3$Z]R<]MYU+P(>
M<00F0K_L:)C8M,>2YX].X,0EP\T".AX\CY6L8;)F^1Z,Q+]F=03W+EJ1"S2'
MNR`2LJ42E7&YW#E[1D?`*_2B=,,"*+K=!=&>4K*B(5W[_4I5-$\>2*SYFQ"/
M,7/]+J(DU2B?Z1RD.MB)Y:+Y?]L$[*WZC>D_N1N9**YVBA[Y*Z8C[&.09$-I
M2CQ&3/Z7:!7X3YSB!%J#`R$>^T,<94\;\8@X'PU*P!2"=P)?1W'Y_D<*3!`7
MN/B._`R]P=.(L(4>4#?E"%RYNT%[-&@'+O&JF8A7'B/VLY]N?/;GD)(]=6+"
MD,A?\6?.HWC+\$0[&C-B&8?NWF6D^&L2,#^1QM].W*I_]$^96Z$Z05MXI185
MO],Y0G=@][4>H&9?:IV$U"AW8UIUD)IG(':4#`GONZ@Y>)(O[4J&VJKG-#+;
M.</<:[*GO!_A(9@;_@+,90;ERO<T]B-//&0A?G\=Q1]I_.R[1R]`]0:"7+G[
M"455]FX0$"M_3T9Z)[?XNT0"+A$(B<"XD(^K+/*_@H>5X[5C(2:6S87Z=)-\
MM(GYD0D-?28*^H6Z6>H_XTE1W[;<@]:/1FX>6MC4IZMO9W#+N(WBOJOW($&-
MX+[O6)R627F/8<"BC7G8VUB!TC)E5GI9S[!>.:OC9Z.A&K)/7[R`9D'^'$?)
M2-MKE#J!N7Z.QF=?)=7D**M4PR$TT/LA"AMRE`9SD*I>)Y:+'&7;!.PY2F/Z
M^Z[.@\<_PR@\JTD1>A(QB:D;/87^/YA#Z(B$(G^M$)*9,(Q1.W'F;W0!'7H3
M.0I^*WB<O,&/@N>0/C$./6T2<'36;^$E4?BFQ?=?D)"*]R6K:\2>ZP'6]9$9
M5Q"&QKH?#$%JWYH84ET)]>^(78=:,H=Q%>SX\",QY''?1VI5KF8#.@DJV=S#
M:G`.&L8B51HC%@MG0#<0NQ/02G?OS'#QU'=PL"!7=!W%E&2ALP4+#_M]X0-$
M,6$^P];/M@N2R!(Q3[[P'=.=XWMUIX?Z8\-%>6[X';Q('60>)-]66<HFI"3P
MMW[*$2S@WS3)3S[9D"CTE'\RTIE4,IZZ`[*?G"?*`#NA:!A6OH7,INP`V=47
M@8RXSLY/X6([?XI9.82=V)L9[4L#8/)X$&R-=.QAZ+Z,QRNX+35.;#!M(-8Y
M"IN'M35BMB7^FHG=-2-^H,CK!41=XX=<^,*MP6J%:CZ_&GEA2>Y>.R[MD-BM
M#$=JUDP9U2=TR[&(([)6D@=25^BBQ@S3B+?Z#%HCC<;L?>R'KK^#]FBU#-K2
MRYN0>38T21^8J?J8@B&[9[XN[&Y/9I=W6@#,2G=-A*'7YJ;9L]%O(R8&T_@<
M&P%T"R(0DA(CAF/74252"""&\MQ7#HLXR4Z`_W:T2`.BI^LHOG?V\*^[=4Y$
MN_?2,!.IHO=@7Q.$Z*;-*QIIY:+W!L<KBWA=N+\5U>4[@01^Y^?KG+FHVRA,
M-\&>K'A7=?8+EW=0%@'*BC[Y80@Y'C9K[<<)5*[OX1_4<3=B[H*!(_?A7\+W
MX>5C^!_L/Q]_!PBW#C,I:UYIY&QWD-GYW?W;O_SP_NWWE[^##),:-L7Y0]]K
MQ^44YCDG!L%_I@)1LN`)H'3CLZ$T!$JFSNQ,]/4.0R>>\@%1WI??,$=FH6Y]
M(BE\R.#5$.`U7Z,U2WALL\SB^YRQPFE<AIZLQNULJXW!S<Z`=Q-4LU4W@S5+
M4]^1M0'M?TP5]=F5`1`SJ?DE675?H+]E[*^YYOF,#R<(^%7QK][@3_0-M;O`
M@_HE[RM?,K\E@&UWF$ADY9:A7[[B+ATCIT4)+%9#^"&]6U_$U/,AZ0$72?8_
MAUE"O0MGQ_Z=[J&TVT]Y4H32UA3!*?"0[D.#B:I2E-$7&.)\PND\]6^"$_*#
M#8&;Y,@71*`G.?X%*2D@C`3K"0=[(H/^1$'AY:[ID0#LVJ`*VXW'!^:S9VA?
M&L309DUJIL[,=C1Q,+BE.#`,-EL,3B6+(Q-`7HDC"N@D0+PH")PXZ96,'.4<
ML<4.Z$<CU_L6-AL.$6>@UVT4#Q6PV-;9L?A4S)+5/?H^CEQ*O>2:+=T;64IR
MMS:HI3::B%Q#S9E7E;5]%F*][4!\_X-Q@4(TLKU1ZI,FJ-XVJ`B80`0?:$H*
M,3AKQG(U=29*4:,L35(G]/(7:E-H".RXO.J'&84ANUA=!$Z2W*U_=6*&([V+
M'_RG32K_):^-/T;W3-@;1K^X3,X\%7[YF]\XOPLOHI#)-M'D*0>&C]1NC";*
M(I4])'#LN>U1>!WJ]EN1!'25#@C@/Z<1^;SQW8THU0068-1G03:4M\?`!MDZ
M>ZB"=SF%*?4FSCFCDNU%+J5?2REQ@O)?)'E_#2;<G"C9>H/'=.(3B#X=<-6N
M(,U":AJ59`OY,<'M<L$EA>#<FNX=<#JOE=^$+WO7B?'J"]S*2.A][,.6G',G
M_YJ\U6SH?6$AW64&$5'E]>\^@!#[L*?Q,[@56Y`<-^'(E3%),<A2NR`[HBKD
ML>/R>%5FG:`43A@HB_FGG.%EZ`F.[TI'7"/'EBG(+8D)PZK!:!J/V"X8D7WR
M5@N1F@!/%/BV@ME1>>;/;O"6M:J3FTA78K2R*7%0=A[%<?29L9&?F#4=4_>'
M@E1U3Q2+IC;*!`3VL/$$COKJP2,+]=:4+N`%`,83G#RK==UPN5AV3\[$N?0J
MIP?N$\L3ZK6\^LSS7Y``LEJ&-(G<#I/Y\M2^P%J<WT]Q9M]@3&W)YVJ]IB[T
M3RRKYN#6@#W/*"^BNA(O732D_^M'(C6F!NRI[D_-,,1>3Q.U)U]BD4`7%MNM
MC,'?\NDIYI=\2\63C[L,Z-3<Y<TM;J&7Q-67E(8>]>",H<[\-(Y&JE>&;!;.
MB'XH=J?#@/(!,L]4PA4^`E0T%_U1>#^2B3V&$9DN0!,.F^3`>8&RA:SNB*Q>
M'7Y4_BDM5N71%&21%R(I\6)S.5[[-*16JBOCE0*\ECF(_0)CTOMWU^$(E*H[
M!8?=QWQ'Y_W"239G+N0T&1XGX`U9_#BFSTQOX2D>CFZU9[H.A/"S&$Z)Q1=3
M*A8NN<Z@/=9[/_2WV5;>NTLN,UWYO_ELY$:@HQ@JCZF8345L$KIR,-#NGBR(
M0$4DKOP.:D(8-DLOK4PD"LGX5C(N:X"&+.VYDH_?+4/O0Q3F_Q)GS3OP9]]3
MJ&6H\WK,IR+5ZCX"**(1PWG80Y.N;`P0IS@AX4<!3Y2G]3YO6`C--KM5E&[@
M;\5SC/Q*'.\D7?S*9U%.F/IID#](YU*1_^*YT377E@5)LM7?^#MU$7EFP7E>
M("=>>X1P/?9YF1RS+"Z-4X=-+RMV9/V#!,FQ[:$9@4.2'77]M0]O2,+!Y`*R
MN!Y=^R&_LL>'.T\QY5Q-'&M-]15SR(0AXGVKBU^(\AJ!C'P2Z"9^)0.A).PY
M;+^(A;_\XNL>LZF.0&JB&]A1G2OESX@=J#HJ^ZX_"8M\`F@6WTR7=%Q&6V9&
MF_DNQLQCK559JEEM8@#^]79`Y\DK3L"S]`32M#R=X%A+T.<,CW<7WM.8]Z=@
MBT_O4+=/0:HY71@N'.B6\=@=9U/R!RHISQU9^",OP]V5&"=V-L?F/%=*CH#<
MA41!8=.UM,FWS4-]-]J*1H?\T3G`Q%2BP;%LGH'4A'5@MWK8KQV.V#$PH;K_
MX3_`)@5PDD.W[JIJN&YT7=OFS',UZUW;Q@GS6]$#N8D-:]JJ,XR-Z^ET^8&Y
M1DP/-LO0NZ3/-(AV0*$L\JGUL+O-1*[7'=A7M=M@&F(=[T)]?Z];X.!I/05+
M7LIFR?_$(`)[ROYG&L(Q.73K\^`H+$GA\.V9FJB[Z5SD"M])!*K*&TU$K/3=
MZ.^[YB46ON2K>)`HOFTQV%-^?@F:A\07T1:8%:%*>8!XOB^'R+/WY6<G]L0)
MC'JCZ2$*@NLHAC]JQ#P:,N3F95PAJ_9H'$R(#=C(#/=5=8[S3&035<*(0AE9
M[8DZ+N_]SLE;R"/.9*$6[I%/0"215%HREDA%7K8&EGA>A%$57(W_)0H\7X\I
MK8IV)"LJD'P=!O2`5V2V<T$$?:,8S1UOQW\5UKY+B%?4YT[`CWWD:S`T]/*[
MLH(AWAU"E&P=M8084&X?4R=.9RVYRCLZ9O*;SW;T9]$^*11O3O!'@$?Z3O68
M7OB6U"#>(3>E&C0O>%MJXA;#QO1GV:R#'T,S"N5;W_/TZ,<0-H=)7X@%93'.
MFOK\S?M<2B-]BGI,+]R"-HAW2`M:@^8%6]`F;C%84(6^THQ._>0X9F%?@(,:
M!&AL*!3NBQZ<EUG,7&7!INC"J=P@2/(&=5H3V0<0=@O86S@5`]<9"F;[U9\9
M#.8IIPJ#<9I>D@4D)+9GN/S!KQ0Z^5%O^4QCYXE6VG5".GL]U0F8.2'8;9^U
MCS-2SM>0"LRVUYXP,-CN2M8X9X!(#@X;"G]:KN`8WTWG?QPWU;?*\9SE(N48
M7OSV8/<#_L]&</`9+%C__S'YL[7S+^+8<-0O8W28V-YJ?J;GBE.*MNFT$5,O
M_U;Q)IT.%L;86P>E8.[[Z_"?H],>.QSZ.>^S(TAAS+TVZ7_B:6/'/3V<0O1]
MU#/2%V7W:XY#;!C_[F2\]!V@YX<9=!OH2,-+W@OZB@+%AE![@/M2=X6IOU3U
M\/=%;0[%R9K-K:$K$2]]8^CU40;=%CI1\)(WA7Z"0+$EU!R:O]0-8=JO5#V/
MQ[0=+`,.G'KU$I4W<#5?P7@R<O/;30BJV32;B=C<=62@]Z-".1JB-5A7]8\,
M36-/)A+#8Y0Z@7AS6HK`544P_#M+O3/LG%*>X+AD<."QRU_@K<L#\8V%`ZF]
M&%6D1>O(H1%@[S4Y&K\#-:=TB@?1G@#7F0<_KHOG7XNVZG4:O0N@'SP0FTS<
MQQ*=5#DVV?ZQ]>18CJLXJD183TX:`=H(?X.74V>A828Z`2^KZY0<K%-[/F;1
MIY[&S\R;KA?<ARB$+K#,`>?:PH6D_OTB2M(/4?H7FCY0-WH*X5DAM7A6L[%/
MA1OICF7E$Z@.\B2($?O7T_)_\GL/DDRME[X@!:W"*">+JC%G9)(]34E)Z*+R
M9H2E*Y;S^`P_AW$!N.I'N!&\?TP#'D*E$8F4IC21[7XKHPE79&:NHUC^"L:]
MG?H+ZXCX6BU^XT>9Q/374O`U[@'-@K"_&0#-M3N"()RLHY@HI+^PK6&DK_-E
M1UV0>%Q"S0L0622:-6XAB(\===%2$1\MDR3;BJUN&7KO:;J)O"B(GO;Y!9"A
MBTP[84:^&TPH_D'J^LW1(K;[4W)OL9Z_S,(0A5[^**%"\7PO:DWX-8J;68X\
M:W44@3*WWZ/P4+H?'N4?>81E/1`85,0/?O+WZYC2FY#QS/;>!Q;[3/%I-7B_
M)@/?)/K1S'L=TJ_%N#?RCLZT+PC02X!@DE-,@.078-A'^1(`]&P-XO)S<<60
MG'_EL&T2G'>7D82Y)K"+!/,`Y9<H8&`"/]U/9;FUF+\FV]TL_M&L=SW:K\5^
MMW"/T((7:822Y)=BPD?Z&(7$GDN)H3+@JW;YK335D/J+M`\4WL)BO[^(0A[C
M9$[PR&*0=TU?<G)*YF#@[7R>(X,_+1G8-P!+TL#??:'@@2A,$.#"X@XQLZ]5
MRM!59)C6R'`&.T733@OBTIW+CHKPI=I]8V$/8MY;L;U$*V[.-&;O?88&>7S!
M%](!4\MOW.RI$\^R`6:3L"[]9]^CH3=U>N4`[QQL\!2B'SVUHB+%;I$GX1VS
M8<X)?FE)E4$_1"$M+Y?6WJ>!AR>MDJT2^EO&B+AZ9O_WZ*P"K:6M'XK=.#8P
M6+%G->,PFZ`F<GM;C0(HX5#))P[7XC/Q!VS>^B&]2>E6^SJ4?OB\END1HPU+
MM1@[G^5Z3/)P2Q9@$P[<5A7.5+SV*H/1W*+]><?68YC*/?*!NM1_KMD+VL8B
MU3(C%HO;J;J!V&^9MM(]T&W13.`A.^DPQ@4F`N(6_4*=.-U/>QUT-/9_UO)K
M.=Q.Q),;O(''/8WY[YH\9<UXI$IKS.I16%HW&//FV$KS26%@0@3HA7Q.@$$7
M<9_%F&T\;HD/D,FN;[]_S?[XP.P?6[,;2-_5&9^#OR-5*2TKQ=ZG_A'[?E=+
MZT![7"QABP0KW.+YO/'9/]>9N)'H)\2+F*.YVMO:[@;F7F%W)+6Y^I+2,#'X
MENK`N2C2$7.U&E6,FI-J'1,]D([MRBMR0KFJ2N<Z(5E10@&]1P=^VZR+=@TI
M`)5!FL,=4.&6VRA3G=_K*+Z/(R]STTOZ3(-H!Y^]CF'3B9@5LA/SA8(:S<*N
ML-V8&$B!:>`_^1#V.;M=''WQMU#Q[7!*X"K/BLI0B0HEIPY;^3M!%?$$65/K
M]31R$E@J@3'C_X!UP&0O@'SOA_XVV[ZGVQ6-#R2E&X-4]QM94H/#R@#$`6$]
MG7T7HX1&/@EXEK*BH_!D3WUNH_`)-O%+NDH?&;+E%U]W**$9BER9FAA4=:IN
M'&+5:B2W[VH$H&?<I0.P"P*`R2<`;?'H[)#3RPA*-0W%4@R>V2JM,MFT3L7(
M&:W4`X)/6:O%4I4K58"VM#'8YW/"K#UULYAZ0%*CXU4W#KDF:EFK9.</!R'6
M/SVMO?/3`J)8D7:],4O,G9#8@$3,\C9RPEK%T0Q!JC--#!5IB8._8T]`Z,@=
M(-7@ARQZWCIY&ZA4WCA)(YZ$X$9^20*&FK!!_+$?-O`_G3!SXCUYNR!L,?W?
MB5L3#RV-1\$D0+1D.<9F:V!3<=YN*LYG92IJ&*J8BO-YF8HZ<J<Q%=Q0G%NP
M!T.RS!7G'(4]&(FM,>S!8^R$[H:^-;`+1T-G81_J&3RV$]5QL[$7&K*GL1OG
MPG*D@@;F8E!;-F1@,:BV)`>-PJB,SB?1\SE=3@`"IILP26.N!`UYY-J!2,U2
M.W-J6N!X%.*\0`.Q?5<FCYE+F-93QU46/SC;YN1QP_!9+<]C1O6+M!P[FZ5:
M0_)0"Q9`6TXCX^#UI,H=7N:T#+T'FJ3P"@+L5.R?/+/FI_OE4TSYI4:]^]H#
M!E(-/4DD2FE/-P#8/>'>_(SN(DO*>$ODG#;A:L%O<O)(0=_$OO/D@LOEL3R2
MQ[)6'C8=[OD*9\*3.R`2:+GZ+6.TP75S%@$RO6APV-OF(#6]G5BNG.XU34#L
M)IG1W;L#``=*2JC6W?L#-AM]>]U8Y&NWD<7*"SYU`Q&OU69ZAUJCEGUYRTQ.
MIXF_.M"JI+D6Y'`,<LVK94G5N,H`Q)I63V?O9R\$-,ME'Z/P-&0;@ASDU9>=
M'_-80SPQ5>-EF8Q'JBO&K!:!;--@[$&K$>VC!JB?)05P6Y,65,C[9Q-'HJ-*
M(P=.2NCY0W3]G<Z.JEKK3IK-F*.Z'KN6!L/GJK(#>6+U]T#]4%X#+=25ZRJ=
M^EGYD9EOTE$K7C=2ID<P3;(FD$WX49]#[S)YC@9+*X16VW4T<ZYF3,_(`!;-
MH\SS"!)XLZXP9.G&2:4U`S.7UZ8"`4B,V_`B:5!Y!9G-O/=L9#%&0)4]94GZ
M[LV[AF*X#G/G:`AU(F@/N@XFSM4,:OF8Q@H*]`3P(S&"@PND0>]+7!A-(#))
M3'AKEC)RE0;2;7>[]<.1FD131BMW9S5C$6=O6TGN?:\4`*MMU+%<]ZYAN/G*
M=].$&2[>AJO?VM$S6\!#78T^7,(HKH%/R._B]/O@&G?[;D=A<PN?.$Z]:ZT9
MAU3M6EDK7.:Z0=C=XT::^ZZY`B@)^.K;<K#3NKDC,R;4RJ+S:O'#G6`B/F8K
M#KG%0M0/PVP@&A@K[$/-&.SFH8GDWLT2)$R+QF%4MJR;AE&YBP8S$0/5IAZ\
M!=,<LNI'(S4NAFPV/>:#/UYMH_B$15M]'P5%L%K#;6.LVC1^?JM6'ZEJ!\]K
MY0X4MVG6KM4P%0NWUG2UN6^99NR\=+2A?UG=P/GHYG".T,&;6W9[F4W"I#T%
MS)O&+T-/Z5&MI+/R5]T?HWL:0PWD=13?I1LFM_-]BS,X%&SD"CZH"%6#,`A@
MQ`9D6/[ZGRO+9Q/@+JE"1S6GFY,"%;^2&-YV79"#Y)CF!(&V>LE#P7ZYRMSL
M?0\"^&4J\X!^;J',2[TRE[K\6.KR=:'+&`(!9,(<P#(.?QIV$04,5B3*/9B@
M;GV7A@DM[G5#1Z9$GP+O-AVIU>HKB")EWF$N]E1Z'U9.Z?;%R\_@AH&K(N:Z
M$@C4Q,EQ)R0+/1J7;U#!*.6E%N*4&I40QW7AA1?YL`U_R]U5E&PGE4P+#&9%
M7/LF+GV;\A-4<'%S+[$IG1W$9[)X4F!/(+7+D/<:['6C<AC_]((OZYB_9PB=
MCAIB1\U0I';8A$'5&:P;A]BW:R2W_WHM@<J^5];#IQV3VL91%/20\Y80R7P^
M\H7<61354,=P,N(EWYV'$^K:)29EYZI1#LL!R4S$<4)`\9]9&#TRK\G9T2SU
MW>0F=/7A0]-@I+IMQF01&FA'8@\$V@D?Z&IQ"`NQ"`+X"A5O-9//?KHAGS?1
M5OYMNW/"/:$P@L)=9.;%%T[9M"[Z>,(!R$0%31ALF\[WA*PN@%>5Q3^^+LFY
M93^Q7^:_DE#8;_X_4$L#!!0````(`,>`IT;T/!N#>B,``'J*`@`5`!P`9F%T
M92TR,#$U,#,S,5]P<F4N>&UL550)``.VQ4M5ML5+575X"P`!!"4.```$.0$`
M`.U=6W/C-K)^/U7G/_#,/FRV*A[?QI,XE9PM^9;C78_E\GB2W:<434(R-A2I
M@*3&RJ\_`$A*E$2```D($*R:JK$MX=;='QJ-!M#]X]]?)Y$W`RB%2?S3N^/W
M1^\\$`=)"./Q3^_R],!/`PC?_?U___N_?OR?@P/O$@$_`Z'W//<^`81@%'F7
M"9HFR,]P`][!05GP7Q>/=UZ8!/D$Q)D7E+6^PNQE4>\"P7`,/._L_?')^U/<
M\[+VA9_BTK@]VLS)^^/%-U7_2?R#=W;XW>')T?&9=_[#V?$/'SYX@T^+<I\P
M!2/85C""\>\_D/^><8?>:PI_2(,7,/'ODH#2\].[ERR;_G!X^/7KU_>OSRAZ
MGZ`Q;NKH]'!1BUF"_'50%3L@'QT<GQQ@0E_3\)V'V1ZGM&^!3JKB>(0KI;^>
M5F6/#__UZ>XS'?P!C-/,CX-E+=PFY/2R47YC5&4_Q^?GYX?TVW>8>Y[W(THB
M\`A&'OWLAVP^!3^]2^%D&I&VZ&<O"(Q^>C?",CL@$C@Z+>C_RU4)C>KG(`ZO
MXPQF\]MXE*`)Y?X[C[3_Y?%V92RDK>P%('\*\@P&Z?L@F1R2@H=B;5(:A7A^
MV)?(SQG^B(SD,HE#$&-,XU_2)((AP?"%'Q&N?WX!($ME:95JVDZ2'WR$R[T`
M3)@?::1_K1]KF+'X-AV.AE-0:-`4@_8RF4P1>,$5X`S<):EB<,CT:R6S+OWT
MY29*OFKD2ZV++;+@"J9!E*0Y`D,T]F/X)Q4-ELSG?#+QT7PX^@S',5[7`A]K
MMR!(<JS>XO$#IB"`0)H=O;LSPII!F@(\FC]RF$(RWN'H%X!@\E0C\38.NO-"
MM'TCQ-_X$/WB1SGX!'SR-X5K=UH9S9F1:Q"@'(37KU,R,].[)!X_`32Y`L]X
MNDXF,*.#HVJ*PA!;J;TPW[4_(\SYG"7![R])%&)#_1I#,YMW)[RI+3-$Y<\I
M^"/';+Z>]</Q9DN[H[4-:6_36KS3['ORGZ/MS_FJ5TMF?E\FL%O<G4ES!3(?
M1MN>,XM>=XY1)V8X=6*UC=@;1)+=V&,Q]J:<W^H.K2C],="O6TO6E-YLX#1I
MA6W9GT!6@]+D31%(<0M4H=[A+TN:2']J'9TU]H'7#,0A"!>?PHST=G1T='[D
M'7A50_5?_3CTBE:];OY32BVF-TJ"E;%$Q+F>H#99DD]^XU$X>$XSY`=9U5#D
M/X.H:$FPWJ'4$$N**;4I"-Z/D]EA""`Y6?A`?B'#_W!P=%RZ^/^"/_JMZ/P1
MC"'I,\[N_0E8&R^KV&\?3\\^?CS[_OSXZ/3C^=D'S)C:B.L@&J#5T?LHJ/K`
MOV[@:E5<98G#*?62'@0O,%J@9(22B11#RU$DDE0E"*N-G]X=O_/R%(\UF9)6
MB:]V6P*ZQ)0A/[K%4^3UGV#.E-!:.5=$)$)6*:,3`S*J"'O"S3:(IO[U[DND
ME9I2$*<&!?%`K%Q,4GB%J>1(9*6<.Z)I)ZN4T0<#,AK@$89DE#>1/VZ0S<KW
MNR^3=G)*69P9D,5EC@C!-]B(]*-_`Q^QIPRKZ.Y+2(JR4E@?S5D"Q6@?P31!
M9+M&#@7SE&T0-!;??:%)4U<*[CMC@KN!$4"7F-YQ@M@&W$HI5\343E0IG>_-
M3:MD,DEBZB3X_(+YD`[SC%PZ(M?,V).+4\D5V4G36(KRW*#YMU3E-_B3)N7(
M*+G[0I,AK-K5'AD756&PB@FK5M8U<;615@F,Y8?X\7#==:?*H2=WFT_$KW=\
M1/QZBW;Q[XNFO7K;7MFX)WU7L#.&1W[Z3-O+TX.Q[T\+((,H2ZM/UA%=?OS;
M@ISAZ`;&>-@0"S4ISEX8WD"YJMTG9G>BZ"%2VC+\U4+63,PN@B%S4X(LIF\0
MDSD"V#X-[PI6,<F@-&0`I8"6-"GETJ`6$O9:6>MD+B`[EL!%2'-$[N0B*3G\
MPS_(L=C,C^AQ8';I(S3'-AX]1&7@0*BNI;@0$?$F/+I3[`A<'A"8^K`Z3<:L
M&!*#886E#+`(U'0**EWI99YC[!901"#AKO"%Q;QY2B(IYB3S(Z/Z()D"E,T?
M(K_8^6"M."6&UCU@*P)V%:=`($TH\U1FMZ;^(\!L@@'>O#4OE_=)''#U@G@#
M3N&E)]G,<Z3NZ)DBF""8S:G=8@)*M36S%36-99T"B#B%S&.JW=(D!:U<ZZ%.
M_G?'QWCH1[LK8`Y)S/.KW;(7[J#_#".804"NG&Y>RFSQ/(A6MPX571U0O0AV
M9"M1XX&8?XI=P3I<])(O%RXBE#OBE"B?=Z0/_IP\%&K9=#86MAD8(I)L6$O$
MZ70'!N2EPR;GV$AH+N\D&"1(=63=N"H'^TC.+?%/F/'QP"SO'A[D2%7EJ^J,
M!\;CBT<PS5'PXN-62X;,;Q+T)9[AC30(RP7TJX]"AB+HUH@[:%!(OR.NJY77
M<5QET5#2'6#($JG(]30#Z#EI<#Z=V++O$-YO.`@%*=.AM^/)L)MB<WUL=3_R
MJK@'!VEJ5?FO;/).KVVQ\`9^T\YNQ8U<(^XA20']S-OC.XRM^M+;BJ'FPC9C
M18FS2YQJ#3O:)4*^-W1SBQL$K/&^%KN&ZUB1)=WXEE?5A63)`Y8=.E)1C)!N
M9RM]-[R6;7D>JL%3;O#N?C:4M`XAO3$A2J0C#O3:6R_NM=^U8N[)78A"K3;%
M!T,[FC"$!1D//@QOXTM_"C,:E+IQZ])<VCT\R!#JB.7P2,)'Q2"\]E&,3:44
M;\KR21Z1)UEX[P\#R+Z\UU;1/7QTI%F#T]RX!=$8O%?,TG0/%X(TJKJY:?G=
MKHYWNJR#A;X[.^+T:X.,%6^(US-BU&3*>5!\UN5!L??-2F=_>[=_8&QVTXG%
M,41TL"&UO1\`HH$GA/:AK,K6Z9"N]T%[D.O()G65`T5,DD&>O6"SY\^E6N"B
M9+V2H^@0(M.1NUY-E-^F:2Z%B**"TVC@D.C(QK6):G8P)\%:3F.BC4Y'[G;5
MG'J2-H9`36<`TI56#:\/#8-$T+3@U'`1%#)&Q:X_/]P@FVM1,$J["X)V6T+E
M;2\K`-!N2(C&2W0+"H(FA,H;6F;=55(Y2D7<5R>B\?"6/7O)R%OV3?-AK/3N
M2:9(-3#!;F/,;[`@J<6%Q2QM)#1!P?EX7&76:1D\L[QU6J%%*"L1":2(<L0#
M]8@E@KE)(G1<@1F($AK4I>0`\U244\<Z!,B)M>D\5)9:1Z#Q,X@QYR)RB3F<
MP)CFE<FP*N:#HZ66<_#H0J\C?LH-UHFN%LZ!0(Q"1\*D+8@MUM:Z7<@2_+*D
M=:+O8B"TD*-J>AN6\WT2)ZL45_$?^<9A:[U=QD`WXAPYCKBE#ZD)BPK2;V,\
M(OP)<XO37-PZ^7<3ZB8XI`C68"4N+\R=F@)(03#?1%PKY3`<VNGLNU:<%RB(
MP9@X5&RY>DV#^S'9R+(6N)6L0XF,X2!/F:IS2M,V!,A:K<25,KLLYG9"'+D<
M6UT-KPY1+_P4!L0_`J,\8YXIM=3:9<EW(<V1<\5?`1R_8!H',ZS;QN`^GSP#
M-!Q1-M1.4L0@TJVQ74:.0HJUG5/:<"Y%PD??1,E7T2.HTVY'4*0;K^K'XK.F
MVF'G@C/B=Z8;JA@R#LA('E`R@UB&%_,O6#JW\<+-,@@R."NB<=`W[CG^K'8^
MV>*%4-*X=:I%1/!K-HDN-CARS+'[)JI&&?<P<O4X-HR])?Y/7GAV:/P>S.U;
M/`W3I^01!/AO&($5OCPE@@)I2TZFN=NW#64CW'7D[.\*X/$&D/(=_QX!"I(X
M'$Q(]NH_Z><,4(M4M0Z81K"R"=G.O'-DL:YVUX#>3</F/`]HS87WT&*\[Q;G
MEB,ZK#YI%I=&X_%EDM+`6E<P+:+YL19GP>I[P#&6WS[\TW"B:MS(+.*Q_!/&
M8<O!ZF;!/<880:_$..7(J[#/F#7$G7@'8T""V3(]0:O%]N!A13P1X%/?(YW&
M`UPE&05N8TRT']WX$-$G;_2*8L78X>CZ-7CQXS$@@6J+AP]K<.G6R!Y,#7D)
MU'!1PXF1\34/,QX!;'1>@>)GC=5E8++V=Q2"#>R1R;JFTHN#CCR/V^3"0Y'T
MNHH.WYC\6AB4(HU9!]">R!"!6F>^]'5H*%AW=0%/)(J\,/!$&GN+P.O,%T><
M'_T\[5H.7:V#X;8/UE3SSI$')PS.%+>M-=T3D&S<.N@JNB>@@@V.*$R\4%!3
M_2D9!'_D$`',*\R`;/X0^7&&UP\2X9*^#65Z[40;L`Y-&M'1Y+/KQ2=G#,-^
M3->B[MXV,#7P3L-30>,N'0:;%@<\.I9KR<:MP[&BY5H%&QQYJXA9$P`0IC>8
MSR2X$PF3C)F[#/;#6J7;ZEF''8U8:%B<.[''Q2N!CV!:&BK#43U[&P-7K.)O
M&TY27-'R5G+W5D@M*^/;AJ$&WFGPO1A7>81')"P<_D'V8#,_(C/W`>!QA>L>
M5@9*99JP#I.R5EIO8AUY!=S,AP&><PC-\53B)F@3J>LH4D2H5/2D>$I!B8>-
MLC<&E..W@91C9?='"JA<QZL6E+Y'HN0B:)2D.0)#-/;C\L8H22^43R8^F@]'
MG^$XAB,8$/=@<:R'&?&01+">/YC[8/3X"/_S#KQE7_B/>G<T(FG9(7DH6NO2
M6_;IU3JU^/5HG;#E8]B"J0\U>=4BZ2Z?R;:%!E73MI&H)7V&OD0.028/D$\8
M@Q<1VP.Q[6%8MW@JA>=*'!8;.*OM)<XV-#"]D$./98K`VL/1+V0U>*I5PX:M
MH,H]V52YM'VOU@'1M;0+K]Z'ASMYKTO',J[3KI/.T(,M997<[%UOGJ51^(6M
MF?="[%W<I96C9Z=GV^*^\">\0\1_4STD.+E.-R<7:<ZC[7EK#5ILJRQXL"2E
MS03A5S%A632-J,T,X-:Q9N[*B*F^%,M3M],SN;Q;6(4'KKNZR=D)+&Z!TY0+
MU)0`L<36Y4/#.EKTYU4=?NN1+@](GQ[I]%NOUFV9;6&UXZTNK9VX4^,N;RE6
MUK::I;O3</@+?+\FK5$E6J"P-!LT<&FG51([IW6+NCG;5#?UMO[J+5JSV*RH
M.95&]??NCX!FNJ>/D.E3+#+`L+J2UF)X]&W42"`/T3%?U,?<9KST;-4:G:06
M+BN1/#1P:+?U4?Z<@C]RW-SU3&*?\[%!&RU:\A9-6:R*U@EOB^/'+&[DR?G:
M:-H4`[.\=5.^32PK+\6EJ-KI:=KI#$;J+`8C[>A$X5F,]TWUV]_L5@3.'<OP
M`Q,\Y,]8+,,1AGP%E3EWHR-2SSHUHOPPHQ\K'(D#]B7%9M-UFL$)Y@;K1MQJ
M(?>1(4&W(V^R5MC&UR`B5=X.1*2YX,BK`,:-/#'DB-1]0Q#JS`Y'HFT]`FSK
MYX`$:QG'4%P#M=9[.QCJQ@I5651,1VMK#+@YG):,O8T#S#XX`^39:SFO6)MJ
M^9;>#L94,<>1?"WKJ6K$=%9+K;>#IBZ,<"1"UCWX6O/LH"3&OP8%QPHNB$%)
MMIFW@RTEG"G!]OU..A<['M*2`$YBOL73HP]'IXHO2WC?%`/0YEU\0[<F%%E6
MP0L(\P@,1YLQO:BL6D\IA!NP1CMINSVAB">..!Z77"!,O8TQOW*A$_'VBF\1
M2E*\T.:T-'/=1FK9.MM<MIHNW9A:BS`(9@!E$/?]4`F#CH\<$=;&>05&,("9
MV"*DH%&S*J)YZSE`B`1[IH"_F&_<\1A\]5%(I=BJ27JV;Y?"40:A9DVC@U><
M-:UZJ7]L!H/%P'$O@U?(S%]2+V,-%K8CN4VDM'.#*6U[G(<B3%D2BK>KD1_?
M^Q-PE4Q\*)=&J5]7UL&M7?RBGD4-C''$=KZ>3*-D#@I3J'#`?@(DWS'+Z<@J
M;QUZMH:$!H>D%).T!N*27NL8QN1]$HM"I;7\'BI=F:1AMV7<+&IE/HOW>/<'
M:'*.KFMD:\/V`77+!I@F%FJ%L:$X7#71+*=R^IA$T4V"%GP7]T@)M6(?0/4`
MAKN)[,PHK0OOB6D8+E86@&8P``S)1'0L]&2LO/'Q)Q8,C29$G[N(`U9Q?WMH
M;X>E3IH4#<MD72)UE4$>O!=\3--\4GPFJZH5=+*'NT8^:DU,>[+-$XM.+WVN
M0.;#2.Q4XX/BH&O>-V7O^W<^_=HFP#[[<'KR\?SX^[,/WY,?.I_^\,Z`N!6L
M4V3ZN+^VFY=GBR,^1*JA2>!Y$%[E]-%3$;B49DV]!U_I5\Q=NE!E:U#54=(-
MRUYWNA7!9IJ08%TSX]>M'Q"V;7D^'%K`003P:7/D.5A3<HI&[C$0(%S?/8#T
M(UV1T3L#Z#GIB"#660+(NJ)"NKX[J%!#NK9W7K;O?DZ$MS]JXQR4W7LGEF^`
M-I]]M>QJ>!7L>/KW"48@S9(8?,+(2L(;/+0$L>Q0T>K6*!1QP?%?]TF0:7R_
MPEA0"J-YD&4(/N<9]0<EF\ZDVMG8]6L0Y7CV$QWZ*X#CEPR$`[S2^6-PGY/3
MU](9E0[S+,WPE&>L1%OI>$<19YA!+OJU\>I_&^-U$=PE*2?EU++,CD)'G!:M
MGMTS,U)NA/T5C'+\V0;V!^%_\C3C9#CNV-J.(T<EU1I,9N.:A&:Z(A3[49DG
MLD%17_I15!Z\8&O[5Y^HZ8RE=WJTN.-84TVYAE`*#7BS)S.%W/%4SP05^L^C
M+$I5H?HT_2)/80S2M#:T]&)>S_L@]$1&K!EKM()P*@REE%KULJ&!#LXC%D9I
M:P2J5$Z;XI<AWWHIDU\1X#]&::UGG>1E1"0FX'9Z;76>-"W)['O][-([(>1V
M,:TY,"3I-2YD1;Y4XH_A:/C%]]8)79-.YQ/,]#49DQWW#5>MA'7RXS.:(1CW
M)^0G_Q5.\@E7K"ME[!0L9VR;HFVGQQ'A-FBJNY:W3;PJUHE^>W8VGP?&X^4R
M++#KU^"%S`Y"._=:6)UM3<99IX:L@XNT7-=,-G5<4*1?5J_0+'UQ'ZU1-T6@
MFML80QND65HP;(CH]1+,Q=63M^);<<74H7&7,+D%SMCUGI(9CHCZQJL)20C\
M,B6YE4)0O.08CE9F+B6Z2<MU:L@E1"GF@KT7!:\`F("0A'>EKY`J>O\-LJ?D
M`C3J(>%ZS@&B,]&<\TW#CUD?L1`P`TE(^RLP`U$R)<=L9?@[YCTN3AV7A-Z=
M8,X!8V>!,V9P^Z+WD&1XN-"/Z#&JGX+;>'7=&V#V8;H(4</1(`QA,=K%M;7&
M-6(;_;H$)K-,,Q[&?4OHO00H\V'\@$"`.X?!ME',ZW^/9M7,4Q1BGK5[M%5%
MEWRZ-(GPS<[W\%;*.441[7<5V]B\!HB\%"Y?A9@!.7L4>[3K86$)^W/=L-_&
MY;P;'R(23P-\PMS*BQN,DJ$B3C?OXI%6/=JL5V]W5\)`+)BR)*HMN@._BHEM
M\V)$]-(:N6]:2PM02B4<QH\@R!%]@!B']TF,JC\O_!2FO)M\RMJW3DV)B+^^
M]];+":LNARU(O9C7)C:E@'-1I*66O0#0(E`.@"3X8R<LEC.&+.J#"7D)FW*O
M#8I4M1<@$@+CB%V6=$=N/%SZ",WQ?'D$TP219SJ4\`:N<"^\2+9B+Y9D4;`)
M*!6L<`1;S3/T!H$_<A`'<^G%:J6FO1@RNF"U\\BJ*Y)-6Y\%"6)K%KNFO1"1
M%!E'^)+4NZ99ZCO;Q<SB+E4B5>T%CJ2XQ8`C1+[+R*GK87GP;-9^:_@1Y(`C
M<=1J6GSQZ_]!@,C1__R.'/R+63:<RO8":/O&C2R;F)>HK%$WFQ1)6SK,-NQ%
MCKPD!;6/%"M<6\9NXVF>I92/QV)+UV8->S'36<P<Z`C2[QI0>BCNQ?F@QE,(
M_AFD%6#<]M*GC9O:(D]NVW69DJN6Y`<Y@9[YT8J:6'K:F$Y+P?I.0E+TT%\-
MMQS1I@6_&XBNLY<!-Z&Z>ZCUXI0C.TQ,YZC*@%!CM[AJ$V]@#[C^[-+R;,=X
M&KTU010&\U-"?YX\(3].,6UI<;PE9AARF]@#407#'#'MFOAP4O+AN#OV6$WL
ML:>"81JB)1K%7HWEO92?:#M[%"KCFO%G3)JAV%47BK:SAZ(RKBEZ>V0<BKWV
M(X*U][#KR2M%CX',Y)09!`'*05B^ET[ODGC\!-#D"CQGY'4(S(H\@'%XF=#4
M+B"63ZGYH2%F<=&M5_7[K4=Z/B!=>Z3O;[U:[S3IS$K_YL(8=V/7DMV\L,?*
MVC:AJ\@P;V,\@IP,D_=^HJ&D-3I(BY#KBD:4>([OUG#L_%4*.+<N-@M:(V99
M:;3)<3<>*ZR.^=Z?\.,:LXI;+D6)FPU2%!H_36$M21.ZZF)U]`A2DKDWO$M\
MFA^.6$184PS&"-#3?'988]DV+(=`BR270%!'O'%TJ%$19*W+RK7N"7?&4>]-
M12W'A8R"%R:/<_QE.'[4.@E<;=]<V#J!"HNE7:(VZWI%J4N(`@,A(9A[36VC
MG/5BE[J%)D:><9DSUG>R]1B0%8F]?*\5L4YZ8@)86Y9%B+)99A?M,KMP469M
M1!F_+M(F,^)@#EY`\\U>7E%K9"@L"Y;X!.@R/O7>>JJ/[J:M4#:/IHLUIN.A
M[E-[N#<!]ZD]7!8NC-N%6R_C@G!;Z3%N`2G:71)?&0VV3$/172:3:1+3DQ'V
M<LJM8YWPNR^Q\G3:&X9\C02N%ZFQK'5RE9?.IH3%*75$EY=)F[FZ?*6,=6(7
M%]FFN-LI,RYFQKZV2K9]_3J%B+*[2`+4H*5;RULG4GD-W8W&+>8,8(VM4>\*
MU+!&9MTX+R@YF_6OI*#_X<>YC^:XPCG;!25<>3?$+WY:VX_P7</"(!_G:79R
M=,+Q1HK6?2M($*+;D3W8'0GU/2!\&%.#MNW,GE'<&F@H.+>7(9'S9,'TV7T#
M&?SS>V8%ZX0K)2(Q">_@\C^<`J*UXC&EAZW>F\KMA$C%-;DPB;;*\G..%10>
M>HLH&XHY)DE1"AU9?LN;XK5'(Y<Y(AQN29K06L\Z6'1?D+O1RGG!97AE+NGY
M[$<^6A+#%_1:8>NDVTU&3%F+D*M!E2^A<:KJ;G5!3Y45Z@E!/[I,THPA=:$Z
MS@F_.]5:$S<;>AXS)"_NF"QEJ`E^)><0TX-L16%?%.7ZUFQ%R%H/S@*E$T9Z
MQV-),C^R!2.+3.<@O,K),^?"UU7D=BL^OTG09X!F,-A(P]>M$6?1I(`-&L*N
M&(?8JHE_UQ)_E%':.M"H>N+)IU!;#`"3$*BRZG##G/"J6`X&ODC;`"%`JJH]
M3N-"I.J\>94J\HJ=T'.?Q)P]3EN=%6Z<?/QX=/+=+@J^.ZU]=S;GA>1C,*;O
M42U9(>J1$%C'$+4BCJ!`F#2M>Y./BJ9[G8J?49+R7!FLLHX(5I[&OCN+EFDM
M+6/UTQKKM8"[^6PN[`@B.A"I:B?0N,:?:5WCI1=X!Z>_/*%]PQRVZ`!#;LN5
M($?""L`M0,A2J"K*8./4MR*ZTXT?`(G=W[*X8XB0(E.1+X`5F?P[&X!Q&V,K
M%:39(]9A]#5%^`!00&0Z%@O[QFO`:?!($U["Z5S+KD*/@4&4YTV"'OPY^6LX
MJFANMS18-1V!1%^**X?2D1U^9QDP/()I1>(#@G$`IWXTB,/2IR^-$+'FG(=-
M#S946-)S`\.4APIS=#BZQ&.'9)DFQT3S+S&F+[STI_AO^ORKC.!Y`T#KHM6Y
M/4>0IX</%?3T7/R07M/T06^%*5Q#6K#V&X"5*-45B/2X6PV!:&VCT0(:1FG'
M0")#904*E;EXC(/B`24!`&%Z@YE*KB?X<8!GC<!A3'M%QZ#2D>`*-7V=N*PM
MNZI=UF7DI^EP5#Y\&Z)'.'[)JF=PQ<65I^0A1\&+GX+B.@O6KEB?)C&]\S*,
M+Y,8#S+%U#59VBK;=P19V^%+!4"5N7.,JZU&KEV_8M,0I@#O5LC4K)A8?IL>
M,S19I[8<@:!Z'E1P4YD?Q_B[C(IT$L>;TC[,LS3SXY"='997Q3'P2)-:8427
M&UN/Y['8DUXD""5?,675YI2WU>_8BB/X4$E]!9F^KFH69*1?]:A1+)47K<P'
MP[&W&THZ`A-9"JO[;WH<U:ITQ^J[X^LR?Q79*C3I"'9I1X3<A<I*T'J\R*9<
M>2`CXZD\4[6EDN_#:ZGF"$QZD5OA18_KU]"IP^J<26_R+$>@C`-:'NRE5SGK
MC$&PMF/HZ4-U!2+-KP"WD7^1^@=>D@@3E!;Q">5R*YYMYE:L-_E7KVC46,+$
MPO&1P><(;U%+V=`!DOQ*M8%>@1'$5J98ID0%C1IYPQ>\@#"/\#:=^H@N?')\
MEDR()57.VT74C?1BOBQ33H?!5Q^%O,2*RMJW1M6HA=#*&T"MO+(W>V,Q<'Z4
ML)4RUF!A.Y+;1$H[-ZQ*\MB=*4M"X_`A\N/6!)$ZNK(.;NWB;U`NVV*,K?&P
MKB?3*)D#4*3FKOXJSD+H&-DQL@2K6H>3K<E\;;_>AU_&X:,H0+T@OEK+[T'5
ME4E:(_FH>NDLJXKV^D=`_W15.BKW[B:4SB\@)=X+CAE=*V$?6K9L1+?Q@JD_
M#(J6:_NNE+%.O&WL9@IH!VW-<N04GD,2`GR4H`FY^,56["U5;!6GN%+N0J!Q
M^:HZK0V2"5AD^+DC/1%)L?4TIX9U2-BVWI;E#7-QMP@*7+W.K6,='&3%(RQ@
MF]<!->!XQ,+"C'[!1N\5F($HF=*$8,6]!GZ2T?::NP(4J1UA5[H=`<S/(`:H
M>%T73F`,R=E"!F=`!#)"=9T$37?*'0D1W[I.LY;INY8`C/T;M@YPV[9N-+%0
M4?Q9UC5(0_>K.S.K\`C5+QP_)E%TDR#RI6IP<SNS#_!Z`*@0Z?+\=&2Y5\BQ
M^YQC&BCOQQV0RV-/*_`Y[%6$^6D1ASKS4;;#R/^Y>!979N.C,14U8;^AISWZ
M5:)?E,%OW58OV86%,P*07&1=\$P3\AMZVB-?)?)%&=SW-+,Q&J1U"29J)[MI
M]>*4"6WIAO;(%<Y.(<X_+:&*=U$IVV2('[]E7&^'OXKB,1>F^'7L"/)_!>31
M-P@',X#\,5B)&D!$.=J6-T9P(.XL"08]-7UXO;?H9;AI=MZX,UG48MC8Y-K[
MB-CG,XV>!1US2]T(]O-+V?S2+)2WLFJUL;'!>V%BBDD.8S_/MC;/5$C&D8O\
MO7E9<<KH5),:Q'ZB;6VB]9>+JFS&MD\S1W=B[KC\7-F*N>4D'$2T<1`V,[2\
M9\F*]"!4V9WE0M89UX,_6I.!JLK4TIF13R1G&=VL7>%V;GR(?O&CC0A76OIX
M>VC<'AL=L346#Y(!FN$UH)EU]R2L4$J6#<*EE+*I_OUEDF;W2?9OD#V"(!G'
M\,\R[%"Y`+4%%]#9]]N;`^;9JRK1JZMSH]C>T)Q4]"-2CA7.?;N#V,\6@WSN
MFR[7DFG3662+!7>0IOFDT"^#./P$LI<D3*)D/&=$.MQBSV]W@IABKJK4P2[-
MBD>8_GZ#`*AG2-W&G&CJUYT9T1.HFJ>,,._?^JNB)N81]T.`U^U?D@@W0W+G
M;6O*-/>\GS3;F302W'?I0/RYG7W/TL[B1T`>LY,T)TE,!9K[$4EV<,*;1ML=
MR7Y:\:>5!=+0ZNPUE/:F,V]Y*HNPD.44T-?A?@:IGT'=F.Z(@UG+<GX%9S`$
M<;AM(Z[>[WZF;->$:^6]-J_S5I*;Y,\I^"/'S5W/R%T9N=0F'QM2FRP:](H6
M]><U4:0PUCC1YO-C%C>B[59'PTU!TE#4/IW2(HR562]*D$#*#U.!>]9(X"?_
M8)2V78A289\D2+0KM\?FP/D).ECEK9>F9+X-*3I=<26N$LV-/]A8=A=`(!5K
M4)Q*1R#0')&S9I)6SHNGI(P!?9.@(;':THMYRSJ@I&WK(2:Q:NAC",=):]AT
MZ$%SZ^*DI&WK`*8/)4H1:?L2R<PF&6$4):B0:!S>P8!<P!V,$:`$$\=3RH[[
M+U'=)6`)+Z1*F&0<.VI4WR5)80P0%DPV)QEQ.$ME4U'K\--CY1.FCW,,8GPA
MF^9X\O@U'*]3U;)8"=:W3N["PFM:7_H0;5P/,-:0?^1Q\E1S7-[&`7O%8!:V
M3L[]A+6V!LB1;5S26C;4=VWQUQG%K4.&.D\9GT8-9WOJ<P!^F6+FQ%EY/O,(
M`@!G#?YL;EG;)<P7T]I4ER)2T4R/UJ5K*!GV93*9)#%]^5&$5RS"+C+-O,;2
MKJ"A"YE:TWY*/W)4>+9?$DV?$./M%/V,=R;?5-XU8,@1NA/O7ZM--=G3-JT`
M]>]=$:<888H6\_Z:7D!RU^0&08K'UR;"14%G9<FG4-%E$FU"'4S(CF5I@]PD
MZ`$E81YD-9=7DY"%*CHE].X4*WJ0QP9!X\VB'P\+H95W</`G_P]02P,$%```
M``@`QX"G1IS-Q[@Y"P``:F<``!$`'`!F871E+3(P,34P,S,Q+GAS9%54"0`#
MML5+5;;%2U5U>`L``00E#@``!#D!``#M'=ERXS;R?:OV'Q"];%(5G1Y/RJIQ
M4I*/E%/VR&5K)K-/*8@$)6Q(@`.`/O;KMP$>HL1#E$394JU>QA+1=S<:#;"A
M^?3;B^>B)R(DY>R\T6UU&H@PB]N43<\;@6QB:5':^.W7?_[CTP_-)KH0!"MB
MH\DKNB-"4-=%%USX7&`%!%"S&0%^&S[<(IM;@4>80E:$]4S5+,$;"FI/"4*G
MK6ZO=0*<Y]A#+`$:Z!DRO58W&8GY<]9'I^U?VKU.]Q2=]4^[_0\?T.`N@;L#
M#1RZ"O!%VGUIS8B'D<)B2M1G[!'I8XN<-V9*^?UV^_GYN>4`2S4C`OLD4-22
M+8M[AF#GY*3;0%@I02>!(M=<>)?$P8&KP';L>X!=(P28U"7:$`L`J6'P`9-]
MD&:![?-)BXLI,.ITV]_N;A^-H#&PEFD=(2,6+F5_YS'IGIV=M<UH#)J!?)D(
M-Q;HI*V')^"F&%P0IQ#Z8QM&YR*44/UVFY*`<<8"+Q_:5J*M7GW2!J`F0!%!
MK80#`-DJP4MS.&V'@W.3T]4F;U(F%696HFL%J;(2T1*UEQG8A"Z*+XG5FO*G
M-@QHGWYH=KK-N5=AFDXQ]A,4!\N)(1X-Y*`P,M7SJ%"FL[;@+N@1@C5@LB!D
MI@MFC"LSV<VS^*GO4^;PZ!$\U.'1UR3&8`ZD/WQYN%D=KX;I(]`WT^6",YLP
M2`7P07*7VEJ6(7:UJ1YGA"C90!1T6`<A$3$6TB8.9=0H!%[O0!9""3WXG)!$
M:9HH(HI"JI_:RZ26N01`8<1^-9]]0200-T;4\1YA1R!EF!9VK<#=`'$N63%>
M]#1VVEOX,AF5(V?DDW`1D0,&0!Y8:08(](G<<EG)T6M0*X^"7M4HF'-$W$%S
MG@@S#9GBBC3;8YAL'R876,ZN7?Z\=D3,$<N=?[*9\S5Y9.@?O5SDY4LJ+9?+
M0)"!98F`V%<OOC:LO.5L.B:Z-IJ`(SV/*F-7,W69@E(42E)*Y"51F+J1Y^LB
M5A8-'SH?.EV(@#DO^!*Q0S&_GY'FV-0LD>;Y,TIQC3)!BB_Z,>+\TS%0=A4H
M%Z!QKYXP"4FM"I)>W4'21-IKO6.(%(9(M+>,_X+?KL"`ZO4&ZE#A&56B"*@"
M6;XF=,[TFA`32'_4G@NIH12YH]MJJ.WOL0"X&0$"V%V[T%_$7E7UGVY2]:,?
M%Y@<\WF%?#X24\SH?XWP,!$?`\_#XG7D/-(IHPZ8$>:G9?'`Y,)[,+S.ALN9
M?#,B93'0A1C(+/1I-F:B1XQTN9=BA>:\4,SL&`H5EG8I"?CI>T"E$63D?"6"
M\G$*[899F56\&E:YLWLY59VFBU*$M9<-:92F#5G>:AV]N]J[UYB*K]@-R!W!
M^KLI=):=F0]4[KN3K.\T&63HH#2AHYMV55_74UJO<'3]6Z]C0*P.B$?%K;]G
MW+6)D%>0#-7KLK-S(,H=>9IU9)K&OU!(Y>B="MX))I)\#T#QJZ>\A)H9+_?,
MQQS/)!102.+HEAU5M;56MY6J7"A[LB<56U2YL`&*/AWW/CM;:\=XXM:UXD:T
MRF+D!-;=D]J//$/&QRC9:`'.CX!"N'+OGF:]F[<8'UVVZ_1?\#)C*UKEQ]3U
M'G$<WV.\58ADWF1L1VQ5D-1;(41L4>\8)K6=B16]!UT+N3P,MCPA.R:'K<_*
M"IQ<"EONT^HG9T?W;5>Q%?BN&+#<<14/4(Y>V^8HI<AG!6#E'JMRL/)_Y2[]
MCVX7?B`.,FW&?=TG>]Z0U/-=W?=JGLU,%['V7C/N7/X+U&V]>&X,HNF7=-(:
M)R];*&(<D\#"RE#)M$$#$>X3H:"(:<?"-U"[-K7`%^NJM>2^?=0*`F5=K19C
M:Q^5<O%D7:4`A;B[T>=3>[GA.GJRV)AMVK)!-2X48KFW&DK:O5%X*>*66X9@
M/IHKQ`)64]-I=GO-[L<6,(\E7D.0;/M\%3F6L>J4(WVY8#U9./N\A3BE3?\%
M@N3BZ`_-.?*&!EFZI%#%$@9%?TMN3VA#G&A#K"-&_N6-B@+$")KSZ0+/0GZE
M5R?*#)^+V":NDO&3C!O,38PJ-WY2AHHN$AG)SQLW.G%B]SZ8P'9[Y#@0;VPZ
MF$@EL*7"2D:GLK]6P(6)T%Q2Z<,S&+M1Q-.K..@,98NB*M`:_RYXX,>`%$`:
M"$=$SAM*!`#.J.OJ@\/X>PCKZUVB/39L[$!$S7F%:CW.L"#F#ICNH2=,AB<=
M0F`V-7##USG(/7XU77W/6-ACR(#N[P"F+D'M9*N4LD3]I-/&\SB#DDZ\;F`^
M![NRT'Z3L.\,C$<F5&UC53F(+JMI)F.>U75N"7GU8KF!3>QKP;T_"9W.(,D/
MGJ"JGA+(;1,B1DY(<Q0H/<7UG<%E4^^>WT+PFN&ZK;^FG?,.7>Z(EC]EG#*@
M4*/P]EO?YAZF['WGXS"0E!$I4V<_X8[SABD"!E?RGBL`AQ0#:@@"_KUABRX;
M6#-*G@S1D7,!Q0THI=\9$6$!5G2X>$==(`9S2*8L]1[,MXBIO38X5).Z4_5-
M[9S#\VW-&YLVT13RS$PG'4W'G*/<2!D0^S+0*]^](17KDY@"I`Y=LRGRDMQ;
MF*!,Y>U+BAV%P;T@UCM$7P';=PY`_<K\!JIB$=Y+H-*\-_G,V44@=$-Y'&L5
MX$K":NUB)*M*6+JKPC)DS6C+&"+=M@`"2;ED@)+Q]U$<(L_>1//L/,OW;:+?
MBEA)X/:C^DS,5>3H"Q=+.7+^Q+K<4R/QH*N[Z)L,,^B8WP<"<JLD49'GZ"6:
M,Y-D1[!>L^A7*N+@J)GFH23HLFM,.5N_:N#[M@-\('[DN%N*)]0%N:^Y^`+N
MDK`I"%<&LRV3V1FS`>Z;SJ(DAZR<1EF[0.Z_\GR7OY*P^!CYIG1=WEV4@^W=
M_B*6%6*THH*5,?9.UZ\0A3"]S!YXQ*!@-+,1`B-GB[@"<N]T6VY`R$E'Q2#[
MEH*6)1V3%S5T(<!*M$G!+#A'Q<_?=AN9>^QG6G->\[2I!KZE8KLY<PE7<D6!
M#I3\(+G0/_X`<NGVJ-2K\DOB4(NJ5,],-D1KH/6^L9RIOCX3=2^X18@M]=F:
MKHUT'LGU=UQ=K8FSVW(\53_5LA')"Z"D+C2J@BY??,X>B$T\/VRF6MCYFXIP
M(6@VPM^[P\NZ]^$#VS9$WFC;G\]N[ZP<S:+D+0)DEH']GT"J4(O22-L`=ZO9
MN,,W$O%F[>K%IR%P>(`V>*%IC<O!-LBUMNK;U-,_S,1-Q;2C"J)([DM3JE50
M,`;<NT*O2.`_,`L@MGJ=[EFFG%T#YV#T'013F'B]3J];6=TLRMYI>TG@FWV%
M!3-O2>-U[=]$C?F0A"<K"R=45<#W+@</X+--;$B?#[!0Z`:66XY-.SVQ`J'/
M"*:"&(2,;]='W3L?ZU/5@98ZHUQF9"]E'Q;*/MPCV5><_&MQK[F(7H6/G+CH
MR3__+X$NJ;YCF=[E]+*:_@_$CW6ZA_7;HCYV=5437CJL9)3*)`[&4DDHCV$9
M`=ADN5B:`YGA7`WKF0%O&!I?F&XO'G(A^#.4=!?8QY8^R"4$EE%+-_=.27Y$
M5,3,-Q/8R`^A]B,*HI\49=-;O?6Y>E%FX='.CY4OA3B8:%_48C'4"\9JC/.=
MJK;AKU/FG"I%=4M]],I>>6UW:K6'%DT=86YCR#29LA!<_V3T+6P6=^.,!<7N
M!9=J^8U[!;C#>O.>L<0?`2MJO`M-4`9P*$GGB^\(B-JH5GP@%J%/6O!8QY+Q
MP^XH@0T9P<*:I9?(I6<'LRBFY38+>[K[H6CP8+0;>+J191YZ>FLCN!U8ZI(\
M$9?[7CHM500^[."]X%K\Z/]2@87GEEIZ:4I.$[2OY6*R6@_E4-+78P!2Z@:.
M;#68/[2/BH77LL([(_#U?U!+`0(>`Q0````(`,>`IT9C^[GY068``.`&!0`1
M`!@```````$```"D@0````!F871E+3(P,34P,S,Q+GAM;%54!0`#ML5+575X
M"P`!!"4.```$.0$``%!+`0(>`Q0````(`,>`IT;D9/3&L0@``/=P```5`!@`
M``````$```"D@8QF``!F871E+3(P,34P,S,Q7V-A;"YX;6Q55`4``[;%2U5U
M>`L``00E#@``!#D!``!02P$"'@,4````"`#'@*=&5L9ZWN83```N/0$`%0`8
M```````!````I(&,;P``9F%T92TR,#$U,#,S,5]D968N>&UL550%``.VQ4M5
M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`QX"G1H7/7L6>0@``RRD$`!4`
M&````````0```*2!P8,``&9A=&4M,C`Q-3`S,S%?;&%B+GAM;%54!0`#ML5+
M575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`,>`IT;T/!N#>B,``'J*`@`5
M`!@```````$```"D@:[&``!F871E+3(P,34P,S,Q7W!R92YX;6Q55`4``[;%
M2U5U>`L``00E#@``!#D!``!02P$"'@,4````"`#'@*=&G,W'N#D+``!J9P``
M$0`8```````!````I(%WZ@``9F%T92TR,#$U,#,S,2YX<V155`4``[;%2U5U
D>`L``00E#@``!#D!``!02P4&``````8`!@`:`@``^_4`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">3.</font><font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Fair Value Measurements</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The carrying amounts of accounts payable and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Based on the borrowing rates currently available to the Company for loans with similar terms, which is considered a Level 2 input as described below, the Company believes that the fair value of long-term debt approximates its carrying value.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Level 1: Observable inputs such as quoted prices in active markets;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</font>
		</p>
		<p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 46.05pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Financial assets measured at fair value on a recurring basis consist of the Company&#x2019;s cash equivalents. As of March 31, 2015 and December&nbsp;31, 2014, the carrying amount of cash equivalents was $35.3 million, which approximates fair value and was determined based upon Level 1 inputs. Cash equivalents primarily consisted of money market funds. As of March 31, 2015 and December&nbsp;31, 2014, the Company did not hold any Level 2 or Level 3 financial assets that are recorded at fair value on a recurring basis.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">None of the Company&#x2019;s non-financial assets or liabilities is recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">As of March 31, 2015 and December&nbsp;31, 2014, the Company had no material liabilities measured at fair value on a recurring basis.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13504-108611<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 42,349</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 49,101</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">443</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">771</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">42,792</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">49,872</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">1,544</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">1,200</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" onclick="toggleNextSibling(this);">122</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" onclick="toggleNextSibling(this);">122</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">32</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">44,490</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">51,204</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">1,271</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">645</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">1,827</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">2,260</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Current portion of deferred rent</a></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditCurrent" onclick="toggleNextSibling(this);">26</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditCurrent" onclick="toggleNextSibling(this);">85</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent', window );">Repurchase liability for unvested equity awards</a></td>
        <td class="nump"><a title="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" onclick="toggleNextSibling(this);">33</a><span style="display:none;white-space:normal;text-align:left;">fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent</span><span></span></td>
        <td class="nump"><a title="fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent" onclick="toggleNextSibling(this);">45</a><span style="display:none;white-space:normal;text-align:left;">fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current portion</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">3,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">1,546</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">6,413</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">4,581</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">100</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditNoncurrent" onclick="toggleNextSibling(this);">51</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">312</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">149</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">16,414</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">18,083</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; authorized shares-5,000,000 at March 31,2015 and December 31, 2014; no shares issued or outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; authorized shares - 150,000,000 at March 31,2015 and December 31, 2014; issued and outstanding shares - 20,637,217 at March 31,2015 and 20,569,399 at December 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">141,503</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">140,711</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(120,273)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(112,392)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">21,251</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">28,340</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 44,490</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 51,204</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the carrying value, as of the balance sheet date, of repurchase liability for unvested equity awards, which is expected to be paid within one year (or the operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_RepurchaseLiabilityForUnvestedEquityAwardsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">1.</font><font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 18pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Organization and Summary of Significant Accounting Policies</font>
		</p>
		<p style="margin:0pt 0pt 0pt 24.5pt;text-indent: -24.5pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Organization</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Fate Therapeutics,&nbsp;Inc. (the &#x201C;Company&#x201D;) was incorporated in the state of Delaware on April&nbsp;27, 2007 and has its principal operations in San Diego, California. The Company is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases. The Company has built a novel platform to program the function and fate of cells </font><font style="display: inline;font-style:italic;font-size:10pt;">ex vivo</font><font style="display: inline;font-size:10pt;"> using pharmacologic modulators, such as small molecules. The Company&#x2019;s lead product candidate, ProHema&#xAE;, is an </font><font style="display: inline;font-style:italic;font-size:10pt;">ex vivo</font><font style="display: inline;font-size:10pt;"> programmed hematopoietic cellular therapeutic, which is currently in clinical development for the treatment of hematologic malignancies and rare genetic disorders in patients undergoing hematopoietic stem cell transplantation. The Company is also developing </font><font style="display: inline;font-style:italic;font-size:10pt;">ex vivo</font><font style="display: inline;font-size:10pt;"> programmed hematopoietic and myogenic cellular product candidates using its patent-protected induced pluripotent stem cell technology.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">As of March 31, 2015, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated revenues from its planned principal operations.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Initial Public Offering</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On October&nbsp;4, 2013, the Company completed its initial public offering (the &#x201C;IPO&#x201D;) whereby it sold 7,666,667 shares of common stock at a public offering price of $6.00 per share. Gross proceeds from the offering were $46.0&nbsp;million. After giving effect to underwriting discounts, commissions and other cash costs related to the offering, net proceeds were $40.5&nbsp;million.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company&#x2019;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (&#x201C;GAAP&#x201D;). The preparation of the Company&#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Principles of Consolidation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Canada, Fate Therapeutics&nbsp;Ltd., incorporated in the United Kingdom, and Destin Therapeutics&nbsp;Inc., incorporated in Canada, which was dissolved in June 2014. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Unaudited Interim Financial Information</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The accompanying interim condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with GAAP and following the requirements of the United States Securities and Exchange Commission (&#x201C;SEC&#x201D;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted.&nbsp;&nbsp;In management&#x2019;s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#x2019;s financial position and its results of operations and comprehensive loss and its cash flows for periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company&#x2019;s </font><font style="display: inline;font-size:10pt;">financial statements and accompanying notes for the fiscal year ended December 31, 2014, contained in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2014 filed by the Company with the SEC on March 12, 2015. </font><font style="display: inline;font-size:10pt;">The results for the three months ended March 31, 2015 are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company recognizes revenues when all four of the following criteria are met: (i)&nbsp;persuasive evidence that an agreement exists; (ii)&nbsp;delivery of the products and/or services has occurred; (iii)&nbsp;the selling price is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&#x2019;s control.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Beginning in 2011, revenue has been allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&#x201C;VSOE&#x201D;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&#x201C;TPE&#x201D;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&nbsp;the consideration being earned should be commensurate with either the Company&#x2019;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the Company&#x2019;s performance to achieve the milestone; (ii)&nbsp;the consideration being earned should relate solely to past performance; (iii)&nbsp;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&nbsp;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&#x2019;s revenue recognition criteria are recorded as deferred revenue on the Company&#x2019;s consolidated balance sheets.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition is determined to be probable of achievement or when it has been achieved.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Net Loss per Common Share</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 58,453 shares and 88,043 shares for the three months ended March 31, 2015 and 2014, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents for the periods presented include warrants for the purchase of common stock, and common stock options outstanding under the Company&#x2019;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">For the three months ended March 31, 2015, the Company realized a net loss of $7.9 million. Shares of potentially dilutive securities totaled 3.1 million for the three months ended March 31, 2015, including options to purchase 3.0 million shares of common stock.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">For the three months ended March 31, 2014, the Company realized a net loss of $7.0 million. Shares of potentially dilutive securities totaled 2.5 million for the three months ended March 31, 2014, including options to purchase 2.4 million shares of common stock.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In August 2014, the Financial Accounting Standards Board (the &#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2014-15, which defined management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern and to provide related disclosure. ASU 2014-15 defined the term substantial doubt and requires an assessment for a period of one year after the date of the issuance of the financial statements. It requires certain disclosures when substantial doubt is alleviated as a result of consideration of management&#x2019;s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The guidance becomes effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company does not believe that the adoption of this guidance will have a material impact on its Consolidated Financial Statements.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, which created a single, principle-based revenue recognition model that will supersede and replace nearly all existing U.S. GAAP revenue recognition guidance. Entities will recognize revenue in a manner that depicts the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. The model provides that entities follow five steps: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue. For public business entities, the guidance becomes effective for annual reporting periods beginning after December 15, 2016, and interim periods therein. The Company is currently evaluating the impact the adoption of this guidance will have on its Consolidated Financial Statements.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Asset Acquisition of Verio Therapeutics Inc.<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition of Verio Therapeutics Inc.</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AssetAcquisitionTextBlock', window );">Asset Acquisition of Verio Therapeutics Inc.</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 22.5pt;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">2.</font><font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 16pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Asset Acquisition of Verio Therapeutics Inc.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 22.5pt;text-indent: -22.5pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On April&nbsp;7, 2010, the Company acquired Verio Therapeutics&nbsp;Inc. (&#x201C;Verio&#x201D;), a development stage company headquartered in Ottawa, Ontario to gain access to its exclusively licensed intellectual property. In connection with the asset acquisition of Verio, the stockholders of Verio received 900,000 non-voting shares of Fate Canada (the &#x201C;Exchangeable Shares&#x201D;) that were initially exchangeable into 138,462 shares of the Company&#x2019;s common stock and, subject to the validation of certain scientific data and the achievement of certain preclinical, clinical, commercial and financial milestones, were exchangeable for up to 884,605 shares of the Company&#x2019;s common stock.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">As a result of the Company&#x2019;s IPO on October&nbsp;4, 2013, 480,763 shares of the Company&#x2019;s common stock were issued during the fourth quarter of 2013 pursuant to the redemption of the Exchangeable Shares. The total number of shares of the Company&#x2019;s common stock issued upon the exchange of the Exchangeable Shares as a result of the IPO had increased from 138,462 shares of the Company&#x2019;s common stock to a total of 480,763 shares of the Company&#x2019;s common stock based upon the achievement of certain contractual milestones.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">During the three months ended March 31, 2014, based on the achievement of certain preclinical milestones, an additional 38,463 shares of the Company&#x2019;s common stock were earned and issued, resulting in a $0.4&nbsp;million charge to research and development expense. The Company may issue an additional 365,379 shares of the Company&#x2019;s common stock based on the achievement of additional contractual milestones as follows: (i)&nbsp;38,461 shares for the achievement of certain preclinical milestones, (ii)&nbsp;211,538 shares for the achievement of certain clinical milestones and (iii)&nbsp;115,380 shares for the achievement of certain commercialization milestones, such that the maximum aggregate number of shares of the Company&#x2019;s common stock issuable in connection with the Verio acquisition is 884,605.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">At the date of achievement of a milestone, the fair value of the additional shares is charged to research and development expense and recorded in additional paid-in capital.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AssetAcquisitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_AssetAcquisitionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AssetAcquisitionTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for an asset acquisition completed during the period, including background, timing, and recognized assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_AssetAcquisitionTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets (Parenthetical)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued shares</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding shares</a></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized shares</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">150,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">150,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">20,637,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">20,569,399</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding shares</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">20,637,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">20,569,399</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOTAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Asset Acquisition of Verio Therapeutics Inc. (Details) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 04, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 07, 2010</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_CommonStockIssuableUponRedemptionOfExchangeableShares', window );">Common stock issued pursuant to the redemption of the exchangeable shares</a></td>
        <td class="nump"><a title="fate_CommonStockIssuableUponRedemptionOfExchangeableShares" onclick="toggleNextSibling(this);">480,763</a><span style="display:none;white-space:normal;text-align:left;">fate_CommonStockIssuableUponRedemptionOfExchangeableShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 4,568</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 4,522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions', window );">Exchangeable Shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">884,605</a><span style="display:none;white-space:normal;text-align:left;">fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember', window );">Verio Therapeutics Inc</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions', window );">Exchangeable Shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions[us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember]" onclick="toggleNextSibling(this);">900,000</a><span style="display:none;white-space:normal;text-align:left;">fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions<br>/ us-gaap_BusinessAcquisitionAxis<br>= fate_VerioTherapeuticsIncMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued[us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember]" onclick="toggleNextSibling(this);">138,462</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued<br>/ us-gaap_BusinessAcquisitionAxis<br>= fate_VerioTherapeuticsIncMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DeemedEarnedCommonStockYetToBeIssued', window );">Deemed Earned Common Stock Yet to be Issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_DeemedEarnedCommonStockYetToBeIssued[us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember]" onclick="toggleNextSibling(this);">38,463</a><span style="display:none;white-space:normal;text-align:left;">fate_DeemedEarnedCommonStockYetToBeIssued<br>/ us-gaap_BusinessAcquisitionAxis<br>= fate_VerioTherapeuticsIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense[us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember]" onclick="toggleNextSibling(this);">$ 400</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense<br>/ us-gaap_BusinessAcquisitionAxis<br>= fate_VerioTherapeuticsIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones', window );">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of additional milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones[us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember]" onclick="toggleNextSibling(this);">365,379</a><span style="display:none;white-space:normal;text-align:left;">fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones<br>/ us-gaap_BusinessAcquisitionAxis<br>= fate_VerioTherapeuticsIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones', window );">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain preclinical milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones[us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember]" onclick="toggleNextSibling(this);">38,461</a><span style="display:none;white-space:normal;text-align:left;">fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones<br>/ us-gaap_BusinessAcquisitionAxis<br>= fate_VerioTherapeuticsIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones', window );">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain clinical milestones</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones[us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember]" onclick="toggleNextSibling(this);">211,538</a><span style="display:none;white-space:normal;text-align:left;">fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones<br>/ us-gaap_BusinessAcquisitionAxis<br>= fate_VerioTherapeuticsIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones', window );">Potential increase in shares issuable on exchange of Exchangeable Shares based on achievement of certain commercialization milestone</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones[us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember]" onclick="toggleNextSibling(this);">115,380</a><span style="display:none;white-space:normal;text-align:left;">fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones<br>/ us-gaap_BusinessAcquisitionAxis<br>= fate_VerioTherapeuticsIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember', window );">Verio Therapeutics Inc | Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Acquisition</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issuable on exchange of Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued[us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">884,605</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued<br>/ us-gaap_BusinessAcquisitionAxis<br>= fate_VerioTherapeuticsIncMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of potential future increase in number of shares of the entity's common stock to be issued upon achievement of additional milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfAdditionalMilestones</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of potential future increase in number of shares of the entity's common stock to be issued upon achievement of certain clinical milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainClinicalMilestones</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of potential future increase in number of shares of the entity's common stock to be issued upon achievement of certain commercialization milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainCommercializationMilestones</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the amount of potential future increase in number of shares of the entity's common stock to be issued upon achievement of certain preclinical milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_BusinessAcquisitionEquityInterestsPotentialIncreaseInNumberOfSharesAchievementOfCertainPreclinicalMilestones</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_CommonStockIssuableUponRedemptionOfExchangeableShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of common stocks issuable on the redemption of exchangeable shares during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_CommonStockIssuableUponRedemptionOfExchangeableShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DeemedEarnedCommonStockYetToBeIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of common shares that were deemed earned but not issued by the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_DeemedEarnedCommonStockYetToBeIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of exchangeable stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_ExchangeableStockIssuedDuringPeriodSharesAcquisitions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fate_VerioTherapeuticsIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>May 05, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">FATE THERAPEUTICS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001434316<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">20,683,345</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFTAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Fair Value Measurements (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Transfer of assets from level 1 to level 2</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Transfer of assets from level 2 to level 1</a></td>
        <td class="nump"><a title="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Transfer of liabilities from level 1 to level 2</a></td>
        <td class="nump"><a title="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Transfer of liabilities from level 2 to level 1</a></td>
        <td class="nump"><a title="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements Recurring</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Liabilities</a></td>
        <td class="nump"><a title="us-gaap_FinancialLiabilitiesFairValueDisclosure[us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FinancialLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_FinancialLiabilitiesFairValueDisclosure[us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FinancialLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value Measurements Nonrecurring</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureNonrecurring', window );">Non-financial assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsFairValueDisclosureNonrecurring[us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsFairValueDisclosureNonrecurring<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsNonrecurringMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure', window );">Non-financial liabilities</a></td>
        <td class="nump"><a title="us-gaap_NonfinancialLiabilitiesFairValueDisclosure[us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonfinancialLiabilitiesFairValueDisclosure<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsNonrecurringMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Reported Amount Fair Value Disclosure | Fair Value Measurements Recurring | Fair Value Inputs Level 1</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">$ 35,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementBasisAxis<br>= us-gaap_CarryingReportedAmountFairValueDisclosureMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsFairValueDisclosure[us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member;us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember;us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember]" onclick="toggleNextSibling(this);">$ 35,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsFairValueDisclosure<br>/ us-gaap_FairValueByFairValueHierarchyLevelAxis<br>= us-gaap_FairValueInputsLevel1Member<br>/ us-gaap_FairValueByMeasurementBasisAxis<br>= us-gaap_CarryingReportedAmountFairValueDisclosureMember<br>/ us-gaap_FairValueByMeasurementFrequencyAxis<br>= us-gaap_FairValueMeasurementsRecurringMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureNonrecurring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a nonrecurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureNonrecurring</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonfinancialLiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonfinancialLiabilitiesFairValueDisclosure</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2EAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 4,568</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 4,522</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">2,756</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">2,415</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">7,324</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">6,937</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(7,324)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(6,937)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(558)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(43)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(557)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherNonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(43)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherNonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,881)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,980)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.38)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.34)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used to compute basic and diluted net loss per share (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">20,554,478</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">20,346,856</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Summary of Significant Accounting Policies</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_InitialPublicOfferingPolicyTextBlock', window );">Initial Public Offering</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Initial Public Offering</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On October&nbsp;4, 2013, the Company completed its initial public offering (the &#x201C;IPO&#x201D;) whereby it sold 7,666,667 shares of common stock at a public offering price of $6.00 per share. Gross proceeds from the offering were $46.0&nbsp;million. After giving effect to underwriting discounts, commissions and other cash costs related to the offering, net proceeds were $40.5&nbsp;million.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Use of Estimates</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company&#x2019;s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (&#x201C;GAAP&#x201D;). The preparation of the Company&#x2019;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to accrued expenses. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Principles of Consolidation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries, Fate Canada, Fate Therapeutics&nbsp;Ltd., incorporated in the United Kingdom, and Destin Therapeutics&nbsp;Inc., incorporated in Canada, which was dissolved in June 2014. To date, the aggregate operations of these subsidiaries have not been significant and all intercompany transactions and balances have been eliminated in consolidation.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Cash and Cash Equivalents</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Cash and cash equivalents include cash in readily available checking and savings accounts, money market accounts and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less from the date of purchase to be cash equivalents.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company recognizes revenues when all four of the following criteria are met: (i)&nbsp;persuasive evidence that an agreement exists; (ii)&nbsp;delivery of the products and/or services has occurred; (iii)&nbsp;the selling price is fixed or determinable; and (iv)&nbsp;collectability is reasonably assured.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Revenue arrangements with multiple elements are analyzed to determine whether the elements can be divided into separate units of accounting or whether the elements must be accounted for as a single unit of accounting. The Company divides the elements into separate units of accounting and applies the applicable revenue recognition criteria to each of the elements, if the delivered elements have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative to the delivered elements, and if the delivery or performance of the undelivered elements is considered probable and substantially within the Company&#x2019;s control.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">For transactions entered into prior to 2011, revenue was allocated to each element based on its relative fair value when objective and reliable evidence of fair value existed for all elements in an arrangement. If an element was sold on a stand-alone basis, the fair value of the element was the price charged for the element. When the Company was unable to establish fair value for delivered elements or when fair value of undelivered elements had not been established, revenue was deferred until all elements were delivered or until fair value could be objectively determined for any undelivered elements.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Beginning in 2011, revenue has been allocated to each element at the inception of the arrangement using the relative selling price method that is based on a three-tier hierarchy. The relative selling price method requires that the estimated selling price for each element be based on vendor-specific objective evidence (&#x201C;VSOE&#x201D;) of fair value, which represents the price charged for each element when it is sold separately or, for an element not yet being sold separately, the price established by management. When VSOE of fair value is not available, third-party evidence (&#x201C;TPE&#x201D;) of fair value is acceptable, or a best estimate of selling price is used if neither VSOE nor TPE is available. A best estimate of selling price should be consistent with the objective of determining the price at which the Company would transact if the element were sold regularly on a stand-alone basis and should also take into account market conditions and company-specific factors. The Company has not entered into or materially modified any multiple element arrangements subsequent to 2010.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Revenue arrangements with multiple elements may include license fees, research and development payments, milestone payments, other contingent payments, and royalties on any product sales derived from collaborations. The Company recognizes nonrefundable license fees with stand-alone value as revenue at the time that the Company has satisfied all performance obligations, and recognizes license fees without stand-alone value as revenue in combination with any undelivered performance obligations. The Company recognizes a research and development payment as revenue over the term of the collaboration agreement as contracted amounts are earned, or reimbursable costs are incurred, under the agreement, where contracted amounts are considered to be earned in relative proportion to the performance required under the applicable agreement. The Company recognizes a milestone payment, which is contingent upon the achievement of a milestone in its entirety, as revenue in the period in which the milestone is achieved only if the milestone meets all criteria to be considered substantive. These criteria include the following: (i)&nbsp;the consideration being earned should be commensurate with either the Company&#x2019;s performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from the Company&#x2019;s performance to achieve the milestone; (ii)&nbsp;the consideration being earned should relate solely to past performance; (iii)&nbsp;the consideration being earned should be reasonable relative to all deliverables and payment terms in the arrangement; and (iv)&nbsp;the milestone should be considered in its entirety and cannot be bifurcated into substantive and nonsubstantive components. Any amounts received pursuant to revenue arrangements with multiple elements prior to satisfying the Company&#x2019;s revenue recognition criteria are recorded as deferred revenue on the Company&#x2019;s consolidated balance sheets.</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Revenue from government grants is recorded when reimbursable expenses are incurred under the grant in accordance with the terms of the grant award.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Stock-Based Compensation</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Stock-based compensation expense represents the cost of the grant date fair value of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants for which vesting is subject to both performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, with the exception of option grants for which vesting is subject to both performance-based milestones and market conditions, which are valued using a lattice-based model.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The Company accounts for stock options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. For stock option grants for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the performance condition is determined to be probable of achievement or when it has been achieved</font><font style="display: inline;font-size:10pt;">.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Net Loss per Common Share</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Excluded from the weighted-average number of shares outstanding are shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock totaling 58,453 shares and 88,043 shares for the three months ended March 31, 2015 and 2014, respectively. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents for the periods presented include warrants for the purchase of common stock, and common stock options outstanding under the Company&#x2019;s stock option plan. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">For the three months ended March 31, 2015, the Company realized a net loss of $7.9 million. Shares of potentially dilutive securities totaled 3.1 million for the three months ended March 31, 2015, including options to purchase 3.0 million shares of common stock.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">For the three months ended March 31, 2014, the Company realized a net loss of $7.0 million. Shares of potentially dilutive securities totaled 2.5 million for the three months ended March 31, 2014, including options to purchase 2.4 million shares of common stock.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In August 2014, the Financial Accounting Standards Board (the &#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2014-15, which defined management&#x2019;s responsibility to evaluate whether there is substantial doubt about an entity&#x2019;s ability to continue as a going concern and to provide related disclosure. ASU 2014-15 defined the term substantial doubt and requires an assessment for a period of one year after the date of the issuance of the financial statements. It requires certain disclosures when substantial doubt is alleviated as a result of consideration of management&#x2019;s plans and requires an express statement and other disclosures when substantial doubt is not alleviated. The guidance becomes effective for reporting periods beginning after December 15, 2016, with early adoption permitted. The Company does not believe that the adoption of this guidance will have a material impact on its Consolidated Financial Statements.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, which created a single, principle-based revenue recognition model that will supersede and replace nearly all existing U.S. GAAP revenue recognition guidance. Entities will recognize revenue in a manner that depicts the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. The model provides that entities follow five steps: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue. For public business entities, the guidance becomes effective for annual reporting periods beginning after December 15, 2016, and interim periods therein. The Company is currently evaluating the impact the adoption of this guidance will have on its Consolidated Financial Statements.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_InitialPublicOfferingPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for initial public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_InitialPublicOfferingPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">6.</font><font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 16pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Subsequent Events</font>
		</p>
		<p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On May 4, 2015, the Company entered into a research collaboration and license agreement (the &#x201C;Agreement&#x201D;) with Juno Therapeutics, Inc. (&#x201C;Juno&#x201D;) to identify small molecules to program the therapeutic properties of Juno&#x2019;s genetically-engineered T cell product candidates. Pursuant to the terms of the Agreement, Juno has agreed to pay the Company an upfront payment of $5.0 million and to purchase 1,000,000 shares of the Company&#x2019;s common stock at $8.00 per share.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Pursuant to the collaboration&#x2019;s research plan, the Company will be responsible for screening and identifying small molecule modulators of immunological cells, while Juno will be responsible for the development and commercialization of engineered T cell immunotherapies incorporating the Company&#x2019;s modulators. Juno has agreed to fund all of the Company&#x2019;s collaboration activities for an exclusive four-year research term beginning on the effective date of the Agreement, with minimum annual payments to the Company for research funding. Juno has the option to extend the exclusive research term for an additional two years, subject to the payment of an extension fee, and the continued funding of all collaboration activities during the extended term, with minimum annual payments to the Company for research funding.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Under the Agreement, the Company has granted Juno an exclusive worldwide license to certain of its intellectual property, including its intellectual property arising under the collaboration, to make, use, sell and otherwise exploit genetically-engineered T cell immunotherapies using or incorporating small molecule modulators directed against certain designated tumor-associated antigen targets, subject to the selection of a target by Juno. The Company has retained exclusive rights to such intellectual property, including its intellectual property arising under the collaboration, for all other purposes, including its use outside of those targets selected by Juno.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">For each product developed by Juno that incorporates modulators identified through the research collaboration, the Company is eligible to receive approximately $50.0 million in target selection fees and clinical, regulatory and commercial milestones, as well as low single-digit royalties on sales.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EK1AK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Jul. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Current accrued expenses</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and other employee benefits</a></td>
        <td class="nump"><a title="us-gaap_AccruedSalariesCurrent" onclick="toggleNextSibling(this);">$ 562,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedSalariesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedSalariesCurrent" onclick="toggleNextSibling(this);">$ 562,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedSalariesCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AccruedSalariesCurrent" onclick="toggleNextSibling(this);">$ 1,234,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedSalariesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AccruedClinicalTrialCostsCurrent', window );">Accrued clinical trial costs</a></td>
        <td class="nump"><a title="fate_AccruedClinicalTrialCostsCurrent" onclick="toggleNextSibling(this);">498,000</a><span style="display:none;white-space:normal;text-align:left;">fate_AccruedClinicalTrialCostsCurrent</span><span></span></td>
        <td class="nump"><a title="fate_AccruedClinicalTrialCostsCurrent" onclick="toggleNextSibling(this);">498,000</a><span style="display:none;white-space:normal;text-align:left;">fate_AccruedClinicalTrialCostsCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_AccruedClinicalTrialCostsCurrent" onclick="toggleNextSibling(this);">415,000</a><span style="display:none;white-space:normal;text-align:left;">fate_AccruedClinicalTrialCostsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">767,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">767,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">611,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">1,827,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">1,827,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">2,260,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued to senior executives</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" onclick="toggleNextSibling(this);">19,956</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentCarryingAmount" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentCarryingAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentCarryingAmount" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentCarryingAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentCarryingAmount" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentCarryingAmount</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DebtInstrumentDiscountNonCurrent', window );">Less debt discount, net of current portion</a></td>
        <td class="num"><a title="fate_DebtInstrumentDiscountNonCurrent" onclick="toggleNextSibling(this);">(167,000)</a><span style="display:none;white-space:normal;text-align:left;">fate_DebtInstrumentDiscountNonCurrent</span><span></span></td>
        <td class="num"><a title="fate_DebtInstrumentDiscountNonCurrent" onclick="toggleNextSibling(this);">(167,000)</a><span style="display:none;white-space:normal;text-align:left;">fate_DebtInstrumentDiscountNonCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="fate_DebtInstrumentDiscountNonCurrent" onclick="toggleNextSibling(this);">(371,000)</a><span style="display:none;white-space:normal;text-align:left;">fate_DebtInstrumentDiscountNonCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net of discount</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebt" onclick="toggleNextSibling(this);">19,833,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebt" onclick="toggleNextSibling(this);">19,833,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebt" onclick="toggleNextSibling(this);">19,629,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_LongTermDebtGrossCurrent', window );">Less current portion of long-term debt</a></td>
        <td class="num"><a title="fate_LongTermDebtGrossCurrent" onclick="toggleNextSibling(this);">(3,419,000)</a><span style="display:none;white-space:normal;text-align:left;">fate_LongTermDebtGrossCurrent</span><span></span></td>
        <td class="num"><a title="fate_LongTermDebtGrossCurrent" onclick="toggleNextSibling(this);">(3,419,000)</a><span style="display:none;white-space:normal;text-align:left;">fate_LongTermDebtGrossCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="fate_LongTermDebtGrossCurrent" onclick="toggleNextSibling(this);">(1,546,000)</a><span style="display:none;white-space:normal;text-align:left;">fate_LongTermDebtGrossCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current potion</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">16,414,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">16,414,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtNoncurrent" onclick="toggleNextSibling(this);">18,083,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtNoncurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DebtInstrumentDiscountCurrent', window );">Current portion of debt discount</a></td>
        <td class="num"><a title="fate_DebtInstrumentDiscountCurrent" onclick="toggleNextSibling(this);">(163,000)</a><span style="display:none;white-space:normal;text-align:left;">fate_DebtInstrumentDiscountCurrent</span><span></span></td>
        <td class="num"><a title="fate_DebtInstrumentDiscountCurrent" onclick="toggleNextSibling(this);">(163,000)</a><span style="display:none;white-space:normal;text-align:left;">fate_DebtInstrumentDiscountCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">3,256,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">3,256,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">1,546,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_OperatingLeaseExtendedTerm', window );">Extended term of lease</a></td>
        <td class="text">15 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Cash-collateralized irrevocable standby letter of credit</a></td>
        <td class="nump"><a title="us-gaap_LettersOfCreditOutstandingAmount" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LettersOfCreditOutstandingAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_LettersOfCreditOutstandingAmount" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LettersOfCreditOutstandingAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=fate_OperatingLeaseMember', window );">Operating lease member</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum payments</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue[us-gaap_LeaseArrangementTypeAxis=fate_OperatingLeaseMember]" onclick="toggleNextSibling(this);">2,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue<br>/ us-gaap_LeaseArrangementTypeAxis<br>= fate_OperatingLeaseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue[us-gaap_LeaseArrangementTypeAxis=fate_OperatingLeaseMember]" onclick="toggleNextSibling(this);">2,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue<br>/ us-gaap_LeaseArrangementTypeAxis<br>= fate_OperatingLeaseMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=fate_SubleaseLeaseMember', window );">Sublease operating lease member</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum payments</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue[us-gaap_LeaseArrangementTypeAxis=fate_SubleaseLeaseMember]" onclick="toggleNextSibling(this);">800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue<br>/ us-gaap_LeaseArrangementTypeAxis<br>= fate_SubleaseLeaseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue[us-gaap_LeaseArrangementTypeAxis=fate_SubleaseLeaseMember]" onclick="toggleNextSibling(this);">800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue<br>/ us-gaap_LeaseArrangementTypeAxis<br>= fate_SubleaseLeaseMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion', window );">Warrants to purchase shares of common stock issued on conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">36,074</a><span style="display:none;white-space:normal;text-align:left;">fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 7.21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 7.21</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Warrants Expiration Period January2019 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion', window );">Warrants to purchase shares of common stock issued on conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember;fate_WarrantsExpirationPeriodAxis=fate_WarrantsExpirationPeriodJanuary2019Member]" onclick="toggleNextSibling(this);">5,305</a><span style="display:none;white-space:normal;text-align:left;">fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember<br>/ fate_WarrantsExpirationPeriodAxis<br>= fate_WarrantsExpirationPeriodJanuary2019Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants | Warrants Expiration Period August2021 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion', window );">Warrants to purchase shares of common stock issued on conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember;fate_WarrantsExpirationPeriodAxis=fate_WarrantsExpirationPeriodAugust2021Member]" onclick="toggleNextSibling(this);">30,769</a><span style="display:none;white-space:normal;text-align:left;">fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember<br>/ fate_WarrantsExpirationPeriodAxis<br>= fate_WarrantsExpirationPeriodAugust2021Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=fate_TermALoanMember', window );">Term A Loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage', window );">Effective interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage[us-gaap_LongtermDebtTypeAxis=fate_TermALoanMember]" onclick="toggleNextSibling(this);">10.30%</a><span style="display:none;white-space:normal;text-align:left;">fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermALoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember', window );">Term B Loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage', window );">Effective interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage[us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember]" onclick="toggleNextSibling(this);">12.00%</a><span style="display:none;white-space:normal;text-align:left;">fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember', window );">Term B Loan | Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember;us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 4.08</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember;us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 4.08</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair values of warrants issued</a></td>
        <td class="nump"><a title="us-gaap_WarrantsAndRightsOutstanding[us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember;us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WarrantsAndRightsOutstanding<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_WarrantsAndRightsOutstanding[us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember;us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WarrantsAndRightsOutstanding<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember', window );">Amended And Restated Loan And Security Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Commitment fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFeeAmount[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember]" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFeeAmount<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Aggregate interest expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseDebt[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember]" onclick="toggleNextSibling(this);">600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseDebt<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember', window );">Amended And Restated Loan And Security Agreement [Member] | Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">20,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember', window );">Amended And Restated Loan And Security Agreement [Member] | Secured Debt [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DebtInstrumentTermForPaymentOfInterest', window );">Number of monthly payment of interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">12 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest', window );">Number of equal monthly installments to repay principal and accrued interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">30 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember', window );">Amended And Restated Loan And Security Agreement [Member] | Term A Loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermALoanMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermALoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermALoanMember]" onclick="toggleNextSibling(this);">7.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermALoanMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermALoanMember]" onclick="toggleNextSibling(this);">7.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermALoanMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermALoanMember]" onclick="toggleNextSibling(this);">6.94%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermALoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net Proceeds after repayment of loans outstanding and transaction fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfLongTermDebt[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermALoanMember]" onclick="toggleNextSibling(this);">8,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfLongTermDebt<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermALoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember', window );">Amended And Restated Loan And Security Agreement [Member] | Term B Loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember]" onclick="toggleNextSibling(this);">7.07%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Final payment fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember]" onclick="toggleNextSibling(this);">7.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Final payment fee (amounts in dollars)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LineOfCreditFacilityCommitmentFeeAmount[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember]" onclick="toggleNextSibling(this);">800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Net Proceeds after repayment of loans outstanding and transaction fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfLongTermDebt[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfLongTermDebt<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion', window );">Warrants to purchase shares of common stock issued on conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember]" onclick="toggleNextSibling(this);">98,039</a><span style="display:none;white-space:normal;text-align:left;">fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember', window );">Amended And Restated Loan And Security Agreement [Member] | Term B Loan | Maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember', window );">Amended And Restated Loan And Security Agreement [Member] | Term B Loan Tranch 1 [Member] | Minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember;us-gaap_LongtermDebtTypeAxis=fate_TermBLoanTranche1Member;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);"> 10,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_DebtInstrumentAxis<br>= fate_AmendedAndRestatedLoanAndSecurityAgreementMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= fate_TermBLoanTranche1Member<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AccruedClinicalTrialCostsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_AccruedClinicalTrialCostsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the number of common stocks into which the class of warrant or right may be converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DebtInstrumentDiscountCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the current portion of discount recognized at the issuance of debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_DebtInstrumentDiscountCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DebtInstrumentDiscountNonCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the non-current portion of discount recognized at the issuance of debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_DebtInstrumentDiscountNonCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DebtInstrumentTermForPaymentOfInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time for payment of interest on monthly basis on cash at the beginning of first day of each month, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_DebtInstrumentTermForPaymentOfInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period of time for repayment of principal and accrued interest on equal monthly installments, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_DebtInstrumentTermForRepaymentOfPrincipalAndAccruedInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fee, expressed as a percentage of the unused borrowing capacity, for the term loan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_DebtInstrumentUnusedBorrowingCapacityFeePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_LongTermDebtGrossCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, before unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_LongTermDebtGrossCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_OperatingLeaseExtendedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents extended term of operating lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_OperatingLeaseExtendedTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the fee that accompanies borrowing money under the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the fee for available but unused credit capacity under the credit facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fate_AmendedAndRestatedLoanAndSecurityAgreementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=fate_OperatingLeaseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=fate_OperatingLeaseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=fate_SubleaseLeaseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=fate_SubleaseLeaseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=fate_TermALoanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=fate_TermALoanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=fate_TermBLoanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6BAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 04, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold in initial public offering</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">7,666,667</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Public offering price (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_SharePrice" onclick="toggleNextSibling(this);">$ 6.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from initial public offering</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceInitialPublicOffering" onclick="toggleNextSibling(this);">$ 46.0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_NetProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
        <td class="nump"><a title="fate_NetProceedsFromIssuanceInitialPublicOffering" onclick="toggleNextSibling(this);">$ 40.5</a><span style="display:none;white-space:normal;text-align:left;">fate_NetProceedsFromIssuanceInitialPublicOffering</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_InitialPublicOfferingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_InitialPublicOfferingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_NetProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Proceeds from Issuance Initial Public Offering</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_NetProceedsFromIssuanceInitialPublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Accrued Expenses, Long-Term Debt, Commitments and Contingencies.</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Current accrued expenses consist of the following (in thousands):</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 78.00%;margin-left:64.8pt;">
			<tr>
				<td valign="bottom" style="width:61.84%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accrued payroll and other employee benefits</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>562&nbsp;
				</td>
				<td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,234&nbsp;
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.84%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accrued clinical trial costs</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>498&nbsp;
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>415&nbsp;
				</td>
				<td valign="bottom" style="width:01.28%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.84%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accrued other</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>767&nbsp;
				</td>
				<td valign="bottom" style="width:03.18%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>611&nbsp;
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.84%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Accrued expenses</font></p>
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,827&nbsp;
				</td>
				<td valign="bottom" style="width:03.18%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:13.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,260&nbsp;
				</td>
				<td valign="bottom" style="width:01.28%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of long-term debt and unamortized discount balances (excluding convertible debt)</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Long-term debt and unamortized discount balances are as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-size:10pt;"></font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:68.4pt;">
			<tr>
				<td valign="bottom" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;">31,&nbsp;2015</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">31,2014</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Long-term debt</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,000
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,000
				</td>
				<td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Less debt discount, net of current portion</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(167
				</td>
				<td valign="bottom" style="width:03.24%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(371
				</td>
				<td valign="bottom" style="width:01.24%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Long-term debt, net of discount</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,833
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>19,629
				</td>
				<td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Less current portion of long-term debt</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3,419
				</td>
				<td valign="bottom" style="width:03.24%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,546
				</td>
				<td valign="bottom" style="width:01.24%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Long-term debt, net of current portion</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>16,414
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18,083
				</td>
				<td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Current portion of long-term debt</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,419
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,546
				</td>
				<td valign="bottom" style="width:01.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Current portion of debt discount</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(163
				</td>
				<td valign="bottom" style="width:03.24%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:15.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.20%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Current portion of long-term debt, net</font></p>
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,256
				</td>
				<td valign="bottom" style="width:03.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:14.24%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,546
				</td>
				<td valign="bottom" style="width:01.24%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_AccruedExpensesLongTermDebtCommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of accrued liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(e),(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 470<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ERJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Summary of stock option activity under the Plan</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;">
			<tr>
				<td valign="bottom" style="width:65.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Average&nbsp;Price</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.40%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:65.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Balance at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,425,969
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.83
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:65.40%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>793,152
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.87
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:65.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Canceled </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(213,630
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.49
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:65.40%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47,862
				</td>
				<td valign="bottom" style="width:02.88%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.56
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Balance at March 31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,957,629
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.03
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of allocation of stock-based compensation for all options and restricted stock awards</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 59.00%;margin-left:118.8pt;">
			<tr>
				<td valign="bottom" style="width:49.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:44.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>304&nbsp;
				</td>
				<td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>565&nbsp;
				</td>
				<td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">General and administrative </font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>304&nbsp;
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>306&nbsp;
				</td>
				<td valign="bottom" style="width:01.60%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>608&nbsp;
				</td>
				<td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>871&nbsp;
				</td>
				<td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to determine the fair value of stock option grants</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:61.2pt;">
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.6&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.0&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82.5&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94.5&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.1&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember', window );">Non Employee Stock Option</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions used to determine the fair value of stock option grants</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-indent:23.05pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:61.2pt;">
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Risk-free interest rate </font></p>
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.2&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected volatility </font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87.1&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94.5&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Remaining contractual term (in years) </font></p>
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.0&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.7&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected dividend yield </font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the change in stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2HAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details 2) (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodFactors', window );">Four criteria needed for Company to recognize revenue</a></td>
        <td class="text">(i)&#xA0;persuasive evidence that an agreement exists; (ii)&#xA0;delivery of the products and/or services has occurred; (iii)&#xA0;the selling price is fixed or determinable; and (iv)&#xA0;collectability is reasonably assured.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding', window );">Shares excluded from weighted average number of shares attributable to share based payments</a></td>
        <td class="nump"><a title="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" onclick="toggleNextSibling(this);">58,453</a><span style="display:none;white-space:normal;text-align:left;">fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding" onclick="toggleNextSibling(this);">88,043</a><span style="display:none;white-space:normal;text-align:left;">fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,881)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,980)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potentially dilutive securities (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" onclick="toggleNextSibling(this);">3,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" onclick="toggleNextSibling(this);">2,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Options to purchase shares of common stock included in potentially dilutive securities (in shares)</a></td>
        <td class="nump"><a title="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" onclick="toggleNextSibling(this);">2,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the shares excluded from the weighted-average number of shares outstanding attributable to share based payment arrangements including shares which have been issued upon the early exercise of stock options and are subject to future vesting and unvested restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Warrant<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 23<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1757-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Treasury Stock Method<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6527216<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Call Option<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506649<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodFactors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A description of the factors that the entity considered in determining whether the milestone or milestones are substantive.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodFactors</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ECQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>May 04, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">20,637,217</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">20,569,399</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Collaboration and license agreement terms | Juno Therapeutics, Inc</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_UpfrontPaymentReceivable', window );">Upfront payment receivable</a></td>
        <td class="nump"><a title="fate_UpfrontPaymentReceivable[us-gaap_CounterpartyNameAxis=fate_JunoTherapeuticsIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fate_CollaborationAndLicenseAgreementTermsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 5.0</a><span style="display:none;white-space:normal;text-align:left;">fate_UpfrontPaymentReceivable<br>/ us-gaap_CounterpartyNameAxis<br>= fate_JunoTherapeuticsIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= fate_CollaborationAndLicenseAgreementTermsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued[us-gaap_CounterpartyNameAxis=fate_JunoTherapeuticsIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fate_CollaborationAndLicenseAgreementTermsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued<br>/ us-gaap_CounterpartyNameAxis<br>= fate_JunoTherapeuticsIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= fate_CollaborationAndLicenseAgreementTermsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price</a></td>
        <td class="nump"><a title="us-gaap_SharesIssuedPricePerShare[us-gaap_CounterpartyNameAxis=fate_JunoTherapeuticsIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fate_CollaborationAndLicenseAgreementTermsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 8.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssuedPricePerShare<br>/ us-gaap_CounterpartyNameAxis<br>= fate_JunoTherapeuticsIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= fate_CollaborationAndLicenseAgreementTermsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ResearchTerm', window );">Research term</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ResearchTermExtension', window );">Research term extension</a></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_AmountReceivableForProductDevelopment', window );">Amount receivable for product development</a></td>
        <td class="nump"><a title="fate_AmountReceivableForProductDevelopment[us-gaap_CounterpartyNameAxis=fate_JunoTherapeuticsIncMember;us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fate_CollaborationAndLicenseAgreementTermsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 50.0</a><span style="display:none;white-space:normal;text-align:left;">fate_AmountReceivableForProductDevelopment<br>/ us-gaap_CounterpartyNameAxis<br>= fate_JunoTherapeuticsIncMember<br>/ us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis<br>= fate_CollaborationAndLicenseAgreementTermsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_AmountReceivableForProductDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the eligible approximate amount to be received for each product developed</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_AmountReceivableForProductDevelopment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ResearchTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the research term for which funding is done by the party</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_ResearchTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ResearchTermExtension">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the period for which research term can be extended</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_ResearchTermExtension</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_UpfrontPaymentReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the upfront payment receivable from the party</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_UpfrontPaymentReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit of equity securities issued by non-development stage entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,881)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (6,980)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">128</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">123</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">608</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">871</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of discounts and debt issuance costs</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCostsAndDiscounts" onclick="toggleNextSibling(this);">44</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfFinancingCostsAndDiscounts" onclick="toggleNextSibling(this);">8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Noncash interest expense</a></td>
        <td class="nump"><a title="us-gaap_PaidInKindInterest" onclick="toggleNextSibling(this);">164</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaidInKindInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_PaidInKindInterest" onclick="toggleNextSibling(this);">10</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaidInKindInterest</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StraightLineRent', window );">Deferred rent</a></td>
        <td class="num"><a title="us-gaap_StraightLineRent" onclick="toggleNextSibling(this);">(10)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StraightLineRent</span><span></span></td>
        <td class="num"><a title="us-gaap_StraightLineRent" onclick="toggleNextSibling(this);">(9)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StraightLineRent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_InitialFairValueAndAdjustmentOfExchangeableShares', window );">Stock-based milestone charges and change in fair value of exchangeable shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="fate_InitialFairValueAndAdjustmentOfExchangeableShares" onclick="toggleNextSibling(this);">375</a><span style="display:none;white-space:normal;text-align:left;">fate_InitialFairValueAndAdjustmentOfExchangeableShares</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">303</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">304</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">269</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">43</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(6,375)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(5,255)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(452)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(398)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(452)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(398)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net of repurchases and issuance cost</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="num"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">(2)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on long-term debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_RepaymentsOfLongTermDebt" onclick="toggleNextSibling(this);">(500)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfLongTermDebt</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by (used in) financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" onclick="toggleNextSibling(this);">(502)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(6,752)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(6,155)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of the period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">49,101</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">54,036</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of the period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 42,349</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 47,881</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_InitialFairValueAndAdjustmentOfExchangeableShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the initial fair value and change in fair value amounts of exchangeable shares during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_InitialFairValueAndAdjustmentOfExchangeableShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StraightLineRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Difference between actual rental income due and rental income recognized on a straight-line basis.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StraightLineRent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stockholders' Equity.</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-size:10pt;">5.</font><font style="display: inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman;text-indent:0pt;margin-left:0pt;padding:0pt 16pt 0pt 0pt;"></font><font style="display: inline;font-weight:bold;font-size:3pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Stockholders&#x2019; Equity</font>
		</p>
		<p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">Stock option activity under all equity and stock option plans is summarized as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 86.00%;margin-left:36pt;">
			<tr>
				<td valign="bottom" style="width:65.40%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Number&nbsp;of</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">Average&nbsp;Price</font></p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.40%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:65.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Balance at December&nbsp;31, 2014 </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,425,969
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.83
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:65.40%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Granted </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>793,152
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.87
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:65.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Canceled </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(213,630
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.49
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:65.40%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Exercised </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(47,862
				</td>
				<td valign="bottom" style="width:02.88%;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">)</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.56
				</td>
				<td valign="bottom" style="width:01.16%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:65.40%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Balance at March 31, 2015 </font></p>
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:13.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,957,629
				</td>
				<td valign="bottom" style="width:02.88%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:12.54%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.03
				</td>
				<td valign="bottom" style="width:01.16%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The allocation of stock-based compensation for all options and restricted stock awards is as follows (in thousands):</font>
		</p>
		<p style="margin:0pt;text-indent:23pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 59.00%;margin-left:118.8pt;">
			<tr>
				<td valign="bottom" style="width:49.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:44.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.60%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.60%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Research and development </font></p>
				</td>
				<td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>304&nbsp;
				</td>
				<td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>565&nbsp;
				</td>
				<td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">General and administrative </font></p>
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>304&nbsp;
				</td>
				<td valign="bottom" style="width:04.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:20.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>306&nbsp;
				</td>
				<td valign="bottom" style="width:01.60%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:49.48%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.32%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>608&nbsp;
				</td>
				<td valign="bottom" style="width:04.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="width:18.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>871&nbsp;
				</td>
				<td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">As of March 31, 2015, the outstanding options included 122,780 performance-based options for which the achievement of the performance-based vesting provisions was determined not to be probable. The aggregate grant date fair value of these unvested options at March 31, 2015 was $0.5 million.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">As of March 31, 2015, the unrecognized compensation cost related to outstanding options (excluding those with performance-based conditions) was $4.9 million and is expected to be recognized as expense over approximately 3.0 years.</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows:</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:61.2pt;">
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.6&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.0&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82.5&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94.5&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected term (in years)</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.0&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.1&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected dividend yield</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:27pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the non-employee stock option grants were as follows:</font>
		</p>
		<p style="margin:0pt;text-indent:23.05pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 77.00%;margin-left:61.2pt;">
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:34.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;Months&nbsp;Ended</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Risk-free interest rate </font></p>
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.2&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.2&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected volatility </font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>87.1&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94.5&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Remaining contractual term (in years) </font></p>
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.0&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6.7&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:61.22%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">Expected dividend yield </font></p>
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp;
				</td>
				<td valign="bottom" style="width:03.22%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
				<td valign="bottom" style="width:15.52%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp;
				</td>
				<td valign="bottom" style="width:01.30%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-size:10pt;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 0pt 22.3pt;text-indent: -22.3pt;font-family:Times New Roman;font-size: 12pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>55</ContextCount>
  <ElementCount>157</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>26</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Asset Acquisition of Verio Therapeutics Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsInc</Role>
      <ShortName>Asset Acquisition of Verio Therapeutics Inc.</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingencies</Role>
      <ShortName>Accrued Expenses, Long-Term Debt, Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>20102 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesTables</Role>
      <ShortName>Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>40102 - Disclosure - Organization and Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Asset Acquisition of Verio Therapeutics Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureAssetAcquisitionOfVerioTherapeuticsIncDetails</Role>
      <ShortName>Asset Acquisition of Verio Therapeutics Inc. (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureAccruedExpensesLongTermDebtCommitmentsAndContingenciesDetails</Role>
      <ShortName>Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.fatetherapeutics.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_ResearchAndDevelopmentExpense had a mix of decimals attribute values: -5 -3.</Log>
    <Log type="Info">'Monetary' elements on report '40301 - Disclosure - Fair Value Measurements (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '40401 - Disclosure - Accrued Expenses, Long-Term Debt, Commitments and Contingencies (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '40501 - Disclosure - Stockholders' Equity (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 00100 - Statement - Condensed Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</Log>
    <Log type="Info">Process Flow-Through: 00300 - Statement - Condensed Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>fate-20150331.xml</File>
    <File>fate-20150331.xsd</File>
    <File>fate-20150331_cal.xml</File>
    <File>fate-20150331_def.xml</File>
    <File>fate-20150331_lab.xml</File>
    <File>fate-20150331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ESPBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 608,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 871,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research And Development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">304,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">565,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General And Administrative</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">304,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">306,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember', window );">Employee And Non Employee Stock Option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2,425,969</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">793,152</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled (in shares)</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(213,630)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">(47,862)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2,957,629</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 3.83</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 4.87</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 5.49</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 1.56</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">$ 4.03</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to outstanding options</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">4,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected recognition period of unrecognized compensation cost</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember', window );">Employee And Non Employee Stock Option | Vesting Based On Performance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember;us-gaap_VestingAxis=fate_VestingBasedOnPerformanceMember]" onclick="toggleNextSibling(this);">122,780</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember<br>/ us-gaap_VestingAxis<br>= fate_VestingBasedOnPerformanceMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Price</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue', window );">Aggregate grant date fair value</a></td>
        <td class="nump"><a title="fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue[us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember;us-gaap_VestingAxis=fate_VestingBasedOnPerformanceMember]" onclick="toggleNextSibling(this);">$ 500,000</a><span style="display:none;white-space:normal;text-align:left;">fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= fate_EmployeeAndNonEmployeeStockOptionMember<br>/ us-gaap_VestingAxis<br>= fate_VestingBasedOnPerformanceMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1.60%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">82.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">94.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">6 years 1 month 6 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember', window );">Non Employee Stock Option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions to determine fair value of stock options</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= fate_NonEmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2.20%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= fate_NonEmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">87.10%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= fate_NonEmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">94.50%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= fate_NonEmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining contractual term</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">6 years 8 months 12 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as a percent)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= fate_NonEmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= fate_NonEmployeeStockOptionMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the aggregate grant-date fair value of share-based compensation plan awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">fate_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>fate_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fate_EmployeeAndNonEmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fate_NonEmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
